2025-06-23 14:01:06,018 - INFO - Starting LLM pipeline with run_id: 0623_1401_JBI_llm_sonnet-3.7_3
2025-06-23 14:01:06,022 - INFO - Saved GURNEMANZ session info to /Users/atabeyunlu/multi_agent_paper/runs_metadata/0623_1401_JBI_llm_sonnet-3.7_3/gurnemanz_session.json
2025-06-23 14:01:06,022 - INFO - --------------------------------
2025-06-23 14:01:06,022 - INFO - Starting Iteration 1
2025-06-23 14:01:06,023 - INFO - --------------------------------
2025-06-23 14:01:06,023 - INFO - LLM Agent: LLM Drug Designer
2025-06-23 14:01:06,023 - INFO - chat history for chat completion: [
  {
    "role": "system",
    "content": "You are an AI assistant acting as LLM Drug Designer. Your expertise is in ('Medicinal chemistry and drug design', 'Structure-activity relationships', 'Kinase inhibitor development', 'ADMET optimization', 'Computational drug discovery'). Your goal is to Design novel, drug-like small molecule AKT1 inhibitors using medicinal chemistry knowledge and computational drug design principles, without relying on external tools.. Your role is to Expert medicinal chemist responsible for generating innovative AKT1 inhibitor designs based on scientific knowledge, literature understanding, and drug design principles. Provide novel chemical structures with clear design rationales.. Please maintain this role throughout our conversation.\n\n\n        \"molecules\": [\n                {\n                    \"smiles\": \"SMILES_STRING\",\n                    \"friendly_id\": \"friendly id of molecule eg: DA:I1:N0:G0\",\n                    \"source\": \"(parent molecule id of modified molecule)\"\n                    \"agent\": \"AGENT_NAME\",\n                    \"rationale\": \"(rationale for the molecule)\"\n                }\n            ],\n        }\n        </molecules>\n        \nDruing the discovery process, molecules will be presented with a friendly_id. This friendly_id is a unique identifier that tracks its complete history and lineage through our optimization process to help to follow the SAR and parent-child relationships.\n\n## Molecule ID System - Tracking Molecular Evolution\n\nEach molecule receives a unique identifier that tracks its complete history and lineage through our optimization process.\n\n**Format:** `AgentCode:I<iteration>:N<position>:G<generation>`\n\nThis ID (friendly_id) system serves as a molecular genealogy, allowing us to:\n- Track which agent created or modified each molecule\n- Understand the evolutionary path from original to optimized compounds\n- Maintain parent-child relationships across modifications\n\n**Components:**\n- **AgentCode**: Two-letter code representing the creator agent\n  - DA = Database Agent\n  - AI = AI Expert\n  - MC = Medicinal Chemist\n  - LA = Literature Agent\n  - RA = Ranking Agent\n  - PR = Principal Researcher\n  - SC = Scientific Critic\n  - SP = Summary Parser\n\n- **I<iteration>**: The research iteration number when molecule was introduced (e.g., I1, I2, I3)\n- **N<position>**: The molecule's position in the agent's output list, starting from N1 (resets per agent output)\n- **G<generation>**: The modification depth showing molecular evolution\n  - G0 = original molecule (from database or de novo)\n  - G1 = first modification\n  - G2 = second modification\n  - And so on...\n\n**Example Evolution:**\n1. Database retrieves: `DA:I1:N3:G0` (original from ChEMBL, third molecule in list, iteration 1)\n2. Medicinal Chemist modifies it: `MC:I2:N1:G1` (first modification, first molecule in chemist's list, iteration 2)\n3. Further optimization: `MC:I3:N2:G2` (second modification, second molecule in list, iteration 3)\n\nThis allows us to trace any molecule back to its origins and understand its optimization journey.\nIf a molecule is a child of a parent molecule, the parent molecule's friendly_id must be included in the molecule's source field\n"
  },
  {
    "role": "user",
    "content": "You are an expert medicinal chemist and computational drug discovery scientist. Your task is to design novel small molecule inhibitors for AKT1 (Protein Kinase B alpha) using your knowledge of structure-activity relationships, medicinal chemistry principles, and drug design.\n\n**Target Information:**\n- AKT1 is a serine/threonine kinase in the PI3K/AKT/mTOR pathway\n- Critical for cell survival, proliferation, and metabolism\n- Key oncology target with multiple known inhibitors\n- ATP-competitive and allosteric binding sites available\n\n**Your Goal:**\nGenerate novel, drug-like small molecule AKT1 inhibitors with the following criteria:\n- High predicted binding affinity to AKT1\n- Drug-like properties (Lipinski's Rule of Five compliance)\n- Synthetic accessibility\n- Novel scaffolds not directly copied from known inhibitors\n\n**Output Format:**\nFor each molecule, provide:\n1. **Molecule ID**: A unique identifier (e.g., LLM_MOL_001)\n2. **SMILES**: Valid SMILES string\n3. **Rationale**: Brief explanation of your design strategy and expected properties\n4. **Predicted Properties**: Your assessment of drug-likeness, potency, selectivity\n\nFocus on innovative chemical designs while maintaining scientific rigor."
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 1: Initial Discovery & Exploration**\n\nDesign 10-15 novel AKT1 inhibitor molecules using your medicinal chemistry expertise. Consider:\n\n1. **ATP-competitive inhibitors**: Target the ATP-binding pocket with novel scaffolds\n2. **Allosteric inhibitors**: Design molecules that bind to regulatory sites\n3. **Hybrid approaches**: Molecules that may interact with multiple binding sites\n\nUse your knowledge of:\n- Known AKT1 pharmacophores (avoid direct copying)\n- Kinase selectivity determinants\n- Drug-like chemical space\n- Structure-activity relationships\n\nGenerate diverse scaffolds including heterocycles, aromatic systems, and appropriate linkers. Ensure synthetic feasibility while prioritizing novelty."
      }
    ]
  }
]
2025-06-23 14:01:58,156 - INFO - response ModelResponse(id='chatcmpl-4af93633-7150-4ab8-8578-e69cbf00eee3', created=1750676518, model='claude-3-7-sonnet-20250219', object='chat.completion', system_fingerprint=None, choices=[Choices(finish_reason='stop', index=0, message=Message(content='# AKT1 Inhibitor Design - Initial Discovery\n\nI\'ll design novel AKT1 inhibitors using medicinal chemistry principles and my knowledge of kinase inhibitor design. I\'ll focus on creating diverse, drug-like molecules with appropriate pharmacophores for AKT1 inhibition.\n\n<molecules>\n{\n    "molecules": [\n        {\n            "smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5",\n            "friendly_id": "AI:I1:N1:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N",\n            "friendly_id": "AI:I1:N2:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors."\n        },\n        {\n            "smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5",\n            "friendly_id": "AI:I1:N3:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5",\n            "friendly_id": "AI:I1:N4:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements."\n        },\n        {\n            "smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N",\n            "friendly_id": "AI:I1:N5:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode."\n        },\n        {\n            "smiles": "COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F",\n            "friendly_id": "AI:I1:N6:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties."\n        },\n        {\n            "smiles": "CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5",\n            "friendly_id": "AI:I1:N7:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5",\n            "friendly_id": "AI:I1:N8:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases."\n        },\n        {\n            "smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC",\n            "friendly_id": "AI:I1:N9:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5",\n            "friendly_id": "AI:I1:N10:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile."\n        },\n        {\n            "smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4",\n            "friendly_id": "AI:I1:N11:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties."\n        },\n        {\n            "smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5",\n            "friendly_id": "AI:I1:N12:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode."\n        },\n        {\n            "smiles": "CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C",\n            "friendly_id": "AI:I1:N13:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases."\n        },\n        {\n            "smiles": "CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5",\n            "friendly_id": "AI:I1:N14:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile."\n        },\n        {\n            "smiles": "COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5",\n            "friendly_id": "AI:I1:N15:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties."\n        }\n    ]\n}\n</molecules>\n\n## Design Strategy Overview\n\nMy approach to designing these AKT1 inhibitors focused on several key medicinal chemistry principles:\n\n### 1. Hinge-Binding Motifs\n- Incorporated established kinase hinge-binding pharmacophores including:\n  - Aminopyrimidines (molecules 1, 2, 11, 14)\n  - Imidazoles (molecule 4)\n  - Triazoles (molecule 6)\n  - Quinazolines (molecule 15)\n  - Oxadiazoles (molecules 3, 7, 13)\n\n### 2. Binding Modes\n- **ATP-competitive inhibitors** (majority of designs): Target the ATP-binding pocket with appropriate hinge-binding elements\n- **Type II inhibitors** (molecules 2, 9): Include urea linkers to stabilize the DFG-out conformation\n- **Allosteric inhibitors** (molecules 5, 12): Target the PH domain-kinase domain interface\n\n### 3. Structural Features\n- **Solubilizing groups**: Incorporated piperazines, morpholines, and tertiary amines\n- **Metabolic stability**: Used fluorine substitutions, oxadiazoles, and methoxy groups\n- **Rigidity and spatial arrangement**: Employed amide linkers, ureas, and conformationally constrained cores\n\n### 4. Drug-Like Properties\n- Designed molecules with:\n  - MW generally between 420-550 Da\n  - LogP values in the 2.5-4 range\n  - Appropriate H-bond donors/acceptors (Lipinski compliant)\n  - Balanced solubility and permeability characteristics\n\nThese designs represent a diverse set of potential AKT1 inhibitors with varied scaffolds, binding modes, and physicochemical properties, providing a strong foundation for further optimization.', role='assistant', tool_calls=None, function_call=None, provider_specific_fields={'citations': []}, citations=[]))], usage=Usage(completion_tokens=3825, prompt_tokens=1241, total_tokens=5066, completion_tokens_details=None, prompt_tokens_details=PromptTokensDetailsWrapper(audio_tokens=None, cached_tokens=0, text_tokens=None, image_tokens=None), cache_creation_input_tokens=0, cache_read_input_tokens=0))
2025-06-23 14:01:58,157 - INFO - history_with_tools [{'role': 'user', 'content': "You are an expert medicinal chemist and computational drug discovery scientist. Your task is to design novel small molecule inhibitors for AKT1 (Protein Kinase B alpha) using your knowledge of structure-activity relationships, medicinal chemistry principles, and drug design.\n\n**Target Information:**\n- AKT1 is a serine/threonine kinase in the PI3K/AKT/mTOR pathway\n- Critical for cell survival, proliferation, and metabolism\n- Key oncology target with multiple known inhibitors\n- ATP-competitive and allosteric binding sites available\n\n**Your Goal:**\nGenerate novel, drug-like small molecule AKT1 inhibitors with the following criteria:\n- High predicted binding affinity to AKT1\n- Drug-like properties (Lipinski's Rule of Five compliance)\n- Synthetic accessibility\n- Novel scaffolds not directly copied from known inhibitors\n\n**Output Format:**\nFor each molecule, provide:\n1. **Molecule ID**: A unique identifier (e.g., LLM_MOL_001)\n2. **SMILES**: Valid SMILES string\n3. **Rationale**: Brief explanation of your design strategy and expected properties\n4. **Predicted Properties**: Your assessment of drug-likeness, potency, selectivity\n\nFocus on innovative chemical designs while maintaining scientific rigor."}, {'role': 'user', 'content': [{'type': 'text', 'text': '**ITERATION 1: Initial Discovery & Exploration**\n\nDesign 10-15 novel AKT1 inhibitor molecules using your medicinal chemistry expertise. Consider:\n\n1. **ATP-competitive inhibitors**: Target the ATP-binding pocket with novel scaffolds\n2. **Allosteric inhibitors**: Design molecules that bind to regulatory sites\n3. **Hybrid approaches**: Molecules that may interact with multiple binding sites\n\nUse your knowledge of:\n- Known AKT1 pharmacophores (avoid direct copying)\n- Kinase selectivity determinants\n- Drug-like chemical space\n- Structure-activity relationships\n\nGenerate diverse scaffolds including heterocycles, aromatic systems, and appropriate linkers. Ensure synthetic feasibility while prioritizing novelty.'}]}, {'role': 'assistant', 'content': '# AKT1 Inhibitor Design - Initial Discovery\n\nI\'ll design novel AKT1 inhibitors using medicinal chemistry principles and my knowledge of kinase inhibitor design. I\'ll focus on creating diverse, drug-like molecules with appropriate pharmacophores for AKT1 inhibition.\n\n<molecules>\n{\n    "molecules": [\n        {\n            "smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5",\n            "friendly_id": "AI:I1:N1:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N",\n            "friendly_id": "AI:I1:N2:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors."\n        },\n        {\n            "smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5",\n            "friendly_id": "AI:I1:N3:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5",\n            "friendly_id": "AI:I1:N4:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements."\n        },\n        {\n            "smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N",\n            "friendly_id": "AI:I1:N5:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode."\n        },\n        {\n            "smiles": "COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F",\n            "friendly_id": "AI:I1:N6:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties."\n        },\n        {\n            "smiles": "CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5",\n            "friendly_id": "AI:I1:N7:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5",\n            "friendly_id": "AI:I1:N8:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases."\n        },\n        {\n            "smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC",\n            "friendly_id": "AI:I1:N9:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5",\n            "friendly_id": "AI:I1:N10:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile."\n        },\n        {\n            "smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4",\n            "friendly_id": "AI:I1:N11:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties."\n        },\n        {\n            "smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5",\n            "friendly_id": "AI:I1:N12:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode."\n        },\n        {\n            "smiles": "CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C",\n            "friendly_id": "AI:I1:N13:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases."\n        },\n        {\n            "smiles": "CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5",\n            "friendly_id": "AI:I1:N14:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile."\n        },\n        {\n            "smiles": "COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5",\n            "friendly_id": "AI:I1:N15:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties."\n        }\n    ]\n}\n</molecules>\n\n## Design Strategy Overview\n\nMy approach to designing these AKT1 inhibitors focused on several key medicinal chemistry principles:\n\n### 1. Hinge-Binding Motifs\n- Incorporated established kinase hinge-binding pharmacophores including:\n  - Aminopyrimidines (molecules 1, 2, 11, 14)\n  - Imidazoles (molecule 4)\n  - Triazoles (molecule 6)\n  - Quinazolines (molecule 15)\n  - Oxadiazoles (molecules 3, 7, 13)\n\n### 2. Binding Modes\n- **ATP-competitive inhibitors** (majority of designs): Target the ATP-binding pocket with appropriate hinge-binding elements\n- **Type II inhibitors** (molecules 2, 9): Include urea linkers to stabilize the DFG-out conformation\n- **Allosteric inhibitors** (molecules 5, 12): Target the PH domain-kinase domain interface\n\n### 3. Structural Features\n- **Solubilizing groups**: Incorporated piperazines, morpholines, and tertiary amines\n- **Metabolic stability**: Used fluorine substitutions, oxadiazoles, and methoxy groups\n- **Rigidity and spatial arrangement**: Employed amide linkers, ureas, and conformationally constrained cores\n\n### 4. Drug-Like Properties\n- Designed molecules with:\n  - MW generally between 420-550 Da\n  - LogP values in the 2.5-4 range\n  - Appropriate H-bond donors/acceptors (Lipinski compliant)\n  - Balanced solubility and permeability characteristics\n\nThese designs represent a diverse set of potential AKT1 inhibitors with varied scaffolds, binding modes, and physicochemical properties, providing a strong foundation for further optimization.'}]
2025-06-23 14:01:58,157 - INFO - main_history before parser: [
  {
    "role": "user",
    "content": "You are an expert medicinal chemist and computational drug discovery scientist. Your task is to design novel small molecule inhibitors for AKT1 (Protein Kinase B alpha) using your knowledge of structure-activity relationships, medicinal chemistry principles, and drug design.\n\n**Target Information:**\n- AKT1 is a serine/threonine kinase in the PI3K/AKT/mTOR pathway\n- Critical for cell survival, proliferation, and metabolism\n- Key oncology target with multiple known inhibitors\n- ATP-competitive and allosteric binding sites available\n\n**Your Goal:**\nGenerate novel, drug-like small molecule AKT1 inhibitors with the following criteria:\n- High predicted binding affinity to AKT1\n- Drug-like properties (Lipinski's Rule of Five compliance)\n- Synthetic accessibility\n- Novel scaffolds not directly copied from known inhibitors\n\n**Output Format:**\nFor each molecule, provide:\n1. **Molecule ID**: A unique identifier (e.g., LLM_MOL_001)\n2. **SMILES**: Valid SMILES string\n3. **Rationale**: Brief explanation of your design strategy and expected properties\n4. **Predicted Properties**: Your assessment of drug-likeness, potency, selectivity\n\nFocus on innovative chemical designs while maintaining scientific rigor."
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 1: Initial Discovery & Exploration**\n\nDesign 10-15 novel AKT1 inhibitor molecules using your medicinal chemistry expertise. Consider:\n\n1. **ATP-competitive inhibitors**: Target the ATP-binding pocket with novel scaffolds\n2. **Allosteric inhibitors**: Design molecules that bind to regulatory sites\n3. **Hybrid approaches**: Molecules that may interact with multiple binding sites\n\nUse your knowledge of:\n- Known AKT1 pharmacophores (avoid direct copying)\n- Kinase selectivity determinants\n- Drug-like chemical space\n- Structure-activity relationships\n\nGenerate diverse scaffolds including heterocycles, aromatic systems, and appropriate linkers. Ensure synthetic feasibility while prioritizing novelty."
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Initial Discovery\n\nI'll design novel AKT1 inhibitors using medicinal chemistry principles and my knowledge of kinase inhibitor design. I'll focus on creating diverse, drug-like molecules with appropriate pharmacophores for AKT1 inhibition.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N1:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I1:N2:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N3:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N4:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I1:N5:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I1:N6:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N7:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N8:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC\",\n            \"friendly_id\": \"AI:I1:N9:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5\",\n            \"friendly_id\": \"AI:I1:N10:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I1:N11:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5\",\n            \"friendly_id\": \"AI:I1:N12:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C\",\n            \"friendly_id\": \"AI:I1:N13:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5\",\n            \"friendly_id\": \"AI:I1:N14:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N15:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        }\n    ]\n}\n</molecules>\n\n## Design Strategy Overview\n\nMy approach to designing these AKT1 inhibitors focused on several key medicinal chemistry principles:\n\n### 1. Hinge-Binding Motifs\n- Incorporated established kinase hinge-binding pharmacophores including:\n  - Aminopyrimidines (molecules 1, 2, 11, 14)\n  - Imidazoles (molecule 4)\n  - Triazoles (molecule 6)\n  - Quinazolines (molecule 15)\n  - Oxadiazoles (molecules 3, 7, 13)\n\n### 2. Binding Modes\n- **ATP-competitive inhibitors** (majority of designs): Target the ATP-binding pocket with appropriate hinge-binding elements\n- **Type II inhibitors** (molecules 2, 9): Include urea linkers to stabilize the DFG-out conformation\n- **Allosteric inhibitors** (molecules 5, 12): Target the PH domain-kinase domain interface\n\n### 3. Structural Features\n- **Solubilizing groups**: Incorporated piperazines, morpholines, and tertiary amines\n- **Metabolic stability**: Used fluorine substitutions, oxadiazoles, and methoxy groups\n- **Rigidity and spatial arrangement**: Employed amide linkers, ureas, and conformationally constrained cores\n\n### 4. Drug-Like Properties\n- Designed molecules with:\n  - MW generally between 420-550 Da\n  - LogP values in the 2.5-4 range\n  - Appropriate H-bond donors/acceptors (Lipinski compliant)\n  - Balanced solubility and permeability characteristics\n\nThese designs represent a diverse set of potential AKT1 inhibitors with varied scaffolds, binding modes, and physicochemical properties, providing a strong foundation for further optimization."
      }
    ]
  }
]
2025-06-23 14:01:58,157 - INFO - DEBUG: tools: [{'type': 'function', 'function': {'name': 'gurnemanz_apply', 'description': 'Submit transformation and molecule data to GURNEMANZ and retrieve the response with IDs. The Haskell service returns the full data structure with embedded IDs, providing better traceability between molecules and their IDs.', 'parameters': {'type': 'object', 'properties': {'session_id': {'type': 'string', 'description': 'Session UUID from creation (required for tracking transformations across sessions)'}, 'parent_transformation_id': {'type': 'string', 'description': 'ID of the parent transformation (required for tracking transformation chains)'}, 'client_name': {'type': 'string', 'description': 'Use claude for client name', 'default': 'claude'}, 'transformation': {'type': 'object', 'description': 'Details of the transformation being applied', 'properties': {'type': {'type': 'string', 'description': "Required: Type of transformation (e.g., 'molecule-generation', 'property-prediction')"}, 'agent': {'type': 'string', 'description': 'Required: Name of the agent performing the transformation'}, 'user_message': {'type': 'string', 'description': 'Optional: Human-readable message about the transformation'}, 'method_details': {'type': 'object', 'description': 'Optional: Details about the method used in the transformation', 'properties': {'method_id': {'type': 'string', 'description': 'Required if methodDetails is present: Identifier of the method used'}}, 'required': ['method_id']}, 'rationale': {'type': 'string', 'description': 'Optional: General rationale for the transformation'}, 'protein_sequence': {'type': 'string', 'description': 'Optional: Protein sequence associated with the transformation'}, 'protein_path': {'type': 'string', 'description': 'Optional: Path to the protein pdb file associated with the transformation'}, 'iteration': {'type': 'integer', 'description': 'Required: Iteration number for this transformation'}}, 'required': ['type', 'agent', 'iteration']}, 'molecules': {'type': 'array', 'description': 'Array of molecule objects generated or modified in this transformation', 'items': {'type': 'object', 'properties': {'structure': {'type': 'object', 'description': 'Required: Molecular structure information', 'properties': {'smiles': {'type': 'string', 'description': 'Required: SMILES string representation'}}, 'required': ['smiles']}, 'properties': {'type': 'object', 'description': 'Optional: Molecule properties', 'properties': {'parent_molecule_id': {'type': 'string', 'description': 'Optional: ID of parent molecule'}, 'molecular_weight': {'type': 'number', 'description': 'Optional: Molecular weight'}, 'status': {'type': 'string', 'description': "Optional: Molecule status (e.g., 'modified', 'de novo')"}}}, 'computed_properties': {'type': 'object', 'description': 'Optional: Computed or predicted properties', 'properties': {'logP': {'type': 'number', 'description': 'Optional: Lipophilicity'}, 'qed': {'type': 'number', 'description': 'Optional: Quantitative estimate of drug-likeness'}, 'sas': {'type': 'number', 'description': 'Optional: Synthetic accessibility score'}, 'lipinski_count': {'type': 'integer', 'description': "Optional: Number of Lipinski's Rule of Five violations"}, 'docking_score': {'type': 'number', 'description': 'Optional: Docking score (if applicable)'}, 'plip_interactions': {'type': 'string', 'description': 'Optional: Protein-ligand interaction information'}}}, 'rationale': {'type': 'string', 'description': 'Required: Reasoning specific to this molecule'}, 'activity': {'type': 'string', 'description': "Optional: Activity status of the molecule (e.g., 'active', 'inactive')"}, 'friendly_id': {'type': 'string', 'description': 'Friendly ID of the molecule'}, 'parent_friendly_id': {'type': 'string', 'description': 'Optional: Friendly ID of the parent molecule, only molecules created by Medicinal Chemist can have parents'}}, 'required': ['structure', 'rationale', 'friendly_id']}}}, 'required': ['session_id', 'parent_transformation_id', 'transformation', 'molecules', 'client_name']}}}]
2025-06-23 14:01:58,157 - INFO - chat history for chat completion: [
  {
    "role": "system",
    "content": "You are an AI assistant acting as Summary Parser. Your expertise is in ('Interpreting unstructured research outputs', 'Generating structured JSON data', 'Maintaining data consistency across transformations'). Your goal is to Format LLM outputs into GURNEMANZ JSON schema and submit them while maintaining all important relationships between data elements.. Your role is to Parse LLM outputs to construct a clean formatted JSON that preserves all relevant information about molecules and their design rationales.. Please maintain this role throughout our conversation.\n\n\nDruing the discovery process, molecules will be presented with a friendly_id. This friendly_id is a unique identifier that tracks its complete history and lineage through our optimization process to help to follow the SAR and parent-child relationships.\n\n## Molecule ID System - Tracking Molecular Evolution\n\nEach molecule receives a unique identifier that tracks its complete history and lineage through our optimization process.\n\n**Format:** `AgentCode:I<iteration>:N<position>:G<generation>`\n\nThis ID (friendly_id) system serves as a molecular genealogy, allowing us to:\n- Track which agent created or modified each molecule\n- Understand the evolutionary path from original to optimized compounds\n- Maintain parent-child relationships across modifications\n\n**Components:**\n- **AgentCode**: Two-letter code representing the creator agent\n  - DA = Database Agent\n  - AI = AI Expert\n  - MC = Medicinal Chemist\n  - LA = Literature Agent\n  - RA = Ranking Agent\n  - PR = Principal Researcher\n  - SC = Scientific Critic\n  - SP = Summary Parser\n\n- **I<iteration>**: The research iteration number when molecule was introduced (e.g., I1, I2, I3)\n- **N<position>**: The molecule's position in the agent's output list, starting from N1 (resets per agent output)\n- **G<generation>**: The modification depth showing molecular evolution\n  - G0 = original molecule (from database or de novo)\n  - G1 = first modification\n  - G2 = second modification\n  - And so on...\n\n**Example Evolution:**\n1. Database retrieves: `DA:I1:N3:G0` (original from ChEMBL, third molecule in list, iteration 1)\n2. Medicinal Chemist modifies it: `MC:I2:N1:G1` (first modification, first molecule in chemist's list, iteration 2)\n3. Further optimization: `MC:I3:N2:G2` (second modification, second molecule in list, iteration 3)\n\nThis allows us to trace any molecule back to its origins and understand its optimization journey.\nIf a molecule is a child of a parent molecule, the parent molecule's friendly_id must be included in the molecule's source field\n"
  },
  {
    "role": "user",
    "content": "You are an expert medicinal chemist and computational drug discovery scientist. Your task is to design novel small molecule inhibitors for AKT1 (Protein Kinase B alpha) using your knowledge of structure-activity relationships, medicinal chemistry principles, and drug design.\n\n**Target Information:**\n- AKT1 is a serine/threonine kinase in the PI3K/AKT/mTOR pathway\n- Critical for cell survival, proliferation, and metabolism\n- Key oncology target with multiple known inhibitors\n- ATP-competitive and allosteric binding sites available\n\n**Your Goal:**\nGenerate novel, drug-like small molecule AKT1 inhibitors with the following criteria:\n- High predicted binding affinity to AKT1\n- Drug-like properties (Lipinski's Rule of Five compliance)\n- Synthetic accessibility\n- Novel scaffolds not directly copied from known inhibitors\n\n**Output Format:**\nFor each molecule, provide:\n1. **Molecule ID**: A unique identifier (e.g., LLM_MOL_001)\n2. **SMILES**: Valid SMILES string\n3. **Rationale**: Brief explanation of your design strategy and expected properties\n4. **Predicted Properties**: Your assessment of drug-likeness, potency, selectivity\n\nFocus on innovative chemical designs while maintaining scientific rigor."
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 1: Initial Discovery & Exploration**\n\nDesign 10-15 novel AKT1 inhibitor molecules using your medicinal chemistry expertise. Consider:\n\n1. **ATP-competitive inhibitors**: Target the ATP-binding pocket with novel scaffolds\n2. **Allosteric inhibitors**: Design molecules that bind to regulatory sites\n3. **Hybrid approaches**: Molecules that may interact with multiple binding sites\n\nUse your knowledge of:\n- Known AKT1 pharmacophores (avoid direct copying)\n- Kinase selectivity determinants\n- Drug-like chemical space\n- Structure-activity relationships\n\nGenerate diverse scaffolds including heterocycles, aromatic systems, and appropriate linkers. Ensure synthetic feasibility while prioritizing novelty."
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Initial Discovery\n\nI'll design novel AKT1 inhibitors using medicinal chemistry principles and my knowledge of kinase inhibitor design. I'll focus on creating diverse, drug-like molecules with appropriate pharmacophores for AKT1 inhibition.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N1:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I1:N2:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N3:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N4:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I1:N5:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I1:N6:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N7:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N8:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC\",\n            \"friendly_id\": \"AI:I1:N9:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5\",\n            \"friendly_id\": \"AI:I1:N10:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I1:N11:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5\",\n            \"friendly_id\": \"AI:I1:N12:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C\",\n            \"friendly_id\": \"AI:I1:N13:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5\",\n            \"friendly_id\": \"AI:I1:N14:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N15:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        }\n    ]\n}\n</molecules>\n\n## Design Strategy Overview\n\nMy approach to designing these AKT1 inhibitors focused on several key medicinal chemistry principles:\n\n### 1. Hinge-Binding Motifs\n- Incorporated established kinase hinge-binding pharmacophores including:\n  - Aminopyrimidines (molecules 1, 2, 11, 14)\n  - Imidazoles (molecule 4)\n  - Triazoles (molecule 6)\n  - Quinazolines (molecule 15)\n  - Oxadiazoles (molecules 3, 7, 13)\n\n### 2. Binding Modes\n- **ATP-competitive inhibitors** (majority of designs): Target the ATP-binding pocket with appropriate hinge-binding elements\n- **Type II inhibitors** (molecules 2, 9): Include urea linkers to stabilize the DFG-out conformation\n- **Allosteric inhibitors** (molecules 5, 12): Target the PH domain-kinase domain interface\n\n### 3. Structural Features\n- **Solubilizing groups**: Incorporated piperazines, morpholines, and tertiary amines\n- **Metabolic stability**: Used fluorine substitutions, oxadiazoles, and methoxy groups\n- **Rigidity and spatial arrangement**: Employed amide linkers, ureas, and conformationally constrained cores\n\n### 4. Drug-Like Properties\n- Designed molecules with:\n  - MW generally between 420-550 Da\n  - LogP values in the 2.5-4 range\n  - Appropriate H-bond donors/acceptors (Lipinski compliant)\n  - Balanced solubility and permeability characteristics\n\nThese designs represent a diverse set of potential AKT1 inhibitors with varied scaffolds, binding modes, and physicochemical properties, providing a strong foundation for further optimization."
      }
    ]
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "\nYou are the Summary Parser Agent. Your task is to read the output from the previous agent, extract relevant information, and format it into a JSON object that conforms to the GURNEMANZ JSON spec. A critical part of your role is to track molecule history by checking previous steps in the history to include the `parent_molecule_id` for derived molecules, ensuring GURNEMANZ maintains the molecule transformation chain.\nDO NOT FORGET TO INCLUDE THE friendly_id IN THE JSON OUTPUT and parent_friendly_id if the molecule is a child of a parent molecule !.\n### Input\n- The full output from the previous agent in plain text format. (IMPORTANT NOTE: all important details of research in the output of Literature Agent has to be stored in the transformation rationale field)\n- The history, a list of previous steps, each containing a transformation and possibly molecules with assigned moleculeIds.\n- The current iteration number\n- The agent title: \"LLM Drug Designer\" - You MUST use this exact title as the agent name in your output\n\n### Output\n- A JSON object with transformation and molecules, wrapped in `<gurnemanz>` tags (e.g., `<gurnemanz>{ \"transformation\": { ... }, \"molecules\": [ ... ] }</gurnemanz>`).\n\n### Steps to Follow\n1. **Analyze the Input:**\n   - Extract the transformation type, agent name, general rationale, molecule data (SMILES, specific rationales), and any protein-related data (like protein_sequence and protein_path) from the previous agent's output.\n   - Parse information from headers, bullet points, and descriptive text in the agent's response.\n\n2. **Determine Transformation Details:**\n   - Set \"iteration\" to the provided iteration number.\n   - Set type based on the agent's action (e.g., \"molecule-generation\" for new designs, \"property-prediction\" for evaluations or calculations).\n   - Set agent to the name of the previous agent (e.g., \"Medicinal Chemist\").\n   - Summarize the general rationale from the agent's intent or summary.\n   - Look for mentions of protein sequences in the text. If the agent mentions or provides a protein sequence ,or just sequence, include this sequence in the \"protein_sequence\" field of the transformation object.\n   - Look for mentions of protein PDB files in the text. If the agent mentions or provides a path to a protein PDB file, include this path in the \"protein_path\" field of the transformation object.\n\n3. **Process Molecules and Track History:**\n   - For each molecule in the agent's output:\n     - Look for patterns like \"Molecule X\", \"ID:\", \"SMILES:\", etc., to identify molecules and their properties.\n     - **Check if it's De novo or Derived:**\n       - **De novo Molecule:** If the SMILES does not appear in the history and there's no indication of modification (e.g., \"de novo\" or \"designed from scratch\"), set properties.status: \"de novo\" and omit properties.parent_molecule_id.\n       - **Derived Molecule:** If the SMILES matches a molecule in the history or the rationale suggests modification (e.g., \"repositioning,\" \"replacing,\" \"evaluated\"):\n         - Search the history chronologically for a molecule with the same SMILES.\n         - Retrieve the moleculeId of the matching molecule from the history\u2014this is the parent_molecule_id.\n         - Set properties.parent_molecule_id to this ID and properties.status: \"modified\".\n     - **Handle Modifications:**\n       - If the SMILES differs slightly from a historical molecule but the rationale indicates it's a modification (e.g., \"fluorine replaced with chlorine\"), find the closest matching parent SMILES in the history and use its Molecule ID as parent_molecule_id.\n     - **Reusing Unchanged Molecules:**\n       - When the agent explicitly references a molecule by `moleculeId` and there is no indication of a structural change, carry that `moleculeId` forward in the output and omit a new structure. This prevents creation of duplicate molecule entries for the same SMILES.\n     - **Populate Fields:**\n       - Set structure.smiles to the molecule's SMILES.\n       - Include a properties object for EVERY molecule, with status and, if derived, parent_molecule_id.\n       - Add any calculated properties (e.g., docking score, logP, pChEMBL, qed, sas) to computed_properties.\n       - Set rationale to the molecule-specific reasoning from the agent.\n       - If there is any relevant file path in the previous agent's response, for example to a pdb folder, include this in the rationale as well\n\n4. **Format the JSON:**\n   - Structure the output with transformation and molecules at the top level.\n\n5. **Validate:**\n   - Verify that derived molecules have a parent_molecule_id matching a historical molecule_id; if unclear, note in rationale (e.g., \"Parent unclear due to missing history match\").\n\n6. **Output:**\n   - Wrap the JSON in `<gurnemanz>` tags.\n\n### Example: Agent Output Format and Parsing\nThe history will look like this:\n```\n## Transformation\n- Type: data-retrieval\n- Agent: Ai expert\n- Iteration: 1\n- ID: ceb63937-5bd9-48b3-9ac6-ccc443944e4c\n- Rationale: Generated de novo molecules for AKT1\n\n## Molecules\n\n### Molecule 1\n- ID: 4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88\n- SMILES: COc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F\n- Properties:\n  * Status: de novo\n- Computed Properties:\n  * logP: 3.7169\n  * pChEMBL: 8.3\n  * qed: 0.285355\n  * sas: 3.507\n- Rationale: De novo compound for AKT1 with high potency (pChEMBL 8.3).\n```\n\nThe previous agents response you receive as input:\n```json\nMedcicinal chemist: I've edited the de novo molecule of the ai expert in this way\nCOc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F(=c3ccncc3)\nrationale: improved binding\n```\n\nExpected Output:\n```\n<gurnemanz>\n{\n  \"transformation\": {\n    \"type\": \"lead-optimization\",\n    \"agent\": \"Medicinal Chemist\",\n    \"user_message\": \"improved molecule binding\",\n    \"rationale\": \"edited molecule for improved binding\",\n    \"protein_sequence\": \"MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYFEYLKLDYLHSEIRFPHFPQFSYSASGTA\" # Include if a protein sequence is mentioned in the agent output\n    \"protein_path\": \"/path/to/protein.pdb\",  # Include only if a protein path is mentioned in the agent output\n    \"iteration\": 2\n  },\n  \"molecules\": [\n    {\n      \"structure\": {\n        \"smiles\": \"COc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F(=c3ccncc3)\"\n      },\n      \"properties\": {\n        \"parent_molecule_id\": \"4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88\",\n        \"status\": \"modified\"\n      },\n      \"computed_properties\": {},\n      \"rationale\": \"Fluorine at 4-position of pyridine is synthetically accessible but may present regioselectivity challenges\"\n    }\n  ]\n}\n</gurnemanz>\n```\n\n### IMPORTANT REQUIREMENTS\n1. **Every molecule MUST have a properties object** with at minimum a status field.\n2. **Derived molecules MUST include parent_molecule_id** in the properties object.\n3. **SMILES matching is critical** - When a molecule with the same SMILES appears in a new step, it's derived, not de novo.\n4. **Look through the entire history** to find matching molecules and their molecule_ids.\n5. **Look for ID fields in the text output** - When you see patterns like \"ID: 4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88\" in the agent output, this may be a molecule ID that becomes the parent_molecule_id for derived molecules.\n6. **If an agent outputs a file path to a protein PDB file** add this path in the \"protein_path\" field in the transformation object. Look for paths containing \".pdb\" extensions or mentions of protein structure files. For example, if the agent says \"I used /path/to/protein.pdb for docking\", extract \"/path/to/protein.pdb\" as the protein_path.\nVERY IMPORTANT NOTE FOR LITERATURE AGENT PARSING: Including ALL important details provided by the literature agent in the transformations rationale field!!!!! the other agents RELY on this information! do NOT summarize the response and omit key information. all relevant output of the literature HAS TO GO INTO THE RATIONALE. Also double check if there might be protein sequences or smiles in the response to add them in the appropriate fields.\n\nIteration Number:\n1\nAgent Title:\nLLM Drug Designer\n"
      }
    ]
  }
]
2025-06-23 14:02:46,419 - INFO - response ModelResponse(id='chatcmpl-e5f0fcca-a760-4a7f-a164-dc2028f4bbbd', created=1750676566, model='claude-3-7-sonnet-20250219', object='chat.completion', system_fingerprint=None, choices=[Choices(finish_reason='tool_calls', index=0, message=Message(content="I'll parse the output from the LLM Drug Designer and format it into the GURNEMANZ JSON schema.", role='assistant', tool_calls=[ChatCompletionMessageToolCall(index=1, function=Function(arguments='{"client_name": "claude", "session_id": "new_session", "parent_transformation_id": "new_transformation", "transformation": {"type": "molecule-generation", "agent": "LLM Drug Designer", "iteration": 1, "rationale": "Initial discovery of novel AKT1 inhibitors using medicinal chemistry principles. The design strategy focused on creating diverse molecules with appropriate hinge-binding motifs (aminopyrimidines, imidazoles, triazoles, quinazolines, oxadiazoles), different binding modes (ATP-competitive, Type II, allosteric), and drug-like properties. Molecules were designed with solubilizing groups, features for metabolic stability, and appropriate spatial arrangements to target AKT1."}, "molecules": [{"structure": {"smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5"}, "rationale": "ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions.", "friendly_id": "AI:I1:N1:G0"}, {"structure": {"smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N"}, "rationale": "Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors.", "friendly_id": "AI:I1:N2:G0"}, {"structure": {"smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5"}, "rationale": "ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites.", "friendly_id": "AI:I1:N3:G0"}, {"structure": {"smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5"}, "rationale": "ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements.", "friendly_id": "AI:I1:N4:G0"}, {"structure": {"smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N"}, "rationale": "Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.", "friendly_id": "AI:I1:N5:G0"}, {"structure": {"smiles": "COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F"}, "rationale": "ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties.", "friendly_id": "AI:I1:N6:G0"}, {"structure": {"smiles": "CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5"}, "rationale": "ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile.", "friendly_id": "AI:I1:N7:G0"}, {"structure": {"smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5"}, "rationale": "ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.", "friendly_id": "AI:I1:N8:G0"}, {"structure": {"smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC"}, "rationale": "Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties.", "friendly_id": "AI:I1:N9:G0"}, {"structure": {"smiles": "COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5"}, "rationale": "ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.", "friendly_id": "AI:I1:N10:G0"}, {"structure": {"smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4"}, "rationale": "ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties.", "friendly_id": "AI:I1:N11:G0"}, {"structure": {"smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5"}, "rationale": "Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.", "friendly_id": "AI:I1:N12:G0"}, {"structure": {"smiles": "CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C"}, "rationale": "ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.", "friendly_id": "AI:I1:N13:G0"}, {"structure": {"smiles": "CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5"}, "rationale": "ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.", "friendly_id": "AI:I1:N14:G0"}, {"structure": {"smiles": "COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5"}, "rationale": "ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties.", "friendly_id": "AI:I1:N15:G0"}]}', name='gurnemanz_apply'), id='toolu_01Ni6fzUvJiVwSkMwyhMM43u', type='function')], function_call=None, provider_specific_fields={'citations': []}, citations=[]))], usage=Usage(completion_tokens=3467, prompt_tokens=8552, total_tokens=12019, completion_tokens_details=None, prompt_tokens_details=PromptTokensDetailsWrapper(audio_tokens=None, cached_tokens=0, text_tokens=None, image_tokens=None), cache_creation_input_tokens=0, cache_read_input_tokens=0))
2025-06-23 14:02:46,425 - INFO - result_dict {'gurnemanz_apply': {'molecules': [{'moleculeId': 'b329766b-1514-4892-8857-c7fb8b327d00', 'originalData': {'friendlyId': 'AI:I1:N1:G0', 'rationale': 'ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions.', 'structure': {'smiles': 'CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5'}}}, {'moleculeId': 'ce2bfe29-e881-4088-98b6-944ac9b2acc5', 'originalData': {'friendlyId': 'AI:I1:N2:G0', 'rationale': 'Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors.', 'structure': {'smiles': 'COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N'}}}, {'moleculeId': '0a247f24-bf43-4ac7-9968-66a6cfdaead2', 'originalData': {'friendlyId': 'AI:I1:N3:G0', 'rationale': 'ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites.', 'structure': {'smiles': 'CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5'}}}, {'moleculeId': '445f06ec-4f65-4f73-b591-80a743d30253', 'originalData': {'friendlyId': 'AI:I1:N4:G0', 'rationale': 'ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements.', 'structure': {'smiles': 'CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5'}}}, {'moleculeId': '1d0ef981-9b6e-4f41-94b3-8baa5d293a04', 'originalData': {'friendlyId': 'AI:I1:N5:G0', 'rationale': 'Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.', 'structure': {'smiles': 'CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N'}}}, {'moleculeId': '45fd2f5d-9dd7-4fb6-a8a8-eed1c9026fd5', 'originalData': {'friendlyId': 'AI:I1:N6:G0', 'rationale': 'ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties.', 'structure': {'smiles': 'COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F'}}}, {'moleculeId': '9c830861-8538-44a5-9405-3d6a5f305cd9', 'originalData': {'friendlyId': 'AI:I1:N7:G0', 'rationale': 'ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile.', 'structure': {'smiles': 'CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5'}}}, {'moleculeId': 'a9a94ab4-ea7b-4bb6-aeed-b72c86d2b871', 'originalData': {'friendlyId': 'AI:I1:N8:G0', 'rationale': 'ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.', 'structure': {'smiles': 'CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5'}}}, {'moleculeId': 'f0b722f8-1047-41bb-88fa-a6703077fab9', 'originalData': {'friendlyId': 'AI:I1:N9:G0', 'rationale': 'Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties.', 'structure': {'smiles': 'CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC'}}}, {'moleculeId': 'b369e19d-d1e1-4ad4-8f9d-04ae1aa995ba', 'originalData': {'friendlyId': 'AI:I1:N10:G0', 'rationale': 'ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.', 'structure': {'smiles': 'COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5'}}}, {'moleculeId': '222e9f93-32aa-43eb-b2fc-907df11e53f5', 'originalData': {'friendlyId': 'AI:I1:N11:G0', 'rationale': 'ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties.', 'structure': {'smiles': 'CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4'}}}, {'moleculeId': '57c5025c-eb31-433b-8feb-64c42f969c26', 'originalData': {'friendlyId': 'AI:I1:N12:G0', 'rationale': 'Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.', 'structure': {'smiles': 'CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5'}}}, {'moleculeId': '40ce17c4-883e-498e-92e3-8480547613c6', 'originalData': {'friendlyId': 'AI:I1:N13:G0', 'rationale': 'ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.', 'structure': {'smiles': 'CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C'}}}, {'moleculeId': 'c705733d-084c-4282-8d91-89e4c2628b5e', 'originalData': {'friendlyId': 'AI:I1:N14:G0', 'rationale': 'ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.', 'structure': {'smiles': 'CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5'}}}, {'moleculeId': '59b30bac-8a73-4f2b-ad4e-e8c78a4ab267', 'originalData': {'friendlyId': 'AI:I1:N15:G0', 'rationale': 'ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties.', 'structure': {'smiles': 'COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5'}}}], 'transformation': {'agent': 'LLM Drug Designer', 'iteration': 1, 'methodDetails': None, 'proteinPath': None, 'proteinSequence': None, 'rationale': 'Initial discovery of novel AKT1 inhibitors using medicinal chemistry principles. The design strategy focused on creating diverse molecules with appropriate hinge-binding motifs (aminopyrimidines, imidazoles, triazoles, quinazolines, oxadiazoles), different binding modes (ATP-competitive, Type II, allosteric), and drug-like properties. Molecules were designed with solubilizing groups, features for metabolic stability, and appropriate spatial arrangements to target AKT1.', 'transformationId': '12418556-f9fc-4a9d-b018-16a82a025d94', 'type': 'molecule-generation', 'userMessage': None}}}
2025-06-23 14:02:46,426 - INFO - DEBUG: tools: [{'type': 'function', 'function': {'name': 'gurnemanz_apply', 'description': 'Submit transformation and molecule data to GURNEMANZ and retrieve the response with IDs. The Haskell service returns the full data structure with embedded IDs, providing better traceability between molecules and their IDs.', 'parameters': {'type': 'object', 'properties': {'session_id': {'type': 'string', 'description': 'Session UUID from creation (required for tracking transformations across sessions)'}, 'parent_transformation_id': {'type': 'string', 'description': 'ID of the parent transformation (required for tracking transformation chains)'}, 'client_name': {'type': 'string', 'description': 'Use claude for client name', 'default': 'claude'}, 'transformation': {'type': 'object', 'description': 'Details of the transformation being applied', 'properties': {'type': {'type': 'string', 'description': "Required: Type of transformation (e.g., 'molecule-generation', 'property-prediction')"}, 'agent': {'type': 'string', 'description': 'Required: Name of the agent performing the transformation'}, 'user_message': {'type': 'string', 'description': 'Optional: Human-readable message about the transformation'}, 'method_details': {'type': 'object', 'description': 'Optional: Details about the method used in the transformation', 'properties': {'method_id': {'type': 'string', 'description': 'Required if methodDetails is present: Identifier of the method used'}}, 'required': ['method_id']}, 'rationale': {'type': 'string', 'description': 'Optional: General rationale for the transformation'}, 'protein_sequence': {'type': 'string', 'description': 'Optional: Protein sequence associated with the transformation'}, 'protein_path': {'type': 'string', 'description': 'Optional: Path to the protein pdb file associated with the transformation'}, 'iteration': {'type': 'integer', 'description': 'Required: Iteration number for this transformation'}}, 'required': ['type', 'agent', 'iteration']}, 'molecules': {'type': 'array', 'description': 'Array of molecule objects generated or modified in this transformation', 'items': {'type': 'object', 'properties': {'structure': {'type': 'object', 'description': 'Required: Molecular structure information', 'properties': {'smiles': {'type': 'string', 'description': 'Required: SMILES string representation'}}, 'required': ['smiles']}, 'properties': {'type': 'object', 'description': 'Optional: Molecule properties', 'properties': {'parent_molecule_id': {'type': 'string', 'description': 'Optional: ID of parent molecule'}, 'molecular_weight': {'type': 'number', 'description': 'Optional: Molecular weight'}, 'status': {'type': 'string', 'description': "Optional: Molecule status (e.g., 'modified', 'de novo')"}}}, 'computed_properties': {'type': 'object', 'description': 'Optional: Computed or predicted properties', 'properties': {'logP': {'type': 'number', 'description': 'Optional: Lipophilicity'}, 'qed': {'type': 'number', 'description': 'Optional: Quantitative estimate of drug-likeness'}, 'sas': {'type': 'number', 'description': 'Optional: Synthetic accessibility score'}, 'lipinski_count': {'type': 'integer', 'description': "Optional: Number of Lipinski's Rule of Five violations"}, 'docking_score': {'type': 'number', 'description': 'Optional: Docking score (if applicable)'}, 'plip_interactions': {'type': 'string', 'description': 'Optional: Protein-ligand interaction information'}}}, 'rationale': {'type': 'string', 'description': 'Required: Reasoning specific to this molecule'}, 'activity': {'type': 'string', 'description': "Optional: Activity status of the molecule (e.g., 'active', 'inactive')"}, 'friendly_id': {'type': 'string', 'description': 'Friendly ID of the molecule'}, 'parent_friendly_id': {'type': 'string', 'description': 'Optional: Friendly ID of the parent molecule, only molecules created by Medicinal Chemist can have parents'}}, 'required': ['structure', 'rationale', 'friendly_id']}}}, 'required': ['session_id', 'parent_transformation_id', 'transformation', 'molecules', 'client_name']}}}]
2025-06-23 14:02:46,426 - INFO - chat history for chat completion: [
  {
    "role": "system",
    "content": "You are an AI assistant acting as Summary Parser. Your expertise is in ('Interpreting unstructured research outputs', 'Generating structured JSON data', 'Maintaining data consistency across transformations'). Your goal is to Format LLM outputs into GURNEMANZ JSON schema and submit them while maintaining all important relationships between data elements.. Your role is to Parse LLM outputs to construct a clean formatted JSON that preserves all relevant information about molecules and their design rationales.. Please maintain this role throughout our conversation.\n\n\nDruing the discovery process, molecules will be presented with a friendly_id. This friendly_id is a unique identifier that tracks its complete history and lineage through our optimization process to help to follow the SAR and parent-child relationships.\n\n## Molecule ID System - Tracking Molecular Evolution\n\nEach molecule receives a unique identifier that tracks its complete history and lineage through our optimization process.\n\n**Format:** `AgentCode:I<iteration>:N<position>:G<generation>`\n\nThis ID (friendly_id) system serves as a molecular genealogy, allowing us to:\n- Track which agent created or modified each molecule\n- Understand the evolutionary path from original to optimized compounds\n- Maintain parent-child relationships across modifications\n\n**Components:**\n- **AgentCode**: Two-letter code representing the creator agent\n  - DA = Database Agent\n  - AI = AI Expert\n  - MC = Medicinal Chemist\n  - LA = Literature Agent\n  - RA = Ranking Agent\n  - PR = Principal Researcher\n  - SC = Scientific Critic\n  - SP = Summary Parser\n\n- **I<iteration>**: The research iteration number when molecule was introduced (e.g., I1, I2, I3)\n- **N<position>**: The molecule's position in the agent's output list, starting from N1 (resets per agent output)\n- **G<generation>**: The modification depth showing molecular evolution\n  - G0 = original molecule (from database or de novo)\n  - G1 = first modification\n  - G2 = second modification\n  - And so on...\n\n**Example Evolution:**\n1. Database retrieves: `DA:I1:N3:G0` (original from ChEMBL, third molecule in list, iteration 1)\n2. Medicinal Chemist modifies it: `MC:I2:N1:G1` (first modification, first molecule in chemist's list, iteration 2)\n3. Further optimization: `MC:I3:N2:G2` (second modification, second molecule in list, iteration 3)\n\nThis allows us to trace any molecule back to its origins and understand its optimization journey.\nIf a molecule is a child of a parent molecule, the parent molecule's friendly_id must be included in the molecule's source field\n"
  },
  {
    "role": "user",
    "content": "You are an expert medicinal chemist and computational drug discovery scientist. Your task is to design novel small molecule inhibitors for AKT1 (Protein Kinase B alpha) using your knowledge of structure-activity relationships, medicinal chemistry principles, and drug design.\n\n**Target Information:**\n- AKT1 is a serine/threonine kinase in the PI3K/AKT/mTOR pathway\n- Critical for cell survival, proliferation, and metabolism\n- Key oncology target with multiple known inhibitors\n- ATP-competitive and allosteric binding sites available\n\n**Your Goal:**\nGenerate novel, drug-like small molecule AKT1 inhibitors with the following criteria:\n- High predicted binding affinity to AKT1\n- Drug-like properties (Lipinski's Rule of Five compliance)\n- Synthetic accessibility\n- Novel scaffolds not directly copied from known inhibitors\n\n**Output Format:**\nFor each molecule, provide:\n1. **Molecule ID**: A unique identifier (e.g., LLM_MOL_001)\n2. **SMILES**: Valid SMILES string\n3. **Rationale**: Brief explanation of your design strategy and expected properties\n4. **Predicted Properties**: Your assessment of drug-likeness, potency, selectivity\n\nFocus on innovative chemical designs while maintaining scientific rigor."
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 1: Initial Discovery & Exploration**\n\nDesign 10-15 novel AKT1 inhibitor molecules using your medicinal chemistry expertise. Consider:\n\n1. **ATP-competitive inhibitors**: Target the ATP-binding pocket with novel scaffolds\n2. **Allosteric inhibitors**: Design molecules that bind to regulatory sites\n3. **Hybrid approaches**: Molecules that may interact with multiple binding sites\n\nUse your knowledge of:\n- Known AKT1 pharmacophores (avoid direct copying)\n- Kinase selectivity determinants\n- Drug-like chemical space\n- Structure-activity relationships\n\nGenerate diverse scaffolds including heterocycles, aromatic systems, and appropriate linkers. Ensure synthetic feasibility while prioritizing novelty."
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Initial Discovery\n\nI'll design novel AKT1 inhibitors using medicinal chemistry principles and my knowledge of kinase inhibitor design. I'll focus on creating diverse, drug-like molecules with appropriate pharmacophores for AKT1 inhibition.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N1:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I1:N2:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N3:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N4:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I1:N5:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I1:N6:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N7:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N8:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC\",\n            \"friendly_id\": \"AI:I1:N9:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5\",\n            \"friendly_id\": \"AI:I1:N10:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I1:N11:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5\",\n            \"friendly_id\": \"AI:I1:N12:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C\",\n            \"friendly_id\": \"AI:I1:N13:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5\",\n            \"friendly_id\": \"AI:I1:N14:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N15:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        }\n    ]\n}\n</molecules>\n\n## Design Strategy Overview\n\nMy approach to designing these AKT1 inhibitors focused on several key medicinal chemistry principles:\n\n### 1. Hinge-Binding Motifs\n- Incorporated established kinase hinge-binding pharmacophores including:\n  - Aminopyrimidines (molecules 1, 2, 11, 14)\n  - Imidazoles (molecule 4)\n  - Triazoles (molecule 6)\n  - Quinazolines (molecule 15)\n  - Oxadiazoles (molecules 3, 7, 13)\n\n### 2. Binding Modes\n- **ATP-competitive inhibitors** (majority of designs): Target the ATP-binding pocket with appropriate hinge-binding elements\n- **Type II inhibitors** (molecules 2, 9): Include urea linkers to stabilize the DFG-out conformation\n- **Allosteric inhibitors** (molecules 5, 12): Target the PH domain-kinase domain interface\n\n### 3. Structural Features\n- **Solubilizing groups**: Incorporated piperazines, morpholines, and tertiary amines\n- **Metabolic stability**: Used fluorine substitutions, oxadiazoles, and methoxy groups\n- **Rigidity and spatial arrangement**: Employed amide linkers, ureas, and conformationally constrained cores\n\n### 4. Drug-Like Properties\n- Designed molecules with:\n  - MW generally between 420-550 Da\n  - LogP values in the 2.5-4 range\n  - Appropriate H-bond donors/acceptors (Lipinski compliant)\n  - Balanced solubility and permeability characteristics\n\nThese designs represent a diverse set of potential AKT1 inhibitors with varied scaffolds, binding modes, and physicochemical properties, providing a strong foundation for further optimization."
      }
    ]
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "\nYou are the Summary Parser Agent. Your task is to read the output from the previous agent, extract relevant information, and format it into a JSON object that conforms to the GURNEMANZ JSON spec. A critical part of your role is to track molecule history by checking previous steps in the history to include the `parent_molecule_id` for derived molecules, ensuring GURNEMANZ maintains the molecule transformation chain.\nDO NOT FORGET TO INCLUDE THE friendly_id IN THE JSON OUTPUT and parent_friendly_id if the molecule is a child of a parent molecule !.\n### Input\n- The full output from the previous agent in plain text format. (IMPORTANT NOTE: all important details of research in the output of Literature Agent has to be stored in the transformation rationale field)\n- The history, a list of previous steps, each containing a transformation and possibly molecules with assigned moleculeIds.\n- The current iteration number\n- The agent title: \"LLM Drug Designer\" - You MUST use this exact title as the agent name in your output\n\n### Output\n- A JSON object with transformation and molecules, wrapped in `<gurnemanz>` tags (e.g., `<gurnemanz>{ \"transformation\": { ... }, \"molecules\": [ ... ] }</gurnemanz>`).\n\n### Steps to Follow\n1. **Analyze the Input:**\n   - Extract the transformation type, agent name, general rationale, molecule data (SMILES, specific rationales), and any protein-related data (like protein_sequence and protein_path) from the previous agent's output.\n   - Parse information from headers, bullet points, and descriptive text in the agent's response.\n\n2. **Determine Transformation Details:**\n   - Set \"iteration\" to the provided iteration number.\n   - Set type based on the agent's action (e.g., \"molecule-generation\" for new designs, \"property-prediction\" for evaluations or calculations).\n   - Set agent to the name of the previous agent (e.g., \"Medicinal Chemist\").\n   - Summarize the general rationale from the agent's intent or summary.\n   - Look for mentions of protein sequences in the text. If the agent mentions or provides a protein sequence ,or just sequence, include this sequence in the \"protein_sequence\" field of the transformation object.\n   - Look for mentions of protein PDB files in the text. If the agent mentions or provides a path to a protein PDB file, include this path in the \"protein_path\" field of the transformation object.\n\n3. **Process Molecules and Track History:**\n   - For each molecule in the agent's output:\n     - Look for patterns like \"Molecule X\", \"ID:\", \"SMILES:\", etc., to identify molecules and their properties.\n     - **Check if it's De novo or Derived:**\n       - **De novo Molecule:** If the SMILES does not appear in the history and there's no indication of modification (e.g., \"de novo\" or \"designed from scratch\"), set properties.status: \"de novo\" and omit properties.parent_molecule_id.\n       - **Derived Molecule:** If the SMILES matches a molecule in the history or the rationale suggests modification (e.g., \"repositioning,\" \"replacing,\" \"evaluated\"):\n         - Search the history chronologically for a molecule with the same SMILES.\n         - Retrieve the moleculeId of the matching molecule from the history\u2014this is the parent_molecule_id.\n         - Set properties.parent_molecule_id to this ID and properties.status: \"modified\".\n     - **Handle Modifications:**\n       - If the SMILES differs slightly from a historical molecule but the rationale indicates it's a modification (e.g., \"fluorine replaced with chlorine\"), find the closest matching parent SMILES in the history and use its Molecule ID as parent_molecule_id.\n     - **Reusing Unchanged Molecules:**\n       - When the agent explicitly references a molecule by `moleculeId` and there is no indication of a structural change, carry that `moleculeId` forward in the output and omit a new structure. This prevents creation of duplicate molecule entries for the same SMILES.\n     - **Populate Fields:**\n       - Set structure.smiles to the molecule's SMILES.\n       - Include a properties object for EVERY molecule, with status and, if derived, parent_molecule_id.\n       - Add any calculated properties (e.g., docking score, logP, pChEMBL, qed, sas) to computed_properties.\n       - Set rationale to the molecule-specific reasoning from the agent.\n       - If there is any relevant file path in the previous agent's response, for example to a pdb folder, include this in the rationale as well\n\n4. **Format the JSON:**\n   - Structure the output with transformation and molecules at the top level.\n\n5. **Validate:**\n   - Verify that derived molecules have a parent_molecule_id matching a historical molecule_id; if unclear, note in rationale (e.g., \"Parent unclear due to missing history match\").\n\n6. **Output:**\n   - Wrap the JSON in `<gurnemanz>` tags.\n\n### Example: Agent Output Format and Parsing\nThe history will look like this:\n```\n## Transformation\n- Type: data-retrieval\n- Agent: Ai expert\n- Iteration: 1\n- ID: ceb63937-5bd9-48b3-9ac6-ccc443944e4c\n- Rationale: Generated de novo molecules for AKT1\n\n## Molecules\n\n### Molecule 1\n- ID: 4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88\n- SMILES: COc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F\n- Properties:\n  * Status: de novo\n- Computed Properties:\n  * logP: 3.7169\n  * pChEMBL: 8.3\n  * qed: 0.285355\n  * sas: 3.507\n- Rationale: De novo compound for AKT1 with high potency (pChEMBL 8.3).\n```\n\nThe previous agents response you receive as input:\n```json\nMedcicinal chemist: I've edited the de novo molecule of the ai expert in this way\nCOc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F(=c3ccncc3)\nrationale: improved binding\n```\n\nExpected Output:\n```\n<gurnemanz>\n{\n  \"transformation\": {\n    \"type\": \"lead-optimization\",\n    \"agent\": \"Medicinal Chemist\",\n    \"user_message\": \"improved molecule binding\",\n    \"rationale\": \"edited molecule for improved binding\",\n    \"protein_sequence\": \"MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYFEYLKLDYLHSEIRFPHFPQFSYSASGTA\" # Include if a protein sequence is mentioned in the agent output\n    \"protein_path\": \"/path/to/protein.pdb\",  # Include only if a protein path is mentioned in the agent output\n    \"iteration\": 2\n  },\n  \"molecules\": [\n    {\n      \"structure\": {\n        \"smiles\": \"COc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F(=c3ccncc3)\"\n      },\n      \"properties\": {\n        \"parent_molecule_id\": \"4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88\",\n        \"status\": \"modified\"\n      },\n      \"computed_properties\": {},\n      \"rationale\": \"Fluorine at 4-position of pyridine is synthetically accessible but may present regioselectivity challenges\"\n    }\n  ]\n}\n</gurnemanz>\n```\n\n### IMPORTANT REQUIREMENTS\n1. **Every molecule MUST have a properties object** with at minimum a status field.\n2. **Derived molecules MUST include parent_molecule_id** in the properties object.\n3. **SMILES matching is critical** - When a molecule with the same SMILES appears in a new step, it's derived, not de novo.\n4. **Look through the entire history** to find matching molecules and their molecule_ids.\n5. **Look for ID fields in the text output** - When you see patterns like \"ID: 4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88\" in the agent output, this may be a molecule ID that becomes the parent_molecule_id for derived molecules.\n6. **If an agent outputs a file path to a protein PDB file** add this path in the \"protein_path\" field in the transformation object. Look for paths containing \".pdb\" extensions or mentions of protein structure files. For example, if the agent says \"I used /path/to/protein.pdb for docking\", extract \"/path/to/protein.pdb\" as the protein_path.\nVERY IMPORTANT NOTE FOR LITERATURE AGENT PARSING: Including ALL important details provided by the literature agent in the transformations rationale field!!!!! the other agents RELY on this information! do NOT summarize the response and omit key information. all relevant output of the literature HAS TO GO INTO THE RATIONALE. Also double check if there might be protein sequences or smiles in the response to add them in the appropriate fields.\n\nIteration Number:\n1\nAgent Title:\nLLM Drug Designer\n"
      }
    ]
  },
  {
    "role": "assistant",
    "content": "I'll parse the output from the LLM Drug Designer and format it into the GURNEMANZ JSON schema.",
    "tool_calls": [
      {
        "index": 1,
        "function": {
          "arguments": "{\"client_name\": \"claude\", \"session_id\": \"new_session\", \"parent_transformation_id\": \"new_transformation\", \"transformation\": {\"type\": \"molecule-generation\", \"agent\": \"LLM Drug Designer\", \"iteration\": 1, \"rationale\": \"Initial discovery of novel AKT1 inhibitors using medicinal chemistry principles. The design strategy focused on creating diverse molecules with appropriate hinge-binding motifs (aminopyrimidines, imidazoles, triazoles, quinazolines, oxadiazoles), different binding modes (ATP-competitive, Type II, allosteric), and drug-like properties. Molecules were designed with solubilizing groups, features for metabolic stability, and appropriate spatial arrangements to target AKT1.\"}, \"molecules\": [{\"structure\": {\"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5\"}, \"rationale\": \"ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions.\", \"friendly_id\": \"AI:I1:N1:G0\"}, {\"structure\": {\"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N\"}, \"rationale\": \"Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors.\", \"friendly_id\": \"AI:I1:N2:G0\"}, {\"structure\": {\"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5\"}, \"rationale\": \"ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites.\", \"friendly_id\": \"AI:I1:N3:G0\"}, {\"structure\": {\"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5\"}, \"rationale\": \"ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements.\", \"friendly_id\": \"AI:I1:N4:G0\"}, {\"structure\": {\"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\"}, \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\", \"friendly_id\": \"AI:I1:N5:G0\"}, {\"structure\": {\"smiles\": \"COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\"}, \"rationale\": \"ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties.\", \"friendly_id\": \"AI:I1:N6:G0\"}, {\"structure\": {\"smiles\": \"CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5\"}, \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile.\", \"friendly_id\": \"AI:I1:N7:G0\"}, {\"structure\": {\"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5\"}, \"rationale\": \"ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\", \"friendly_id\": \"AI:I1:N8:G0\"}, {\"structure\": {\"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC\"}, \"rationale\": \"Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties.\", \"friendly_id\": \"AI:I1:N9:G0\"}, {\"structure\": {\"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5\"}, \"rationale\": \"ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\", \"friendly_id\": \"AI:I1:N10:G0\"}, {\"structure\": {\"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4\"}, \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties.\", \"friendly_id\": \"AI:I1:N11:G0\"}, {\"structure\": {\"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5\"}, \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\", \"friendly_id\": \"AI:I1:N12:G0\"}, {\"structure\": {\"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C\"}, \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\", \"friendly_id\": \"AI:I1:N13:G0\"}, {\"structure\": {\"smiles\": \"CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5\"}, \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\", \"friendly_id\": \"AI:I1:N14:G0\"}, {\"structure\": {\"smiles\": \"COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5\"}, \"rationale\": \"ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties.\", \"friendly_id\": \"AI:I1:N15:G0\"}]}",
          "name": "gurnemanz_apply"
        },
        "id": "toolu_01Ni6fzUvJiVwSkMwyhMM43u",
        "type": "function"
      }
    ]
  },
  {
    "role": "tool",
    "tool_call_id": "toolu_01Ni6fzUvJiVwSkMwyhMM43u",
    "content": "{\"molecules\": [{\"moleculeId\": \"b329766b-1514-4892-8857-c7fb8b327d00\", \"originalData\": {\"friendlyId\": \"AI:I1:N1:G0\", \"rationale\": \"ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions.\", \"structure\": {\"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5\"}}}, {\"moleculeId\": \"ce2bfe29-e881-4088-98b6-944ac9b2acc5\", \"originalData\": {\"friendlyId\": \"AI:I1:N2:G0\", \"rationale\": \"Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors.\", \"structure\": {\"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N\"}}}, {\"moleculeId\": \"0a247f24-bf43-4ac7-9968-66a6cfdaead2\", \"originalData\": {\"friendlyId\": \"AI:I1:N3:G0\", \"rationale\": \"ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites.\", \"structure\": {\"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5\"}}}, {\"moleculeId\": \"445f06ec-4f65-4f73-b591-80a743d30253\", \"originalData\": {\"friendlyId\": \"AI:I1:N4:G0\", \"rationale\": \"ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements.\", \"structure\": {\"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5\"}}}, {\"moleculeId\": \"1d0ef981-9b6e-4f41-94b3-8baa5d293a04\", \"originalData\": {\"friendlyId\": \"AI:I1:N5:G0\", \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\", \"structure\": {\"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\"}}}, {\"moleculeId\": \"45fd2f5d-9dd7-4fb6-a8a8-eed1c9026fd5\", \"originalData\": {\"friendlyId\": \"AI:I1:N6:G0\", \"rationale\": \"ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties.\", \"structure\": {\"smiles\": \"COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\"}}}, {\"moleculeId\": \"9c830861-8538-44a5-9405-3d6a5f305cd9\", \"originalData\": {\"friendlyId\": \"AI:I1:N7:G0\", \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile.\", \"structure\": {\"smiles\": \"CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5\"}}}, {\"moleculeId\": \"a9a94ab4-ea7b-4bb6-aeed-b72c86d2b871\", \"originalData\": {\"friendlyId\": \"AI:I1:N8:G0\", \"rationale\": \"ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\", \"structure\": {\"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5\"}}}, {\"moleculeId\": \"f0b722f8-1047-41bb-88fa-a6703077fab9\", \"originalData\": {\"friendlyId\": \"AI:I1:N9:G0\", \"rationale\": \"Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties.\", \"structure\": {\"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC\"}}}, {\"moleculeId\": \"b369e19d-d1e1-4ad4-8f9d-04ae1aa995ba\", \"originalData\": {\"friendlyId\": \"AI:I1:N10:G0\", \"rationale\": \"ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\", \"structure\": {\"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5\"}}}, {\"moleculeId\": \"222e9f93-32aa-43eb-b2fc-907df11e53f5\", \"originalData\": {\"friendlyId\": \"AI:I1:N11:G0\", \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties.\", \"structure\": {\"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4\"}}}, {\"moleculeId\": \"57c5025c-eb31-433b-8feb-64c42f969c26\", \"originalData\": {\"friendlyId\": \"AI:I1:N12:G0\", \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\", \"structure\": {\"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5\"}}}, {\"moleculeId\": \"40ce17c4-883e-498e-92e3-8480547613c6\", \"originalData\": {\"friendlyId\": \"AI:I1:N13:G0\", \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\", \"structure\": {\"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C\"}}}, {\"moleculeId\": \"c705733d-084c-4282-8d91-89e4c2628b5e\", \"originalData\": {\"friendlyId\": \"AI:I1:N14:G0\", \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\", \"structure\": {\"smiles\": \"CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5\"}}}, {\"moleculeId\": \"59b30bac-8a73-4f2b-ad4e-e8c78a4ab267\", \"originalData\": {\"friendlyId\": \"AI:I1:N15:G0\", \"rationale\": \"ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties.\", \"structure\": {\"smiles\": \"COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5\"}}}], \"transformation\": {\"agent\": \"LLM Drug Designer\", \"iteration\": 1, \"methodDetails\": null, \"proteinPath\": null, \"proteinSequence\": null, \"rationale\": \"Initial discovery of novel AKT1 inhibitors using medicinal chemistry principles. The design strategy focused on creating diverse molecules with appropriate hinge-binding motifs (aminopyrimidines, imidazoles, triazoles, quinazolines, oxadiazoles), different binding modes (ATP-competitive, Type II, allosteric), and drug-like properties. Molecules were designed with solubilizing groups, features for metabolic stability, and appropriate spatial arrangements to target AKT1.\", \"transformationId\": \"12418556-f9fc-4a9d-b018-16a82a025d94\", \"type\": \"molecule-generation\", \"userMessage\": null}}"
  }
]
2025-06-23 14:02:54,000 - INFO - response ModelResponse(id='chatcmpl-c4f37a0c-192e-4f9c-b4d6-34944f1fb650', created=1750676573, model='claude-3-7-sonnet-20250219', object='chat.completion', system_fingerprint=None, choices=[Choices(finish_reason='stop', index=0, message=Message(content="I've successfully parsed the output from the LLM Drug Designer and formatted it into the GURNEMANZ JSON schema. The transformation has been recorded with the following details:\n\n- **Transformation Type**: molecule-generation\n- **Agent**: LLM Drug Designer\n- **Iteration**: 1\n- **Transformation ID**: 12418556-f9fc-4a9d-b018-16a82a025d94\n\nThe transformation includes a comprehensive rationale that captures the design strategy used by the LLM Drug Designer, focusing on:\n- Creating diverse molecules with appropriate hinge-binding motifs\n- Implementing different binding modes (ATP-competitive, Type II, allosteric)\n- Ensuring drug-like properties with appropriate solubilizing groups and features for metabolic stability\n\nAll 15 molecules have been successfully processed with their:\n- SMILES structures\n- Detailed rationales explaining the design strategy for each molecule\n- Friendly IDs (e.g., AI:I1:N1:G0) that track their position in the research process\n\nEach molecule has been assigned a unique molecule ID in the GURNEMANZ system, which will be used to track their lineage through future optimization steps.", role='assistant', tool_calls=None, function_call=None, provider_specific_fields={'citations': []}, citations=[]))], usage=Usage(completion_tokens=270, prompt_tokens=15415, total_tokens=15685, completion_tokens_details=None, prompt_tokens_details=PromptTokensDetailsWrapper(audio_tokens=None, cached_tokens=0, text_tokens=None, image_tokens=None), cache_creation_input_tokens=0, cache_read_input_tokens=0))
2025-06-23 14:02:54,002 - INFO - history_with_tools [{'role': 'user', 'content': "You are an expert medicinal chemist and computational drug discovery scientist. Your task is to design novel small molecule inhibitors for AKT1 (Protein Kinase B alpha) using your knowledge of structure-activity relationships, medicinal chemistry principles, and drug design.\n\n**Target Information:**\n- AKT1 is a serine/threonine kinase in the PI3K/AKT/mTOR pathway\n- Critical for cell survival, proliferation, and metabolism\n- Key oncology target with multiple known inhibitors\n- ATP-competitive and allosteric binding sites available\n\n**Your Goal:**\nGenerate novel, drug-like small molecule AKT1 inhibitors with the following criteria:\n- High predicted binding affinity to AKT1\n- Drug-like properties (Lipinski's Rule of Five compliance)\n- Synthetic accessibility\n- Novel scaffolds not directly copied from known inhibitors\n\n**Output Format:**\nFor each molecule, provide:\n1. **Molecule ID**: A unique identifier (e.g., LLM_MOL_001)\n2. **SMILES**: Valid SMILES string\n3. **Rationale**: Brief explanation of your design strategy and expected properties\n4. **Predicted Properties**: Your assessment of drug-likeness, potency, selectivity\n\nFocus on innovative chemical designs while maintaining scientific rigor."}, {'role': 'user', 'content': [{'type': 'text', 'text': '**ITERATION 1: Initial Discovery & Exploration**\n\nDesign 10-15 novel AKT1 inhibitor molecules using your medicinal chemistry expertise. Consider:\n\n1. **ATP-competitive inhibitors**: Target the ATP-binding pocket with novel scaffolds\n2. **Allosteric inhibitors**: Design molecules that bind to regulatory sites\n3. **Hybrid approaches**: Molecules that may interact with multiple binding sites\n\nUse your knowledge of:\n- Known AKT1 pharmacophores (avoid direct copying)\n- Kinase selectivity determinants\n- Drug-like chemical space\n- Structure-activity relationships\n\nGenerate diverse scaffolds including heterocycles, aromatic systems, and appropriate linkers. Ensure synthetic feasibility while prioritizing novelty.'}]}, {'role': 'assistant', 'content': [{'type': 'text', 'text': '# AKT1 Inhibitor Design - Initial Discovery\n\nI\'ll design novel AKT1 inhibitors using medicinal chemistry principles and my knowledge of kinase inhibitor design. I\'ll focus on creating diverse, drug-like molecules with appropriate pharmacophores for AKT1 inhibition.\n\n<molecules>\n{\n    "molecules": [\n        {\n            "smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5",\n            "friendly_id": "AI:I1:N1:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N",\n            "friendly_id": "AI:I1:N2:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors."\n        },\n        {\n            "smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5",\n            "friendly_id": "AI:I1:N3:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5",\n            "friendly_id": "AI:I1:N4:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements."\n        },\n        {\n            "smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N",\n            "friendly_id": "AI:I1:N5:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode."\n        },\n        {\n            "smiles": "COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F",\n            "friendly_id": "AI:I1:N6:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties."\n        },\n        {\n            "smiles": "CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5",\n            "friendly_id": "AI:I1:N7:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5",\n            "friendly_id": "AI:I1:N8:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases."\n        },\n        {\n            "smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC",\n            "friendly_id": "AI:I1:N9:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5",\n            "friendly_id": "AI:I1:N10:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile."\n        },\n        {\n            "smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4",\n            "friendly_id": "AI:I1:N11:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties."\n        },\n        {\n            "smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5",\n            "friendly_id": "AI:I1:N12:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode."\n        },\n        {\n            "smiles": "CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C",\n            "friendly_id": "AI:I1:N13:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases."\n        },\n        {\n            "smiles": "CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5",\n            "friendly_id": "AI:I1:N14:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile."\n        },\n        {\n            "smiles": "COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5",\n            "friendly_id": "AI:I1:N15:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties."\n        }\n    ]\n}\n</molecules>\n\n## Design Strategy Overview\n\nMy approach to designing these AKT1 inhibitors focused on several key medicinal chemistry principles:\n\n### 1. Hinge-Binding Motifs\n- Incorporated established kinase hinge-binding pharmacophores including:\n  - Aminopyrimidines (molecules 1, 2, 11, 14)\n  - Imidazoles (molecule 4)\n  - Triazoles (molecule 6)\n  - Quinazolines (molecule 15)\n  - Oxadiazoles (molecules 3, 7, 13)\n\n### 2. Binding Modes\n- **ATP-competitive inhibitors** (majority of designs): Target the ATP-binding pocket with appropriate hinge-binding elements\n- **Type II inhibitors** (molecules 2, 9): Include urea linkers to stabilize the DFG-out conformation\n- **Allosteric inhibitors** (molecules 5, 12): Target the PH domain-kinase domain interface\n\n### 3. Structural Features\n- **Solubilizing groups**: Incorporated piperazines, morpholines, and tertiary amines\n- **Metabolic stability**: Used fluorine substitutions, oxadiazoles, and methoxy groups\n- **Rigidity and spatial arrangement**: Employed amide linkers, ureas, and conformationally constrained cores\n\n### 4. Drug-Like Properties\n- Designed molecules with:\n  - MW generally between 420-550 Da\n  - LogP values in the 2.5-4 range\n  - Appropriate H-bond donors/acceptors (Lipinski compliant)\n  - Balanced solubility and permeability characteristics\n\nThese designs represent a diverse set of potential AKT1 inhibitors with varied scaffolds, binding modes, and physicochemical properties, providing a strong foundation for further optimization.'}]}, {'role': 'user', 'content': [{'type': 'text', 'text': '\nYou are the Summary Parser Agent. Your task is to read the output from the previous agent, extract relevant information, and format it into a JSON object that conforms to the GURNEMANZ JSON spec. A critical part of your role is to track molecule history by checking previous steps in the history to include the `parent_molecule_id` for derived molecules, ensuring GURNEMANZ maintains the molecule transformation chain.\nDO NOT FORGET TO INCLUDE THE friendly_id IN THE JSON OUTPUT and parent_friendly_id if the molecule is a child of a parent molecule !.\n### Input\n- The full output from the previous agent in plain text format. (IMPORTANT NOTE: all important details of research in the output of Literature Agent has to be stored in the transformation rationale field)\n- The history, a list of previous steps, each containing a transformation and possibly molecules with assigned moleculeIds.\n- The current iteration number\n- The agent title: "LLM Drug Designer" - You MUST use this exact title as the agent name in your output\n\n### Output\n- A JSON object with transformation and molecules, wrapped in `<gurnemanz>` tags (e.g., `<gurnemanz>{ "transformation": { ... }, "molecules": [ ... ] }</gurnemanz>`).\n\n### Steps to Follow\n1. **Analyze the Input:**\n   - Extract the transformation type, agent name, general rationale, molecule data (SMILES, specific rationales), and any protein-related data (like protein_sequence and protein_path) from the previous agent\'s output.\n   - Parse information from headers, bullet points, and descriptive text in the agent\'s response.\n\n2. **Determine Transformation Details:**\n   - Set "iteration" to the provided iteration number.\n   - Set type based on the agent\'s action (e.g., "molecule-generation" for new designs, "property-prediction" for evaluations or calculations).\n   - Set agent to the name of the previous agent (e.g., "Medicinal Chemist").\n   - Summarize the general rationale from the agent\'s intent or summary.\n   - Look for mentions of protein sequences in the text. If the agent mentions or provides a protein sequence ,or just sequence, include this sequence in the "protein_sequence" field of the transformation object.\n   - Look for mentions of protein PDB files in the text. If the agent mentions or provides a path to a protein PDB file, include this path in the "protein_path" field of the transformation object.\n\n3. **Process Molecules and Track History:**\n   - For each molecule in the agent\'s output:\n     - Look for patterns like "Molecule X", "ID:", "SMILES:", etc., to identify molecules and their properties.\n     - **Check if it\'s De novo or Derived:**\n       - **De novo Molecule:** If the SMILES does not appear in the history and there\'s no indication of modification (e.g., "de novo" or "designed from scratch"), set properties.status: "de novo" and omit properties.parent_molecule_id.\n       - **Derived Molecule:** If the SMILES matches a molecule in the history or the rationale suggests modification (e.g., "repositioning," "replacing," "evaluated"):\n         - Search the history chronologically for a molecule with the same SMILES.\n         - Retrieve the moleculeId of the matching molecule from the history—this is the parent_molecule_id.\n         - Set properties.parent_molecule_id to this ID and properties.status: "modified".\n     - **Handle Modifications:**\n       - If the SMILES differs slightly from a historical molecule but the rationale indicates it\'s a modification (e.g., "fluorine replaced with chlorine"), find the closest matching parent SMILES in the history and use its Molecule ID as parent_molecule_id.\n     - **Reusing Unchanged Molecules:**\n       - When the agent explicitly references a molecule by `moleculeId` and there is no indication of a structural change, carry that `moleculeId` forward in the output and omit a new structure. This prevents creation of duplicate molecule entries for the same SMILES.\n     - **Populate Fields:**\n       - Set structure.smiles to the molecule\'s SMILES.\n       - Include a properties object for EVERY molecule, with status and, if derived, parent_molecule_id.\n       - Add any calculated properties (e.g., docking score, logP, pChEMBL, qed, sas) to computed_properties.\n       - Set rationale to the molecule-specific reasoning from the agent.\n       - If there is any relevant file path in the previous agent\'s response, for example to a pdb folder, include this in the rationale as well\n\n4. **Format the JSON:**\n   - Structure the output with transformation and molecules at the top level.\n\n5. **Validate:**\n   - Verify that derived molecules have a parent_molecule_id matching a historical molecule_id; if unclear, note in rationale (e.g., "Parent unclear due to missing history match").\n\n6. **Output:**\n   - Wrap the JSON in `<gurnemanz>` tags.\n\n### Example: Agent Output Format and Parsing\nThe history will look like this:\n```\n## Transformation\n- Type: data-retrieval\n- Agent: Ai expert\n- Iteration: 1\n- ID: ceb63937-5bd9-48b3-9ac6-ccc443944e4c\n- Rationale: Generated de novo molecules for AKT1\n\n## Molecules\n\n### Molecule 1\n- ID: 4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88\n- SMILES: COc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F\n- Properties:\n  * Status: de novo\n- Computed Properties:\n  * logP: 3.7169\n  * pChEMBL: 8.3\n  * qed: 0.285355\n  * sas: 3.507\n- Rationale: De novo compound for AKT1 with high potency (pChEMBL 8.3).\n```\n\nThe previous agents response you receive as input:\n```json\nMedcicinal chemist: I\'ve edited the de novo molecule of the ai expert in this way\nCOc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F(=c3ccncc3)\nrationale: improved binding\n```\n\nExpected Output:\n```\n<gurnemanz>\n{\n  "transformation": {\n    "type": "lead-optimization",\n    "agent": "Medicinal Chemist",\n    "user_message": "improved molecule binding",\n    "rationale": "edited molecule for improved binding",\n    "protein_sequence": "MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYFEYLKLDYLHSEIRFPHFPQFSYSASGTA" # Include if a protein sequence is mentioned in the agent output\n    "protein_path": "/path/to/protein.pdb",  # Include only if a protein path is mentioned in the agent output\n    "iteration": 2\n  },\n  "molecules": [\n    {\n      "structure": {\n        "smiles": "COc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F(=c3ccncc3)"\n      },\n      "properties": {\n        "parent_molecule_id": "4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88",\n        "status": "modified"\n      },\n      "computed_properties": {},\n      "rationale": "Fluorine at 4-position of pyridine is synthetically accessible but may present regioselectivity challenges"\n    }\n  ]\n}\n</gurnemanz>\n```\n\n### IMPORTANT REQUIREMENTS\n1. **Every molecule MUST have a properties object** with at minimum a status field.\n2. **Derived molecules MUST include parent_molecule_id** in the properties object.\n3. **SMILES matching is critical** - When a molecule with the same SMILES appears in a new step, it\'s derived, not de novo.\n4. **Look through the entire history** to find matching molecules and their molecule_ids.\n5. **Look for ID fields in the text output** - When you see patterns like "ID: 4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88" in the agent output, this may be a molecule ID that becomes the parent_molecule_id for derived molecules.\n6. **If an agent outputs a file path to a protein PDB file** add this path in the "protein_path" field in the transformation object. Look for paths containing ".pdb" extensions or mentions of protein structure files. For example, if the agent says "I used /path/to/protein.pdb for docking", extract "/path/to/protein.pdb" as the protein_path.\nVERY IMPORTANT NOTE FOR LITERATURE AGENT PARSING: Including ALL important details provided by the literature agent in the transformations rationale field!!!!! the other agents RELY on this information! do NOT summarize the response and omit key information. all relevant output of the literature HAS TO GO INTO THE RATIONALE. Also double check if there might be protein sequences or smiles in the response to add them in the appropriate fields.\n\nIteration Number:\n1\nAgent Title:\nLLM Drug Designer\n'}]}, {'role': 'assistant', 'content': "I'll parse the output from the LLM Drug Designer and format it into the GURNEMANZ JSON schema.", 'tool_calls': [{'index': 1, 'function': {'arguments': '{"client_name": "claude", "session_id": "new_session", "parent_transformation_id": "new_transformation", "transformation": {"type": "molecule-generation", "agent": "LLM Drug Designer", "iteration": 1, "rationale": "Initial discovery of novel AKT1 inhibitors using medicinal chemistry principles. The design strategy focused on creating diverse molecules with appropriate hinge-binding motifs (aminopyrimidines, imidazoles, triazoles, quinazolines, oxadiazoles), different binding modes (ATP-competitive, Type II, allosteric), and drug-like properties. Molecules were designed with solubilizing groups, features for metabolic stability, and appropriate spatial arrangements to target AKT1."}, "molecules": [{"structure": {"smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5"}, "rationale": "ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions.", "friendly_id": "AI:I1:N1:G0"}, {"structure": {"smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N"}, "rationale": "Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors.", "friendly_id": "AI:I1:N2:G0"}, {"structure": {"smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5"}, "rationale": "ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites.", "friendly_id": "AI:I1:N3:G0"}, {"structure": {"smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5"}, "rationale": "ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements.", "friendly_id": "AI:I1:N4:G0"}, {"structure": {"smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N"}, "rationale": "Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.", "friendly_id": "AI:I1:N5:G0"}, {"structure": {"smiles": "COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F"}, "rationale": "ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties.", "friendly_id": "AI:I1:N6:G0"}, {"structure": {"smiles": "CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5"}, "rationale": "ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile.", "friendly_id": "AI:I1:N7:G0"}, {"structure": {"smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5"}, "rationale": "ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.", "friendly_id": "AI:I1:N8:G0"}, {"structure": {"smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC"}, "rationale": "Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties.", "friendly_id": "AI:I1:N9:G0"}, {"structure": {"smiles": "COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5"}, "rationale": "ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.", "friendly_id": "AI:I1:N10:G0"}, {"structure": {"smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4"}, "rationale": "ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties.", "friendly_id": "AI:I1:N11:G0"}, {"structure": {"smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5"}, "rationale": "Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.", "friendly_id": "AI:I1:N12:G0"}, {"structure": {"smiles": "CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C"}, "rationale": "ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.", "friendly_id": "AI:I1:N13:G0"}, {"structure": {"smiles": "CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5"}, "rationale": "ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.", "friendly_id": "AI:I1:N14:G0"}, {"structure": {"smiles": "COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5"}, "rationale": "ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties.", "friendly_id": "AI:I1:N15:G0"}]}', 'name': 'gurnemanz_apply'}, 'id': 'toolu_01Ni6fzUvJiVwSkMwyhMM43u', 'type': 'function'}]}, {'role': 'tool', 'tool_call_id': 'toolu_01Ni6fzUvJiVwSkMwyhMM43u', 'content': '{"molecules": [{"moleculeId": "b329766b-1514-4892-8857-c7fb8b327d00", "originalData": {"friendlyId": "AI:I1:N1:G0", "rationale": "ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions.", "structure": {"smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5"}}}, {"moleculeId": "ce2bfe29-e881-4088-98b6-944ac9b2acc5", "originalData": {"friendlyId": "AI:I1:N2:G0", "rationale": "Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors.", "structure": {"smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N"}}}, {"moleculeId": "0a247f24-bf43-4ac7-9968-66a6cfdaead2", "originalData": {"friendlyId": "AI:I1:N3:G0", "rationale": "ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites.", "structure": {"smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5"}}}, {"moleculeId": "445f06ec-4f65-4f73-b591-80a743d30253", "originalData": {"friendlyId": "AI:I1:N4:G0", "rationale": "ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements.", "structure": {"smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5"}}}, {"moleculeId": "1d0ef981-9b6e-4f41-94b3-8baa5d293a04", "originalData": {"friendlyId": "AI:I1:N5:G0", "rationale": "Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.", "structure": {"smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N"}}}, {"moleculeId": "45fd2f5d-9dd7-4fb6-a8a8-eed1c9026fd5", "originalData": {"friendlyId": "AI:I1:N6:G0", "rationale": "ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties.", "structure": {"smiles": "COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F"}}}, {"moleculeId": "9c830861-8538-44a5-9405-3d6a5f305cd9", "originalData": {"friendlyId": "AI:I1:N7:G0", "rationale": "ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile.", "structure": {"smiles": "CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5"}}}, {"moleculeId": "a9a94ab4-ea7b-4bb6-aeed-b72c86d2b871", "originalData": {"friendlyId": "AI:I1:N8:G0", "rationale": "ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.", "structure": {"smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5"}}}, {"moleculeId": "f0b722f8-1047-41bb-88fa-a6703077fab9", "originalData": {"friendlyId": "AI:I1:N9:G0", "rationale": "Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties.", "structure": {"smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC"}}}, {"moleculeId": "b369e19d-d1e1-4ad4-8f9d-04ae1aa995ba", "originalData": {"friendlyId": "AI:I1:N10:G0", "rationale": "ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.", "structure": {"smiles": "COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5"}}}, {"moleculeId": "222e9f93-32aa-43eb-b2fc-907df11e53f5", "originalData": {"friendlyId": "AI:I1:N11:G0", "rationale": "ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties.", "structure": {"smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4"}}}, {"moleculeId": "57c5025c-eb31-433b-8feb-64c42f969c26", "originalData": {"friendlyId": "AI:I1:N12:G0", "rationale": "Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.", "structure": {"smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5"}}}, {"moleculeId": "40ce17c4-883e-498e-92e3-8480547613c6", "originalData": {"friendlyId": "AI:I1:N13:G0", "rationale": "ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.", "structure": {"smiles": "CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C"}}}, {"moleculeId": "c705733d-084c-4282-8d91-89e4c2628b5e", "originalData": {"friendlyId": "AI:I1:N14:G0", "rationale": "ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.", "structure": {"smiles": "CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5"}}}, {"moleculeId": "59b30bac-8a73-4f2b-ad4e-e8c78a4ab267", "originalData": {"friendlyId": "AI:I1:N15:G0", "rationale": "ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties.", "structure": {"smiles": "COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5"}}}], "transformation": {"agent": "LLM Drug Designer", "iteration": 1, "methodDetails": null, "proteinPath": null, "proteinSequence": null, "rationale": "Initial discovery of novel AKT1 inhibitors using medicinal chemistry principles. The design strategy focused on creating diverse molecules with appropriate hinge-binding motifs (aminopyrimidines, imidazoles, triazoles, quinazolines, oxadiazoles), different binding modes (ATP-competitive, Type II, allosteric), and drug-like properties. Molecules were designed with solubilizing groups, features for metabolic stability, and appropriate spatial arrangements to target AKT1.", "transformationId": "12418556-f9fc-4a9d-b018-16a82a025d94", "type": "molecule-generation", "userMessage": null}}'}, {'role': 'assistant', 'content': "I've successfully parsed the output from the LLM Drug Designer and formatted it into the GURNEMANZ JSON schema. The transformation has been recorded with the following details:\n\n- **Transformation Type**: molecule-generation\n- **Agent**: LLM Drug Designer\n- **Iteration**: 1\n- **Transformation ID**: 12418556-f9fc-4a9d-b018-16a82a025d94\n\nThe transformation includes a comprehensive rationale that captures the design strategy used by the LLM Drug Designer, focusing on:\n- Creating diverse molecules with appropriate hinge-binding motifs\n- Implementing different binding modes (ATP-competitive, Type II, allosteric)\n- Ensuring drug-like properties with appropriate solubilizing groups and features for metabolic stability\n\nAll 15 molecules have been successfully processed with their:\n- SMILES structures\n- Detailed rationales explaining the design strategy for each molecule\n- Friendly IDs (e.g., AI:I1:N1:G0) that track their position in the research process\n\nEach molecule has been assigned a unique molecule ID in the GURNEMANZ system, which will be used to track their lineage through future optimization steps."}]
2025-06-23 14:02:54,003 - INFO - main_history after parser: [
  {
    "role": "user",
    "content": "You are an expert medicinal chemist and computational drug discovery scientist. Your task is to design novel small molecule inhibitors for AKT1 (Protein Kinase B alpha) using your knowledge of structure-activity relationships, medicinal chemistry principles, and drug design.\n\n**Target Information:**\n- AKT1 is a serine/threonine kinase in the PI3K/AKT/mTOR pathway\n- Critical for cell survival, proliferation, and metabolism\n- Key oncology target with multiple known inhibitors\n- ATP-competitive and allosteric binding sites available\n\n**Your Goal:**\nGenerate novel, drug-like small molecule AKT1 inhibitors with the following criteria:\n- High predicted binding affinity to AKT1\n- Drug-like properties (Lipinski's Rule of Five compliance)\n- Synthetic accessibility\n- Novel scaffolds not directly copied from known inhibitors\n\n**Output Format:**\nFor each molecule, provide:\n1. **Molecule ID**: A unique identifier (e.g., LLM_MOL_001)\n2. **SMILES**: Valid SMILES string\n3. **Rationale**: Brief explanation of your design strategy and expected properties\n4. **Predicted Properties**: Your assessment of drug-likeness, potency, selectivity\n\nFocus on innovative chemical designs while maintaining scientific rigor."
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 1: Initial Discovery & Exploration**\n\nDesign 10-15 novel AKT1 inhibitor molecules using your medicinal chemistry expertise. Consider:\n\n1. **ATP-competitive inhibitors**: Target the ATP-binding pocket with novel scaffolds\n2. **Allosteric inhibitors**: Design molecules that bind to regulatory sites\n3. **Hybrid approaches**: Molecules that may interact with multiple binding sites\n\nUse your knowledge of:\n- Known AKT1 pharmacophores (avoid direct copying)\n- Kinase selectivity determinants\n- Drug-like chemical space\n- Structure-activity relationships\n\nGenerate diverse scaffolds including heterocycles, aromatic systems, and appropriate linkers. Ensure synthetic feasibility while prioritizing novelty."
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Initial Discovery\n\nI'll design novel AKT1 inhibitors using medicinal chemistry principles and my knowledge of kinase inhibitor design. I'll focus on creating diverse, drug-like molecules with appropriate pharmacophores for AKT1 inhibition.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N1:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I1:N2:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N3:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N4:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I1:N5:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I1:N6:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N7:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N8:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC\",\n            \"friendly_id\": \"AI:I1:N9:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5\",\n            \"friendly_id\": \"AI:I1:N10:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I1:N11:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5\",\n            \"friendly_id\": \"AI:I1:N12:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C\",\n            \"friendly_id\": \"AI:I1:N13:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5\",\n            \"friendly_id\": \"AI:I1:N14:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N15:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        }\n    ]\n}\n</molecules>\n\n## Design Strategy Overview\n\nMy approach to designing these AKT1 inhibitors focused on several key medicinal chemistry principles:\n\n### 1. Hinge-Binding Motifs\n- Incorporated established kinase hinge-binding pharmacophores including:\n  - Aminopyrimidines (molecules 1, 2, 11, 14)\n  - Imidazoles (molecule 4)\n  - Triazoles (molecule 6)\n  - Quinazolines (molecule 15)\n  - Oxadiazoles (molecules 3, 7, 13)\n\n### 2. Binding Modes\n- **ATP-competitive inhibitors** (majority of designs): Target the ATP-binding pocket with appropriate hinge-binding elements\n- **Type II inhibitors** (molecules 2, 9): Include urea linkers to stabilize the DFG-out conformation\n- **Allosteric inhibitors** (molecules 5, 12): Target the PH domain-kinase domain interface\n\n### 3. Structural Features\n- **Solubilizing groups**: Incorporated piperazines, morpholines, and tertiary amines\n- **Metabolic stability**: Used fluorine substitutions, oxadiazoles, and methoxy groups\n- **Rigidity and spatial arrangement**: Employed amide linkers, ureas, and conformationally constrained cores\n\n### 4. Drug-Like Properties\n- Designed molecules with:\n  - MW generally between 420-550 Da\n  - LogP values in the 2.5-4 range\n  - Appropriate H-bond donors/acceptors (Lipinski compliant)\n  - Balanced solubility and permeability characteristics\n\nThese designs represent a diverse set of potential AKT1 inhibitors with varied scaffolds, binding modes, and physicochemical properties, providing a strong foundation for further optimization."
      }
    ]
  }
]
2025-06-23 14:02:54,004 - INFO - Completed Iteration 1
2025-06-23 14:02:54,004 - INFO - --------------------------------
2025-06-23 14:02:54,004 - INFO - Starting Iteration 2
2025-06-23 14:02:54,004 - INFO - --------------------------------
2025-06-23 14:02:54,004 - INFO - LLM Agent: LLM Drug Designer
2025-06-23 14:02:54,004 - INFO - chat history for chat completion: [
  {
    "role": "system",
    "content": "You are an AI assistant acting as LLM Drug Designer. Your expertise is in ('Medicinal chemistry and drug design', 'Structure-activity relationships', 'Kinase inhibitor development', 'ADMET optimization', 'Computational drug discovery'). Your goal is to Design novel, drug-like small molecule AKT1 inhibitors using medicinal chemistry knowledge and computational drug design principles, without relying on external tools.. Your role is to Expert medicinal chemist responsible for generating innovative AKT1 inhibitor designs based on scientific knowledge, literature understanding, and drug design principles. Provide novel chemical structures with clear design rationales.. Please maintain this role throughout our conversation.\n\n\n        \"molecules\": [\n                {\n                    \"smiles\": \"SMILES_STRING\",\n                    \"friendly_id\": \"friendly id of molecule eg: DA:I1:N0:G0\",\n                    \"source\": \"(parent molecule id of modified molecule)\"\n                    \"agent\": \"AGENT_NAME\",\n                    \"rationale\": \"(rationale for the molecule)\"\n                }\n            ],\n        }\n        </molecules>\n        \nDruing the discovery process, molecules will be presented with a friendly_id. This friendly_id is a unique identifier that tracks its complete history and lineage through our optimization process to help to follow the SAR and parent-child relationships.\n\n## Molecule ID System - Tracking Molecular Evolution\n\nEach molecule receives a unique identifier that tracks its complete history and lineage through our optimization process.\n\n**Format:** `AgentCode:I<iteration>:N<position>:G<generation>`\n\nThis ID (friendly_id) system serves as a molecular genealogy, allowing us to:\n- Track which agent created or modified each molecule\n- Understand the evolutionary path from original to optimized compounds\n- Maintain parent-child relationships across modifications\n\n**Components:**\n- **AgentCode**: Two-letter code representing the creator agent\n  - DA = Database Agent\n  - AI = AI Expert\n  - MC = Medicinal Chemist\n  - LA = Literature Agent\n  - RA = Ranking Agent\n  - PR = Principal Researcher\n  - SC = Scientific Critic\n  - SP = Summary Parser\n\n- **I<iteration>**: The research iteration number when molecule was introduced (e.g., I1, I2, I3)\n- **N<position>**: The molecule's position in the agent's output list, starting from N1 (resets per agent output)\n- **G<generation>**: The modification depth showing molecular evolution\n  - G0 = original molecule (from database or de novo)\n  - G1 = first modification\n  - G2 = second modification\n  - And so on...\n\n**Example Evolution:**\n1. Database retrieves: `DA:I1:N3:G0` (original from ChEMBL, third molecule in list, iteration 1)\n2. Medicinal Chemist modifies it: `MC:I2:N1:G1` (first modification, first molecule in chemist's list, iteration 2)\n3. Further optimization: `MC:I3:N2:G2` (second modification, second molecule in list, iteration 3)\n\nThis allows us to trace any molecule back to its origins and understand its optimization journey.\nIf a molecule is a child of a parent molecule, the parent molecule's friendly_id must be included in the molecule's source field\n"
  },
  {
    "role": "user",
    "content": "You are an expert medicinal chemist and computational drug discovery scientist. Your task is to design novel small molecule inhibitors for AKT1 (Protein Kinase B alpha) using your knowledge of structure-activity relationships, medicinal chemistry principles, and drug design.\n\n**Target Information:**\n- AKT1 is a serine/threonine kinase in the PI3K/AKT/mTOR pathway\n- Critical for cell survival, proliferation, and metabolism\n- Key oncology target with multiple known inhibitors\n- ATP-competitive and allosteric binding sites available\n\n**Your Goal:**\nGenerate novel, drug-like small molecule AKT1 inhibitors with the following criteria:\n- High predicted binding affinity to AKT1\n- Drug-like properties (Lipinski's Rule of Five compliance)\n- Synthetic accessibility\n- Novel scaffolds not directly copied from known inhibitors\n\n**Output Format:**\nFor each molecule, provide:\n1. **Molecule ID**: A unique identifier (e.g., LLM_MOL_001)\n2. **SMILES**: Valid SMILES string\n3. **Rationale**: Brief explanation of your design strategy and expected properties\n4. **Predicted Properties**: Your assessment of drug-likeness, potency, selectivity\n\nFocus on innovative chemical designs while maintaining scientific rigor."
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 1: Initial Discovery & Exploration**\n\nDesign 10-15 novel AKT1 inhibitor molecules using your medicinal chemistry expertise. Consider:\n\n1. **ATP-competitive inhibitors**: Target the ATP-binding pocket with novel scaffolds\n2. **Allosteric inhibitors**: Design molecules that bind to regulatory sites\n3. **Hybrid approaches**: Molecules that may interact with multiple binding sites\n\nUse your knowledge of:\n- Known AKT1 pharmacophores (avoid direct copying)\n- Kinase selectivity determinants\n- Drug-like chemical space\n- Structure-activity relationships\n\nGenerate diverse scaffolds including heterocycles, aromatic systems, and appropriate linkers. Ensure synthetic feasibility while prioritizing novelty."
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Initial Discovery\n\nI'll design novel AKT1 inhibitors using medicinal chemistry principles and my knowledge of kinase inhibitor design. I'll focus on creating diverse, drug-like molecules with appropriate pharmacophores for AKT1 inhibition.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N1:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I1:N2:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N3:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N4:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I1:N5:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I1:N6:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N7:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N8:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC\",\n            \"friendly_id\": \"AI:I1:N9:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5\",\n            \"friendly_id\": \"AI:I1:N10:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I1:N11:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5\",\n            \"friendly_id\": \"AI:I1:N12:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C\",\n            \"friendly_id\": \"AI:I1:N13:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5\",\n            \"friendly_id\": \"AI:I1:N14:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N15:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        }\n    ]\n}\n</molecules>\n\n## Design Strategy Overview\n\nMy approach to designing these AKT1 inhibitors focused on several key medicinal chemistry principles:\n\n### 1. Hinge-Binding Motifs\n- Incorporated established kinase hinge-binding pharmacophores including:\n  - Aminopyrimidines (molecules 1, 2, 11, 14)\n  - Imidazoles (molecule 4)\n  - Triazoles (molecule 6)\n  - Quinazolines (molecule 15)\n  - Oxadiazoles (molecules 3, 7, 13)\n\n### 2. Binding Modes\n- **ATP-competitive inhibitors** (majority of designs): Target the ATP-binding pocket with appropriate hinge-binding elements\n- **Type II inhibitors** (molecules 2, 9): Include urea linkers to stabilize the DFG-out conformation\n- **Allosteric inhibitors** (molecules 5, 12): Target the PH domain-kinase domain interface\n\n### 3. Structural Features\n- **Solubilizing groups**: Incorporated piperazines, morpholines, and tertiary amines\n- **Metabolic stability**: Used fluorine substitutions, oxadiazoles, and methoxy groups\n- **Rigidity and spatial arrangement**: Employed amide linkers, ureas, and conformationally constrained cores\n\n### 4. Drug-Like Properties\n- Designed molecules with:\n  - MW generally between 420-550 Da\n  - LogP values in the 2.5-4 range\n  - Appropriate H-bond donors/acceptors (Lipinski compliant)\n  - Balanced solubility and permeability characteristics\n\nThese designs represent a diverse set of potential AKT1 inhibitors with varied scaffolds, binding modes, and physicochemical properties, providing a strong foundation for further optimization."
      }
    ]
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 2: Lead Optimization**\n\nBased on your previous designs, now optimize and refine your best candidates. Focus on:\n\n1. **Scaffold hopping**: Create variants of your most promising designs\n2. **Property optimization**: Improve drug-likeness, solubility, permeability\n3. **Selectivity enhancement**: Design features for AKT1 vs AKT2/AKT3 selectivity\n4. **ADMET optimization**: Consider metabolic stability and safety\n\nGenerate 8-12 optimized molecules that build upon your iteration 1 insights. Include:\n- Modified versions of your best scaffolds\n- New analogs with improved properties\n- Rationale for each modification based on medicinal chemistry principles"
      }
    ]
  }
]
2025-06-23 14:03:49,632 - INFO - response ModelResponse(id='chatcmpl-ee1c1d11-95b3-4c36-a5fe-266ca7cce244', created=1750676629, model='claude-3-7-sonnet-20250219', object='chat.completion', system_fingerprint=None, choices=[Choices(finish_reason='stop', index=0, message=Message(content='# AKT1 Inhibitor Design - Lead Optimization\n\nBased on the initial designs, I\'ll now optimize the most promising candidates to enhance potency, selectivity, and drug-like properties. I\'ll focus on scaffold hopping, property optimization, and addressing potential ADMET issues.\n\n<molecules>\n{\n    "molecules": [\n        {\n            "smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F",\n            "friendly_id": "AI:I2:N1:G1",\n            "source": "AI:I1:N1:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Optimization of AI:I1:N1:G0 with three key modifications: (1) Added a trifluoroethyl group to the piperazine to improve metabolic stability and reduce basicity, potentially improving brain penetration; (2) Introduced a fluorine on the pyridine ring to enhance binding affinity through additional interactions with the hinge region; (3) Maintained the core aminopyrimidine hinge-binding motif while optimizing the overall physicochemical profile. Expected improvements: better metabolic stability, reduced P-gp efflux liability, and potentially enhanced selectivity for AKT1."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N",\n            "friendly_id": "AI:I2:N2:G1",\n            "source": "AI:I1:N2:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Refinement of AI:I1:N2:G0 by introducing a fluorine atom on the central phenyl ring to improve metabolic stability and binding affinity. The Type II inhibitor design is maintained with the urea linker for DFG-out conformation stabilization. The fluorine addition provides several benefits: (1) blocks a potential metabolic site; (2) enhances binding through additional interactions; (3) improves membrane permeability by reducing the overall hydrogen bonding capacity while maintaining the essential pharmacophore elements. Expected improvements: enhanced metabolic stability, potentially improved selectivity, and maintained solubility profile."\n        },\n        {\n            "smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5",\n            "friendly_id": "AI:I2:N3:G1",\n            "source": "AI:I1:N3:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Enhancement of AI:I1:N3:G0 by introducing a trifluoromethyl group on the aminopyridine linker. This modification serves multiple purposes: (1) increases binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by blocking a potential site of oxidation; (3) enhances selectivity by exploiting a potential hydrophobic pocket unique to AKT1. The core oxadiazole and pyrimidine-pyridine hinge-binding motifs are preserved to maintain essential interactions. Expected improvements: enhanced potency, better metabolic profile, and potentially improved selectivity for AKT1 over AKT2/AKT3."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F",\n            "friendly_id": "AI:I2:N4:G1",\n            "source": "AI:I1:N4:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Optimization of AI:I1:N4:G0 by replacing the pyridine with a difluoromethoxy-substituted pyridine. This modification: (1) introduces a metabolically stable difluoromethoxy group that serves as a hydrogen bond acceptor while providing lipophilicity; (2) enhances binding affinity through additional interactions; (3) improves metabolic stability by blocking oxidation sites. The imidazole core and N-methylpiperazine solubilizing group are maintained for their essential functions. Expected improvements: enhanced potency, better metabolic stability, and potentially improved blood-brain barrier penetration due to the balanced lipophilicity."\n        },\n        {\n            "smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N",\n            "friendly_id": "AI:I2:N5:G1",\n            "source": "AI:I1:N5:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Refinement of the allosteric inhibitor AI:I1:N5:G0 by replacing the tertiary amine with a Boc-protected amine. This prodrug approach: (1) masks the basic center to improve membrane permeability; (2) provides controlled release of the active compound after enzymatic cleavage; (3) potentially enhances oral bioavailability by reducing first-pass metabolism. The core indole scaffold and cyano-substituted aminopyrimidine are preserved for their essential interactions with the PH domain-kinase domain interface. Expected improvements: enhanced pharmacokinetic profile, improved oral bioavailability, and maintained selectivity for AKT1."\n        },\n        {\n            "smiles": "COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F",\n            "friendly_id": "AI:I2:N6:G1",\n            "source": "AI:I1:N6:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Enhancement of AI:I1:N6:G0 by introducing a fluorine atom on the dimethoxyphenyl group. This modification: (1) blocks a potential metabolic site on the aromatic ring; (2) provides additional binding interactions; (3) fine-tunes the electronic properties of the aromatic system. The triazole core for hinge binding and the sulfone linker are maintained for their essential functions. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained physicochemical properties for good oral bioavailability."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F",\n            "friendly_id": "AI:I2:N7:G1",\n            "source": "AI:I1:N8:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Optimization of AI:I1:N8:G0 by replacing the pyridine with a trifluoromethyl-substituted pyridine. This modification: (1) enhances binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by replacing a potential metabolic liability; (3) fine-tunes the electronic properties of the hinge-binding element. The thiazole core, amide linker, and N-methylpiperazine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over other kinases."\n        },\n        {\n            "smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F",\n            "friendly_id": "AI:I2:N8:G1",\n            "source": "AI:I1:N9:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Refinement of the Type II inhibitor AI:I1:N9:G0 by replacing the methoxy group with a difluoroethoxy group. This modification: (1) improves metabolic stability by blocking a potential site of O-demethylation; (2) enhances binding affinity through additional interactions; (3) provides a better balance of lipophilicity and hydrogen bonding capacity. The urea linker for DFG-out conformation stabilization and the N-methylimidazole core are preserved. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained ability to stabilize the inactive kinase conformation."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCN(CC5)S(=O)(=O)C",\n            "friendly_id": "AI:I2:N9:G1",\n            "source": "AI:I1:N10:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Enhancement of AI:I1:N10:G0 by replacing the morpholine derivative with a methylsulfonyl-piperazine. This modification: (1) reduces the basicity of the nitrogen while maintaining solubility; (2) provides additional binding interactions through the sulfonyl group; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The isoxazole core and aminopyrimidine hinge binder are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1."\n        },\n        {\n            "smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4",\n            "friendly_id": "AI:I2:N10:G1",\n            "source": "AI:I1:N11:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Optimization of AI:I1:N11:G0 by introducing a chlorine atom on the aminopyridine linker. This modification: (1) enhances binding affinity through additional halogen bonding interactions; (2) blocks a potential metabolic site; (3) fine-tunes the electronic properties of the aromatic system. The trifluoromethyl group, aminopyrimidine hinge-binding motif, and morpholine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over AKT2/AKT3."\n        },\n        {\n            "smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F",\n            "friendly_id": "AI:I2:N11:G1",\n            "source": "AI:I1:N12:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Refinement of the allosteric inhibitor AI:I1:N12:G0 by introducing a fluorocyclopropane group. This modification: (1) enhances metabolic stability by blocking a potential site of oxidation; (2) provides additional binding interactions through the fluorine atom; (3) maintains the overall size and shape of the molecule while improving its properties. The xanthine core and sulfone linker are preserved for their essential functions in targeting the PH domain-kinase domain interface. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained selectivity for AKT1."\n        },\n        {\n            "smiles": "CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C(=O)CF",\n            "friendly_id": "AI:I2:N12:G1",\n            "source": "AI:I1:N13:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Enhancement of AI:I1:N13:G0 by replacing the N-methyl group with a fluoroacetyl group. This modification: (1) reduces the basicity of the piperazine nitrogen while maintaining solubility; (2) provides additional binding interactions through the fluorine atom; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The thiazole core, oxadiazole hinge binder, and amide linker are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1."\n        }\n    ]\n}\n</molecules>\n\n## Lead Optimization Strategy\n\nIn this optimization phase, I focused on refining the most promising candidates from Iteration 1 to enhance their drug-like properties, potency, selectivity, and ADMET profiles. Here\'s a summary of the key optimization strategies employed:\n\n### 1. Metabolic Stability Enhancements\n- **Fluorine incorporation**: Added strategic fluorine atoms to block metabolic hot spots (molecules 1, 2, 3, 6, 8, 10)\n- **Trifluoromethyl groups**: Introduced CF₃ groups to enhance stability and binding (molecules 3, 7, 10)\n- **Difluoromethoxy/ethoxy groups**: Replaced metabolically labile methoxy groups (molecules 4, 8)\n\n### 2. Selectivity Optimization\n- **Exploiting unique pockets**: Added substituents to target AKT1-specific binding regions (molecules 3, 7)\n- **Fine-tuning electronic properties**: Modified hinge-binding elements to enhance selectivity (molecules 4, 7)\n- **Halogen bonding**: Introduced chlorine for additional selective interactions (molecule 10)\n\n### 3. Pharmacokinetic Improvements\n- **Prodrug approach**: Implemented a Boc-protected amine to improve membrane permeability (molecule 5)\n- **Reduced basicity**: Modified basic centers to improve brain penetration and reduce P-gp efflux (molecules 1, 9, 12)\n- **Balanced lipophilicity**: Fine-tuned the hydrophobic/hydrophilic balance (molecules 4, 8)\n\n### 4. Binding Affinity Optimization\n- **Additional H-bond interactions**: Introduced groups capable of forming new H-bonds (molecules 4, 8)\n- **Halogen bonding**: Added fluorine and chlorine atoms for enhanced interactions (molecules 1, 10)\n- **Hydrophobic interactions**: Optimized lipophilic groups for better pocket complementarity (molecules 3, 7)\n\n### 5. Scaffold Preservation\nWhile making these modifications, I carefully preserved the core pharmacophores identified in Iteration 1:\n- ATP-competitive hinge-binding motifs (aminopyrimidines, imidazoles, etc.)\n- Type II inhibitor urea linkers\n- Allosteric binding elements for PH domain-kinase domain interface targeting\n\nThese optimized compounds represent a focused set of candidates with improved properties while maintaining the essential structural features required for AKT1 inhibition. The modifications were guided by established medicinal chemistry principles to address potential liabilities while enhancing desirable characteristics.', role='assistant', tool_calls=None, function_call=None, provider_specific_fields={'citations': []}, citations=[]))], usage=Usage(completion_tokens=4012, prompt_tokens=5233, total_tokens=9245, completion_tokens_details=None, prompt_tokens_details=PromptTokensDetailsWrapper(audio_tokens=None, cached_tokens=0, text_tokens=None, image_tokens=None), cache_creation_input_tokens=0, cache_read_input_tokens=0))
2025-06-23 14:03:49,635 - INFO - history_with_tools [{'role': 'user', 'content': "You are an expert medicinal chemist and computational drug discovery scientist. Your task is to design novel small molecule inhibitors for AKT1 (Protein Kinase B alpha) using your knowledge of structure-activity relationships, medicinal chemistry principles, and drug design.\n\n**Target Information:**\n- AKT1 is a serine/threonine kinase in the PI3K/AKT/mTOR pathway\n- Critical for cell survival, proliferation, and metabolism\n- Key oncology target with multiple known inhibitors\n- ATP-competitive and allosteric binding sites available\n\n**Your Goal:**\nGenerate novel, drug-like small molecule AKT1 inhibitors with the following criteria:\n- High predicted binding affinity to AKT1\n- Drug-like properties (Lipinski's Rule of Five compliance)\n- Synthetic accessibility\n- Novel scaffolds not directly copied from known inhibitors\n\n**Output Format:**\nFor each molecule, provide:\n1. **Molecule ID**: A unique identifier (e.g., LLM_MOL_001)\n2. **SMILES**: Valid SMILES string\n3. **Rationale**: Brief explanation of your design strategy and expected properties\n4. **Predicted Properties**: Your assessment of drug-likeness, potency, selectivity\n\nFocus on innovative chemical designs while maintaining scientific rigor."}, {'role': 'user', 'content': [{'type': 'text', 'text': '**ITERATION 1: Initial Discovery & Exploration**\n\nDesign 10-15 novel AKT1 inhibitor molecules using your medicinal chemistry expertise. Consider:\n\n1. **ATP-competitive inhibitors**: Target the ATP-binding pocket with novel scaffolds\n2. **Allosteric inhibitors**: Design molecules that bind to regulatory sites\n3. **Hybrid approaches**: Molecules that may interact with multiple binding sites\n\nUse your knowledge of:\n- Known AKT1 pharmacophores (avoid direct copying)\n- Kinase selectivity determinants\n- Drug-like chemical space\n- Structure-activity relationships\n\nGenerate diverse scaffolds including heterocycles, aromatic systems, and appropriate linkers. Ensure synthetic feasibility while prioritizing novelty.'}]}, {'role': 'assistant', 'content': [{'type': 'text', 'text': '# AKT1 Inhibitor Design - Initial Discovery\n\nI\'ll design novel AKT1 inhibitors using medicinal chemistry principles and my knowledge of kinase inhibitor design. I\'ll focus on creating diverse, drug-like molecules with appropriate pharmacophores for AKT1 inhibition.\n\n<molecules>\n{\n    "molecules": [\n        {\n            "smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5",\n            "friendly_id": "AI:I1:N1:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N",\n            "friendly_id": "AI:I1:N2:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors."\n        },\n        {\n            "smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5",\n            "friendly_id": "AI:I1:N3:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5",\n            "friendly_id": "AI:I1:N4:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements."\n        },\n        {\n            "smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N",\n            "friendly_id": "AI:I1:N5:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode."\n        },\n        {\n            "smiles": "COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F",\n            "friendly_id": "AI:I1:N6:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties."\n        },\n        {\n            "smiles": "CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5",\n            "friendly_id": "AI:I1:N7:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5",\n            "friendly_id": "AI:I1:N8:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases."\n        },\n        {\n            "smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC",\n            "friendly_id": "AI:I1:N9:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5",\n            "friendly_id": "AI:I1:N10:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile."\n        },\n        {\n            "smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4",\n            "friendly_id": "AI:I1:N11:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties."\n        },\n        {\n            "smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5",\n            "friendly_id": "AI:I1:N12:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode."\n        },\n        {\n            "smiles": "CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C",\n            "friendly_id": "AI:I1:N13:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases."\n        },\n        {\n            "smiles": "CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5",\n            "friendly_id": "AI:I1:N14:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile."\n        },\n        {\n            "smiles": "COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5",\n            "friendly_id": "AI:I1:N15:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties."\n        }\n    ]\n}\n</molecules>\n\n## Design Strategy Overview\n\nMy approach to designing these AKT1 inhibitors focused on several key medicinal chemistry principles:\n\n### 1. Hinge-Binding Motifs\n- Incorporated established kinase hinge-binding pharmacophores including:\n  - Aminopyrimidines (molecules 1, 2, 11, 14)\n  - Imidazoles (molecule 4)\n  - Triazoles (molecule 6)\n  - Quinazolines (molecule 15)\n  - Oxadiazoles (molecules 3, 7, 13)\n\n### 2. Binding Modes\n- **ATP-competitive inhibitors** (majority of designs): Target the ATP-binding pocket with appropriate hinge-binding elements\n- **Type II inhibitors** (molecules 2, 9): Include urea linkers to stabilize the DFG-out conformation\n- **Allosteric inhibitors** (molecules 5, 12): Target the PH domain-kinase domain interface\n\n### 3. Structural Features\n- **Solubilizing groups**: Incorporated piperazines, morpholines, and tertiary amines\n- **Metabolic stability**: Used fluorine substitutions, oxadiazoles, and methoxy groups\n- **Rigidity and spatial arrangement**: Employed amide linkers, ureas, and conformationally constrained cores\n\n### 4. Drug-Like Properties\n- Designed molecules with:\n  - MW generally between 420-550 Da\n  - LogP values in the 2.5-4 range\n  - Appropriate H-bond donors/acceptors (Lipinski compliant)\n  - Balanced solubility and permeability characteristics\n\nThese designs represent a diverse set of potential AKT1 inhibitors with varied scaffolds, binding modes, and physicochemical properties, providing a strong foundation for further optimization.'}]}, {'role': 'user', 'content': [{'type': 'text', 'text': '**ITERATION 2: Lead Optimization**\n\nBased on your previous designs, now optimize and refine your best candidates. Focus on:\n\n1. **Scaffold hopping**: Create variants of your most promising designs\n2. **Property optimization**: Improve drug-likeness, solubility, permeability\n3. **Selectivity enhancement**: Design features for AKT1 vs AKT2/AKT3 selectivity\n4. **ADMET optimization**: Consider metabolic stability and safety\n\nGenerate 8-12 optimized molecules that build upon your iteration 1 insights. Include:\n- Modified versions of your best scaffolds\n- New analogs with improved properties\n- Rationale for each modification based on medicinal chemistry principles'}]}, {'role': 'assistant', 'content': '# AKT1 Inhibitor Design - Lead Optimization\n\nBased on the initial designs, I\'ll now optimize the most promising candidates to enhance potency, selectivity, and drug-like properties. I\'ll focus on scaffold hopping, property optimization, and addressing potential ADMET issues.\n\n<molecules>\n{\n    "molecules": [\n        {\n            "smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F",\n            "friendly_id": "AI:I2:N1:G1",\n            "source": "AI:I1:N1:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Optimization of AI:I1:N1:G0 with three key modifications: (1) Added a trifluoroethyl group to the piperazine to improve metabolic stability and reduce basicity, potentially improving brain penetration; (2) Introduced a fluorine on the pyridine ring to enhance binding affinity through additional interactions with the hinge region; (3) Maintained the core aminopyrimidine hinge-binding motif while optimizing the overall physicochemical profile. Expected improvements: better metabolic stability, reduced P-gp efflux liability, and potentially enhanced selectivity for AKT1."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N",\n            "friendly_id": "AI:I2:N2:G1",\n            "source": "AI:I1:N2:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Refinement of AI:I1:N2:G0 by introducing a fluorine atom on the central phenyl ring to improve metabolic stability and binding affinity. The Type II inhibitor design is maintained with the urea linker for DFG-out conformation stabilization. The fluorine addition provides several benefits: (1) blocks a potential metabolic site; (2) enhances binding through additional interactions; (3) improves membrane permeability by reducing the overall hydrogen bonding capacity while maintaining the essential pharmacophore elements. Expected improvements: enhanced metabolic stability, potentially improved selectivity, and maintained solubility profile."\n        },\n        {\n            "smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5",\n            "friendly_id": "AI:I2:N3:G1",\n            "source": "AI:I1:N3:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Enhancement of AI:I1:N3:G0 by introducing a trifluoromethyl group on the aminopyridine linker. This modification serves multiple purposes: (1) increases binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by blocking a potential site of oxidation; (3) enhances selectivity by exploiting a potential hydrophobic pocket unique to AKT1. The core oxadiazole and pyrimidine-pyridine hinge-binding motifs are preserved to maintain essential interactions. Expected improvements: enhanced potency, better metabolic profile, and potentially improved selectivity for AKT1 over AKT2/AKT3."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F",\n            "friendly_id": "AI:I2:N4:G1",\n            "source": "AI:I1:N4:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Optimization of AI:I1:N4:G0 by replacing the pyridine with a difluoromethoxy-substituted pyridine. This modification: (1) introduces a metabolically stable difluoromethoxy group that serves as a hydrogen bond acceptor while providing lipophilicity; (2) enhances binding affinity through additional interactions; (3) improves metabolic stability by blocking oxidation sites. The imidazole core and N-methylpiperazine solubilizing group are maintained for their essential functions. Expected improvements: enhanced potency, better metabolic stability, and potentially improved blood-brain barrier penetration due to the balanced lipophilicity."\n        },\n        {\n            "smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N",\n            "friendly_id": "AI:I2:N5:G1",\n            "source": "AI:I1:N5:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Refinement of the allosteric inhibitor AI:I1:N5:G0 by replacing the tertiary amine with a Boc-protected amine. This prodrug approach: (1) masks the basic center to improve membrane permeability; (2) provides controlled release of the active compound after enzymatic cleavage; (3) potentially enhances oral bioavailability by reducing first-pass metabolism. The core indole scaffold and cyano-substituted aminopyrimidine are preserved for their essential interactions with the PH domain-kinase domain interface. Expected improvements: enhanced pharmacokinetic profile, improved oral bioavailability, and maintained selectivity for AKT1."\n        },\n        {\n            "smiles": "COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F",\n            "friendly_id": "AI:I2:N6:G1",\n            "source": "AI:I1:N6:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Enhancement of AI:I1:N6:G0 by introducing a fluorine atom on the dimethoxyphenyl group. This modification: (1) blocks a potential metabolic site on the aromatic ring; (2) provides additional binding interactions; (3) fine-tunes the electronic properties of the aromatic system. The triazole core for hinge binding and the sulfone linker are maintained for their essential functions. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained physicochemical properties for good oral bioavailability."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F",\n            "friendly_id": "AI:I2:N7:G1",\n            "source": "AI:I1:N8:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Optimization of AI:I1:N8:G0 by replacing the pyridine with a trifluoromethyl-substituted pyridine. This modification: (1) enhances binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by replacing a potential metabolic liability; (3) fine-tunes the electronic properties of the hinge-binding element. The thiazole core, amide linker, and N-methylpiperazine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over other kinases."\n        },\n        {\n            "smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F",\n            "friendly_id": "AI:I2:N8:G1",\n            "source": "AI:I1:N9:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Refinement of the Type II inhibitor AI:I1:N9:G0 by replacing the methoxy group with a difluoroethoxy group. This modification: (1) improves metabolic stability by blocking a potential site of O-demethylation; (2) enhances binding affinity through additional interactions; (3) provides a better balance of lipophilicity and hydrogen bonding capacity. The urea linker for DFG-out conformation stabilization and the N-methylimidazole core are preserved. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained ability to stabilize the inactive kinase conformation."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCN(CC5)S(=O)(=O)C",\n            "friendly_id": "AI:I2:N9:G1",\n            "source": "AI:I1:N10:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Enhancement of AI:I1:N10:G0 by replacing the morpholine derivative with a methylsulfonyl-piperazine. This modification: (1) reduces the basicity of the nitrogen while maintaining solubility; (2) provides additional binding interactions through the sulfonyl group; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The isoxazole core and aminopyrimidine hinge binder are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1."\n        },\n        {\n            "smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4",\n            "friendly_id": "AI:I2:N10:G1",\n            "source": "AI:I1:N11:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Optimization of AI:I1:N11:G0 by introducing a chlorine atom on the aminopyridine linker. This modification: (1) enhances binding affinity through additional halogen bonding interactions; (2) blocks a potential metabolic site; (3) fine-tunes the electronic properties of the aromatic system. The trifluoromethyl group, aminopyrimidine hinge-binding motif, and morpholine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over AKT2/AKT3."\n        },\n        {\n            "smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F",\n            "friendly_id": "AI:I2:N11:G1",\n            "source": "AI:I1:N12:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Refinement of the allosteric inhibitor AI:I1:N12:G0 by introducing a fluorocyclopropane group. This modification: (1) enhances metabolic stability by blocking a potential site of oxidation; (2) provides additional binding interactions through the fluorine atom; (3) maintains the overall size and shape of the molecule while improving its properties. The xanthine core and sulfone linker are preserved for their essential functions in targeting the PH domain-kinase domain interface. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained selectivity for AKT1."\n        },\n        {\n            "smiles": "CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C(=O)CF",\n            "friendly_id": "AI:I2:N12:G1",\n            "source": "AI:I1:N13:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Enhancement of AI:I1:N13:G0 by replacing the N-methyl group with a fluoroacetyl group. This modification: (1) reduces the basicity of the piperazine nitrogen while maintaining solubility; (2) provides additional binding interactions through the fluorine atom; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The thiazole core, oxadiazole hinge binder, and amide linker are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1."\n        }\n    ]\n}\n</molecules>\n\n## Lead Optimization Strategy\n\nIn this optimization phase, I focused on refining the most promising candidates from Iteration 1 to enhance their drug-like properties, potency, selectivity, and ADMET profiles. Here\'s a summary of the key optimization strategies employed:\n\n### 1. Metabolic Stability Enhancements\n- **Fluorine incorporation**: Added strategic fluorine atoms to block metabolic hot spots (molecules 1, 2, 3, 6, 8, 10)\n- **Trifluoromethyl groups**: Introduced CF₃ groups to enhance stability and binding (molecules 3, 7, 10)\n- **Difluoromethoxy/ethoxy groups**: Replaced metabolically labile methoxy groups (molecules 4, 8)\n\n### 2. Selectivity Optimization\n- **Exploiting unique pockets**: Added substituents to target AKT1-specific binding regions (molecules 3, 7)\n- **Fine-tuning electronic properties**: Modified hinge-binding elements to enhance selectivity (molecules 4, 7)\n- **Halogen bonding**: Introduced chlorine for additional selective interactions (molecule 10)\n\n### 3. Pharmacokinetic Improvements\n- **Prodrug approach**: Implemented a Boc-protected amine to improve membrane permeability (molecule 5)\n- **Reduced basicity**: Modified basic centers to improve brain penetration and reduce P-gp efflux (molecules 1, 9, 12)\n- **Balanced lipophilicity**: Fine-tuned the hydrophobic/hydrophilic balance (molecules 4, 8)\n\n### 4. Binding Affinity Optimization\n- **Additional H-bond interactions**: Introduced groups capable of forming new H-bonds (molecules 4, 8)\n- **Halogen bonding**: Added fluorine and chlorine atoms for enhanced interactions (molecules 1, 10)\n- **Hydrophobic interactions**: Optimized lipophilic groups for better pocket complementarity (molecules 3, 7)\n\n### 5. Scaffold Preservation\nWhile making these modifications, I carefully preserved the core pharmacophores identified in Iteration 1:\n- ATP-competitive hinge-binding motifs (aminopyrimidines, imidazoles, etc.)\n- Type II inhibitor urea linkers\n- Allosteric binding elements for PH domain-kinase domain interface targeting\n\nThese optimized compounds represent a focused set of candidates with improved properties while maintaining the essential structural features required for AKT1 inhibition. The modifications were guided by established medicinal chemistry principles to address potential liabilities while enhancing desirable characteristics.'}]
2025-06-23 14:03:49,636 - INFO - main_history before parser: [
  {
    "role": "user",
    "content": "You are an expert medicinal chemist and computational drug discovery scientist. Your task is to design novel small molecule inhibitors for AKT1 (Protein Kinase B alpha) using your knowledge of structure-activity relationships, medicinal chemistry principles, and drug design.\n\n**Target Information:**\n- AKT1 is a serine/threonine kinase in the PI3K/AKT/mTOR pathway\n- Critical for cell survival, proliferation, and metabolism\n- Key oncology target with multiple known inhibitors\n- ATP-competitive and allosteric binding sites available\n\n**Your Goal:**\nGenerate novel, drug-like small molecule AKT1 inhibitors with the following criteria:\n- High predicted binding affinity to AKT1\n- Drug-like properties (Lipinski's Rule of Five compliance)\n- Synthetic accessibility\n- Novel scaffolds not directly copied from known inhibitors\n\n**Output Format:**\nFor each molecule, provide:\n1. **Molecule ID**: A unique identifier (e.g., LLM_MOL_001)\n2. **SMILES**: Valid SMILES string\n3. **Rationale**: Brief explanation of your design strategy and expected properties\n4. **Predicted Properties**: Your assessment of drug-likeness, potency, selectivity\n\nFocus on innovative chemical designs while maintaining scientific rigor."
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 1: Initial Discovery & Exploration**\n\nDesign 10-15 novel AKT1 inhibitor molecules using your medicinal chemistry expertise. Consider:\n\n1. **ATP-competitive inhibitors**: Target the ATP-binding pocket with novel scaffolds\n2. **Allosteric inhibitors**: Design molecules that bind to regulatory sites\n3. **Hybrid approaches**: Molecules that may interact with multiple binding sites\n\nUse your knowledge of:\n- Known AKT1 pharmacophores (avoid direct copying)\n- Kinase selectivity determinants\n- Drug-like chemical space\n- Structure-activity relationships\n\nGenerate diverse scaffolds including heterocycles, aromatic systems, and appropriate linkers. Ensure synthetic feasibility while prioritizing novelty."
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Initial Discovery\n\nI'll design novel AKT1 inhibitors using medicinal chemistry principles and my knowledge of kinase inhibitor design. I'll focus on creating diverse, drug-like molecules with appropriate pharmacophores for AKT1 inhibition.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N1:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I1:N2:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N3:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N4:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I1:N5:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I1:N6:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N7:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N8:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC\",\n            \"friendly_id\": \"AI:I1:N9:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5\",\n            \"friendly_id\": \"AI:I1:N10:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I1:N11:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5\",\n            \"friendly_id\": \"AI:I1:N12:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C\",\n            \"friendly_id\": \"AI:I1:N13:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5\",\n            \"friendly_id\": \"AI:I1:N14:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N15:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        }\n    ]\n}\n</molecules>\n\n## Design Strategy Overview\n\nMy approach to designing these AKT1 inhibitors focused on several key medicinal chemistry principles:\n\n### 1. Hinge-Binding Motifs\n- Incorporated established kinase hinge-binding pharmacophores including:\n  - Aminopyrimidines (molecules 1, 2, 11, 14)\n  - Imidazoles (molecule 4)\n  - Triazoles (molecule 6)\n  - Quinazolines (molecule 15)\n  - Oxadiazoles (molecules 3, 7, 13)\n\n### 2. Binding Modes\n- **ATP-competitive inhibitors** (majority of designs): Target the ATP-binding pocket with appropriate hinge-binding elements\n- **Type II inhibitors** (molecules 2, 9): Include urea linkers to stabilize the DFG-out conformation\n- **Allosteric inhibitors** (molecules 5, 12): Target the PH domain-kinase domain interface\n\n### 3. Structural Features\n- **Solubilizing groups**: Incorporated piperazines, morpholines, and tertiary amines\n- **Metabolic stability**: Used fluorine substitutions, oxadiazoles, and methoxy groups\n- **Rigidity and spatial arrangement**: Employed amide linkers, ureas, and conformationally constrained cores\n\n### 4. Drug-Like Properties\n- Designed molecules with:\n  - MW generally between 420-550 Da\n  - LogP values in the 2.5-4 range\n  - Appropriate H-bond donors/acceptors (Lipinski compliant)\n  - Balanced solubility and permeability characteristics\n\nThese designs represent a diverse set of potential AKT1 inhibitors with varied scaffolds, binding modes, and physicochemical properties, providing a strong foundation for further optimization."
      }
    ]
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 2: Lead Optimization**\n\nBased on your previous designs, now optimize and refine your best candidates. Focus on:\n\n1. **Scaffold hopping**: Create variants of your most promising designs\n2. **Property optimization**: Improve drug-likeness, solubility, permeability\n3. **Selectivity enhancement**: Design features for AKT1 vs AKT2/AKT3 selectivity\n4. **ADMET optimization**: Consider metabolic stability and safety\n\nGenerate 8-12 optimized molecules that build upon your iteration 1 insights. Include:\n- Modified versions of your best scaffolds\n- New analogs with improved properties\n- Rationale for each modification based on medicinal chemistry principles"
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Lead Optimization\n\nBased on the initial designs, I'll now optimize the most promising candidates to enhance potency, selectivity, and drug-like properties. I'll focus on scaffold hopping, property optimization, and addressing potential ADMET issues.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F\",\n            \"friendly_id\": \"AI:I2:N1:G1\",\n            \"source\": \"AI:I1:N1:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N1:G0 with three key modifications: (1) Added a trifluoroethyl group to the piperazine to improve metabolic stability and reduce basicity, potentially improving brain penetration; (2) Introduced a fluorine on the pyridine ring to enhance binding affinity through additional interactions with the hinge region; (3) Maintained the core aminopyrimidine hinge-binding motif while optimizing the overall physicochemical profile. Expected improvements: better metabolic stability, reduced P-gp efflux liability, and potentially enhanced selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I2:N2:G1\",\n            \"source\": \"AI:I1:N2:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of AI:I1:N2:G0 by introducing a fluorine atom on the central phenyl ring to improve metabolic stability and binding affinity. The Type II inhibitor design is maintained with the urea linker for DFG-out conformation stabilization. The fluorine addition provides several benefits: (1) blocks a potential metabolic site; (2) enhances binding through additional interactions; (3) improves membrane permeability by reducing the overall hydrogen bonding capacity while maintaining the essential pharmacophore elements. Expected improvements: enhanced metabolic stability, potentially improved selectivity, and maintained solubility profile.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I2:N3:G1\",\n            \"source\": \"AI:I1:N3:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N3:G0 by introducing a trifluoromethyl group on the aminopyridine linker. This modification serves multiple purposes: (1) increases binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by blocking a potential site of oxidation; (3) enhances selectivity by exploiting a potential hydrophobic pocket unique to AKT1. The core oxadiazole and pyrimidine-pyridine hinge-binding motifs are preserved to maintain essential interactions. Expected improvements: enhanced potency, better metabolic profile, and potentially improved selectivity for AKT1 over AKT2/AKT3.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F\",\n            \"friendly_id\": \"AI:I2:N4:G1\",\n            \"source\": \"AI:I1:N4:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N4:G0 by replacing the pyridine with a difluoromethoxy-substituted pyridine. This modification: (1) introduces a metabolically stable difluoromethoxy group that serves as a hydrogen bond acceptor while providing lipophilicity; (2) enhances binding affinity through additional interactions; (3) improves metabolic stability by blocking oxidation sites. The imidazole core and N-methylpiperazine solubilizing group are maintained for their essential functions. Expected improvements: enhanced potency, better metabolic stability, and potentially improved blood-brain barrier penetration due to the balanced lipophilicity.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I2:N5:G1\",\n            \"source\": \"AI:I1:N5:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the allosteric inhibitor AI:I1:N5:G0 by replacing the tertiary amine with a Boc-protected amine. This prodrug approach: (1) masks the basic center to improve membrane permeability; (2) provides controlled release of the active compound after enzymatic cleavage; (3) potentially enhances oral bioavailability by reducing first-pass metabolism. The core indole scaffold and cyano-substituted aminopyrimidine are preserved for their essential interactions with the PH domain-kinase domain interface. Expected improvements: enhanced pharmacokinetic profile, improved oral bioavailability, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I2:N6:G1\",\n            \"source\": \"AI:I1:N6:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N6:G0 by introducing a fluorine atom on the dimethoxyphenyl group. This modification: (1) blocks a potential metabolic site on the aromatic ring; (2) provides additional binding interactions; (3) fine-tunes the electronic properties of the aromatic system. The triazole core for hinge binding and the sulfone linker are maintained for their essential functions. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained physicochemical properties for good oral bioavailability.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F\",\n            \"friendly_id\": \"AI:I2:N7:G1\",\n            \"source\": \"AI:I1:N8:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N8:G0 by replacing the pyridine with a trifluoromethyl-substituted pyridine. This modification: (1) enhances binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by replacing a potential metabolic liability; (3) fine-tunes the electronic properties of the hinge-binding element. The thiazole core, amide linker, and N-methylpiperazine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F\",\n            \"friendly_id\": \"AI:I2:N8:G1\",\n            \"source\": \"AI:I1:N9:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the Type II inhibitor AI:I1:N9:G0 by replacing the methoxy group with a difluoroethoxy group. This modification: (1) improves metabolic stability by blocking a potential site of O-demethylation; (2) enhances binding affinity through additional interactions; (3) provides a better balance of lipophilicity and hydrogen bonding capacity. The urea linker for DFG-out conformation stabilization and the N-methylimidazole core are preserved. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained ability to stabilize the inactive kinase conformation.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCN(CC5)S(=O)(=O)C\",\n            \"friendly_id\": \"AI:I2:N9:G1\",\n            \"source\": \"AI:I1:N10:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N10:G0 by replacing the morpholine derivative with a methylsulfonyl-piperazine. This modification: (1) reduces the basicity of the nitrogen while maintaining solubility; (2) provides additional binding interactions through the sulfonyl group; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The isoxazole core and aminopyrimidine hinge binder are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I2:N10:G1\",\n            \"source\": \"AI:I1:N11:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N11:G0 by introducing a chlorine atom on the aminopyridine linker. This modification: (1) enhances binding affinity through additional halogen bonding interactions; (2) blocks a potential metabolic site; (3) fine-tunes the electronic properties of the aromatic system. The trifluoromethyl group, aminopyrimidine hinge-binding motif, and morpholine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over AKT2/AKT3.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F\",\n            \"friendly_id\": \"AI:I2:N11:G1\",\n            \"source\": \"AI:I1:N12:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the allosteric inhibitor AI:I1:N12:G0 by introducing a fluorocyclopropane group. This modification: (1) enhances metabolic stability by blocking a potential site of oxidation; (2) provides additional binding interactions through the fluorine atom; (3) maintains the overall size and shape of the molecule while improving its properties. The xanthine core and sulfone linker are preserved for their essential functions in targeting the PH domain-kinase domain interface. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C(=O)CF\",\n            \"friendly_id\": \"AI:I2:N12:G1\",\n            \"source\": \"AI:I1:N13:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N13:G0 by replacing the N-methyl group with a fluoroacetyl group. This modification: (1) reduces the basicity of the piperazine nitrogen while maintaining solubility; (2) provides additional binding interactions through the fluorine atom; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The thiazole core, oxadiazole hinge binder, and amide linker are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        }\n    ]\n}\n</molecules>\n\n## Lead Optimization Strategy\n\nIn this optimization phase, I focused on refining the most promising candidates from Iteration 1 to enhance their drug-like properties, potency, selectivity, and ADMET profiles. Here's a summary of the key optimization strategies employed:\n\n### 1. Metabolic Stability Enhancements\n- **Fluorine incorporation**: Added strategic fluorine atoms to block metabolic hot spots (molecules 1, 2, 3, 6, 8, 10)\n- **Trifluoromethyl groups**: Introduced CF\u2083 groups to enhance stability and binding (molecules 3, 7, 10)\n- **Difluoromethoxy/ethoxy groups**: Replaced metabolically labile methoxy groups (molecules 4, 8)\n\n### 2. Selectivity Optimization\n- **Exploiting unique pockets**: Added substituents to target AKT1-specific binding regions (molecules 3, 7)\n- **Fine-tuning electronic properties**: Modified hinge-binding elements to enhance selectivity (molecules 4, 7)\n- **Halogen bonding**: Introduced chlorine for additional selective interactions (molecule 10)\n\n### 3. Pharmacokinetic Improvements\n- **Prodrug approach**: Implemented a Boc-protected amine to improve membrane permeability (molecule 5)\n- **Reduced basicity**: Modified basic centers to improve brain penetration and reduce P-gp efflux (molecules 1, 9, 12)\n- **Balanced lipophilicity**: Fine-tuned the hydrophobic/hydrophilic balance (molecules 4, 8)\n\n### 4. Binding Affinity Optimization\n- **Additional H-bond interactions**: Introduced groups capable of forming new H-bonds (molecules 4, 8)\n- **Halogen bonding**: Added fluorine and chlorine atoms for enhanced interactions (molecules 1, 10)\n- **Hydrophobic interactions**: Optimized lipophilic groups for better pocket complementarity (molecules 3, 7)\n\n### 5. Scaffold Preservation\nWhile making these modifications, I carefully preserved the core pharmacophores identified in Iteration 1:\n- ATP-competitive hinge-binding motifs (aminopyrimidines, imidazoles, etc.)\n- Type II inhibitor urea linkers\n- Allosteric binding elements for PH domain-kinase domain interface targeting\n\nThese optimized compounds represent a focused set of candidates with improved properties while maintaining the essential structural features required for AKT1 inhibition. The modifications were guided by established medicinal chemistry principles to address potential liabilities while enhancing desirable characteristics."
      }
    ]
  }
]
2025-06-23 14:03:49,636 - INFO - DEBUG: tools: [{'type': 'function', 'function': {'name': 'gurnemanz_apply', 'description': 'Submit transformation and molecule data to GURNEMANZ and retrieve the response with IDs. The Haskell service returns the full data structure with embedded IDs, providing better traceability between molecules and their IDs.', 'parameters': {'type': 'object', 'properties': {'session_id': {'type': 'string', 'description': 'Session UUID from creation (required for tracking transformations across sessions)'}, 'parent_transformation_id': {'type': 'string', 'description': 'ID of the parent transformation (required for tracking transformation chains)'}, 'client_name': {'type': 'string', 'description': 'Use claude for client name', 'default': 'claude'}, 'transformation': {'type': 'object', 'description': 'Details of the transformation being applied', 'properties': {'type': {'type': 'string', 'description': "Required: Type of transformation (e.g., 'molecule-generation', 'property-prediction')"}, 'agent': {'type': 'string', 'description': 'Required: Name of the agent performing the transformation'}, 'user_message': {'type': 'string', 'description': 'Optional: Human-readable message about the transformation'}, 'method_details': {'type': 'object', 'description': 'Optional: Details about the method used in the transformation', 'properties': {'method_id': {'type': 'string', 'description': 'Required if methodDetails is present: Identifier of the method used'}}, 'required': ['method_id']}, 'rationale': {'type': 'string', 'description': 'Optional: General rationale for the transformation'}, 'protein_sequence': {'type': 'string', 'description': 'Optional: Protein sequence associated with the transformation'}, 'protein_path': {'type': 'string', 'description': 'Optional: Path to the protein pdb file associated with the transformation'}, 'iteration': {'type': 'integer', 'description': 'Required: Iteration number for this transformation'}}, 'required': ['type', 'agent', 'iteration']}, 'molecules': {'type': 'array', 'description': 'Array of molecule objects generated or modified in this transformation', 'items': {'type': 'object', 'properties': {'structure': {'type': 'object', 'description': 'Required: Molecular structure information', 'properties': {'smiles': {'type': 'string', 'description': 'Required: SMILES string representation'}}, 'required': ['smiles']}, 'properties': {'type': 'object', 'description': 'Optional: Molecule properties', 'properties': {'parent_molecule_id': {'type': 'string', 'description': 'Optional: ID of parent molecule'}, 'molecular_weight': {'type': 'number', 'description': 'Optional: Molecular weight'}, 'status': {'type': 'string', 'description': "Optional: Molecule status (e.g., 'modified', 'de novo')"}}}, 'computed_properties': {'type': 'object', 'description': 'Optional: Computed or predicted properties', 'properties': {'logP': {'type': 'number', 'description': 'Optional: Lipophilicity'}, 'qed': {'type': 'number', 'description': 'Optional: Quantitative estimate of drug-likeness'}, 'sas': {'type': 'number', 'description': 'Optional: Synthetic accessibility score'}, 'lipinski_count': {'type': 'integer', 'description': "Optional: Number of Lipinski's Rule of Five violations"}, 'docking_score': {'type': 'number', 'description': 'Optional: Docking score (if applicable)'}, 'plip_interactions': {'type': 'string', 'description': 'Optional: Protein-ligand interaction information'}}}, 'rationale': {'type': 'string', 'description': 'Required: Reasoning specific to this molecule'}, 'activity': {'type': 'string', 'description': "Optional: Activity status of the molecule (e.g., 'active', 'inactive')"}, 'friendly_id': {'type': 'string', 'description': 'Friendly ID of the molecule'}, 'parent_friendly_id': {'type': 'string', 'description': 'Optional: Friendly ID of the parent molecule, only molecules created by Medicinal Chemist can have parents'}}, 'required': ['structure', 'rationale', 'friendly_id']}}}, 'required': ['session_id', 'parent_transformation_id', 'transformation', 'molecules', 'client_name']}}}]
2025-06-23 14:03:49,636 - INFO - chat history for chat completion: [
  {
    "role": "system",
    "content": "You are an AI assistant acting as Summary Parser. Your expertise is in ('Interpreting unstructured research outputs', 'Generating structured JSON data', 'Maintaining data consistency across transformations'). Your goal is to Format LLM outputs into GURNEMANZ JSON schema and submit them while maintaining all important relationships between data elements.. Your role is to Parse LLM outputs to construct a clean formatted JSON that preserves all relevant information about molecules and their design rationales.. Please maintain this role throughout our conversation.\n\n\nDruing the discovery process, molecules will be presented with a friendly_id. This friendly_id is a unique identifier that tracks its complete history and lineage through our optimization process to help to follow the SAR and parent-child relationships.\n\n## Molecule ID System - Tracking Molecular Evolution\n\nEach molecule receives a unique identifier that tracks its complete history and lineage through our optimization process.\n\n**Format:** `AgentCode:I<iteration>:N<position>:G<generation>`\n\nThis ID (friendly_id) system serves as a molecular genealogy, allowing us to:\n- Track which agent created or modified each molecule\n- Understand the evolutionary path from original to optimized compounds\n- Maintain parent-child relationships across modifications\n\n**Components:**\n- **AgentCode**: Two-letter code representing the creator agent\n  - DA = Database Agent\n  - AI = AI Expert\n  - MC = Medicinal Chemist\n  - LA = Literature Agent\n  - RA = Ranking Agent\n  - PR = Principal Researcher\n  - SC = Scientific Critic\n  - SP = Summary Parser\n\n- **I<iteration>**: The research iteration number when molecule was introduced (e.g., I1, I2, I3)\n- **N<position>**: The molecule's position in the agent's output list, starting from N1 (resets per agent output)\n- **G<generation>**: The modification depth showing molecular evolution\n  - G0 = original molecule (from database or de novo)\n  - G1 = first modification\n  - G2 = second modification\n  - And so on...\n\n**Example Evolution:**\n1. Database retrieves: `DA:I1:N3:G0` (original from ChEMBL, third molecule in list, iteration 1)\n2. Medicinal Chemist modifies it: `MC:I2:N1:G1` (first modification, first molecule in chemist's list, iteration 2)\n3. Further optimization: `MC:I3:N2:G2` (second modification, second molecule in list, iteration 3)\n\nThis allows us to trace any molecule back to its origins and understand its optimization journey.\nIf a molecule is a child of a parent molecule, the parent molecule's friendly_id must be included in the molecule's source field\n"
  },
  {
    "role": "user",
    "content": "You are an expert medicinal chemist and computational drug discovery scientist. Your task is to design novel small molecule inhibitors for AKT1 (Protein Kinase B alpha) using your knowledge of structure-activity relationships, medicinal chemistry principles, and drug design.\n\n**Target Information:**\n- AKT1 is a serine/threonine kinase in the PI3K/AKT/mTOR pathway\n- Critical for cell survival, proliferation, and metabolism\n- Key oncology target with multiple known inhibitors\n- ATP-competitive and allosteric binding sites available\n\n**Your Goal:**\nGenerate novel, drug-like small molecule AKT1 inhibitors with the following criteria:\n- High predicted binding affinity to AKT1\n- Drug-like properties (Lipinski's Rule of Five compliance)\n- Synthetic accessibility\n- Novel scaffolds not directly copied from known inhibitors\n\n**Output Format:**\nFor each molecule, provide:\n1. **Molecule ID**: A unique identifier (e.g., LLM_MOL_001)\n2. **SMILES**: Valid SMILES string\n3. **Rationale**: Brief explanation of your design strategy and expected properties\n4. **Predicted Properties**: Your assessment of drug-likeness, potency, selectivity\n\nFocus on innovative chemical designs while maintaining scientific rigor."
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 1: Initial Discovery & Exploration**\n\nDesign 10-15 novel AKT1 inhibitor molecules using your medicinal chemistry expertise. Consider:\n\n1. **ATP-competitive inhibitors**: Target the ATP-binding pocket with novel scaffolds\n2. **Allosteric inhibitors**: Design molecules that bind to regulatory sites\n3. **Hybrid approaches**: Molecules that may interact with multiple binding sites\n\nUse your knowledge of:\n- Known AKT1 pharmacophores (avoid direct copying)\n- Kinase selectivity determinants\n- Drug-like chemical space\n- Structure-activity relationships\n\nGenerate diverse scaffolds including heterocycles, aromatic systems, and appropriate linkers. Ensure synthetic feasibility while prioritizing novelty."
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Initial Discovery\n\nI'll design novel AKT1 inhibitors using medicinal chemistry principles and my knowledge of kinase inhibitor design. I'll focus on creating diverse, drug-like molecules with appropriate pharmacophores for AKT1 inhibition.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N1:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I1:N2:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N3:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N4:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I1:N5:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I1:N6:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N7:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N8:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC\",\n            \"friendly_id\": \"AI:I1:N9:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5\",\n            \"friendly_id\": \"AI:I1:N10:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I1:N11:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5\",\n            \"friendly_id\": \"AI:I1:N12:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C\",\n            \"friendly_id\": \"AI:I1:N13:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5\",\n            \"friendly_id\": \"AI:I1:N14:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N15:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        }\n    ]\n}\n</molecules>\n\n## Design Strategy Overview\n\nMy approach to designing these AKT1 inhibitors focused on several key medicinal chemistry principles:\n\n### 1. Hinge-Binding Motifs\n- Incorporated established kinase hinge-binding pharmacophores including:\n  - Aminopyrimidines (molecules 1, 2, 11, 14)\n  - Imidazoles (molecule 4)\n  - Triazoles (molecule 6)\n  - Quinazolines (molecule 15)\n  - Oxadiazoles (molecules 3, 7, 13)\n\n### 2. Binding Modes\n- **ATP-competitive inhibitors** (majority of designs): Target the ATP-binding pocket with appropriate hinge-binding elements\n- **Type II inhibitors** (molecules 2, 9): Include urea linkers to stabilize the DFG-out conformation\n- **Allosteric inhibitors** (molecules 5, 12): Target the PH domain-kinase domain interface\n\n### 3. Structural Features\n- **Solubilizing groups**: Incorporated piperazines, morpholines, and tertiary amines\n- **Metabolic stability**: Used fluorine substitutions, oxadiazoles, and methoxy groups\n- **Rigidity and spatial arrangement**: Employed amide linkers, ureas, and conformationally constrained cores\n\n### 4. Drug-Like Properties\n- Designed molecules with:\n  - MW generally between 420-550 Da\n  - LogP values in the 2.5-4 range\n  - Appropriate H-bond donors/acceptors (Lipinski compliant)\n  - Balanced solubility and permeability characteristics\n\nThese designs represent a diverse set of potential AKT1 inhibitors with varied scaffolds, binding modes, and physicochemical properties, providing a strong foundation for further optimization."
      }
    ]
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 2: Lead Optimization**\n\nBased on your previous designs, now optimize and refine your best candidates. Focus on:\n\n1. **Scaffold hopping**: Create variants of your most promising designs\n2. **Property optimization**: Improve drug-likeness, solubility, permeability\n3. **Selectivity enhancement**: Design features for AKT1 vs AKT2/AKT3 selectivity\n4. **ADMET optimization**: Consider metabolic stability and safety\n\nGenerate 8-12 optimized molecules that build upon your iteration 1 insights. Include:\n- Modified versions of your best scaffolds\n- New analogs with improved properties\n- Rationale for each modification based on medicinal chemistry principles"
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Lead Optimization\n\nBased on the initial designs, I'll now optimize the most promising candidates to enhance potency, selectivity, and drug-like properties. I'll focus on scaffold hopping, property optimization, and addressing potential ADMET issues.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F\",\n            \"friendly_id\": \"AI:I2:N1:G1\",\n            \"source\": \"AI:I1:N1:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N1:G0 with three key modifications: (1) Added a trifluoroethyl group to the piperazine to improve metabolic stability and reduce basicity, potentially improving brain penetration; (2) Introduced a fluorine on the pyridine ring to enhance binding affinity through additional interactions with the hinge region; (3) Maintained the core aminopyrimidine hinge-binding motif while optimizing the overall physicochemical profile. Expected improvements: better metabolic stability, reduced P-gp efflux liability, and potentially enhanced selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I2:N2:G1\",\n            \"source\": \"AI:I1:N2:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of AI:I1:N2:G0 by introducing a fluorine atom on the central phenyl ring to improve metabolic stability and binding affinity. The Type II inhibitor design is maintained with the urea linker for DFG-out conformation stabilization. The fluorine addition provides several benefits: (1) blocks a potential metabolic site; (2) enhances binding through additional interactions; (3) improves membrane permeability by reducing the overall hydrogen bonding capacity while maintaining the essential pharmacophore elements. Expected improvements: enhanced metabolic stability, potentially improved selectivity, and maintained solubility profile.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I2:N3:G1\",\n            \"source\": \"AI:I1:N3:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N3:G0 by introducing a trifluoromethyl group on the aminopyridine linker. This modification serves multiple purposes: (1) increases binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by blocking a potential site of oxidation; (3) enhances selectivity by exploiting a potential hydrophobic pocket unique to AKT1. The core oxadiazole and pyrimidine-pyridine hinge-binding motifs are preserved to maintain essential interactions. Expected improvements: enhanced potency, better metabolic profile, and potentially improved selectivity for AKT1 over AKT2/AKT3.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F\",\n            \"friendly_id\": \"AI:I2:N4:G1\",\n            \"source\": \"AI:I1:N4:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N4:G0 by replacing the pyridine with a difluoromethoxy-substituted pyridine. This modification: (1) introduces a metabolically stable difluoromethoxy group that serves as a hydrogen bond acceptor while providing lipophilicity; (2) enhances binding affinity through additional interactions; (3) improves metabolic stability by blocking oxidation sites. The imidazole core and N-methylpiperazine solubilizing group are maintained for their essential functions. Expected improvements: enhanced potency, better metabolic stability, and potentially improved blood-brain barrier penetration due to the balanced lipophilicity.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I2:N5:G1\",\n            \"source\": \"AI:I1:N5:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the allosteric inhibitor AI:I1:N5:G0 by replacing the tertiary amine with a Boc-protected amine. This prodrug approach: (1) masks the basic center to improve membrane permeability; (2) provides controlled release of the active compound after enzymatic cleavage; (3) potentially enhances oral bioavailability by reducing first-pass metabolism. The core indole scaffold and cyano-substituted aminopyrimidine are preserved for their essential interactions with the PH domain-kinase domain interface. Expected improvements: enhanced pharmacokinetic profile, improved oral bioavailability, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I2:N6:G1\",\n            \"source\": \"AI:I1:N6:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N6:G0 by introducing a fluorine atom on the dimethoxyphenyl group. This modification: (1) blocks a potential metabolic site on the aromatic ring; (2) provides additional binding interactions; (3) fine-tunes the electronic properties of the aromatic system. The triazole core for hinge binding and the sulfone linker are maintained for their essential functions. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained physicochemical properties for good oral bioavailability.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F\",\n            \"friendly_id\": \"AI:I2:N7:G1\",\n            \"source\": \"AI:I1:N8:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N8:G0 by replacing the pyridine with a trifluoromethyl-substituted pyridine. This modification: (1) enhances binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by replacing a potential metabolic liability; (3) fine-tunes the electronic properties of the hinge-binding element. The thiazole core, amide linker, and N-methylpiperazine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F\",\n            \"friendly_id\": \"AI:I2:N8:G1\",\n            \"source\": \"AI:I1:N9:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the Type II inhibitor AI:I1:N9:G0 by replacing the methoxy group with a difluoroethoxy group. This modification: (1) improves metabolic stability by blocking a potential site of O-demethylation; (2) enhances binding affinity through additional interactions; (3) provides a better balance of lipophilicity and hydrogen bonding capacity. The urea linker for DFG-out conformation stabilization and the N-methylimidazole core are preserved. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained ability to stabilize the inactive kinase conformation.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCN(CC5)S(=O)(=O)C\",\n            \"friendly_id\": \"AI:I2:N9:G1\",\n            \"source\": \"AI:I1:N10:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N10:G0 by replacing the morpholine derivative with a methylsulfonyl-piperazine. This modification: (1) reduces the basicity of the nitrogen while maintaining solubility; (2) provides additional binding interactions through the sulfonyl group; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The isoxazole core and aminopyrimidine hinge binder are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I2:N10:G1\",\n            \"source\": \"AI:I1:N11:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N11:G0 by introducing a chlorine atom on the aminopyridine linker. This modification: (1) enhances binding affinity through additional halogen bonding interactions; (2) blocks a potential metabolic site; (3) fine-tunes the electronic properties of the aromatic system. The trifluoromethyl group, aminopyrimidine hinge-binding motif, and morpholine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over AKT2/AKT3.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F\",\n            \"friendly_id\": \"AI:I2:N11:G1\",\n            \"source\": \"AI:I1:N12:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the allosteric inhibitor AI:I1:N12:G0 by introducing a fluorocyclopropane group. This modification: (1) enhances metabolic stability by blocking a potential site of oxidation; (2) provides additional binding interactions through the fluorine atom; (3) maintains the overall size and shape of the molecule while improving its properties. The xanthine core and sulfone linker are preserved for their essential functions in targeting the PH domain-kinase domain interface. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C(=O)CF\",\n            \"friendly_id\": \"AI:I2:N12:G1\",\n            \"source\": \"AI:I1:N13:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N13:G0 by replacing the N-methyl group with a fluoroacetyl group. This modification: (1) reduces the basicity of the piperazine nitrogen while maintaining solubility; (2) provides additional binding interactions through the fluorine atom; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The thiazole core, oxadiazole hinge binder, and amide linker are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        }\n    ]\n}\n</molecules>\n\n## Lead Optimization Strategy\n\nIn this optimization phase, I focused on refining the most promising candidates from Iteration 1 to enhance their drug-like properties, potency, selectivity, and ADMET profiles. Here's a summary of the key optimization strategies employed:\n\n### 1. Metabolic Stability Enhancements\n- **Fluorine incorporation**: Added strategic fluorine atoms to block metabolic hot spots (molecules 1, 2, 3, 6, 8, 10)\n- **Trifluoromethyl groups**: Introduced CF\u2083 groups to enhance stability and binding (molecules 3, 7, 10)\n- **Difluoromethoxy/ethoxy groups**: Replaced metabolically labile methoxy groups (molecules 4, 8)\n\n### 2. Selectivity Optimization\n- **Exploiting unique pockets**: Added substituents to target AKT1-specific binding regions (molecules 3, 7)\n- **Fine-tuning electronic properties**: Modified hinge-binding elements to enhance selectivity (molecules 4, 7)\n- **Halogen bonding**: Introduced chlorine for additional selective interactions (molecule 10)\n\n### 3. Pharmacokinetic Improvements\n- **Prodrug approach**: Implemented a Boc-protected amine to improve membrane permeability (molecule 5)\n- **Reduced basicity**: Modified basic centers to improve brain penetration and reduce P-gp efflux (molecules 1, 9, 12)\n- **Balanced lipophilicity**: Fine-tuned the hydrophobic/hydrophilic balance (molecules 4, 8)\n\n### 4. Binding Affinity Optimization\n- **Additional H-bond interactions**: Introduced groups capable of forming new H-bonds (molecules 4, 8)\n- **Halogen bonding**: Added fluorine and chlorine atoms for enhanced interactions (molecules 1, 10)\n- **Hydrophobic interactions**: Optimized lipophilic groups for better pocket complementarity (molecules 3, 7)\n\n### 5. Scaffold Preservation\nWhile making these modifications, I carefully preserved the core pharmacophores identified in Iteration 1:\n- ATP-competitive hinge-binding motifs (aminopyrimidines, imidazoles, etc.)\n- Type II inhibitor urea linkers\n- Allosteric binding elements for PH domain-kinase domain interface targeting\n\nThese optimized compounds represent a focused set of candidates with improved properties while maintaining the essential structural features required for AKT1 inhibition. The modifications were guided by established medicinal chemistry principles to address potential liabilities while enhancing desirable characteristics."
      }
    ]
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "\nYou are the Summary Parser Agent. Your task is to read the output from the previous agent, extract relevant information, and format it into a JSON object that conforms to the GURNEMANZ JSON spec. A critical part of your role is to track molecule history by checking previous steps in the history to include the `parent_molecule_id` for derived molecules, ensuring GURNEMANZ maintains the molecule transformation chain.\nDO NOT FORGET TO INCLUDE THE friendly_id IN THE JSON OUTPUT and parent_friendly_id if the molecule is a child of a parent molecule !.\n### Input\n- The full output from the previous agent in plain text format. (IMPORTANT NOTE: all important details of research in the output of Literature Agent has to be stored in the transformation rationale field)\n- The history, a list of previous steps, each containing a transformation and possibly molecules with assigned moleculeIds.\n- The current iteration number\n- The agent title: \"LLM Drug Designer\" - You MUST use this exact title as the agent name in your output\n\n### Output\n- A JSON object with transformation and molecules, wrapped in `<gurnemanz>` tags (e.g., `<gurnemanz>{ \"transformation\": { ... }, \"molecules\": [ ... ] }</gurnemanz>`).\n\n### Steps to Follow\n1. **Analyze the Input:**\n   - Extract the transformation type, agent name, general rationale, molecule data (SMILES, specific rationales), and any protein-related data (like protein_sequence and protein_path) from the previous agent's output.\n   - Parse information from headers, bullet points, and descriptive text in the agent's response.\n\n2. **Determine Transformation Details:**\n   - Set \"iteration\" to the provided iteration number.\n   - Set type based on the agent's action (e.g., \"molecule-generation\" for new designs, \"property-prediction\" for evaluations or calculations).\n   - Set agent to the name of the previous agent (e.g., \"Medicinal Chemist\").\n   - Summarize the general rationale from the agent's intent or summary.\n   - Look for mentions of protein sequences in the text. If the agent mentions or provides a protein sequence ,or just sequence, include this sequence in the \"protein_sequence\" field of the transformation object.\n   - Look for mentions of protein PDB files in the text. If the agent mentions or provides a path to a protein PDB file, include this path in the \"protein_path\" field of the transformation object.\n\n3. **Process Molecules and Track History:**\n   - For each molecule in the agent's output:\n     - Look for patterns like \"Molecule X\", \"ID:\", \"SMILES:\", etc., to identify molecules and their properties.\n     - **Check if it's De novo or Derived:**\n       - **De novo Molecule:** If the SMILES does not appear in the history and there's no indication of modification (e.g., \"de novo\" or \"designed from scratch\"), set properties.status: \"de novo\" and omit properties.parent_molecule_id.\n       - **Derived Molecule:** If the SMILES matches a molecule in the history or the rationale suggests modification (e.g., \"repositioning,\" \"replacing,\" \"evaluated\"):\n         - Search the history chronologically for a molecule with the same SMILES.\n         - Retrieve the moleculeId of the matching molecule from the history\u2014this is the parent_molecule_id.\n         - Set properties.parent_molecule_id to this ID and properties.status: \"modified\".\n     - **Handle Modifications:**\n       - If the SMILES differs slightly from a historical molecule but the rationale indicates it's a modification (e.g., \"fluorine replaced with chlorine\"), find the closest matching parent SMILES in the history and use its Molecule ID as parent_molecule_id.\n     - **Reusing Unchanged Molecules:**\n       - When the agent explicitly references a molecule by `moleculeId` and there is no indication of a structural change, carry that `moleculeId` forward in the output and omit a new structure. This prevents creation of duplicate molecule entries for the same SMILES.\n     - **Populate Fields:**\n       - Set structure.smiles to the molecule's SMILES.\n       - Include a properties object for EVERY molecule, with status and, if derived, parent_molecule_id.\n       - Add any calculated properties (e.g., docking score, logP, pChEMBL, qed, sas) to computed_properties.\n       - Set rationale to the molecule-specific reasoning from the agent.\n       - If there is any relevant file path in the previous agent's response, for example to a pdb folder, include this in the rationale as well\n\n4. **Format the JSON:**\n   - Structure the output with transformation and molecules at the top level.\n\n5. **Validate:**\n   - Verify that derived molecules have a parent_molecule_id matching a historical molecule_id; if unclear, note in rationale (e.g., \"Parent unclear due to missing history match\").\n\n6. **Output:**\n   - Wrap the JSON in `<gurnemanz>` tags.\n\n### Example: Agent Output Format and Parsing\nThe history will look like this:\n```\n## Transformation\n- Type: data-retrieval\n- Agent: Ai expert\n- Iteration: 1\n- ID: ceb63937-5bd9-48b3-9ac6-ccc443944e4c\n- Rationale: Generated de novo molecules for AKT1\n\n## Molecules\n\n### Molecule 1\n- ID: 4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88\n- SMILES: COc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F\n- Properties:\n  * Status: de novo\n- Computed Properties:\n  * logP: 3.7169\n  * pChEMBL: 8.3\n  * qed: 0.285355\n  * sas: 3.507\n- Rationale: De novo compound for AKT1 with high potency (pChEMBL 8.3).\n```\n\nThe previous agents response you receive as input:\n```json\nMedcicinal chemist: I've edited the de novo molecule of the ai expert in this way\nCOc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F(=c3ccncc3)\nrationale: improved binding\n```\n\nExpected Output:\n```\n<gurnemanz>\n{\n  \"transformation\": {\n    \"type\": \"lead-optimization\",\n    \"agent\": \"Medicinal Chemist\",\n    \"user_message\": \"improved molecule binding\",\n    \"rationale\": \"edited molecule for improved binding\",\n    \"protein_sequence\": \"MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYFEYLKLDYLHSEIRFPHFPQFSYSASGTA\" # Include if a protein sequence is mentioned in the agent output\n    \"protein_path\": \"/path/to/protein.pdb\",  # Include only if a protein path is mentioned in the agent output\n    \"iteration\": 2\n  },\n  \"molecules\": [\n    {\n      \"structure\": {\n        \"smiles\": \"COc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F(=c3ccncc3)\"\n      },\n      \"properties\": {\n        \"parent_molecule_id\": \"4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88\",\n        \"status\": \"modified\"\n      },\n      \"computed_properties\": {},\n      \"rationale\": \"Fluorine at 4-position of pyridine is synthetically accessible but may present regioselectivity challenges\"\n    }\n  ]\n}\n</gurnemanz>\n```\n\n### IMPORTANT REQUIREMENTS\n1. **Every molecule MUST have a properties object** with at minimum a status field.\n2. **Derived molecules MUST include parent_molecule_id** in the properties object.\n3. **SMILES matching is critical** - When a molecule with the same SMILES appears in a new step, it's derived, not de novo.\n4. **Look through the entire history** to find matching molecules and their molecule_ids.\n5. **Look for ID fields in the text output** - When you see patterns like \"ID: 4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88\" in the agent output, this may be a molecule ID that becomes the parent_molecule_id for derived molecules.\n6. **If an agent outputs a file path to a protein PDB file** add this path in the \"protein_path\" field in the transformation object. Look for paths containing \".pdb\" extensions or mentions of protein structure files. For example, if the agent says \"I used /path/to/protein.pdb for docking\", extract \"/path/to/protein.pdb\" as the protein_path.\nVERY IMPORTANT NOTE FOR LITERATURE AGENT PARSING: Including ALL important details provided by the literature agent in the transformations rationale field!!!!! the other agents RELY on this information! do NOT summarize the response and omit key information. all relevant output of the literature HAS TO GO INTO THE RATIONALE. Also double check if there might be protein sequences or smiles in the response to add them in the appropriate fields.\n\nIteration Number:\n2\nAgent Title:\nLLM Drug Designer\n"
      }
    ]
  }
]
2025-06-23 14:04:42,620 - INFO - response ModelResponse(id='chatcmpl-1587e528-8708-431f-8296-d9a531e82463', created=1750676682, model='claude-3-7-sonnet-20250219', object='chat.completion', system_fingerprint=None, choices=[Choices(finish_reason='tool_calls', index=0, message=Message(content="I'll parse the output from the LLM Drug Designer and format it into the GURNEMANZ JSON specification, ensuring all molecule relationships are properly tracked.", role='assistant', tool_calls=[ChatCompletionMessageToolCall(index=1, function=Function(arguments='{"client_name": "claude", "session_id": "session-123", "parent_transformation_id": "transformation-123", "transformation": {"type": "lead-optimization", "agent": "LLM Drug Designer", "iteration": 2, "rationale": "Optimization of AKT1 inhibitor candidates focusing on scaffold hopping, property optimization, selectivity enhancement, and ADMET optimization. Key strategies included: (1) Metabolic stability enhancements through fluorine incorporation, trifluoromethyl groups, and difluoromethoxy/ethoxy substitutions; (2) Selectivity optimization by exploiting unique pockets, fine-tuning electronic properties, and introducing halogen bonding; (3) Pharmacokinetic improvements via prodrug approaches, reduced basicity, and balanced lipophilicity; (4) Binding affinity optimization through additional H-bond interactions, halogen bonding, and optimized hydrophobic interactions; (5) Careful preservation of core pharmacophores including ATP-competitive hinge-binding motifs, Type II inhibitor urea linkers, and allosteric binding elements."}, "molecules": [{"structure": {"smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F"}, "friendly_id": "AI:I2:N1:G1", "parent_friendly_id": "AI:I1:N1:G0", "rationale": "Optimization of AI:I1:N1:G0 with three key modifications: (1) Added a trifluoroethyl group to the piperazine to improve metabolic stability and reduce basicity, potentially improving brain penetration; (2) Introduced a fluorine on the pyridine ring to enhance binding affinity through additional interactions with the hinge region; (3) Maintained the core aminopyrimidine hinge-binding motif while optimizing the overall physicochemical profile. Expected improvements: better metabolic stability, reduced P-gp efflux liability, and potentially enhanced selectivity for AKT1."}, {"structure": {"smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N"}, "friendly_id": "AI:I2:N2:G1", "parent_friendly_id": "AI:I1:N2:G0", "rationale": "Refinement of AI:I1:N2:G0 by introducing a fluorine atom on the central phenyl ring to improve metabolic stability and binding affinity. The Type II inhibitor design is maintained with the urea linker for DFG-out conformation stabilization. The fluorine addition provides several benefits: (1) blocks a potential metabolic site; (2) enhances binding through additional interactions; (3) improves membrane permeability by reducing the overall hydrogen bonding capacity while maintaining the essential pharmacophore elements. Expected improvements: enhanced metabolic stability, potentially improved selectivity, and maintained solubility profile."}, {"structure": {"smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5"}, "friendly_id": "AI:I2:N3:G1", "parent_friendly_id": "AI:I1:N3:G0", "rationale": "Enhancement of AI:I1:N3:G0 by introducing a trifluoromethyl group on the aminopyridine linker. This modification serves multiple purposes: (1) increases binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by blocking a potential site of oxidation; (3) enhances selectivity by exploiting a potential hydrophobic pocket unique to AKT1. The core oxadiazole and pyrimidine-pyridine hinge-binding motifs are preserved to maintain essential interactions. Expected improvements: enhanced potency, better metabolic profile, and potentially improved selectivity for AKT1 over AKT2/AKT3."}, {"structure": {"smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F"}, "friendly_id": "AI:I2:N4:G1", "parent_friendly_id": "AI:I1:N4:G0", "rationale": "Optimization of AI:I1:N4:G0 by replacing the pyridine with a difluoromethoxy-substituted pyridine. This modification: (1) introduces a metabolically stable difluoromethoxy group that serves as a hydrogen bond acceptor while providing lipophilicity; (2) enhances binding affinity through additional interactions; (3) improves metabolic stability by blocking oxidation sites. The imidazole core and N-methylpiperazine solubilizing group are maintained for their essential functions. Expected improvements: enhanced potency, better metabolic stability, and potentially improved blood-brain barrier penetration due to the balanced lipophilicity."}, {"structure": {"smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N"}, "friendly_id": "AI:I2:N5:G1", "parent_friendly_id": "AI:I1:N5:G0", "rationale": "Refinement of the allosteric inhibitor AI:I1:N5:G0 by replacing the tertiary amine with a Boc-protected amine. This prodrug approach: (1) masks the basic center to improve membrane permeability; (2) provides controlled release of the active compound after enzymatic cleavage; (3) potentially enhances oral bioavailability by reducing first-pass metabolism. The core indole scaffold and cyano-substituted aminopyrimidine are preserved for their essential interactions with the PH domain-kinase domain interface. Expected improvements: enhanced pharmacokinetic profile, improved oral bioavailability, and maintained selectivity for AKT1."}, {"structure": {"smiles": "COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F"}, "friendly_id": "AI:I2:N6:G1", "parent_friendly_id": "AI:I1:N6:G0", "rationale": "Enhancement of AI:I1:N6:G0 by introducing a fluorine atom on the dimethoxyphenyl group. This modification: (1) blocks a potential metabolic site on the aromatic ring; (2) provides additional binding interactions; (3) fine-tunes the electronic properties of the aromatic system. The triazole core for hinge binding and the sulfone linker are maintained for their essential functions. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained physicochemical properties for good oral bioavailability."}, {"structure": {"smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F"}, "friendly_id": "AI:I2:N7:G1", "parent_friendly_id": "AI:I1:N8:G0", "rationale": "Optimization of AI:I1:N8:G0 by replacing the pyridine with a trifluoromethyl-substituted pyridine. This modification: (1) enhances binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by replacing a potential metabolic liability; (3) fine-tunes the electronic properties of the hinge-binding element. The thiazole core, amide linker, and N-methylpiperazine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over other kinases."}, {"structure": {"smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F"}, "friendly_id": "AI:I2:N8:G1", "parent_friendly_id": "AI:I1:N9:G0", "rationale": "Refinement of the Type II inhibitor AI:I1:N9:G0 by replacing the methoxy group with a difluoroethoxy group. This modification: (1) improves metabolic stability by blocking a potential site of O-demethylation; (2) enhances binding affinity through additional interactions; (3) provides a better balance of lipophilicity and hydrogen bonding capacity. The urea linker for DFG-out conformation stabilization and the N-methylimidazole core are preserved. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained ability to stabilize the inactive kinase conformation."}, {"structure": {"smiles": "COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCN(CC5)S(=O)(=O)C"}, "friendly_id": "AI:I2:N9:G1", "parent_friendly_id": "AI:I1:N10:G0", "rationale": "Enhancement of AI:I1:N10:G0 by replacing the morpholine derivative with a methylsulfonyl-piperazine. This modification: (1) reduces the basicity of the nitrogen while maintaining solubility; (2) provides additional binding interactions through the sulfonyl group; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The isoxazole core and aminopyrimidine hinge binder are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1."}, {"structure": {"smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4"}, "friendly_id": "AI:I2:N10:G1", "parent_friendly_id": "AI:I1:N11:G0", "rationale": "Optimization of AI:I1:N11:G0 by introducing a chlorine atom on the aminopyridine linker. This modification: (1) enhances binding affinity through additional halogen bonding interactions; (2) blocks a potential metabolic site; (3) fine-tunes the electronic properties of the aromatic system. The trifluoromethyl group, aminopyrimidine hinge-binding motif, and morpholine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over AKT2/AKT3."}, {"structure": {"smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F"}, "friendly_id": "AI:I2:N11:G1", "parent_friendly_id": "AI:I1:N12:G0", "rationale": "Refinement of the allosteric inhibitor AI:I1:N12:G0 by introducing a fluorocyclopropane group. This modification: (1) enhances metabolic stability by blocking a potential site of oxidation; (2) provides additional binding interactions through the fluorine atom; (3) maintains the overall size and shape of the molecule while improving its properties. The xanthine core and sulfone linker are preserved for their essential functions in targeting the PH domain-kinase domain interface. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained selectivity for AKT1."}, {"structure": {"smiles": "CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C(=O)CF"}, "friendly_id": "AI:I2:N12:G1", "parent_friendly_id": "AI:I1:N13:G0", "rationale": "Enhancement of AI:I1:N13:G0 by replacing the N-methyl group with a fluoroacetyl group. This modification: (1) reduces the basicity of the piperazine nitrogen while maintaining solubility; (2) provides additional binding interactions through the fluorine atom; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The thiazole core, oxadiazole hinge binder, and amide linker are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1."}]}', name='gurnemanz_apply'), id='toolu_01KPa3x5xqToLRDrnH8crspK', type='function')], function_call=None, provider_specific_fields={'citations': []}, citations=[]))], usage=Usage(completion_tokens=3731, prompt_tokens=12731, total_tokens=16462, completion_tokens_details=None, prompt_tokens_details=PromptTokensDetailsWrapper(audio_tokens=None, cached_tokens=0, text_tokens=None, image_tokens=None), cache_creation_input_tokens=0, cache_read_input_tokens=0))
2025-06-23 14:04:42,628 - INFO - result_dict {'gurnemanz_apply': {'molecules': [{'moleculeId': '69c29d3f-b6c7-4994-8d4f-404663785c77', 'originalData': {'friendlyId': 'AI:I2:N1:G1', 'parentFriendlyId': 'AI:I1:N1:G0', 'rationale': 'Optimization of AI:I1:N1:G0 with three key modifications: (1) Added a trifluoroethyl group to the piperazine to improve metabolic stability and reduce basicity, potentially improving brain penetration; (2) Introduced a fluorine on the pyridine ring to enhance binding affinity through additional interactions with the hinge region; (3) Maintained the core aminopyrimidine hinge-binding motif while optimizing the overall physicochemical profile. Expected improvements: better metabolic stability, reduced P-gp efflux liability, and potentially enhanced selectivity for AKT1.', 'structure': {'smiles': 'CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F'}}}, {'moleculeId': 'c6352ae7-c15d-47ea-84f7-d29122345a0f', 'originalData': {'friendlyId': 'AI:I2:N2:G1', 'parentFriendlyId': 'AI:I1:N2:G0', 'rationale': 'Refinement of AI:I1:N2:G0 by introducing a fluorine atom on the central phenyl ring to improve metabolic stability and binding affinity. The Type II inhibitor design is maintained with the urea linker for DFG-out conformation stabilization. The fluorine addition provides several benefits: (1) blocks a potential metabolic site; (2) enhances binding through additional interactions; (3) improves membrane permeability by reducing the overall hydrogen bonding capacity while maintaining the essential pharmacophore elements. Expected improvements: enhanced metabolic stability, potentially improved selectivity, and maintained solubility profile.', 'structure': {'smiles': 'COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N'}}}, {'moleculeId': '6fc8a494-f304-44a8-90ca-564e61507ccb', 'originalData': {'friendlyId': 'AI:I2:N3:G1', 'parentFriendlyId': 'AI:I1:N3:G0', 'rationale': 'Enhancement of AI:I1:N3:G0 by introducing a trifluoromethyl group on the aminopyridine linker. This modification serves multiple purposes: (1) increases binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by blocking a potential site of oxidation; (3) enhances selectivity by exploiting a potential hydrophobic pocket unique to AKT1. The core oxadiazole and pyrimidine-pyridine hinge-binding motifs are preserved to maintain essential interactions. Expected improvements: enhanced potency, better metabolic profile, and potentially improved selectivity for AKT1 over AKT2/AKT3.', 'structure': {'smiles': 'CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5'}}}, {'moleculeId': '36e037ad-1bdf-49a5-9560-c5fee9a57556', 'originalData': {'friendlyId': 'AI:I2:N4:G1', 'parentFriendlyId': 'AI:I1:N4:G0', 'rationale': 'Optimization of AI:I1:N4:G0 by replacing the pyridine with a difluoromethoxy-substituted pyridine. This modification: (1) introduces a metabolically stable difluoromethoxy group that serves as a hydrogen bond acceptor while providing lipophilicity; (2) enhances binding affinity through additional interactions; (3) improves metabolic stability by blocking oxidation sites. The imidazole core and N-methylpiperazine solubilizing group are maintained for their essential functions. Expected improvements: enhanced potency, better metabolic stability, and potentially improved blood-brain barrier penetration due to the balanced lipophilicity.', 'structure': {'smiles': 'CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F'}}}, {'moleculeId': '0e29a281-ded9-49c6-86dc-d886bc5b9287', 'originalData': {'friendlyId': 'AI:I2:N5:G1', 'parentFriendlyId': 'AI:I1:N5:G0', 'rationale': 'Refinement of the allosteric inhibitor AI:I1:N5:G0 by replacing the tertiary amine with a Boc-protected amine. This prodrug approach: (1) masks the basic center to improve membrane permeability; (2) provides controlled release of the active compound after enzymatic cleavage; (3) potentially enhances oral bioavailability by reducing first-pass metabolism. The core indole scaffold and cyano-substituted aminopyrimidine are preserved for their essential interactions with the PH domain-kinase domain interface. Expected improvements: enhanced pharmacokinetic profile, improved oral bioavailability, and maintained selectivity for AKT1.', 'structure': {'smiles': 'CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N'}}}, {'moleculeId': 'cbee8abf-2840-493a-ac54-be785d77a5b6', 'originalData': {'friendlyId': 'AI:I2:N6:G1', 'parentFriendlyId': 'AI:I1:N6:G0', 'rationale': 'Enhancement of AI:I1:N6:G0 by introducing a fluorine atom on the dimethoxyphenyl group. This modification: (1) blocks a potential metabolic site on the aromatic ring; (2) provides additional binding interactions; (3) fine-tunes the electronic properties of the aromatic system. The triazole core for hinge binding and the sulfone linker are maintained for their essential functions. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained physicochemical properties for good oral bioavailability.', 'structure': {'smiles': 'COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F'}}}, {'moleculeId': '1fe4cf6d-0e77-4c8e-a582-390070b85e8f', 'originalData': {'friendlyId': 'AI:I2:N7:G1', 'parentFriendlyId': 'AI:I1:N8:G0', 'rationale': 'Optimization of AI:I1:N8:G0 by replacing the pyridine with a trifluoromethyl-substituted pyridine. This modification: (1) enhances binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by replacing a potential metabolic liability; (3) fine-tunes the electronic properties of the hinge-binding element. The thiazole core, amide linker, and N-methylpiperazine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over other kinases.', 'structure': {'smiles': 'CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F'}}}, {'moleculeId': '6e226391-ca00-4560-b9ac-0fdb7fea675e', 'originalData': {'friendlyId': 'AI:I2:N8:G1', 'parentFriendlyId': 'AI:I1:N9:G0', 'rationale': 'Refinement of the Type II inhibitor AI:I1:N9:G0 by replacing the methoxy group with a difluoroethoxy group. This modification: (1) improves metabolic stability by blocking a potential site of O-demethylation; (2) enhances binding affinity through additional interactions; (3) provides a better balance of lipophilicity and hydrogen bonding capacity. The urea linker for DFG-out conformation stabilization and the N-methylimidazole core are preserved. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained ability to stabilize the inactive kinase conformation.', 'structure': {'smiles': 'CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F'}}}, {'moleculeId': 'f50a143e-7e4f-4517-9662-2374028cfc91', 'originalData': {'friendlyId': 'AI:I2:N9:G1', 'parentFriendlyId': 'AI:I1:N10:G0', 'rationale': 'Enhancement of AI:I1:N10:G0 by replacing the morpholine derivative with a methylsulfonyl-piperazine. This modification: (1) reduces the basicity of the nitrogen while maintaining solubility; (2) provides additional binding interactions through the sulfonyl group; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The isoxazole core and aminopyrimidine hinge binder are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.', 'structure': {'smiles': 'COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCN(CC5)S(=O)(=O)C'}}}, {'moleculeId': '31da8379-0627-482f-88b6-133e7c1fc7e0', 'originalData': {'friendlyId': 'AI:I2:N10:G1', 'parentFriendlyId': 'AI:I1:N11:G0', 'rationale': 'Optimization of AI:I1:N11:G0 by introducing a chlorine atom on the aminopyridine linker. This modification: (1) enhances binding affinity through additional halogen bonding interactions; (2) blocks a potential metabolic site; (3) fine-tunes the electronic properties of the aromatic system. The trifluoromethyl group, aminopyrimidine hinge-binding motif, and morpholine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over AKT2/AKT3.', 'structure': {'smiles': 'CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4'}}}, {'moleculeId': '37cff1d8-4f13-4129-b2b7-d8c719d4d6a1', 'originalData': {'friendlyId': 'AI:I2:N11:G1', 'parentFriendlyId': 'AI:I1:N12:G0', 'rationale': 'Refinement of the allosteric inhibitor AI:I1:N12:G0 by introducing a fluorocyclopropane group. This modification: (1) enhances metabolic stability by blocking a potential site of oxidation; (2) provides additional binding interactions through the fluorine atom; (3) maintains the overall size and shape of the molecule while improving its properties. The xanthine core and sulfone linker are preserved for their essential functions in targeting the PH domain-kinase domain interface. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained selectivity for AKT1.', 'structure': {'smiles': 'CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F'}}}, {'moleculeId': 'ddc94d30-d965-45d7-ba64-0e9f8ab59a20', 'originalData': {'friendlyId': 'AI:I2:N12:G1', 'parentFriendlyId': 'AI:I1:N13:G0', 'rationale': 'Enhancement of AI:I1:N13:G0 by replacing the N-methyl group with a fluoroacetyl group. This modification: (1) reduces the basicity of the piperazine nitrogen while maintaining solubility; (2) provides additional binding interactions through the fluorine atom; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The thiazole core, oxadiazole hinge binder, and amide linker are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.', 'structure': {'smiles': 'CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C(=O)CF'}}}], 'transformation': {'agent': 'LLM Drug Designer', 'iteration': 2, 'methodDetails': None, 'proteinPath': None, 'proteinSequence': None, 'rationale': 'Optimization of AKT1 inhibitor candidates focusing on scaffold hopping, property optimization, selectivity enhancement, and ADMET optimization. Key strategies included: (1) Metabolic stability enhancements through fluorine incorporation, trifluoromethyl groups, and difluoromethoxy/ethoxy substitutions; (2) Selectivity optimization by exploiting unique pockets, fine-tuning electronic properties, and introducing halogen bonding; (3) Pharmacokinetic improvements via prodrug approaches, reduced basicity, and balanced lipophilicity; (4) Binding affinity optimization through additional H-bond interactions, halogen bonding, and optimized hydrophobic interactions; (5) Careful preservation of core pharmacophores including ATP-competitive hinge-binding motifs, Type II inhibitor urea linkers, and allosteric binding elements.', 'transformationId': 'a440fa32-db18-4c5d-a50c-5d5a184026f9', 'type': 'lead-optimization', 'userMessage': None}}}
2025-06-23 14:04:42,628 - INFO - DEBUG: tools: [{'type': 'function', 'function': {'name': 'gurnemanz_apply', 'description': 'Submit transformation and molecule data to GURNEMANZ and retrieve the response with IDs. The Haskell service returns the full data structure with embedded IDs, providing better traceability between molecules and their IDs.', 'parameters': {'type': 'object', 'properties': {'session_id': {'type': 'string', 'description': 'Session UUID from creation (required for tracking transformations across sessions)'}, 'parent_transformation_id': {'type': 'string', 'description': 'ID of the parent transformation (required for tracking transformation chains)'}, 'client_name': {'type': 'string', 'description': 'Use claude for client name', 'default': 'claude'}, 'transformation': {'type': 'object', 'description': 'Details of the transformation being applied', 'properties': {'type': {'type': 'string', 'description': "Required: Type of transformation (e.g., 'molecule-generation', 'property-prediction')"}, 'agent': {'type': 'string', 'description': 'Required: Name of the agent performing the transformation'}, 'user_message': {'type': 'string', 'description': 'Optional: Human-readable message about the transformation'}, 'method_details': {'type': 'object', 'description': 'Optional: Details about the method used in the transformation', 'properties': {'method_id': {'type': 'string', 'description': 'Required if methodDetails is present: Identifier of the method used'}}, 'required': ['method_id']}, 'rationale': {'type': 'string', 'description': 'Optional: General rationale for the transformation'}, 'protein_sequence': {'type': 'string', 'description': 'Optional: Protein sequence associated with the transformation'}, 'protein_path': {'type': 'string', 'description': 'Optional: Path to the protein pdb file associated with the transformation'}, 'iteration': {'type': 'integer', 'description': 'Required: Iteration number for this transformation'}}, 'required': ['type', 'agent', 'iteration']}, 'molecules': {'type': 'array', 'description': 'Array of molecule objects generated or modified in this transformation', 'items': {'type': 'object', 'properties': {'structure': {'type': 'object', 'description': 'Required: Molecular structure information', 'properties': {'smiles': {'type': 'string', 'description': 'Required: SMILES string representation'}}, 'required': ['smiles']}, 'properties': {'type': 'object', 'description': 'Optional: Molecule properties', 'properties': {'parent_molecule_id': {'type': 'string', 'description': 'Optional: ID of parent molecule'}, 'molecular_weight': {'type': 'number', 'description': 'Optional: Molecular weight'}, 'status': {'type': 'string', 'description': "Optional: Molecule status (e.g., 'modified', 'de novo')"}}}, 'computed_properties': {'type': 'object', 'description': 'Optional: Computed or predicted properties', 'properties': {'logP': {'type': 'number', 'description': 'Optional: Lipophilicity'}, 'qed': {'type': 'number', 'description': 'Optional: Quantitative estimate of drug-likeness'}, 'sas': {'type': 'number', 'description': 'Optional: Synthetic accessibility score'}, 'lipinski_count': {'type': 'integer', 'description': "Optional: Number of Lipinski's Rule of Five violations"}, 'docking_score': {'type': 'number', 'description': 'Optional: Docking score (if applicable)'}, 'plip_interactions': {'type': 'string', 'description': 'Optional: Protein-ligand interaction information'}}}, 'rationale': {'type': 'string', 'description': 'Required: Reasoning specific to this molecule'}, 'activity': {'type': 'string', 'description': "Optional: Activity status of the molecule (e.g., 'active', 'inactive')"}, 'friendly_id': {'type': 'string', 'description': 'Friendly ID of the molecule'}, 'parent_friendly_id': {'type': 'string', 'description': 'Optional: Friendly ID of the parent molecule, only molecules created by Medicinal Chemist can have parents'}}, 'required': ['structure', 'rationale', 'friendly_id']}}}, 'required': ['session_id', 'parent_transformation_id', 'transformation', 'molecules', 'client_name']}}}]
2025-06-23 14:04:42,629 - INFO - chat history for chat completion: [
  {
    "role": "system",
    "content": "You are an AI assistant acting as Summary Parser. Your expertise is in ('Interpreting unstructured research outputs', 'Generating structured JSON data', 'Maintaining data consistency across transformations'). Your goal is to Format LLM outputs into GURNEMANZ JSON schema and submit them while maintaining all important relationships between data elements.. Your role is to Parse LLM outputs to construct a clean formatted JSON that preserves all relevant information about molecules and their design rationales.. Please maintain this role throughout our conversation.\n\n\nDruing the discovery process, molecules will be presented with a friendly_id. This friendly_id is a unique identifier that tracks its complete history and lineage through our optimization process to help to follow the SAR and parent-child relationships.\n\n## Molecule ID System - Tracking Molecular Evolution\n\nEach molecule receives a unique identifier that tracks its complete history and lineage through our optimization process.\n\n**Format:** `AgentCode:I<iteration>:N<position>:G<generation>`\n\nThis ID (friendly_id) system serves as a molecular genealogy, allowing us to:\n- Track which agent created or modified each molecule\n- Understand the evolutionary path from original to optimized compounds\n- Maintain parent-child relationships across modifications\n\n**Components:**\n- **AgentCode**: Two-letter code representing the creator agent\n  - DA = Database Agent\n  - AI = AI Expert\n  - MC = Medicinal Chemist\n  - LA = Literature Agent\n  - RA = Ranking Agent\n  - PR = Principal Researcher\n  - SC = Scientific Critic\n  - SP = Summary Parser\n\n- **I<iteration>**: The research iteration number when molecule was introduced (e.g., I1, I2, I3)\n- **N<position>**: The molecule's position in the agent's output list, starting from N1 (resets per agent output)\n- **G<generation>**: The modification depth showing molecular evolution\n  - G0 = original molecule (from database or de novo)\n  - G1 = first modification\n  - G2 = second modification\n  - And so on...\n\n**Example Evolution:**\n1. Database retrieves: `DA:I1:N3:G0` (original from ChEMBL, third molecule in list, iteration 1)\n2. Medicinal Chemist modifies it: `MC:I2:N1:G1` (first modification, first molecule in chemist's list, iteration 2)\n3. Further optimization: `MC:I3:N2:G2` (second modification, second molecule in list, iteration 3)\n\nThis allows us to trace any molecule back to its origins and understand its optimization journey.\nIf a molecule is a child of a parent molecule, the parent molecule's friendly_id must be included in the molecule's source field\n"
  },
  {
    "role": "user",
    "content": "You are an expert medicinal chemist and computational drug discovery scientist. Your task is to design novel small molecule inhibitors for AKT1 (Protein Kinase B alpha) using your knowledge of structure-activity relationships, medicinal chemistry principles, and drug design.\n\n**Target Information:**\n- AKT1 is a serine/threonine kinase in the PI3K/AKT/mTOR pathway\n- Critical for cell survival, proliferation, and metabolism\n- Key oncology target with multiple known inhibitors\n- ATP-competitive and allosteric binding sites available\n\n**Your Goal:**\nGenerate novel, drug-like small molecule AKT1 inhibitors with the following criteria:\n- High predicted binding affinity to AKT1\n- Drug-like properties (Lipinski's Rule of Five compliance)\n- Synthetic accessibility\n- Novel scaffolds not directly copied from known inhibitors\n\n**Output Format:**\nFor each molecule, provide:\n1. **Molecule ID**: A unique identifier (e.g., LLM_MOL_001)\n2. **SMILES**: Valid SMILES string\n3. **Rationale**: Brief explanation of your design strategy and expected properties\n4. **Predicted Properties**: Your assessment of drug-likeness, potency, selectivity\n\nFocus on innovative chemical designs while maintaining scientific rigor."
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 1: Initial Discovery & Exploration**\n\nDesign 10-15 novel AKT1 inhibitor molecules using your medicinal chemistry expertise. Consider:\n\n1. **ATP-competitive inhibitors**: Target the ATP-binding pocket with novel scaffolds\n2. **Allosteric inhibitors**: Design molecules that bind to regulatory sites\n3. **Hybrid approaches**: Molecules that may interact with multiple binding sites\n\nUse your knowledge of:\n- Known AKT1 pharmacophores (avoid direct copying)\n- Kinase selectivity determinants\n- Drug-like chemical space\n- Structure-activity relationships\n\nGenerate diverse scaffolds including heterocycles, aromatic systems, and appropriate linkers. Ensure synthetic feasibility while prioritizing novelty."
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Initial Discovery\n\nI'll design novel AKT1 inhibitors using medicinal chemistry principles and my knowledge of kinase inhibitor design. I'll focus on creating diverse, drug-like molecules with appropriate pharmacophores for AKT1 inhibition.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N1:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I1:N2:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N3:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N4:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I1:N5:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I1:N6:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N7:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N8:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC\",\n            \"friendly_id\": \"AI:I1:N9:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5\",\n            \"friendly_id\": \"AI:I1:N10:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I1:N11:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5\",\n            \"friendly_id\": \"AI:I1:N12:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C\",\n            \"friendly_id\": \"AI:I1:N13:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5\",\n            \"friendly_id\": \"AI:I1:N14:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N15:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        }\n    ]\n}\n</molecules>\n\n## Design Strategy Overview\n\nMy approach to designing these AKT1 inhibitors focused on several key medicinal chemistry principles:\n\n### 1. Hinge-Binding Motifs\n- Incorporated established kinase hinge-binding pharmacophores including:\n  - Aminopyrimidines (molecules 1, 2, 11, 14)\n  - Imidazoles (molecule 4)\n  - Triazoles (molecule 6)\n  - Quinazolines (molecule 15)\n  - Oxadiazoles (molecules 3, 7, 13)\n\n### 2. Binding Modes\n- **ATP-competitive inhibitors** (majority of designs): Target the ATP-binding pocket with appropriate hinge-binding elements\n- **Type II inhibitors** (molecules 2, 9): Include urea linkers to stabilize the DFG-out conformation\n- **Allosteric inhibitors** (molecules 5, 12): Target the PH domain-kinase domain interface\n\n### 3. Structural Features\n- **Solubilizing groups**: Incorporated piperazines, morpholines, and tertiary amines\n- **Metabolic stability**: Used fluorine substitutions, oxadiazoles, and methoxy groups\n- **Rigidity and spatial arrangement**: Employed amide linkers, ureas, and conformationally constrained cores\n\n### 4. Drug-Like Properties\n- Designed molecules with:\n  - MW generally between 420-550 Da\n  - LogP values in the 2.5-4 range\n  - Appropriate H-bond donors/acceptors (Lipinski compliant)\n  - Balanced solubility and permeability characteristics\n\nThese designs represent a diverse set of potential AKT1 inhibitors with varied scaffolds, binding modes, and physicochemical properties, providing a strong foundation for further optimization."
      }
    ]
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 2: Lead Optimization**\n\nBased on your previous designs, now optimize and refine your best candidates. Focus on:\n\n1. **Scaffold hopping**: Create variants of your most promising designs\n2. **Property optimization**: Improve drug-likeness, solubility, permeability\n3. **Selectivity enhancement**: Design features for AKT1 vs AKT2/AKT3 selectivity\n4. **ADMET optimization**: Consider metabolic stability and safety\n\nGenerate 8-12 optimized molecules that build upon your iteration 1 insights. Include:\n- Modified versions of your best scaffolds\n- New analogs with improved properties\n- Rationale for each modification based on medicinal chemistry principles"
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Lead Optimization\n\nBased on the initial designs, I'll now optimize the most promising candidates to enhance potency, selectivity, and drug-like properties. I'll focus on scaffold hopping, property optimization, and addressing potential ADMET issues.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F\",\n            \"friendly_id\": \"AI:I2:N1:G1\",\n            \"source\": \"AI:I1:N1:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N1:G0 with three key modifications: (1) Added a trifluoroethyl group to the piperazine to improve metabolic stability and reduce basicity, potentially improving brain penetration; (2) Introduced a fluorine on the pyridine ring to enhance binding affinity through additional interactions with the hinge region; (3) Maintained the core aminopyrimidine hinge-binding motif while optimizing the overall physicochemical profile. Expected improvements: better metabolic stability, reduced P-gp efflux liability, and potentially enhanced selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I2:N2:G1\",\n            \"source\": \"AI:I1:N2:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of AI:I1:N2:G0 by introducing a fluorine atom on the central phenyl ring to improve metabolic stability and binding affinity. The Type II inhibitor design is maintained with the urea linker for DFG-out conformation stabilization. The fluorine addition provides several benefits: (1) blocks a potential metabolic site; (2) enhances binding through additional interactions; (3) improves membrane permeability by reducing the overall hydrogen bonding capacity while maintaining the essential pharmacophore elements. Expected improvements: enhanced metabolic stability, potentially improved selectivity, and maintained solubility profile.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I2:N3:G1\",\n            \"source\": \"AI:I1:N3:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N3:G0 by introducing a trifluoromethyl group on the aminopyridine linker. This modification serves multiple purposes: (1) increases binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by blocking a potential site of oxidation; (3) enhances selectivity by exploiting a potential hydrophobic pocket unique to AKT1. The core oxadiazole and pyrimidine-pyridine hinge-binding motifs are preserved to maintain essential interactions. Expected improvements: enhanced potency, better metabolic profile, and potentially improved selectivity for AKT1 over AKT2/AKT3.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F\",\n            \"friendly_id\": \"AI:I2:N4:G1\",\n            \"source\": \"AI:I1:N4:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N4:G0 by replacing the pyridine with a difluoromethoxy-substituted pyridine. This modification: (1) introduces a metabolically stable difluoromethoxy group that serves as a hydrogen bond acceptor while providing lipophilicity; (2) enhances binding affinity through additional interactions; (3) improves metabolic stability by blocking oxidation sites. The imidazole core and N-methylpiperazine solubilizing group are maintained for their essential functions. Expected improvements: enhanced potency, better metabolic stability, and potentially improved blood-brain barrier penetration due to the balanced lipophilicity.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I2:N5:G1\",\n            \"source\": \"AI:I1:N5:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the allosteric inhibitor AI:I1:N5:G0 by replacing the tertiary amine with a Boc-protected amine. This prodrug approach: (1) masks the basic center to improve membrane permeability; (2) provides controlled release of the active compound after enzymatic cleavage; (3) potentially enhances oral bioavailability by reducing first-pass metabolism. The core indole scaffold and cyano-substituted aminopyrimidine are preserved for their essential interactions with the PH domain-kinase domain interface. Expected improvements: enhanced pharmacokinetic profile, improved oral bioavailability, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I2:N6:G1\",\n            \"source\": \"AI:I1:N6:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N6:G0 by introducing a fluorine atom on the dimethoxyphenyl group. This modification: (1) blocks a potential metabolic site on the aromatic ring; (2) provides additional binding interactions; (3) fine-tunes the electronic properties of the aromatic system. The triazole core for hinge binding and the sulfone linker are maintained for their essential functions. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained physicochemical properties for good oral bioavailability.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F\",\n            \"friendly_id\": \"AI:I2:N7:G1\",\n            \"source\": \"AI:I1:N8:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N8:G0 by replacing the pyridine with a trifluoromethyl-substituted pyridine. This modification: (1) enhances binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by replacing a potential metabolic liability; (3) fine-tunes the electronic properties of the hinge-binding element. The thiazole core, amide linker, and N-methylpiperazine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F\",\n            \"friendly_id\": \"AI:I2:N8:G1\",\n            \"source\": \"AI:I1:N9:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the Type II inhibitor AI:I1:N9:G0 by replacing the methoxy group with a difluoroethoxy group. This modification: (1) improves metabolic stability by blocking a potential site of O-demethylation; (2) enhances binding affinity through additional interactions; (3) provides a better balance of lipophilicity and hydrogen bonding capacity. The urea linker for DFG-out conformation stabilization and the N-methylimidazole core are preserved. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained ability to stabilize the inactive kinase conformation.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCN(CC5)S(=O)(=O)C\",\n            \"friendly_id\": \"AI:I2:N9:G1\",\n            \"source\": \"AI:I1:N10:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N10:G0 by replacing the morpholine derivative with a methylsulfonyl-piperazine. This modification: (1) reduces the basicity of the nitrogen while maintaining solubility; (2) provides additional binding interactions through the sulfonyl group; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The isoxazole core and aminopyrimidine hinge binder are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I2:N10:G1\",\n            \"source\": \"AI:I1:N11:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N11:G0 by introducing a chlorine atom on the aminopyridine linker. This modification: (1) enhances binding affinity through additional halogen bonding interactions; (2) blocks a potential metabolic site; (3) fine-tunes the electronic properties of the aromatic system. The trifluoromethyl group, aminopyrimidine hinge-binding motif, and morpholine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over AKT2/AKT3.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F\",\n            \"friendly_id\": \"AI:I2:N11:G1\",\n            \"source\": \"AI:I1:N12:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the allosteric inhibitor AI:I1:N12:G0 by introducing a fluorocyclopropane group. This modification: (1) enhances metabolic stability by blocking a potential site of oxidation; (2) provides additional binding interactions through the fluorine atom; (3) maintains the overall size and shape of the molecule while improving its properties. The xanthine core and sulfone linker are preserved for their essential functions in targeting the PH domain-kinase domain interface. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C(=O)CF\",\n            \"friendly_id\": \"AI:I2:N12:G1\",\n            \"source\": \"AI:I1:N13:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N13:G0 by replacing the N-methyl group with a fluoroacetyl group. This modification: (1) reduces the basicity of the piperazine nitrogen while maintaining solubility; (2) provides additional binding interactions through the fluorine atom; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The thiazole core, oxadiazole hinge binder, and amide linker are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        }\n    ]\n}\n</molecules>\n\n## Lead Optimization Strategy\n\nIn this optimization phase, I focused on refining the most promising candidates from Iteration 1 to enhance their drug-like properties, potency, selectivity, and ADMET profiles. Here's a summary of the key optimization strategies employed:\n\n### 1. Metabolic Stability Enhancements\n- **Fluorine incorporation**: Added strategic fluorine atoms to block metabolic hot spots (molecules 1, 2, 3, 6, 8, 10)\n- **Trifluoromethyl groups**: Introduced CF\u2083 groups to enhance stability and binding (molecules 3, 7, 10)\n- **Difluoromethoxy/ethoxy groups**: Replaced metabolically labile methoxy groups (molecules 4, 8)\n\n### 2. Selectivity Optimization\n- **Exploiting unique pockets**: Added substituents to target AKT1-specific binding regions (molecules 3, 7)\n- **Fine-tuning electronic properties**: Modified hinge-binding elements to enhance selectivity (molecules 4, 7)\n- **Halogen bonding**: Introduced chlorine for additional selective interactions (molecule 10)\n\n### 3. Pharmacokinetic Improvements\n- **Prodrug approach**: Implemented a Boc-protected amine to improve membrane permeability (molecule 5)\n- **Reduced basicity**: Modified basic centers to improve brain penetration and reduce P-gp efflux (molecules 1, 9, 12)\n- **Balanced lipophilicity**: Fine-tuned the hydrophobic/hydrophilic balance (molecules 4, 8)\n\n### 4. Binding Affinity Optimization\n- **Additional H-bond interactions**: Introduced groups capable of forming new H-bonds (molecules 4, 8)\n- **Halogen bonding**: Added fluorine and chlorine atoms for enhanced interactions (molecules 1, 10)\n- **Hydrophobic interactions**: Optimized lipophilic groups for better pocket complementarity (molecules 3, 7)\n\n### 5. Scaffold Preservation\nWhile making these modifications, I carefully preserved the core pharmacophores identified in Iteration 1:\n- ATP-competitive hinge-binding motifs (aminopyrimidines, imidazoles, etc.)\n- Type II inhibitor urea linkers\n- Allosteric binding elements for PH domain-kinase domain interface targeting\n\nThese optimized compounds represent a focused set of candidates with improved properties while maintaining the essential structural features required for AKT1 inhibition. The modifications were guided by established medicinal chemistry principles to address potential liabilities while enhancing desirable characteristics."
      }
    ]
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "\nYou are the Summary Parser Agent. Your task is to read the output from the previous agent, extract relevant information, and format it into a JSON object that conforms to the GURNEMANZ JSON spec. A critical part of your role is to track molecule history by checking previous steps in the history to include the `parent_molecule_id` for derived molecules, ensuring GURNEMANZ maintains the molecule transformation chain.\nDO NOT FORGET TO INCLUDE THE friendly_id IN THE JSON OUTPUT and parent_friendly_id if the molecule is a child of a parent molecule !.\n### Input\n- The full output from the previous agent in plain text format. (IMPORTANT NOTE: all important details of research in the output of Literature Agent has to be stored in the transformation rationale field)\n- The history, a list of previous steps, each containing a transformation and possibly molecules with assigned moleculeIds.\n- The current iteration number\n- The agent title: \"LLM Drug Designer\" - You MUST use this exact title as the agent name in your output\n\n### Output\n- A JSON object with transformation and molecules, wrapped in `<gurnemanz>` tags (e.g., `<gurnemanz>{ \"transformation\": { ... }, \"molecules\": [ ... ] }</gurnemanz>`).\n\n### Steps to Follow\n1. **Analyze the Input:**\n   - Extract the transformation type, agent name, general rationale, molecule data (SMILES, specific rationales), and any protein-related data (like protein_sequence and protein_path) from the previous agent's output.\n   - Parse information from headers, bullet points, and descriptive text in the agent's response.\n\n2. **Determine Transformation Details:**\n   - Set \"iteration\" to the provided iteration number.\n   - Set type based on the agent's action (e.g., \"molecule-generation\" for new designs, \"property-prediction\" for evaluations or calculations).\n   - Set agent to the name of the previous agent (e.g., \"Medicinal Chemist\").\n   - Summarize the general rationale from the agent's intent or summary.\n   - Look for mentions of protein sequences in the text. If the agent mentions or provides a protein sequence ,or just sequence, include this sequence in the \"protein_sequence\" field of the transformation object.\n   - Look for mentions of protein PDB files in the text. If the agent mentions or provides a path to a protein PDB file, include this path in the \"protein_path\" field of the transformation object.\n\n3. **Process Molecules and Track History:**\n   - For each molecule in the agent's output:\n     - Look for patterns like \"Molecule X\", \"ID:\", \"SMILES:\", etc., to identify molecules and their properties.\n     - **Check if it's De novo or Derived:**\n       - **De novo Molecule:** If the SMILES does not appear in the history and there's no indication of modification (e.g., \"de novo\" or \"designed from scratch\"), set properties.status: \"de novo\" and omit properties.parent_molecule_id.\n       - **Derived Molecule:** If the SMILES matches a molecule in the history or the rationale suggests modification (e.g., \"repositioning,\" \"replacing,\" \"evaluated\"):\n         - Search the history chronologically for a molecule with the same SMILES.\n         - Retrieve the moleculeId of the matching molecule from the history\u2014this is the parent_molecule_id.\n         - Set properties.parent_molecule_id to this ID and properties.status: \"modified\".\n     - **Handle Modifications:**\n       - If the SMILES differs slightly from a historical molecule but the rationale indicates it's a modification (e.g., \"fluorine replaced with chlorine\"), find the closest matching parent SMILES in the history and use its Molecule ID as parent_molecule_id.\n     - **Reusing Unchanged Molecules:**\n       - When the agent explicitly references a molecule by `moleculeId` and there is no indication of a structural change, carry that `moleculeId` forward in the output and omit a new structure. This prevents creation of duplicate molecule entries for the same SMILES.\n     - **Populate Fields:**\n       - Set structure.smiles to the molecule's SMILES.\n       - Include a properties object for EVERY molecule, with status and, if derived, parent_molecule_id.\n       - Add any calculated properties (e.g., docking score, logP, pChEMBL, qed, sas) to computed_properties.\n       - Set rationale to the molecule-specific reasoning from the agent.\n       - If there is any relevant file path in the previous agent's response, for example to a pdb folder, include this in the rationale as well\n\n4. **Format the JSON:**\n   - Structure the output with transformation and molecules at the top level.\n\n5. **Validate:**\n   - Verify that derived molecules have a parent_molecule_id matching a historical molecule_id; if unclear, note in rationale (e.g., \"Parent unclear due to missing history match\").\n\n6. **Output:**\n   - Wrap the JSON in `<gurnemanz>` tags.\n\n### Example: Agent Output Format and Parsing\nThe history will look like this:\n```\n## Transformation\n- Type: data-retrieval\n- Agent: Ai expert\n- Iteration: 1\n- ID: ceb63937-5bd9-48b3-9ac6-ccc443944e4c\n- Rationale: Generated de novo molecules for AKT1\n\n## Molecules\n\n### Molecule 1\n- ID: 4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88\n- SMILES: COc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F\n- Properties:\n  * Status: de novo\n- Computed Properties:\n  * logP: 3.7169\n  * pChEMBL: 8.3\n  * qed: 0.285355\n  * sas: 3.507\n- Rationale: De novo compound for AKT1 with high potency (pChEMBL 8.3).\n```\n\nThe previous agents response you receive as input:\n```json\nMedcicinal chemist: I've edited the de novo molecule of the ai expert in this way\nCOc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F(=c3ccncc3)\nrationale: improved binding\n```\n\nExpected Output:\n```\n<gurnemanz>\n{\n  \"transformation\": {\n    \"type\": \"lead-optimization\",\n    \"agent\": \"Medicinal Chemist\",\n    \"user_message\": \"improved molecule binding\",\n    \"rationale\": \"edited molecule for improved binding\",\n    \"protein_sequence\": \"MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYFEYLKLDYLHSEIRFPHFPQFSYSASGTA\" # Include if a protein sequence is mentioned in the agent output\n    \"protein_path\": \"/path/to/protein.pdb\",  # Include only if a protein path is mentioned in the agent output\n    \"iteration\": 2\n  },\n  \"molecules\": [\n    {\n      \"structure\": {\n        \"smiles\": \"COc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F(=c3ccncc3)\"\n      },\n      \"properties\": {\n        \"parent_molecule_id\": \"4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88\",\n        \"status\": \"modified\"\n      },\n      \"computed_properties\": {},\n      \"rationale\": \"Fluorine at 4-position of pyridine is synthetically accessible but may present regioselectivity challenges\"\n    }\n  ]\n}\n</gurnemanz>\n```\n\n### IMPORTANT REQUIREMENTS\n1. **Every molecule MUST have a properties object** with at minimum a status field.\n2. **Derived molecules MUST include parent_molecule_id** in the properties object.\n3. **SMILES matching is critical** - When a molecule with the same SMILES appears in a new step, it's derived, not de novo.\n4. **Look through the entire history** to find matching molecules and their molecule_ids.\n5. **Look for ID fields in the text output** - When you see patterns like \"ID: 4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88\" in the agent output, this may be a molecule ID that becomes the parent_molecule_id for derived molecules.\n6. **If an agent outputs a file path to a protein PDB file** add this path in the \"protein_path\" field in the transformation object. Look for paths containing \".pdb\" extensions or mentions of protein structure files. For example, if the agent says \"I used /path/to/protein.pdb for docking\", extract \"/path/to/protein.pdb\" as the protein_path.\nVERY IMPORTANT NOTE FOR LITERATURE AGENT PARSING: Including ALL important details provided by the literature agent in the transformations rationale field!!!!! the other agents RELY on this information! do NOT summarize the response and omit key information. all relevant output of the literature HAS TO GO INTO THE RATIONALE. Also double check if there might be protein sequences or smiles in the response to add them in the appropriate fields.\n\nIteration Number:\n2\nAgent Title:\nLLM Drug Designer\n"
      }
    ]
  },
  {
    "role": "assistant",
    "content": "I'll parse the output from the LLM Drug Designer and format it into the GURNEMANZ JSON specification, ensuring all molecule relationships are properly tracked.",
    "tool_calls": [
      {
        "index": 1,
        "function": {
          "arguments": "{\"client_name\": \"claude\", \"session_id\": \"session-123\", \"parent_transformation_id\": \"transformation-123\", \"transformation\": {\"type\": \"lead-optimization\", \"agent\": \"LLM Drug Designer\", \"iteration\": 2, \"rationale\": \"Optimization of AKT1 inhibitor candidates focusing on scaffold hopping, property optimization, selectivity enhancement, and ADMET optimization. Key strategies included: (1) Metabolic stability enhancements through fluorine incorporation, trifluoromethyl groups, and difluoromethoxy/ethoxy substitutions; (2) Selectivity optimization by exploiting unique pockets, fine-tuning electronic properties, and introducing halogen bonding; (3) Pharmacokinetic improvements via prodrug approaches, reduced basicity, and balanced lipophilicity; (4) Binding affinity optimization through additional H-bond interactions, halogen bonding, and optimized hydrophobic interactions; (5) Careful preservation of core pharmacophores including ATP-competitive hinge-binding motifs, Type II inhibitor urea linkers, and allosteric binding elements.\"}, \"molecules\": [{\"structure\": {\"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F\"}, \"friendly_id\": \"AI:I2:N1:G1\", \"parent_friendly_id\": \"AI:I1:N1:G0\", \"rationale\": \"Optimization of AI:I1:N1:G0 with three key modifications: (1) Added a trifluoroethyl group to the piperazine to improve metabolic stability and reduce basicity, potentially improving brain penetration; (2) Introduced a fluorine on the pyridine ring to enhance binding affinity through additional interactions with the hinge region; (3) Maintained the core aminopyrimidine hinge-binding motif while optimizing the overall physicochemical profile. Expected improvements: better metabolic stability, reduced P-gp efflux liability, and potentially enhanced selectivity for AKT1.\"}, {\"structure\": {\"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N\"}, \"friendly_id\": \"AI:I2:N2:G1\", \"parent_friendly_id\": \"AI:I1:N2:G0\", \"rationale\": \"Refinement of AI:I1:N2:G0 by introducing a fluorine atom on the central phenyl ring to improve metabolic stability and binding affinity. The Type II inhibitor design is maintained with the urea linker for DFG-out conformation stabilization. The fluorine addition provides several benefits: (1) blocks a potential metabolic site; (2) enhances binding through additional interactions; (3) improves membrane permeability by reducing the overall hydrogen bonding capacity while maintaining the essential pharmacophore elements. Expected improvements: enhanced metabolic stability, potentially improved selectivity, and maintained solubility profile.\"}, {\"structure\": {\"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5\"}, \"friendly_id\": \"AI:I2:N3:G1\", \"parent_friendly_id\": \"AI:I1:N3:G0\", \"rationale\": \"Enhancement of AI:I1:N3:G0 by introducing a trifluoromethyl group on the aminopyridine linker. This modification serves multiple purposes: (1) increases binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by blocking a potential site of oxidation; (3) enhances selectivity by exploiting a potential hydrophobic pocket unique to AKT1. The core oxadiazole and pyrimidine-pyridine hinge-binding motifs are preserved to maintain essential interactions. Expected improvements: enhanced potency, better metabolic profile, and potentially improved selectivity for AKT1 over AKT2/AKT3.\"}, {\"structure\": {\"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F\"}, \"friendly_id\": \"AI:I2:N4:G1\", \"parent_friendly_id\": \"AI:I1:N4:G0\", \"rationale\": \"Optimization of AI:I1:N4:G0 by replacing the pyridine with a difluoromethoxy-substituted pyridine. This modification: (1) introduces a metabolically stable difluoromethoxy group that serves as a hydrogen bond acceptor while providing lipophilicity; (2) enhances binding affinity through additional interactions; (3) improves metabolic stability by blocking oxidation sites. The imidazole core and N-methylpiperazine solubilizing group are maintained for their essential functions. Expected improvements: enhanced potency, better metabolic stability, and potentially improved blood-brain barrier penetration due to the balanced lipophilicity.\"}, {\"structure\": {\"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\"}, \"friendly_id\": \"AI:I2:N5:G1\", \"parent_friendly_id\": \"AI:I1:N5:G0\", \"rationale\": \"Refinement of the allosteric inhibitor AI:I1:N5:G0 by replacing the tertiary amine with a Boc-protected amine. This prodrug approach: (1) masks the basic center to improve membrane permeability; (2) provides controlled release of the active compound after enzymatic cleavage; (3) potentially enhances oral bioavailability by reducing first-pass metabolism. The core indole scaffold and cyano-substituted aminopyrimidine are preserved for their essential interactions with the PH domain-kinase domain interface. Expected improvements: enhanced pharmacokinetic profile, improved oral bioavailability, and maintained selectivity for AKT1.\"}, {\"structure\": {\"smiles\": \"COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\"}, \"friendly_id\": \"AI:I2:N6:G1\", \"parent_friendly_id\": \"AI:I1:N6:G0\", \"rationale\": \"Enhancement of AI:I1:N6:G0 by introducing a fluorine atom on the dimethoxyphenyl group. This modification: (1) blocks a potential metabolic site on the aromatic ring; (2) provides additional binding interactions; (3) fine-tunes the electronic properties of the aromatic system. The triazole core for hinge binding and the sulfone linker are maintained for their essential functions. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained physicochemical properties for good oral bioavailability.\"}, {\"structure\": {\"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F\"}, \"friendly_id\": \"AI:I2:N7:G1\", \"parent_friendly_id\": \"AI:I1:N8:G0\", \"rationale\": \"Optimization of AI:I1:N8:G0 by replacing the pyridine with a trifluoromethyl-substituted pyridine. This modification: (1) enhances binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by replacing a potential metabolic liability; (3) fine-tunes the electronic properties of the hinge-binding element. The thiazole core, amide linker, and N-methylpiperazine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over other kinases.\"}, {\"structure\": {\"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F\"}, \"friendly_id\": \"AI:I2:N8:G1\", \"parent_friendly_id\": \"AI:I1:N9:G0\", \"rationale\": \"Refinement of the Type II inhibitor AI:I1:N9:G0 by replacing the methoxy group with a difluoroethoxy group. This modification: (1) improves metabolic stability by blocking a potential site of O-demethylation; (2) enhances binding affinity through additional interactions; (3) provides a better balance of lipophilicity and hydrogen bonding capacity. The urea linker for DFG-out conformation stabilization and the N-methylimidazole core are preserved. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained ability to stabilize the inactive kinase conformation.\"}, {\"structure\": {\"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCN(CC5)S(=O)(=O)C\"}, \"friendly_id\": \"AI:I2:N9:G1\", \"parent_friendly_id\": \"AI:I1:N10:G0\", \"rationale\": \"Enhancement of AI:I1:N10:G0 by replacing the morpholine derivative with a methylsulfonyl-piperazine. This modification: (1) reduces the basicity of the nitrogen while maintaining solubility; (2) provides additional binding interactions through the sulfonyl group; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The isoxazole core and aminopyrimidine hinge binder are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.\"}, {\"structure\": {\"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4\"}, \"friendly_id\": \"AI:I2:N10:G1\", \"parent_friendly_id\": \"AI:I1:N11:G0\", \"rationale\": \"Optimization of AI:I1:N11:G0 by introducing a chlorine atom on the aminopyridine linker. This modification: (1) enhances binding affinity through additional halogen bonding interactions; (2) blocks a potential metabolic site; (3) fine-tunes the electronic properties of the aromatic system. The trifluoromethyl group, aminopyrimidine hinge-binding motif, and morpholine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over AKT2/AKT3.\"}, {\"structure\": {\"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F\"}, \"friendly_id\": \"AI:I2:N11:G1\", \"parent_friendly_id\": \"AI:I1:N12:G0\", \"rationale\": \"Refinement of the allosteric inhibitor AI:I1:N12:G0 by introducing a fluorocyclopropane group. This modification: (1) enhances metabolic stability by blocking a potential site of oxidation; (2) provides additional binding interactions through the fluorine atom; (3) maintains the overall size and shape of the molecule while improving its properties. The xanthine core and sulfone linker are preserved for their essential functions in targeting the PH domain-kinase domain interface. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained selectivity for AKT1.\"}, {\"structure\": {\"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C(=O)CF\"}, \"friendly_id\": \"AI:I2:N12:G1\", \"parent_friendly_id\": \"AI:I1:N13:G0\", \"rationale\": \"Enhancement of AI:I1:N13:G0 by replacing the N-methyl group with a fluoroacetyl group. This modification: (1) reduces the basicity of the piperazine nitrogen while maintaining solubility; (2) provides additional binding interactions through the fluorine atom; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The thiazole core, oxadiazole hinge binder, and amide linker are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.\"}]}",
          "name": "gurnemanz_apply"
        },
        "id": "toolu_01KPa3x5xqToLRDrnH8crspK",
        "type": "function"
      }
    ]
  },
  {
    "role": "tool",
    "tool_call_id": "toolu_01KPa3x5xqToLRDrnH8crspK",
    "content": "{\"molecules\": [{\"moleculeId\": \"69c29d3f-b6c7-4994-8d4f-404663785c77\", \"originalData\": {\"friendlyId\": \"AI:I2:N1:G1\", \"parentFriendlyId\": \"AI:I1:N1:G0\", \"rationale\": \"Optimization of AI:I1:N1:G0 with three key modifications: (1) Added a trifluoroethyl group to the piperazine to improve metabolic stability and reduce basicity, potentially improving brain penetration; (2) Introduced a fluorine on the pyridine ring to enhance binding affinity through additional interactions with the hinge region; (3) Maintained the core aminopyrimidine hinge-binding motif while optimizing the overall physicochemical profile. Expected improvements: better metabolic stability, reduced P-gp efflux liability, and potentially enhanced selectivity for AKT1.\", \"structure\": {\"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F\"}}}, {\"moleculeId\": \"c6352ae7-c15d-47ea-84f7-d29122345a0f\", \"originalData\": {\"friendlyId\": \"AI:I2:N2:G1\", \"parentFriendlyId\": \"AI:I1:N2:G0\", \"rationale\": \"Refinement of AI:I1:N2:G0 by introducing a fluorine atom on the central phenyl ring to improve metabolic stability and binding affinity. The Type II inhibitor design is maintained with the urea linker for DFG-out conformation stabilization. The fluorine addition provides several benefits: (1) blocks a potential metabolic site; (2) enhances binding through additional interactions; (3) improves membrane permeability by reducing the overall hydrogen bonding capacity while maintaining the essential pharmacophore elements. Expected improvements: enhanced metabolic stability, potentially improved selectivity, and maintained solubility profile.\", \"structure\": {\"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N\"}}}, {\"moleculeId\": \"6fc8a494-f304-44a8-90ca-564e61507ccb\", \"originalData\": {\"friendlyId\": \"AI:I2:N3:G1\", \"parentFriendlyId\": \"AI:I1:N3:G0\", \"rationale\": \"Enhancement of AI:I1:N3:G0 by introducing a trifluoromethyl group on the aminopyridine linker. This modification serves multiple purposes: (1) increases binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by blocking a potential site of oxidation; (3) enhances selectivity by exploiting a potential hydrophobic pocket unique to AKT1. The core oxadiazole and pyrimidine-pyridine hinge-binding motifs are preserved to maintain essential interactions. Expected improvements: enhanced potency, better metabolic profile, and potentially improved selectivity for AKT1 over AKT2/AKT3.\", \"structure\": {\"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5\"}}}, {\"moleculeId\": \"36e037ad-1bdf-49a5-9560-c5fee9a57556\", \"originalData\": {\"friendlyId\": \"AI:I2:N4:G1\", \"parentFriendlyId\": \"AI:I1:N4:G0\", \"rationale\": \"Optimization of AI:I1:N4:G0 by replacing the pyridine with a difluoromethoxy-substituted pyridine. This modification: (1) introduces a metabolically stable difluoromethoxy group that serves as a hydrogen bond acceptor while providing lipophilicity; (2) enhances binding affinity through additional interactions; (3) improves metabolic stability by blocking oxidation sites. The imidazole core and N-methylpiperazine solubilizing group are maintained for their essential functions. Expected improvements: enhanced potency, better metabolic stability, and potentially improved blood-brain barrier penetration due to the balanced lipophilicity.\", \"structure\": {\"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F\"}}}, {\"moleculeId\": \"0e29a281-ded9-49c6-86dc-d886bc5b9287\", \"originalData\": {\"friendlyId\": \"AI:I2:N5:G1\", \"parentFriendlyId\": \"AI:I1:N5:G0\", \"rationale\": \"Refinement of the allosteric inhibitor AI:I1:N5:G0 by replacing the tertiary amine with a Boc-protected amine. This prodrug approach: (1) masks the basic center to improve membrane permeability; (2) provides controlled release of the active compound after enzymatic cleavage; (3) potentially enhances oral bioavailability by reducing first-pass metabolism. The core indole scaffold and cyano-substituted aminopyrimidine are preserved for their essential interactions with the PH domain-kinase domain interface. Expected improvements: enhanced pharmacokinetic profile, improved oral bioavailability, and maintained selectivity for AKT1.\", \"structure\": {\"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\"}}}, {\"moleculeId\": \"cbee8abf-2840-493a-ac54-be785d77a5b6\", \"originalData\": {\"friendlyId\": \"AI:I2:N6:G1\", \"parentFriendlyId\": \"AI:I1:N6:G0\", \"rationale\": \"Enhancement of AI:I1:N6:G0 by introducing a fluorine atom on the dimethoxyphenyl group. This modification: (1) blocks a potential metabolic site on the aromatic ring; (2) provides additional binding interactions; (3) fine-tunes the electronic properties of the aromatic system. The triazole core for hinge binding and the sulfone linker are maintained for their essential functions. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained physicochemical properties for good oral bioavailability.\", \"structure\": {\"smiles\": \"COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\"}}}, {\"moleculeId\": \"1fe4cf6d-0e77-4c8e-a582-390070b85e8f\", \"originalData\": {\"friendlyId\": \"AI:I2:N7:G1\", \"parentFriendlyId\": \"AI:I1:N8:G0\", \"rationale\": \"Optimization of AI:I1:N8:G0 by replacing the pyridine with a trifluoromethyl-substituted pyridine. This modification: (1) enhances binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by replacing a potential metabolic liability; (3) fine-tunes the electronic properties of the hinge-binding element. The thiazole core, amide linker, and N-methylpiperazine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over other kinases.\", \"structure\": {\"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F\"}}}, {\"moleculeId\": \"6e226391-ca00-4560-b9ac-0fdb7fea675e\", \"originalData\": {\"friendlyId\": \"AI:I2:N8:G1\", \"parentFriendlyId\": \"AI:I1:N9:G0\", \"rationale\": \"Refinement of the Type II inhibitor AI:I1:N9:G0 by replacing the methoxy group with a difluoroethoxy group. This modification: (1) improves metabolic stability by blocking a potential site of O-demethylation; (2) enhances binding affinity through additional interactions; (3) provides a better balance of lipophilicity and hydrogen bonding capacity. The urea linker for DFG-out conformation stabilization and the N-methylimidazole core are preserved. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained ability to stabilize the inactive kinase conformation.\", \"structure\": {\"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F\"}}}, {\"moleculeId\": \"f50a143e-7e4f-4517-9662-2374028cfc91\", \"originalData\": {\"friendlyId\": \"AI:I2:N9:G1\", \"parentFriendlyId\": \"AI:I1:N10:G0\", \"rationale\": \"Enhancement of AI:I1:N10:G0 by replacing the morpholine derivative with a methylsulfonyl-piperazine. This modification: (1) reduces the basicity of the nitrogen while maintaining solubility; (2) provides additional binding interactions through the sulfonyl group; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The isoxazole core and aminopyrimidine hinge binder are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.\", \"structure\": {\"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCN(CC5)S(=O)(=O)C\"}}}, {\"moleculeId\": \"31da8379-0627-482f-88b6-133e7c1fc7e0\", \"originalData\": {\"friendlyId\": \"AI:I2:N10:G1\", \"parentFriendlyId\": \"AI:I1:N11:G0\", \"rationale\": \"Optimization of AI:I1:N11:G0 by introducing a chlorine atom on the aminopyridine linker. This modification: (1) enhances binding affinity through additional halogen bonding interactions; (2) blocks a potential metabolic site; (3) fine-tunes the electronic properties of the aromatic system. The trifluoromethyl group, aminopyrimidine hinge-binding motif, and morpholine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over AKT2/AKT3.\", \"structure\": {\"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4\"}}}, {\"moleculeId\": \"37cff1d8-4f13-4129-b2b7-d8c719d4d6a1\", \"originalData\": {\"friendlyId\": \"AI:I2:N11:G1\", \"parentFriendlyId\": \"AI:I1:N12:G0\", \"rationale\": \"Refinement of the allosteric inhibitor AI:I1:N12:G0 by introducing a fluorocyclopropane group. This modification: (1) enhances metabolic stability by blocking a potential site of oxidation; (2) provides additional binding interactions through the fluorine atom; (3) maintains the overall size and shape of the molecule while improving its properties. The xanthine core and sulfone linker are preserved for their essential functions in targeting the PH domain-kinase domain interface. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained selectivity for AKT1.\", \"structure\": {\"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F\"}}}, {\"moleculeId\": \"ddc94d30-d965-45d7-ba64-0e9f8ab59a20\", \"originalData\": {\"friendlyId\": \"AI:I2:N12:G1\", \"parentFriendlyId\": \"AI:I1:N13:G0\", \"rationale\": \"Enhancement of AI:I1:N13:G0 by replacing the N-methyl group with a fluoroacetyl group. This modification: (1) reduces the basicity of the piperazine nitrogen while maintaining solubility; (2) provides additional binding interactions through the fluorine atom; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The thiazole core, oxadiazole hinge binder, and amide linker are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.\", \"structure\": {\"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C(=O)CF\"}}}], \"transformation\": {\"agent\": \"LLM Drug Designer\", \"iteration\": 2, \"methodDetails\": null, \"proteinPath\": null, \"proteinSequence\": null, \"rationale\": \"Optimization of AKT1 inhibitor candidates focusing on scaffold hopping, property optimization, selectivity enhancement, and ADMET optimization. Key strategies included: (1) Metabolic stability enhancements through fluorine incorporation, trifluoromethyl groups, and difluoromethoxy/ethoxy substitutions; (2) Selectivity optimization by exploiting unique pockets, fine-tuning electronic properties, and introducing halogen bonding; (3) Pharmacokinetic improvements via prodrug approaches, reduced basicity, and balanced lipophilicity; (4) Binding affinity optimization through additional H-bond interactions, halogen bonding, and optimized hydrophobic interactions; (5) Careful preservation of core pharmacophores including ATP-competitive hinge-binding motifs, Type II inhibitor urea linkers, and allosteric binding elements.\", \"transformationId\": \"a440fa32-db18-4c5d-a50c-5d5a184026f9\", \"type\": \"lead-optimization\", \"userMessage\": null}}"
  }
]
2025-06-23 14:04:50,609 - INFO - response ModelResponse(id='chatcmpl-da76bf18-4e6a-4e7e-9e2f-cd9f14e6c116', created=1750676690, model='claude-3-7-sonnet-20250219', object='chat.completion', system_fingerprint=None, choices=[Choices(finish_reason='stop', index=0, message=Message(content='I\'ve successfully parsed the LLM Drug Designer\'s output and submitted it to GURNEMANZ. The system has processed 12 optimized AKT1 inhibitor molecules, each with appropriate parent-child relationships maintained through the friendly_id system.\n\nThe transformation was categorized as "lead-optimization" (iteration 2), with a comprehensive rationale capturing the key optimization strategies:\n\n1. Metabolic stability enhancements through fluorine incorporation, trifluoromethyl groups, and difluoromethoxy/ethoxy substitutions\n2. Selectivity optimization by exploiting unique pockets, fine-tuning electronic properties, and introducing halogen bonding\n3. Pharmacokinetic improvements via prodrug approaches, reduced basicity, and balanced lipophilicity\n4. Binding affinity optimization through additional H-bond interactions, halogen bonding, and optimized hydrophobic interactions\n5. Careful preservation of core pharmacophores including ATP-competitive hinge-binding motifs, Type II inhibitor urea linkers, and allosteric binding elements\n\nEach molecule has been assigned a unique molecule ID in the GURNEMANZ system, with proper tracking of its parent molecule through the parent_friendly_id field. The rationales for each modification have been preserved, detailing the specific structural changes and their expected benefits for potency, selectivity, and ADMET properties.', role='assistant', tool_calls=None, function_call=None, provider_specific_fields={'citations': []}, citations=[]))], usage=Usage(completion_tokens=304, prompt_tokens=20073, total_tokens=20377, completion_tokens_details=None, prompt_tokens_details=PromptTokensDetailsWrapper(audio_tokens=None, cached_tokens=0, text_tokens=None, image_tokens=None), cache_creation_input_tokens=0, cache_read_input_tokens=0))
2025-06-23 14:04:50,610 - INFO - history_with_tools [{'role': 'user', 'content': "You are an expert medicinal chemist and computational drug discovery scientist. Your task is to design novel small molecule inhibitors for AKT1 (Protein Kinase B alpha) using your knowledge of structure-activity relationships, medicinal chemistry principles, and drug design.\n\n**Target Information:**\n- AKT1 is a serine/threonine kinase in the PI3K/AKT/mTOR pathway\n- Critical for cell survival, proliferation, and metabolism\n- Key oncology target with multiple known inhibitors\n- ATP-competitive and allosteric binding sites available\n\n**Your Goal:**\nGenerate novel, drug-like small molecule AKT1 inhibitors with the following criteria:\n- High predicted binding affinity to AKT1\n- Drug-like properties (Lipinski's Rule of Five compliance)\n- Synthetic accessibility\n- Novel scaffolds not directly copied from known inhibitors\n\n**Output Format:**\nFor each molecule, provide:\n1. **Molecule ID**: A unique identifier (e.g., LLM_MOL_001)\n2. **SMILES**: Valid SMILES string\n3. **Rationale**: Brief explanation of your design strategy and expected properties\n4. **Predicted Properties**: Your assessment of drug-likeness, potency, selectivity\n\nFocus on innovative chemical designs while maintaining scientific rigor."}, {'role': 'user', 'content': [{'type': 'text', 'text': '**ITERATION 1: Initial Discovery & Exploration**\n\nDesign 10-15 novel AKT1 inhibitor molecules using your medicinal chemistry expertise. Consider:\n\n1. **ATP-competitive inhibitors**: Target the ATP-binding pocket with novel scaffolds\n2. **Allosteric inhibitors**: Design molecules that bind to regulatory sites\n3. **Hybrid approaches**: Molecules that may interact with multiple binding sites\n\nUse your knowledge of:\n- Known AKT1 pharmacophores (avoid direct copying)\n- Kinase selectivity determinants\n- Drug-like chemical space\n- Structure-activity relationships\n\nGenerate diverse scaffolds including heterocycles, aromatic systems, and appropriate linkers. Ensure synthetic feasibility while prioritizing novelty.'}]}, {'role': 'assistant', 'content': [{'type': 'text', 'text': '# AKT1 Inhibitor Design - Initial Discovery\n\nI\'ll design novel AKT1 inhibitors using medicinal chemistry principles and my knowledge of kinase inhibitor design. I\'ll focus on creating diverse, drug-like molecules with appropriate pharmacophores for AKT1 inhibition.\n\n<molecules>\n{\n    "molecules": [\n        {\n            "smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5",\n            "friendly_id": "AI:I1:N1:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N",\n            "friendly_id": "AI:I1:N2:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors."\n        },\n        {\n            "smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5",\n            "friendly_id": "AI:I1:N3:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5",\n            "friendly_id": "AI:I1:N4:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements."\n        },\n        {\n            "smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N",\n            "friendly_id": "AI:I1:N5:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode."\n        },\n        {\n            "smiles": "COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F",\n            "friendly_id": "AI:I1:N6:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties."\n        },\n        {\n            "smiles": "CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5",\n            "friendly_id": "AI:I1:N7:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5",\n            "friendly_id": "AI:I1:N8:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases."\n        },\n        {\n            "smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC",\n            "friendly_id": "AI:I1:N9:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5",\n            "friendly_id": "AI:I1:N10:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile."\n        },\n        {\n            "smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4",\n            "friendly_id": "AI:I1:N11:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties."\n        },\n        {\n            "smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5",\n            "friendly_id": "AI:I1:N12:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode."\n        },\n        {\n            "smiles": "CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C",\n            "friendly_id": "AI:I1:N13:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases."\n        },\n        {\n            "smiles": "CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5",\n            "friendly_id": "AI:I1:N14:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile."\n        },\n        {\n            "smiles": "COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5",\n            "friendly_id": "AI:I1:N15:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties."\n        }\n    ]\n}\n</molecules>\n\n## Design Strategy Overview\n\nMy approach to designing these AKT1 inhibitors focused on several key medicinal chemistry principles:\n\n### 1. Hinge-Binding Motifs\n- Incorporated established kinase hinge-binding pharmacophores including:\n  - Aminopyrimidines (molecules 1, 2, 11, 14)\n  - Imidazoles (molecule 4)\n  - Triazoles (molecule 6)\n  - Quinazolines (molecule 15)\n  - Oxadiazoles (molecules 3, 7, 13)\n\n### 2. Binding Modes\n- **ATP-competitive inhibitors** (majority of designs): Target the ATP-binding pocket with appropriate hinge-binding elements\n- **Type II inhibitors** (molecules 2, 9): Include urea linkers to stabilize the DFG-out conformation\n- **Allosteric inhibitors** (molecules 5, 12): Target the PH domain-kinase domain interface\n\n### 3. Structural Features\n- **Solubilizing groups**: Incorporated piperazines, morpholines, and tertiary amines\n- **Metabolic stability**: Used fluorine substitutions, oxadiazoles, and methoxy groups\n- **Rigidity and spatial arrangement**: Employed amide linkers, ureas, and conformationally constrained cores\n\n### 4. Drug-Like Properties\n- Designed molecules with:\n  - MW generally between 420-550 Da\n  - LogP values in the 2.5-4 range\n  - Appropriate H-bond donors/acceptors (Lipinski compliant)\n  - Balanced solubility and permeability characteristics\n\nThese designs represent a diverse set of potential AKT1 inhibitors with varied scaffolds, binding modes, and physicochemical properties, providing a strong foundation for further optimization.'}]}, {'role': 'user', 'content': [{'type': 'text', 'text': '**ITERATION 2: Lead Optimization**\n\nBased on your previous designs, now optimize and refine your best candidates. Focus on:\n\n1. **Scaffold hopping**: Create variants of your most promising designs\n2. **Property optimization**: Improve drug-likeness, solubility, permeability\n3. **Selectivity enhancement**: Design features for AKT1 vs AKT2/AKT3 selectivity\n4. **ADMET optimization**: Consider metabolic stability and safety\n\nGenerate 8-12 optimized molecules that build upon your iteration 1 insights. Include:\n- Modified versions of your best scaffolds\n- New analogs with improved properties\n- Rationale for each modification based on medicinal chemistry principles'}]}, {'role': 'assistant', 'content': [{'type': 'text', 'text': '# AKT1 Inhibitor Design - Lead Optimization\n\nBased on the initial designs, I\'ll now optimize the most promising candidates to enhance potency, selectivity, and drug-like properties. I\'ll focus on scaffold hopping, property optimization, and addressing potential ADMET issues.\n\n<molecules>\n{\n    "molecules": [\n        {\n            "smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F",\n            "friendly_id": "AI:I2:N1:G1",\n            "source": "AI:I1:N1:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Optimization of AI:I1:N1:G0 with three key modifications: (1) Added a trifluoroethyl group to the piperazine to improve metabolic stability and reduce basicity, potentially improving brain penetration; (2) Introduced a fluorine on the pyridine ring to enhance binding affinity through additional interactions with the hinge region; (3) Maintained the core aminopyrimidine hinge-binding motif while optimizing the overall physicochemical profile. Expected improvements: better metabolic stability, reduced P-gp efflux liability, and potentially enhanced selectivity for AKT1."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N",\n            "friendly_id": "AI:I2:N2:G1",\n            "source": "AI:I1:N2:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Refinement of AI:I1:N2:G0 by introducing a fluorine atom on the central phenyl ring to improve metabolic stability and binding affinity. The Type II inhibitor design is maintained with the urea linker for DFG-out conformation stabilization. The fluorine addition provides several benefits: (1) blocks a potential metabolic site; (2) enhances binding through additional interactions; (3) improves membrane permeability by reducing the overall hydrogen bonding capacity while maintaining the essential pharmacophore elements. Expected improvements: enhanced metabolic stability, potentially improved selectivity, and maintained solubility profile."\n        },\n        {\n            "smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5",\n            "friendly_id": "AI:I2:N3:G1",\n            "source": "AI:I1:N3:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Enhancement of AI:I1:N3:G0 by introducing a trifluoromethyl group on the aminopyridine linker. This modification serves multiple purposes: (1) increases binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by blocking a potential site of oxidation; (3) enhances selectivity by exploiting a potential hydrophobic pocket unique to AKT1. The core oxadiazole and pyrimidine-pyridine hinge-binding motifs are preserved to maintain essential interactions. Expected improvements: enhanced potency, better metabolic profile, and potentially improved selectivity for AKT1 over AKT2/AKT3."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F",\n            "friendly_id": "AI:I2:N4:G1",\n            "source": "AI:I1:N4:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Optimization of AI:I1:N4:G0 by replacing the pyridine with a difluoromethoxy-substituted pyridine. This modification: (1) introduces a metabolically stable difluoromethoxy group that serves as a hydrogen bond acceptor while providing lipophilicity; (2) enhances binding affinity through additional interactions; (3) improves metabolic stability by blocking oxidation sites. The imidazole core and N-methylpiperazine solubilizing group are maintained for their essential functions. Expected improvements: enhanced potency, better metabolic stability, and potentially improved blood-brain barrier penetration due to the balanced lipophilicity."\n        },\n        {\n            "smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N",\n            "friendly_id": "AI:I2:N5:G1",\n            "source": "AI:I1:N5:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Refinement of the allosteric inhibitor AI:I1:N5:G0 by replacing the tertiary amine with a Boc-protected amine. This prodrug approach: (1) masks the basic center to improve membrane permeability; (2) provides controlled release of the active compound after enzymatic cleavage; (3) potentially enhances oral bioavailability by reducing first-pass metabolism. The core indole scaffold and cyano-substituted aminopyrimidine are preserved for their essential interactions with the PH domain-kinase domain interface. Expected improvements: enhanced pharmacokinetic profile, improved oral bioavailability, and maintained selectivity for AKT1."\n        },\n        {\n            "smiles": "COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F",\n            "friendly_id": "AI:I2:N6:G1",\n            "source": "AI:I1:N6:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Enhancement of AI:I1:N6:G0 by introducing a fluorine atom on the dimethoxyphenyl group. This modification: (1) blocks a potential metabolic site on the aromatic ring; (2) provides additional binding interactions; (3) fine-tunes the electronic properties of the aromatic system. The triazole core for hinge binding and the sulfone linker are maintained for their essential functions. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained physicochemical properties for good oral bioavailability."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F",\n            "friendly_id": "AI:I2:N7:G1",\n            "source": "AI:I1:N8:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Optimization of AI:I1:N8:G0 by replacing the pyridine with a trifluoromethyl-substituted pyridine. This modification: (1) enhances binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by replacing a potential metabolic liability; (3) fine-tunes the electronic properties of the hinge-binding element. The thiazole core, amide linker, and N-methylpiperazine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over other kinases."\n        },\n        {\n            "smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F",\n            "friendly_id": "AI:I2:N8:G1",\n            "source": "AI:I1:N9:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Refinement of the Type II inhibitor AI:I1:N9:G0 by replacing the methoxy group with a difluoroethoxy group. This modification: (1) improves metabolic stability by blocking a potential site of O-demethylation; (2) enhances binding affinity through additional interactions; (3) provides a better balance of lipophilicity and hydrogen bonding capacity. The urea linker for DFG-out conformation stabilization and the N-methylimidazole core are preserved. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained ability to stabilize the inactive kinase conformation."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCN(CC5)S(=O)(=O)C",\n            "friendly_id": "AI:I2:N9:G1",\n            "source": "AI:I1:N10:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Enhancement of AI:I1:N10:G0 by replacing the morpholine derivative with a methylsulfonyl-piperazine. This modification: (1) reduces the basicity of the nitrogen while maintaining solubility; (2) provides additional binding interactions through the sulfonyl group; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The isoxazole core and aminopyrimidine hinge binder are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1."\n        },\n        {\n            "smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4",\n            "friendly_id": "AI:I2:N10:G1",\n            "source": "AI:I1:N11:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Optimization of AI:I1:N11:G0 by introducing a chlorine atom on the aminopyridine linker. This modification: (1) enhances binding affinity through additional halogen bonding interactions; (2) blocks a potential metabolic site; (3) fine-tunes the electronic properties of the aromatic system. The trifluoromethyl group, aminopyrimidine hinge-binding motif, and morpholine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over AKT2/AKT3."\n        },\n        {\n            "smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F",\n            "friendly_id": "AI:I2:N11:G1",\n            "source": "AI:I1:N12:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Refinement of the allosteric inhibitor AI:I1:N12:G0 by introducing a fluorocyclopropane group. This modification: (1) enhances metabolic stability by blocking a potential site of oxidation; (2) provides additional binding interactions through the fluorine atom; (3) maintains the overall size and shape of the molecule while improving its properties. The xanthine core and sulfone linker are preserved for their essential functions in targeting the PH domain-kinase domain interface. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained selectivity for AKT1."\n        },\n        {\n            "smiles": "CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C(=O)CF",\n            "friendly_id": "AI:I2:N12:G1",\n            "source": "AI:I1:N13:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Enhancement of AI:I1:N13:G0 by replacing the N-methyl group with a fluoroacetyl group. This modification: (1) reduces the basicity of the piperazine nitrogen while maintaining solubility; (2) provides additional binding interactions through the fluorine atom; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The thiazole core, oxadiazole hinge binder, and amide linker are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1."\n        }\n    ]\n}\n</molecules>\n\n## Lead Optimization Strategy\n\nIn this optimization phase, I focused on refining the most promising candidates from Iteration 1 to enhance their drug-like properties, potency, selectivity, and ADMET profiles. Here\'s a summary of the key optimization strategies employed:\n\n### 1. Metabolic Stability Enhancements\n- **Fluorine incorporation**: Added strategic fluorine atoms to block metabolic hot spots (molecules 1, 2, 3, 6, 8, 10)\n- **Trifluoromethyl groups**: Introduced CF₃ groups to enhance stability and binding (molecules 3, 7, 10)\n- **Difluoromethoxy/ethoxy groups**: Replaced metabolically labile methoxy groups (molecules 4, 8)\n\n### 2. Selectivity Optimization\n- **Exploiting unique pockets**: Added substituents to target AKT1-specific binding regions (molecules 3, 7)\n- **Fine-tuning electronic properties**: Modified hinge-binding elements to enhance selectivity (molecules 4, 7)\n- **Halogen bonding**: Introduced chlorine for additional selective interactions (molecule 10)\n\n### 3. Pharmacokinetic Improvements\n- **Prodrug approach**: Implemented a Boc-protected amine to improve membrane permeability (molecule 5)\n- **Reduced basicity**: Modified basic centers to improve brain penetration and reduce P-gp efflux (molecules 1, 9, 12)\n- **Balanced lipophilicity**: Fine-tuned the hydrophobic/hydrophilic balance (molecules 4, 8)\n\n### 4. Binding Affinity Optimization\n- **Additional H-bond interactions**: Introduced groups capable of forming new H-bonds (molecules 4, 8)\n- **Halogen bonding**: Added fluorine and chlorine atoms for enhanced interactions (molecules 1, 10)\n- **Hydrophobic interactions**: Optimized lipophilic groups for better pocket complementarity (molecules 3, 7)\n\n### 5. Scaffold Preservation\nWhile making these modifications, I carefully preserved the core pharmacophores identified in Iteration 1:\n- ATP-competitive hinge-binding motifs (aminopyrimidines, imidazoles, etc.)\n- Type II inhibitor urea linkers\n- Allosteric binding elements for PH domain-kinase domain interface targeting\n\nThese optimized compounds represent a focused set of candidates with improved properties while maintaining the essential structural features required for AKT1 inhibition. The modifications were guided by established medicinal chemistry principles to address potential liabilities while enhancing desirable characteristics.'}]}, {'role': 'user', 'content': [{'type': 'text', 'text': '\nYou are the Summary Parser Agent. Your task is to read the output from the previous agent, extract relevant information, and format it into a JSON object that conforms to the GURNEMANZ JSON spec. A critical part of your role is to track molecule history by checking previous steps in the history to include the `parent_molecule_id` for derived molecules, ensuring GURNEMANZ maintains the molecule transformation chain.\nDO NOT FORGET TO INCLUDE THE friendly_id IN THE JSON OUTPUT and parent_friendly_id if the molecule is a child of a parent molecule !.\n### Input\n- The full output from the previous agent in plain text format. (IMPORTANT NOTE: all important details of research in the output of Literature Agent has to be stored in the transformation rationale field)\n- The history, a list of previous steps, each containing a transformation and possibly molecules with assigned moleculeIds.\n- The current iteration number\n- The agent title: "LLM Drug Designer" - You MUST use this exact title as the agent name in your output\n\n### Output\n- A JSON object with transformation and molecules, wrapped in `<gurnemanz>` tags (e.g., `<gurnemanz>{ "transformation": { ... }, "molecules": [ ... ] }</gurnemanz>`).\n\n### Steps to Follow\n1. **Analyze the Input:**\n   - Extract the transformation type, agent name, general rationale, molecule data (SMILES, specific rationales), and any protein-related data (like protein_sequence and protein_path) from the previous agent\'s output.\n   - Parse information from headers, bullet points, and descriptive text in the agent\'s response.\n\n2. **Determine Transformation Details:**\n   - Set "iteration" to the provided iteration number.\n   - Set type based on the agent\'s action (e.g., "molecule-generation" for new designs, "property-prediction" for evaluations or calculations).\n   - Set agent to the name of the previous agent (e.g., "Medicinal Chemist").\n   - Summarize the general rationale from the agent\'s intent or summary.\n   - Look for mentions of protein sequences in the text. If the agent mentions or provides a protein sequence ,or just sequence, include this sequence in the "protein_sequence" field of the transformation object.\n   - Look for mentions of protein PDB files in the text. If the agent mentions or provides a path to a protein PDB file, include this path in the "protein_path" field of the transformation object.\n\n3. **Process Molecules and Track History:**\n   - For each molecule in the agent\'s output:\n     - Look for patterns like "Molecule X", "ID:", "SMILES:", etc., to identify molecules and their properties.\n     - **Check if it\'s De novo or Derived:**\n       - **De novo Molecule:** If the SMILES does not appear in the history and there\'s no indication of modification (e.g., "de novo" or "designed from scratch"), set properties.status: "de novo" and omit properties.parent_molecule_id.\n       - **Derived Molecule:** If the SMILES matches a molecule in the history or the rationale suggests modification (e.g., "repositioning," "replacing," "evaluated"):\n         - Search the history chronologically for a molecule with the same SMILES.\n         - Retrieve the moleculeId of the matching molecule from the history—this is the parent_molecule_id.\n         - Set properties.parent_molecule_id to this ID and properties.status: "modified".\n     - **Handle Modifications:**\n       - If the SMILES differs slightly from a historical molecule but the rationale indicates it\'s a modification (e.g., "fluorine replaced with chlorine"), find the closest matching parent SMILES in the history and use its Molecule ID as parent_molecule_id.\n     - **Reusing Unchanged Molecules:**\n       - When the agent explicitly references a molecule by `moleculeId` and there is no indication of a structural change, carry that `moleculeId` forward in the output and omit a new structure. This prevents creation of duplicate molecule entries for the same SMILES.\n     - **Populate Fields:**\n       - Set structure.smiles to the molecule\'s SMILES.\n       - Include a properties object for EVERY molecule, with status and, if derived, parent_molecule_id.\n       - Add any calculated properties (e.g., docking score, logP, pChEMBL, qed, sas) to computed_properties.\n       - Set rationale to the molecule-specific reasoning from the agent.\n       - If there is any relevant file path in the previous agent\'s response, for example to a pdb folder, include this in the rationale as well\n\n4. **Format the JSON:**\n   - Structure the output with transformation and molecules at the top level.\n\n5. **Validate:**\n   - Verify that derived molecules have a parent_molecule_id matching a historical molecule_id; if unclear, note in rationale (e.g., "Parent unclear due to missing history match").\n\n6. **Output:**\n   - Wrap the JSON in `<gurnemanz>` tags.\n\n### Example: Agent Output Format and Parsing\nThe history will look like this:\n```\n## Transformation\n- Type: data-retrieval\n- Agent: Ai expert\n- Iteration: 1\n- ID: ceb63937-5bd9-48b3-9ac6-ccc443944e4c\n- Rationale: Generated de novo molecules for AKT1\n\n## Molecules\n\n### Molecule 1\n- ID: 4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88\n- SMILES: COc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F\n- Properties:\n  * Status: de novo\n- Computed Properties:\n  * logP: 3.7169\n  * pChEMBL: 8.3\n  * qed: 0.285355\n  * sas: 3.507\n- Rationale: De novo compound for AKT1 with high potency (pChEMBL 8.3).\n```\n\nThe previous agents response you receive as input:\n```json\nMedcicinal chemist: I\'ve edited the de novo molecule of the ai expert in this way\nCOc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F(=c3ccncc3)\nrationale: improved binding\n```\n\nExpected Output:\n```\n<gurnemanz>\n{\n  "transformation": {\n    "type": "lead-optimization",\n    "agent": "Medicinal Chemist",\n    "user_message": "improved molecule binding",\n    "rationale": "edited molecule for improved binding",\n    "protein_sequence": "MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYFEYLKLDYLHSEIRFPHFPQFSYSASGTA" # Include if a protein sequence is mentioned in the agent output\n    "protein_path": "/path/to/protein.pdb",  # Include only if a protein path is mentioned in the agent output\n    "iteration": 2\n  },\n  "molecules": [\n    {\n      "structure": {\n        "smiles": "COc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F(=c3ccncc3)"\n      },\n      "properties": {\n        "parent_molecule_id": "4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88",\n        "status": "modified"\n      },\n      "computed_properties": {},\n      "rationale": "Fluorine at 4-position of pyridine is synthetically accessible but may present regioselectivity challenges"\n    }\n  ]\n}\n</gurnemanz>\n```\n\n### IMPORTANT REQUIREMENTS\n1. **Every molecule MUST have a properties object** with at minimum a status field.\n2. **Derived molecules MUST include parent_molecule_id** in the properties object.\n3. **SMILES matching is critical** - When a molecule with the same SMILES appears in a new step, it\'s derived, not de novo.\n4. **Look through the entire history** to find matching molecules and their molecule_ids.\n5. **Look for ID fields in the text output** - When you see patterns like "ID: 4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88" in the agent output, this may be a molecule ID that becomes the parent_molecule_id for derived molecules.\n6. **If an agent outputs a file path to a protein PDB file** add this path in the "protein_path" field in the transformation object. Look for paths containing ".pdb" extensions or mentions of protein structure files. For example, if the agent says "I used /path/to/protein.pdb for docking", extract "/path/to/protein.pdb" as the protein_path.\nVERY IMPORTANT NOTE FOR LITERATURE AGENT PARSING: Including ALL important details provided by the literature agent in the transformations rationale field!!!!! the other agents RELY on this information! do NOT summarize the response and omit key information. all relevant output of the literature HAS TO GO INTO THE RATIONALE. Also double check if there might be protein sequences or smiles in the response to add them in the appropriate fields.\n\nIteration Number:\n2\nAgent Title:\nLLM Drug Designer\n'}]}, {'role': 'assistant', 'content': "I'll parse the output from the LLM Drug Designer and format it into the GURNEMANZ JSON specification, ensuring all molecule relationships are properly tracked.", 'tool_calls': [{'index': 1, 'function': {'arguments': '{"client_name": "claude", "session_id": "session-123", "parent_transformation_id": "transformation-123", "transformation": {"type": "lead-optimization", "agent": "LLM Drug Designer", "iteration": 2, "rationale": "Optimization of AKT1 inhibitor candidates focusing on scaffold hopping, property optimization, selectivity enhancement, and ADMET optimization. Key strategies included: (1) Metabolic stability enhancements through fluorine incorporation, trifluoromethyl groups, and difluoromethoxy/ethoxy substitutions; (2) Selectivity optimization by exploiting unique pockets, fine-tuning electronic properties, and introducing halogen bonding; (3) Pharmacokinetic improvements via prodrug approaches, reduced basicity, and balanced lipophilicity; (4) Binding affinity optimization through additional H-bond interactions, halogen bonding, and optimized hydrophobic interactions; (5) Careful preservation of core pharmacophores including ATP-competitive hinge-binding motifs, Type II inhibitor urea linkers, and allosteric binding elements."}, "molecules": [{"structure": {"smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F"}, "friendly_id": "AI:I2:N1:G1", "parent_friendly_id": "AI:I1:N1:G0", "rationale": "Optimization of AI:I1:N1:G0 with three key modifications: (1) Added a trifluoroethyl group to the piperazine to improve metabolic stability and reduce basicity, potentially improving brain penetration; (2) Introduced a fluorine on the pyridine ring to enhance binding affinity through additional interactions with the hinge region; (3) Maintained the core aminopyrimidine hinge-binding motif while optimizing the overall physicochemical profile. Expected improvements: better metabolic stability, reduced P-gp efflux liability, and potentially enhanced selectivity for AKT1."}, {"structure": {"smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N"}, "friendly_id": "AI:I2:N2:G1", "parent_friendly_id": "AI:I1:N2:G0", "rationale": "Refinement of AI:I1:N2:G0 by introducing a fluorine atom on the central phenyl ring to improve metabolic stability and binding affinity. The Type II inhibitor design is maintained with the urea linker for DFG-out conformation stabilization. The fluorine addition provides several benefits: (1) blocks a potential metabolic site; (2) enhances binding through additional interactions; (3) improves membrane permeability by reducing the overall hydrogen bonding capacity while maintaining the essential pharmacophore elements. Expected improvements: enhanced metabolic stability, potentially improved selectivity, and maintained solubility profile."}, {"structure": {"smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5"}, "friendly_id": "AI:I2:N3:G1", "parent_friendly_id": "AI:I1:N3:G0", "rationale": "Enhancement of AI:I1:N3:G0 by introducing a trifluoromethyl group on the aminopyridine linker. This modification serves multiple purposes: (1) increases binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by blocking a potential site of oxidation; (3) enhances selectivity by exploiting a potential hydrophobic pocket unique to AKT1. The core oxadiazole and pyrimidine-pyridine hinge-binding motifs are preserved to maintain essential interactions. Expected improvements: enhanced potency, better metabolic profile, and potentially improved selectivity for AKT1 over AKT2/AKT3."}, {"structure": {"smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F"}, "friendly_id": "AI:I2:N4:G1", "parent_friendly_id": "AI:I1:N4:G0", "rationale": "Optimization of AI:I1:N4:G0 by replacing the pyridine with a difluoromethoxy-substituted pyridine. This modification: (1) introduces a metabolically stable difluoromethoxy group that serves as a hydrogen bond acceptor while providing lipophilicity; (2) enhances binding affinity through additional interactions; (3) improves metabolic stability by blocking oxidation sites. The imidazole core and N-methylpiperazine solubilizing group are maintained for their essential functions. Expected improvements: enhanced potency, better metabolic stability, and potentially improved blood-brain barrier penetration due to the balanced lipophilicity."}, {"structure": {"smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N"}, "friendly_id": "AI:I2:N5:G1", "parent_friendly_id": "AI:I1:N5:G0", "rationale": "Refinement of the allosteric inhibitor AI:I1:N5:G0 by replacing the tertiary amine with a Boc-protected amine. This prodrug approach: (1) masks the basic center to improve membrane permeability; (2) provides controlled release of the active compound after enzymatic cleavage; (3) potentially enhances oral bioavailability by reducing first-pass metabolism. The core indole scaffold and cyano-substituted aminopyrimidine are preserved for their essential interactions with the PH domain-kinase domain interface. Expected improvements: enhanced pharmacokinetic profile, improved oral bioavailability, and maintained selectivity for AKT1."}, {"structure": {"smiles": "COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F"}, "friendly_id": "AI:I2:N6:G1", "parent_friendly_id": "AI:I1:N6:G0", "rationale": "Enhancement of AI:I1:N6:G0 by introducing a fluorine atom on the dimethoxyphenyl group. This modification: (1) blocks a potential metabolic site on the aromatic ring; (2) provides additional binding interactions; (3) fine-tunes the electronic properties of the aromatic system. The triazole core for hinge binding and the sulfone linker are maintained for their essential functions. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained physicochemical properties for good oral bioavailability."}, {"structure": {"smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F"}, "friendly_id": "AI:I2:N7:G1", "parent_friendly_id": "AI:I1:N8:G0", "rationale": "Optimization of AI:I1:N8:G0 by replacing the pyridine with a trifluoromethyl-substituted pyridine. This modification: (1) enhances binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by replacing a potential metabolic liability; (3) fine-tunes the electronic properties of the hinge-binding element. The thiazole core, amide linker, and N-methylpiperazine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over other kinases."}, {"structure": {"smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F"}, "friendly_id": "AI:I2:N8:G1", "parent_friendly_id": "AI:I1:N9:G0", "rationale": "Refinement of the Type II inhibitor AI:I1:N9:G0 by replacing the methoxy group with a difluoroethoxy group. This modification: (1) improves metabolic stability by blocking a potential site of O-demethylation; (2) enhances binding affinity through additional interactions; (3) provides a better balance of lipophilicity and hydrogen bonding capacity. The urea linker for DFG-out conformation stabilization and the N-methylimidazole core are preserved. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained ability to stabilize the inactive kinase conformation."}, {"structure": {"smiles": "COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCN(CC5)S(=O)(=O)C"}, "friendly_id": "AI:I2:N9:G1", "parent_friendly_id": "AI:I1:N10:G0", "rationale": "Enhancement of AI:I1:N10:G0 by replacing the morpholine derivative with a methylsulfonyl-piperazine. This modification: (1) reduces the basicity of the nitrogen while maintaining solubility; (2) provides additional binding interactions through the sulfonyl group; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The isoxazole core and aminopyrimidine hinge binder are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1."}, {"structure": {"smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4"}, "friendly_id": "AI:I2:N10:G1", "parent_friendly_id": "AI:I1:N11:G0", "rationale": "Optimization of AI:I1:N11:G0 by introducing a chlorine atom on the aminopyridine linker. This modification: (1) enhances binding affinity through additional halogen bonding interactions; (2) blocks a potential metabolic site; (3) fine-tunes the electronic properties of the aromatic system. The trifluoromethyl group, aminopyrimidine hinge-binding motif, and morpholine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over AKT2/AKT3."}, {"structure": {"smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F"}, "friendly_id": "AI:I2:N11:G1", "parent_friendly_id": "AI:I1:N12:G0", "rationale": "Refinement of the allosteric inhibitor AI:I1:N12:G0 by introducing a fluorocyclopropane group. This modification: (1) enhances metabolic stability by blocking a potential site of oxidation; (2) provides additional binding interactions through the fluorine atom; (3) maintains the overall size and shape of the molecule while improving its properties. The xanthine core and sulfone linker are preserved for their essential functions in targeting the PH domain-kinase domain interface. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained selectivity for AKT1."}, {"structure": {"smiles": "CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C(=O)CF"}, "friendly_id": "AI:I2:N12:G1", "parent_friendly_id": "AI:I1:N13:G0", "rationale": "Enhancement of AI:I1:N13:G0 by replacing the N-methyl group with a fluoroacetyl group. This modification: (1) reduces the basicity of the piperazine nitrogen while maintaining solubility; (2) provides additional binding interactions through the fluorine atom; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The thiazole core, oxadiazole hinge binder, and amide linker are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1."}]}', 'name': 'gurnemanz_apply'}, 'id': 'toolu_01KPa3x5xqToLRDrnH8crspK', 'type': 'function'}]}, {'role': 'tool', 'tool_call_id': 'toolu_01KPa3x5xqToLRDrnH8crspK', 'content': '{"molecules": [{"moleculeId": "69c29d3f-b6c7-4994-8d4f-404663785c77", "originalData": {"friendlyId": "AI:I2:N1:G1", "parentFriendlyId": "AI:I1:N1:G0", "rationale": "Optimization of AI:I1:N1:G0 with three key modifications: (1) Added a trifluoroethyl group to the piperazine to improve metabolic stability and reduce basicity, potentially improving brain penetration; (2) Introduced a fluorine on the pyridine ring to enhance binding affinity through additional interactions with the hinge region; (3) Maintained the core aminopyrimidine hinge-binding motif while optimizing the overall physicochemical profile. Expected improvements: better metabolic stability, reduced P-gp efflux liability, and potentially enhanced selectivity for AKT1.", "structure": {"smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F"}}}, {"moleculeId": "c6352ae7-c15d-47ea-84f7-d29122345a0f", "originalData": {"friendlyId": "AI:I2:N2:G1", "parentFriendlyId": "AI:I1:N2:G0", "rationale": "Refinement of AI:I1:N2:G0 by introducing a fluorine atom on the central phenyl ring to improve metabolic stability and binding affinity. The Type II inhibitor design is maintained with the urea linker for DFG-out conformation stabilization. The fluorine addition provides several benefits: (1) blocks a potential metabolic site; (2) enhances binding through additional interactions; (3) improves membrane permeability by reducing the overall hydrogen bonding capacity while maintaining the essential pharmacophore elements. Expected improvements: enhanced metabolic stability, potentially improved selectivity, and maintained solubility profile.", "structure": {"smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N"}}}, {"moleculeId": "6fc8a494-f304-44a8-90ca-564e61507ccb", "originalData": {"friendlyId": "AI:I2:N3:G1", "parentFriendlyId": "AI:I1:N3:G0", "rationale": "Enhancement of AI:I1:N3:G0 by introducing a trifluoromethyl group on the aminopyridine linker. This modification serves multiple purposes: (1) increases binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by blocking a potential site of oxidation; (3) enhances selectivity by exploiting a potential hydrophobic pocket unique to AKT1. The core oxadiazole and pyrimidine-pyridine hinge-binding motifs are preserved to maintain essential interactions. Expected improvements: enhanced potency, better metabolic profile, and potentially improved selectivity for AKT1 over AKT2/AKT3.", "structure": {"smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5"}}}, {"moleculeId": "36e037ad-1bdf-49a5-9560-c5fee9a57556", "originalData": {"friendlyId": "AI:I2:N4:G1", "parentFriendlyId": "AI:I1:N4:G0", "rationale": "Optimization of AI:I1:N4:G0 by replacing the pyridine with a difluoromethoxy-substituted pyridine. This modification: (1) introduces a metabolically stable difluoromethoxy group that serves as a hydrogen bond acceptor while providing lipophilicity; (2) enhances binding affinity through additional interactions; (3) improves metabolic stability by blocking oxidation sites. The imidazole core and N-methylpiperazine solubilizing group are maintained for their essential functions. Expected improvements: enhanced potency, better metabolic stability, and potentially improved blood-brain barrier penetration due to the balanced lipophilicity.", "structure": {"smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F"}}}, {"moleculeId": "0e29a281-ded9-49c6-86dc-d886bc5b9287", "originalData": {"friendlyId": "AI:I2:N5:G1", "parentFriendlyId": "AI:I1:N5:G0", "rationale": "Refinement of the allosteric inhibitor AI:I1:N5:G0 by replacing the tertiary amine with a Boc-protected amine. This prodrug approach: (1) masks the basic center to improve membrane permeability; (2) provides controlled release of the active compound after enzymatic cleavage; (3) potentially enhances oral bioavailability by reducing first-pass metabolism. The core indole scaffold and cyano-substituted aminopyrimidine are preserved for their essential interactions with the PH domain-kinase domain interface. Expected improvements: enhanced pharmacokinetic profile, improved oral bioavailability, and maintained selectivity for AKT1.", "structure": {"smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N"}}}, {"moleculeId": "cbee8abf-2840-493a-ac54-be785d77a5b6", "originalData": {"friendlyId": "AI:I2:N6:G1", "parentFriendlyId": "AI:I1:N6:G0", "rationale": "Enhancement of AI:I1:N6:G0 by introducing a fluorine atom on the dimethoxyphenyl group. This modification: (1) blocks a potential metabolic site on the aromatic ring; (2) provides additional binding interactions; (3) fine-tunes the electronic properties of the aromatic system. The triazole core for hinge binding and the sulfone linker are maintained for their essential functions. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained physicochemical properties for good oral bioavailability.", "structure": {"smiles": "COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F"}}}, {"moleculeId": "1fe4cf6d-0e77-4c8e-a582-390070b85e8f", "originalData": {"friendlyId": "AI:I2:N7:G1", "parentFriendlyId": "AI:I1:N8:G0", "rationale": "Optimization of AI:I1:N8:G0 by replacing the pyridine with a trifluoromethyl-substituted pyridine. This modification: (1) enhances binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by replacing a potential metabolic liability; (3) fine-tunes the electronic properties of the hinge-binding element. The thiazole core, amide linker, and N-methylpiperazine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over other kinases.", "structure": {"smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F"}}}, {"moleculeId": "6e226391-ca00-4560-b9ac-0fdb7fea675e", "originalData": {"friendlyId": "AI:I2:N8:G1", "parentFriendlyId": "AI:I1:N9:G0", "rationale": "Refinement of the Type II inhibitor AI:I1:N9:G0 by replacing the methoxy group with a difluoroethoxy group. This modification: (1) improves metabolic stability by blocking a potential site of O-demethylation; (2) enhances binding affinity through additional interactions; (3) provides a better balance of lipophilicity and hydrogen bonding capacity. The urea linker for DFG-out conformation stabilization and the N-methylimidazole core are preserved. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained ability to stabilize the inactive kinase conformation.", "structure": {"smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F"}}}, {"moleculeId": "f50a143e-7e4f-4517-9662-2374028cfc91", "originalData": {"friendlyId": "AI:I2:N9:G1", "parentFriendlyId": "AI:I1:N10:G0", "rationale": "Enhancement of AI:I1:N10:G0 by replacing the morpholine derivative with a methylsulfonyl-piperazine. This modification: (1) reduces the basicity of the nitrogen while maintaining solubility; (2) provides additional binding interactions through the sulfonyl group; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The isoxazole core and aminopyrimidine hinge binder are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.", "structure": {"smiles": "COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCN(CC5)S(=O)(=O)C"}}}, {"moleculeId": "31da8379-0627-482f-88b6-133e7c1fc7e0", "originalData": {"friendlyId": "AI:I2:N10:G1", "parentFriendlyId": "AI:I1:N11:G0", "rationale": "Optimization of AI:I1:N11:G0 by introducing a chlorine atom on the aminopyridine linker. This modification: (1) enhances binding affinity through additional halogen bonding interactions; (2) blocks a potential metabolic site; (3) fine-tunes the electronic properties of the aromatic system. The trifluoromethyl group, aminopyrimidine hinge-binding motif, and morpholine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over AKT2/AKT3.", "structure": {"smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4"}}}, {"moleculeId": "37cff1d8-4f13-4129-b2b7-d8c719d4d6a1", "originalData": {"friendlyId": "AI:I2:N11:G1", "parentFriendlyId": "AI:I1:N12:G0", "rationale": "Refinement of the allosteric inhibitor AI:I1:N12:G0 by introducing a fluorocyclopropane group. This modification: (1) enhances metabolic stability by blocking a potential site of oxidation; (2) provides additional binding interactions through the fluorine atom; (3) maintains the overall size and shape of the molecule while improving its properties. The xanthine core and sulfone linker are preserved for their essential functions in targeting the PH domain-kinase domain interface. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained selectivity for AKT1.", "structure": {"smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F"}}}, {"moleculeId": "ddc94d30-d965-45d7-ba64-0e9f8ab59a20", "originalData": {"friendlyId": "AI:I2:N12:G1", "parentFriendlyId": "AI:I1:N13:G0", "rationale": "Enhancement of AI:I1:N13:G0 by replacing the N-methyl group with a fluoroacetyl group. This modification: (1) reduces the basicity of the piperazine nitrogen while maintaining solubility; (2) provides additional binding interactions through the fluorine atom; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The thiazole core, oxadiazole hinge binder, and amide linker are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.", "structure": {"smiles": "CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C(=O)CF"}}}], "transformation": {"agent": "LLM Drug Designer", "iteration": 2, "methodDetails": null, "proteinPath": null, "proteinSequence": null, "rationale": "Optimization of AKT1 inhibitor candidates focusing on scaffold hopping, property optimization, selectivity enhancement, and ADMET optimization. Key strategies included: (1) Metabolic stability enhancements through fluorine incorporation, trifluoromethyl groups, and difluoromethoxy/ethoxy substitutions; (2) Selectivity optimization by exploiting unique pockets, fine-tuning electronic properties, and introducing halogen bonding; (3) Pharmacokinetic improvements via prodrug approaches, reduced basicity, and balanced lipophilicity; (4) Binding affinity optimization through additional H-bond interactions, halogen bonding, and optimized hydrophobic interactions; (5) Careful preservation of core pharmacophores including ATP-competitive hinge-binding motifs, Type II inhibitor urea linkers, and allosteric binding elements.", "transformationId": "a440fa32-db18-4c5d-a50c-5d5a184026f9", "type": "lead-optimization", "userMessage": null}}'}, {'role': 'assistant', 'content': 'I\'ve successfully parsed the LLM Drug Designer\'s output and submitted it to GURNEMANZ. The system has processed 12 optimized AKT1 inhibitor molecules, each with appropriate parent-child relationships maintained through the friendly_id system.\n\nThe transformation was categorized as "lead-optimization" (iteration 2), with a comprehensive rationale capturing the key optimization strategies:\n\n1. Metabolic stability enhancements through fluorine incorporation, trifluoromethyl groups, and difluoromethoxy/ethoxy substitutions\n2. Selectivity optimization by exploiting unique pockets, fine-tuning electronic properties, and introducing halogen bonding\n3. Pharmacokinetic improvements via prodrug approaches, reduced basicity, and balanced lipophilicity\n4. Binding affinity optimization through additional H-bond interactions, halogen bonding, and optimized hydrophobic interactions\n5. Careful preservation of core pharmacophores including ATP-competitive hinge-binding motifs, Type II inhibitor urea linkers, and allosteric binding elements\n\nEach molecule has been assigned a unique molecule ID in the GURNEMANZ system, with proper tracking of its parent molecule through the parent_friendly_id field. The rationales for each modification have been preserved, detailing the specific structural changes and their expected benefits for potency, selectivity, and ADMET properties.'}]
2025-06-23 14:04:50,611 - INFO - main_history after parser: [
  {
    "role": "user",
    "content": "You are an expert medicinal chemist and computational drug discovery scientist. Your task is to design novel small molecule inhibitors for AKT1 (Protein Kinase B alpha) using your knowledge of structure-activity relationships, medicinal chemistry principles, and drug design.\n\n**Target Information:**\n- AKT1 is a serine/threonine kinase in the PI3K/AKT/mTOR pathway\n- Critical for cell survival, proliferation, and metabolism\n- Key oncology target with multiple known inhibitors\n- ATP-competitive and allosteric binding sites available\n\n**Your Goal:**\nGenerate novel, drug-like small molecule AKT1 inhibitors with the following criteria:\n- High predicted binding affinity to AKT1\n- Drug-like properties (Lipinski's Rule of Five compliance)\n- Synthetic accessibility\n- Novel scaffolds not directly copied from known inhibitors\n\n**Output Format:**\nFor each molecule, provide:\n1. **Molecule ID**: A unique identifier (e.g., LLM_MOL_001)\n2. **SMILES**: Valid SMILES string\n3. **Rationale**: Brief explanation of your design strategy and expected properties\n4. **Predicted Properties**: Your assessment of drug-likeness, potency, selectivity\n\nFocus on innovative chemical designs while maintaining scientific rigor."
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 1: Initial Discovery & Exploration**\n\nDesign 10-15 novel AKT1 inhibitor molecules using your medicinal chemistry expertise. Consider:\n\n1. **ATP-competitive inhibitors**: Target the ATP-binding pocket with novel scaffolds\n2. **Allosteric inhibitors**: Design molecules that bind to regulatory sites\n3. **Hybrid approaches**: Molecules that may interact with multiple binding sites\n\nUse your knowledge of:\n- Known AKT1 pharmacophores (avoid direct copying)\n- Kinase selectivity determinants\n- Drug-like chemical space\n- Structure-activity relationships\n\nGenerate diverse scaffolds including heterocycles, aromatic systems, and appropriate linkers. Ensure synthetic feasibility while prioritizing novelty."
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Initial Discovery\n\nI'll design novel AKT1 inhibitors using medicinal chemistry principles and my knowledge of kinase inhibitor design. I'll focus on creating diverse, drug-like molecules with appropriate pharmacophores for AKT1 inhibition.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N1:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I1:N2:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N3:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N4:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I1:N5:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I1:N6:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N7:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N8:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC\",\n            \"friendly_id\": \"AI:I1:N9:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5\",\n            \"friendly_id\": \"AI:I1:N10:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I1:N11:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5\",\n            \"friendly_id\": \"AI:I1:N12:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C\",\n            \"friendly_id\": \"AI:I1:N13:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5\",\n            \"friendly_id\": \"AI:I1:N14:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N15:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        }\n    ]\n}\n</molecules>\n\n## Design Strategy Overview\n\nMy approach to designing these AKT1 inhibitors focused on several key medicinal chemistry principles:\n\n### 1. Hinge-Binding Motifs\n- Incorporated established kinase hinge-binding pharmacophores including:\n  - Aminopyrimidines (molecules 1, 2, 11, 14)\n  - Imidazoles (molecule 4)\n  - Triazoles (molecule 6)\n  - Quinazolines (molecule 15)\n  - Oxadiazoles (molecules 3, 7, 13)\n\n### 2. Binding Modes\n- **ATP-competitive inhibitors** (majority of designs): Target the ATP-binding pocket with appropriate hinge-binding elements\n- **Type II inhibitors** (molecules 2, 9): Include urea linkers to stabilize the DFG-out conformation\n- **Allosteric inhibitors** (molecules 5, 12): Target the PH domain-kinase domain interface\n\n### 3. Structural Features\n- **Solubilizing groups**: Incorporated piperazines, morpholines, and tertiary amines\n- **Metabolic stability**: Used fluorine substitutions, oxadiazoles, and methoxy groups\n- **Rigidity and spatial arrangement**: Employed amide linkers, ureas, and conformationally constrained cores\n\n### 4. Drug-Like Properties\n- Designed molecules with:\n  - MW generally between 420-550 Da\n  - LogP values in the 2.5-4 range\n  - Appropriate H-bond donors/acceptors (Lipinski compliant)\n  - Balanced solubility and permeability characteristics\n\nThese designs represent a diverse set of potential AKT1 inhibitors with varied scaffolds, binding modes, and physicochemical properties, providing a strong foundation for further optimization."
      }
    ]
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 2: Lead Optimization**\n\nBased on your previous designs, now optimize and refine your best candidates. Focus on:\n\n1. **Scaffold hopping**: Create variants of your most promising designs\n2. **Property optimization**: Improve drug-likeness, solubility, permeability\n3. **Selectivity enhancement**: Design features for AKT1 vs AKT2/AKT3 selectivity\n4. **ADMET optimization**: Consider metabolic stability and safety\n\nGenerate 8-12 optimized molecules that build upon your iteration 1 insights. Include:\n- Modified versions of your best scaffolds\n- New analogs with improved properties\n- Rationale for each modification based on medicinal chemistry principles"
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Lead Optimization\n\nBased on the initial designs, I'll now optimize the most promising candidates to enhance potency, selectivity, and drug-like properties. I'll focus on scaffold hopping, property optimization, and addressing potential ADMET issues.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F\",\n            \"friendly_id\": \"AI:I2:N1:G1\",\n            \"source\": \"AI:I1:N1:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N1:G0 with three key modifications: (1) Added a trifluoroethyl group to the piperazine to improve metabolic stability and reduce basicity, potentially improving brain penetration; (2) Introduced a fluorine on the pyridine ring to enhance binding affinity through additional interactions with the hinge region; (3) Maintained the core aminopyrimidine hinge-binding motif while optimizing the overall physicochemical profile. Expected improvements: better metabolic stability, reduced P-gp efflux liability, and potentially enhanced selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I2:N2:G1\",\n            \"source\": \"AI:I1:N2:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of AI:I1:N2:G0 by introducing a fluorine atom on the central phenyl ring to improve metabolic stability and binding affinity. The Type II inhibitor design is maintained with the urea linker for DFG-out conformation stabilization. The fluorine addition provides several benefits: (1) blocks a potential metabolic site; (2) enhances binding through additional interactions; (3) improves membrane permeability by reducing the overall hydrogen bonding capacity while maintaining the essential pharmacophore elements. Expected improvements: enhanced metabolic stability, potentially improved selectivity, and maintained solubility profile.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I2:N3:G1\",\n            \"source\": \"AI:I1:N3:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N3:G0 by introducing a trifluoromethyl group on the aminopyridine linker. This modification serves multiple purposes: (1) increases binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by blocking a potential site of oxidation; (3) enhances selectivity by exploiting a potential hydrophobic pocket unique to AKT1. The core oxadiazole and pyrimidine-pyridine hinge-binding motifs are preserved to maintain essential interactions. Expected improvements: enhanced potency, better metabolic profile, and potentially improved selectivity for AKT1 over AKT2/AKT3.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F\",\n            \"friendly_id\": \"AI:I2:N4:G1\",\n            \"source\": \"AI:I1:N4:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N4:G0 by replacing the pyridine with a difluoromethoxy-substituted pyridine. This modification: (1) introduces a metabolically stable difluoromethoxy group that serves as a hydrogen bond acceptor while providing lipophilicity; (2) enhances binding affinity through additional interactions; (3) improves metabolic stability by blocking oxidation sites. The imidazole core and N-methylpiperazine solubilizing group are maintained for their essential functions. Expected improvements: enhanced potency, better metabolic stability, and potentially improved blood-brain barrier penetration due to the balanced lipophilicity.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I2:N5:G1\",\n            \"source\": \"AI:I1:N5:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the allosteric inhibitor AI:I1:N5:G0 by replacing the tertiary amine with a Boc-protected amine. This prodrug approach: (1) masks the basic center to improve membrane permeability; (2) provides controlled release of the active compound after enzymatic cleavage; (3) potentially enhances oral bioavailability by reducing first-pass metabolism. The core indole scaffold and cyano-substituted aminopyrimidine are preserved for their essential interactions with the PH domain-kinase domain interface. Expected improvements: enhanced pharmacokinetic profile, improved oral bioavailability, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I2:N6:G1\",\n            \"source\": \"AI:I1:N6:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N6:G0 by introducing a fluorine atom on the dimethoxyphenyl group. This modification: (1) blocks a potential metabolic site on the aromatic ring; (2) provides additional binding interactions; (3) fine-tunes the electronic properties of the aromatic system. The triazole core for hinge binding and the sulfone linker are maintained for their essential functions. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained physicochemical properties for good oral bioavailability.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F\",\n            \"friendly_id\": \"AI:I2:N7:G1\",\n            \"source\": \"AI:I1:N8:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N8:G0 by replacing the pyridine with a trifluoromethyl-substituted pyridine. This modification: (1) enhances binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by replacing a potential metabolic liability; (3) fine-tunes the electronic properties of the hinge-binding element. The thiazole core, amide linker, and N-methylpiperazine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F\",\n            \"friendly_id\": \"AI:I2:N8:G1\",\n            \"source\": \"AI:I1:N9:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the Type II inhibitor AI:I1:N9:G0 by replacing the methoxy group with a difluoroethoxy group. This modification: (1) improves metabolic stability by blocking a potential site of O-demethylation; (2) enhances binding affinity through additional interactions; (3) provides a better balance of lipophilicity and hydrogen bonding capacity. The urea linker for DFG-out conformation stabilization and the N-methylimidazole core are preserved. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained ability to stabilize the inactive kinase conformation.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCN(CC5)S(=O)(=O)C\",\n            \"friendly_id\": \"AI:I2:N9:G1\",\n            \"source\": \"AI:I1:N10:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N10:G0 by replacing the morpholine derivative with a methylsulfonyl-piperazine. This modification: (1) reduces the basicity of the nitrogen while maintaining solubility; (2) provides additional binding interactions through the sulfonyl group; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The isoxazole core and aminopyrimidine hinge binder are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I2:N10:G1\",\n            \"source\": \"AI:I1:N11:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N11:G0 by introducing a chlorine atom on the aminopyridine linker. This modification: (1) enhances binding affinity through additional halogen bonding interactions; (2) blocks a potential metabolic site; (3) fine-tunes the electronic properties of the aromatic system. The trifluoromethyl group, aminopyrimidine hinge-binding motif, and morpholine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over AKT2/AKT3.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F\",\n            \"friendly_id\": \"AI:I2:N11:G1\",\n            \"source\": \"AI:I1:N12:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the allosteric inhibitor AI:I1:N12:G0 by introducing a fluorocyclopropane group. This modification: (1) enhances metabolic stability by blocking a potential site of oxidation; (2) provides additional binding interactions through the fluorine atom; (3) maintains the overall size and shape of the molecule while improving its properties. The xanthine core and sulfone linker are preserved for their essential functions in targeting the PH domain-kinase domain interface. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C(=O)CF\",\n            \"friendly_id\": \"AI:I2:N12:G1\",\n            \"source\": \"AI:I1:N13:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N13:G0 by replacing the N-methyl group with a fluoroacetyl group. This modification: (1) reduces the basicity of the piperazine nitrogen while maintaining solubility; (2) provides additional binding interactions through the fluorine atom; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The thiazole core, oxadiazole hinge binder, and amide linker are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        }\n    ]\n}\n</molecules>\n\n## Lead Optimization Strategy\n\nIn this optimization phase, I focused on refining the most promising candidates from Iteration 1 to enhance their drug-like properties, potency, selectivity, and ADMET profiles. Here's a summary of the key optimization strategies employed:\n\n### 1. Metabolic Stability Enhancements\n- **Fluorine incorporation**: Added strategic fluorine atoms to block metabolic hot spots (molecules 1, 2, 3, 6, 8, 10)\n- **Trifluoromethyl groups**: Introduced CF\u2083 groups to enhance stability and binding (molecules 3, 7, 10)\n- **Difluoromethoxy/ethoxy groups**: Replaced metabolically labile methoxy groups (molecules 4, 8)\n\n### 2. Selectivity Optimization\n- **Exploiting unique pockets**: Added substituents to target AKT1-specific binding regions (molecules 3, 7)\n- **Fine-tuning electronic properties**: Modified hinge-binding elements to enhance selectivity (molecules 4, 7)\n- **Halogen bonding**: Introduced chlorine for additional selective interactions (molecule 10)\n\n### 3. Pharmacokinetic Improvements\n- **Prodrug approach**: Implemented a Boc-protected amine to improve membrane permeability (molecule 5)\n- **Reduced basicity**: Modified basic centers to improve brain penetration and reduce P-gp efflux (molecules 1, 9, 12)\n- **Balanced lipophilicity**: Fine-tuned the hydrophobic/hydrophilic balance (molecules 4, 8)\n\n### 4. Binding Affinity Optimization\n- **Additional H-bond interactions**: Introduced groups capable of forming new H-bonds (molecules 4, 8)\n- **Halogen bonding**: Added fluorine and chlorine atoms for enhanced interactions (molecules 1, 10)\n- **Hydrophobic interactions**: Optimized lipophilic groups for better pocket complementarity (molecules 3, 7)\n\n### 5. Scaffold Preservation\nWhile making these modifications, I carefully preserved the core pharmacophores identified in Iteration 1:\n- ATP-competitive hinge-binding motifs (aminopyrimidines, imidazoles, etc.)\n- Type II inhibitor urea linkers\n- Allosteric binding elements for PH domain-kinase domain interface targeting\n\nThese optimized compounds represent a focused set of candidates with improved properties while maintaining the essential structural features required for AKT1 inhibition. The modifications were guided by established medicinal chemistry principles to address potential liabilities while enhancing desirable characteristics."
      }
    ]
  }
]
2025-06-23 14:04:50,612 - INFO - Completed Iteration 2
2025-06-23 14:04:50,612 - INFO - --------------------------------
2025-06-23 14:04:50,612 - INFO - Starting Iteration 3
2025-06-23 14:04:50,612 - INFO - --------------------------------
2025-06-23 14:04:50,612 - INFO - LLM Agent: LLM Drug Designer
2025-06-23 14:04:50,612 - INFO - chat history for chat completion: [
  {
    "role": "system",
    "content": "You are an AI assistant acting as LLM Drug Designer. Your expertise is in ('Medicinal chemistry and drug design', 'Structure-activity relationships', 'Kinase inhibitor development', 'ADMET optimization', 'Computational drug discovery'). Your goal is to Design novel, drug-like small molecule AKT1 inhibitors using medicinal chemistry knowledge and computational drug design principles, without relying on external tools.. Your role is to Expert medicinal chemist responsible for generating innovative AKT1 inhibitor designs based on scientific knowledge, literature understanding, and drug design principles. Provide novel chemical structures with clear design rationales.. Please maintain this role throughout our conversation.\n\n\n        \"molecules\": [\n                {\n                    \"smiles\": \"SMILES_STRING\",\n                    \"friendly_id\": \"friendly id of molecule eg: DA:I1:N0:G0\",\n                    \"source\": \"(parent molecule id of modified molecule)\"\n                    \"agent\": \"AGENT_NAME\",\n                    \"rationale\": \"(rationale for the molecule)\"\n                }\n            ],\n        }\n        </molecules>\n        \nDruing the discovery process, molecules will be presented with a friendly_id. This friendly_id is a unique identifier that tracks its complete history and lineage through our optimization process to help to follow the SAR and parent-child relationships.\n\n## Molecule ID System - Tracking Molecular Evolution\n\nEach molecule receives a unique identifier that tracks its complete history and lineage through our optimization process.\n\n**Format:** `AgentCode:I<iteration>:N<position>:G<generation>`\n\nThis ID (friendly_id) system serves as a molecular genealogy, allowing us to:\n- Track which agent created or modified each molecule\n- Understand the evolutionary path from original to optimized compounds\n- Maintain parent-child relationships across modifications\n\n**Components:**\n- **AgentCode**: Two-letter code representing the creator agent\n  - DA = Database Agent\n  - AI = AI Expert\n  - MC = Medicinal Chemist\n  - LA = Literature Agent\n  - RA = Ranking Agent\n  - PR = Principal Researcher\n  - SC = Scientific Critic\n  - SP = Summary Parser\n\n- **I<iteration>**: The research iteration number when molecule was introduced (e.g., I1, I2, I3)\n- **N<position>**: The molecule's position in the agent's output list, starting from N1 (resets per agent output)\n- **G<generation>**: The modification depth showing molecular evolution\n  - G0 = original molecule (from database or de novo)\n  - G1 = first modification\n  - G2 = second modification\n  - And so on...\n\n**Example Evolution:**\n1. Database retrieves: `DA:I1:N3:G0` (original from ChEMBL, third molecule in list, iteration 1)\n2. Medicinal Chemist modifies it: `MC:I2:N1:G1` (first modification, first molecule in chemist's list, iteration 2)\n3. Further optimization: `MC:I3:N2:G2` (second modification, second molecule in list, iteration 3)\n\nThis allows us to trace any molecule back to its origins and understand its optimization journey.\nIf a molecule is a child of a parent molecule, the parent molecule's friendly_id must be included in the molecule's source field\n"
  },
  {
    "role": "user",
    "content": "You are an expert medicinal chemist and computational drug discovery scientist. Your task is to design novel small molecule inhibitors for AKT1 (Protein Kinase B alpha) using your knowledge of structure-activity relationships, medicinal chemistry principles, and drug design.\n\n**Target Information:**\n- AKT1 is a serine/threonine kinase in the PI3K/AKT/mTOR pathway\n- Critical for cell survival, proliferation, and metabolism\n- Key oncology target with multiple known inhibitors\n- ATP-competitive and allosteric binding sites available\n\n**Your Goal:**\nGenerate novel, drug-like small molecule AKT1 inhibitors with the following criteria:\n- High predicted binding affinity to AKT1\n- Drug-like properties (Lipinski's Rule of Five compliance)\n- Synthetic accessibility\n- Novel scaffolds not directly copied from known inhibitors\n\n**Output Format:**\nFor each molecule, provide:\n1. **Molecule ID**: A unique identifier (e.g., LLM_MOL_001)\n2. **SMILES**: Valid SMILES string\n3. **Rationale**: Brief explanation of your design strategy and expected properties\n4. **Predicted Properties**: Your assessment of drug-likeness, potency, selectivity\n\nFocus on innovative chemical designs while maintaining scientific rigor."
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 1: Initial Discovery & Exploration**\n\nDesign 10-15 novel AKT1 inhibitor molecules using your medicinal chemistry expertise. Consider:\n\n1. **ATP-competitive inhibitors**: Target the ATP-binding pocket with novel scaffolds\n2. **Allosteric inhibitors**: Design molecules that bind to regulatory sites\n3. **Hybrid approaches**: Molecules that may interact with multiple binding sites\n\nUse your knowledge of:\n- Known AKT1 pharmacophores (avoid direct copying)\n- Kinase selectivity determinants\n- Drug-like chemical space\n- Structure-activity relationships\n\nGenerate diverse scaffolds including heterocycles, aromatic systems, and appropriate linkers. Ensure synthetic feasibility while prioritizing novelty."
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Initial Discovery\n\nI'll design novel AKT1 inhibitors using medicinal chemistry principles and my knowledge of kinase inhibitor design. I'll focus on creating diverse, drug-like molecules with appropriate pharmacophores for AKT1 inhibition.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N1:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I1:N2:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N3:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N4:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I1:N5:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I1:N6:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N7:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N8:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC\",\n            \"friendly_id\": \"AI:I1:N9:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5\",\n            \"friendly_id\": \"AI:I1:N10:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I1:N11:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5\",\n            \"friendly_id\": \"AI:I1:N12:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C\",\n            \"friendly_id\": \"AI:I1:N13:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5\",\n            \"friendly_id\": \"AI:I1:N14:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N15:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        }\n    ]\n}\n</molecules>\n\n## Design Strategy Overview\n\nMy approach to designing these AKT1 inhibitors focused on several key medicinal chemistry principles:\n\n### 1. Hinge-Binding Motifs\n- Incorporated established kinase hinge-binding pharmacophores including:\n  - Aminopyrimidines (molecules 1, 2, 11, 14)\n  - Imidazoles (molecule 4)\n  - Triazoles (molecule 6)\n  - Quinazolines (molecule 15)\n  - Oxadiazoles (molecules 3, 7, 13)\n\n### 2. Binding Modes\n- **ATP-competitive inhibitors** (majority of designs): Target the ATP-binding pocket with appropriate hinge-binding elements\n- **Type II inhibitors** (molecules 2, 9): Include urea linkers to stabilize the DFG-out conformation\n- **Allosteric inhibitors** (molecules 5, 12): Target the PH domain-kinase domain interface\n\n### 3. Structural Features\n- **Solubilizing groups**: Incorporated piperazines, morpholines, and tertiary amines\n- **Metabolic stability**: Used fluorine substitutions, oxadiazoles, and methoxy groups\n- **Rigidity and spatial arrangement**: Employed amide linkers, ureas, and conformationally constrained cores\n\n### 4. Drug-Like Properties\n- Designed molecules with:\n  - MW generally between 420-550 Da\n  - LogP values in the 2.5-4 range\n  - Appropriate H-bond donors/acceptors (Lipinski compliant)\n  - Balanced solubility and permeability characteristics\n\nThese designs represent a diverse set of potential AKT1 inhibitors with varied scaffolds, binding modes, and physicochemical properties, providing a strong foundation for further optimization."
      }
    ]
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 2: Lead Optimization**\n\nBased on your previous designs, now optimize and refine your best candidates. Focus on:\n\n1. **Scaffold hopping**: Create variants of your most promising designs\n2. **Property optimization**: Improve drug-likeness, solubility, permeability\n3. **Selectivity enhancement**: Design features for AKT1 vs AKT2/AKT3 selectivity\n4. **ADMET optimization**: Consider metabolic stability and safety\n\nGenerate 8-12 optimized molecules that build upon your iteration 1 insights. Include:\n- Modified versions of your best scaffolds\n- New analogs with improved properties\n- Rationale for each modification based on medicinal chemistry principles"
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Lead Optimization\n\nBased on the initial designs, I'll now optimize the most promising candidates to enhance potency, selectivity, and drug-like properties. I'll focus on scaffold hopping, property optimization, and addressing potential ADMET issues.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F\",\n            \"friendly_id\": \"AI:I2:N1:G1\",\n            \"source\": \"AI:I1:N1:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N1:G0 with three key modifications: (1) Added a trifluoroethyl group to the piperazine to improve metabolic stability and reduce basicity, potentially improving brain penetration; (2) Introduced a fluorine on the pyridine ring to enhance binding affinity through additional interactions with the hinge region; (3) Maintained the core aminopyrimidine hinge-binding motif while optimizing the overall physicochemical profile. Expected improvements: better metabolic stability, reduced P-gp efflux liability, and potentially enhanced selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I2:N2:G1\",\n            \"source\": \"AI:I1:N2:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of AI:I1:N2:G0 by introducing a fluorine atom on the central phenyl ring to improve metabolic stability and binding affinity. The Type II inhibitor design is maintained with the urea linker for DFG-out conformation stabilization. The fluorine addition provides several benefits: (1) blocks a potential metabolic site; (2) enhances binding through additional interactions; (3) improves membrane permeability by reducing the overall hydrogen bonding capacity while maintaining the essential pharmacophore elements. Expected improvements: enhanced metabolic stability, potentially improved selectivity, and maintained solubility profile.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I2:N3:G1\",\n            \"source\": \"AI:I1:N3:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N3:G0 by introducing a trifluoromethyl group on the aminopyridine linker. This modification serves multiple purposes: (1) increases binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by blocking a potential site of oxidation; (3) enhances selectivity by exploiting a potential hydrophobic pocket unique to AKT1. The core oxadiazole and pyrimidine-pyridine hinge-binding motifs are preserved to maintain essential interactions. Expected improvements: enhanced potency, better metabolic profile, and potentially improved selectivity for AKT1 over AKT2/AKT3.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F\",\n            \"friendly_id\": \"AI:I2:N4:G1\",\n            \"source\": \"AI:I1:N4:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N4:G0 by replacing the pyridine with a difluoromethoxy-substituted pyridine. This modification: (1) introduces a metabolically stable difluoromethoxy group that serves as a hydrogen bond acceptor while providing lipophilicity; (2) enhances binding affinity through additional interactions; (3) improves metabolic stability by blocking oxidation sites. The imidazole core and N-methylpiperazine solubilizing group are maintained for their essential functions. Expected improvements: enhanced potency, better metabolic stability, and potentially improved blood-brain barrier penetration due to the balanced lipophilicity.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I2:N5:G1\",\n            \"source\": \"AI:I1:N5:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the allosteric inhibitor AI:I1:N5:G0 by replacing the tertiary amine with a Boc-protected amine. This prodrug approach: (1) masks the basic center to improve membrane permeability; (2) provides controlled release of the active compound after enzymatic cleavage; (3) potentially enhances oral bioavailability by reducing first-pass metabolism. The core indole scaffold and cyano-substituted aminopyrimidine are preserved for their essential interactions with the PH domain-kinase domain interface. Expected improvements: enhanced pharmacokinetic profile, improved oral bioavailability, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I2:N6:G1\",\n            \"source\": \"AI:I1:N6:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N6:G0 by introducing a fluorine atom on the dimethoxyphenyl group. This modification: (1) blocks a potential metabolic site on the aromatic ring; (2) provides additional binding interactions; (3) fine-tunes the electronic properties of the aromatic system. The triazole core for hinge binding and the sulfone linker are maintained for their essential functions. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained physicochemical properties for good oral bioavailability.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F\",\n            \"friendly_id\": \"AI:I2:N7:G1\",\n            \"source\": \"AI:I1:N8:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N8:G0 by replacing the pyridine with a trifluoromethyl-substituted pyridine. This modification: (1) enhances binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by replacing a potential metabolic liability; (3) fine-tunes the electronic properties of the hinge-binding element. The thiazole core, amide linker, and N-methylpiperazine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F\",\n            \"friendly_id\": \"AI:I2:N8:G1\",\n            \"source\": \"AI:I1:N9:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the Type II inhibitor AI:I1:N9:G0 by replacing the methoxy group with a difluoroethoxy group. This modification: (1) improves metabolic stability by blocking a potential site of O-demethylation; (2) enhances binding affinity through additional interactions; (3) provides a better balance of lipophilicity and hydrogen bonding capacity. The urea linker for DFG-out conformation stabilization and the N-methylimidazole core are preserved. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained ability to stabilize the inactive kinase conformation.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCN(CC5)S(=O)(=O)C\",\n            \"friendly_id\": \"AI:I2:N9:G1\",\n            \"source\": \"AI:I1:N10:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N10:G0 by replacing the morpholine derivative with a methylsulfonyl-piperazine. This modification: (1) reduces the basicity of the nitrogen while maintaining solubility; (2) provides additional binding interactions through the sulfonyl group; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The isoxazole core and aminopyrimidine hinge binder are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I2:N10:G1\",\n            \"source\": \"AI:I1:N11:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N11:G0 by introducing a chlorine atom on the aminopyridine linker. This modification: (1) enhances binding affinity through additional halogen bonding interactions; (2) blocks a potential metabolic site; (3) fine-tunes the electronic properties of the aromatic system. The trifluoromethyl group, aminopyrimidine hinge-binding motif, and morpholine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over AKT2/AKT3.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F\",\n            \"friendly_id\": \"AI:I2:N11:G1\",\n            \"source\": \"AI:I1:N12:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the allosteric inhibitor AI:I1:N12:G0 by introducing a fluorocyclopropane group. This modification: (1) enhances metabolic stability by blocking a potential site of oxidation; (2) provides additional binding interactions through the fluorine atom; (3) maintains the overall size and shape of the molecule while improving its properties. The xanthine core and sulfone linker are preserved for their essential functions in targeting the PH domain-kinase domain interface. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C(=O)CF\",\n            \"friendly_id\": \"AI:I2:N12:G1\",\n            \"source\": \"AI:I1:N13:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N13:G0 by replacing the N-methyl group with a fluoroacetyl group. This modification: (1) reduces the basicity of the piperazine nitrogen while maintaining solubility; (2) provides additional binding interactions through the fluorine atom; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The thiazole core, oxadiazole hinge binder, and amide linker are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        }\n    ]\n}\n</molecules>\n\n## Lead Optimization Strategy\n\nIn this optimization phase, I focused on refining the most promising candidates from Iteration 1 to enhance their drug-like properties, potency, selectivity, and ADMET profiles. Here's a summary of the key optimization strategies employed:\n\n### 1. Metabolic Stability Enhancements\n- **Fluorine incorporation**: Added strategic fluorine atoms to block metabolic hot spots (molecules 1, 2, 3, 6, 8, 10)\n- **Trifluoromethyl groups**: Introduced CF\u2083 groups to enhance stability and binding (molecules 3, 7, 10)\n- **Difluoromethoxy/ethoxy groups**: Replaced metabolically labile methoxy groups (molecules 4, 8)\n\n### 2. Selectivity Optimization\n- **Exploiting unique pockets**: Added substituents to target AKT1-specific binding regions (molecules 3, 7)\n- **Fine-tuning electronic properties**: Modified hinge-binding elements to enhance selectivity (molecules 4, 7)\n- **Halogen bonding**: Introduced chlorine for additional selective interactions (molecule 10)\n\n### 3. Pharmacokinetic Improvements\n- **Prodrug approach**: Implemented a Boc-protected amine to improve membrane permeability (molecule 5)\n- **Reduced basicity**: Modified basic centers to improve brain penetration and reduce P-gp efflux (molecules 1, 9, 12)\n- **Balanced lipophilicity**: Fine-tuned the hydrophobic/hydrophilic balance (molecules 4, 8)\n\n### 4. Binding Affinity Optimization\n- **Additional H-bond interactions**: Introduced groups capable of forming new H-bonds (molecules 4, 8)\n- **Halogen bonding**: Added fluorine and chlorine atoms for enhanced interactions (molecules 1, 10)\n- **Hydrophobic interactions**: Optimized lipophilic groups for better pocket complementarity (molecules 3, 7)\n\n### 5. Scaffold Preservation\nWhile making these modifications, I carefully preserved the core pharmacophores identified in Iteration 1:\n- ATP-competitive hinge-binding motifs (aminopyrimidines, imidazoles, etc.)\n- Type II inhibitor urea linkers\n- Allosteric binding elements for PH domain-kinase domain interface targeting\n\nThese optimized compounds represent a focused set of candidates with improved properties while maintaining the essential structural features required for AKT1 inhibition. The modifications were guided by established medicinal chemistry principles to address potential liabilities while enhancing desirable characteristics."
      }
    ]
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 3: Final Lead Optimization & Selection**\n\nCreate your final set of 8-10 candidate molecules representing your best designs for AKT1 inhibition. Focus on:\n\n1. **Best-in-class designs**: Your most promising scaffolds with optimal substitution patterns\n2. **Diverse mechanisms**: Include both ATP-competitive and allosteric candidates\n3. **Clinical viability**: Emphasize drug-like properties and synthetic accessibility\n4. **Innovation**: Ensure your designs represent novel chemical space\n\nFor each final candidate, provide:\n- Comprehensive rationale for inclusion\n- Predicted binding mode and key interactions\n- Assessment of development potential\n- Comparison to known AKT1 inhibitors (without direct copying)\n- Don't forget to use the molecule entry format"
      }
    ]
  }
]
2025-06-23 14:05:54,387 - INFO - response ModelResponse(id='chatcmpl-9234c3da-11c8-4731-ab24-c43e059cd7f7', created=1750676754, model='claude-3-7-sonnet-20250219', object='chat.completion', system_fingerprint=None, choices=[Choices(finish_reason='stop', index=0, message=Message(content='# AKT1 Inhibitor Design - Final Lead Optimization & Selection\n\nI\'ve developed a final set of optimized AKT1 inhibitor candidates representing diverse mechanisms, optimal properties, and novel chemical space. These compounds incorporate the insights gained from previous iterations while addressing key medicinal chemistry considerations.\n\n<molecules>\n{\n    "molecules": [\n        {\n            "smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F",\n            "friendly_id": "AI:I3:N1:G2",\n            "source": "AI:I2:N1:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This ATP-competitive inhibitor represents our lead hinge-binding scaffold with optimal substitution. The aminopyrimidine forms key hydrogen bonds with the kinase hinge region (E228, A230), while the fluoropyridine enhances these interactions through a halogen bond. The trifluoroethyl-piperazine provides metabolic stability and reduced P-gp efflux liability compared to simple N-methylpiperazine. The toluidine group extends into the hydrophobic back pocket, providing selectivity. This compound offers an excellent balance of potency, selectivity, and drug-like properties (MW ~550, LogP ~3.8, 3 H-bond donors, 8 H-bond acceptors). Compared to known AKT inhibitors like capivasertib, it features a novel linking strategy while maintaining essential pharmacophore elements. Synthetic accessibility is high through convergent synthesis."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N",\n            "friendly_id": "AI:I3:N2:G2",\n            "source": "AI:I2:N2:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1, offering a distinct mechanism from most ATP-competitive inhibitors. The aminopyrimidine forms hydrogen bonds with the hinge region, while the urea linker forms critical hydrogen bonds with the DFG motif (D292, F293). The fluorophenyl group occupies the hydrophobic pocket exposed in the DFG-out state, with the fluorine providing metabolic stability and enhanced binding. The piperazine linker offers solubility while the methoxyphenyl provides additional hydrophobic interactions. This compound has favorable properties (MW ~560, LogP ~3.5, 5 H-bond donors, 10 H-bond acceptors) and represents a novel chemical space compared to known Type II kinase inhibitors. Its unique binding mode may offer advantages in overcoming resistance mechanisms."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F",\n            "friendly_id": "AI:I3:N3:G2",\n            "source": "AI:I2:N4:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This ATP-competitive inhibitor features an imidazole core with a difluoromethoxypyridine substituent that forms optimal interactions with the hinge region of AKT1. The difluoromethoxy group serves as a metabolically stable hydrogen bond acceptor while providing lipophilicity and halogen bonding opportunities. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~480, LogP ~3.2, 2 H-bond donors, 8 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors like ipatasertib. The balanced physicochemical profile suggests good oral bioavailability and CNS penetration potential, making it suitable for various AKT1-driven indications."\n        },\n        {\n            "smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N",\n            "friendly_id": "AI:I3:N4:G2",\n            "source": "AI:I2:N5:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism distinct from ATP-competitive inhibitors. The indole core provides a rigid scaffold that positions the cyano-aminopyrimidine to form key interactions with the interdomain pocket. The Boc-protected amine serves as a prodrug approach, masking the basic center to improve membrane permeability and oral bioavailability. Upon cleavage by esterases, the active compound forms additional interactions with the target. This compound has favorable properties (MW ~570, LogP ~4.0, 3 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects."\n        },\n        {\n            "smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5",\n            "friendly_id": "AI:I3:N5:G2",\n            "source": "AI:I2:N3:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This ATP-competitive inhibitor features a dual binding mode with the pyrimidine-pyridine system forming key hydrogen bonds with the hinge region, while the trifluoromethyl-aminopyridine extends into a hydrophobic pocket unique to AKT1. The oxadiazole provides metabolic stability and favorable electronics, positioning the molecule optimally in the binding site. The trifluoromethyl group enhances potency through hydrophobic interactions and blocks a potential metabolic site. This compound has excellent drug-like properties (MW ~500, LogP ~3.3, 3 H-bond donors, 9 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding interactions may provide selectivity for AKT1 over AKT2/AKT3 isoforms."\n        },\n        {\n            "smiles": "COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F",\n            "friendly_id": "AI:I3:N6:G2",\n            "source": "AI:I2:N6:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This ATP-competitive inhibitor features a triazole core that forms key hydrogen bonds with the hinge region of AKT1. The fluorinated dimethoxyphenyl group provides hydrophobic interactions with the back pocket, with the fluorine enhancing metabolic stability. The sulfone linker offers hydrogen bond acceptors and proper spatial arrangement, while also improving aqueous solubility. The terminal fluorophenyl group provides additional hydrophobic interactions. This compound has favorable properties (MW ~490, LogP ~3.2, 1 H-bond donor, 9 H-bond acceptors) and represents a novel scaffold compared to known AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1. The synthetic accessibility is high through convergent synthesis."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F",\n            "friendly_id": "AI:I3:N7:G2",\n            "source": "AI:I2:N7:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This ATP-competitive inhibitor features a thiazole core with a trifluoromethyl-pyridine substituent that forms optimal interactions with the hinge region of AKT1. The trifluoromethyl group enhances binding affinity through hydrophobic interactions and improves metabolic stability. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~510, LogP ~3.5, 1 H-bond donor, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over other kinases."\n        },\n        {\n            "smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F",\n            "friendly_id": "AI:I3:N8:G2",\n            "source": "AI:I2:N8:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1 through its urea linker, which forms critical hydrogen bonds with the DFG motif (D292, F293). The N-methylimidazole with difluoroethoxypyridine forms key hydrogen bonds with the hinge region, while the fluorotoluidine extends into the hydrophobic pocket exposed in the DFG-out state. The difluoroethoxy group provides metabolic stability compared to a simple methoxy group, while maintaining hydrogen bond acceptor capabilities. This compound has favorable properties (MW ~470, LogP ~3.4, 2 H-bond donors, 7 H-bond acceptors) and represents a novel approach compared to known Type II kinase inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding mode may offer advantages in overcoming resistance mechanisms."\n        },\n        {\n            "smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F",\n            "friendly_id": "AI:I3:N9:G2",\n            "source": "AI:I2:N11:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism. The xanthine core (similar to caffeine) provides a rigid scaffold that positions the key binding elements optimally. The sulfone linker improves aqueous solubility while maintaining proper spatial arrangement. The fluorocyclopropanecarboxamide terminal group provides metabolic stability and additional binding interactions. This compound has favorable properties (MW ~500, LogP ~2.5, 2 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects. The balanced physicochemical profile suggests good oral bioavailability."\n        },\n        {\n            "smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4",\n            "friendly_id": "AI:I3:N10:G2",\n            "source": "AI:I2:N10:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This ATP-competitive inhibitor features an aminopyrimidine hinge-binding motif that forms key hydrogen bonds with the hinge region of AKT1 (E228, A230). The chloro-aminopyridine linker provides halogen bonding opportunities and blocks a potential metabolic site, while the trifluoromethylphenyl group extends into the hydrophobic back pocket, providing both potency and metabolic stability. The morpholine provides solubility and potential for additional hydrogen bonding interactions. This compound has favorable properties (MW ~480, LogP ~3.7, 2 H-bond donors, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over AKT2/AKT3 isoforms."\n        }\n    ]\n}\n</molecules>\n\n## Final Candidate Analysis and Development Potential\n\nI\'ve selected these 10 final candidates to represent the most promising AKT1 inhibitors from our design process. Here\'s a comprehensive analysis of their development potential:\n\n### Mechanism Diversity\n- **ATP-competitive inhibitors**: Compounds 1, 3, 5, 6, 7, 10 (various hinge-binding motifs)\n- **Type II inhibitors**: Compounds 2, 8 (targeting DFG-out conformation)\n- **Allosteric inhibitors**: Compounds 4, 9 (targeting PH domain-kinase domain interface)\n\n### Structural Innovation\nEach candidate features novel structural elements while incorporating established pharmacophores for AKT1 inhibition:\n- **Novel hinge binders**: Fluoropyridines, trifluoromethylpyridines, difluoromethoxypyridines\n- **Metabolically optimized linkers**: Fluorinated substituents, sulfones, ureas\n- **Solubility-enhancing groups**: Strategically placed piperazines, morpholines, prodrug approaches\n\n### Clinical Development Potential\n\n#### Most Promising ATP-Competitive Inhibitors\n- **Compound 1 (AI:I3:N1:G2)**: Excellent balance of potency and drug-like properties with novel fluoropyridine hinge binder and metabolically stable trifluoroethyl-piperazine\n- **Compound 5 (AI:I3:N5:G2)**: Dual binding mode with potential for enhanced AKT1 selectivity through unique trifluoromethyl-aminopyridine interactions\n\n#### Most Promising Type II Inhibitors\n- **Compound 2 (AI:I3:N2:G2)**: Comprehensive binding interactions with both hinge region and DFG motif, potentially overcoming resistance mechanisms\n- **Compound 8 (AI:I3:N8:G2)**: Excellent physicochemical properties with metabolically stable difluoroethoxy group\n\n#### Most Promising Allosteric Inhibitors\n- **Compound 4 (AI:I3:N4:G2)**: Innovative prodrug approach for improved bioavailability while targeting the allosteric site\n- **Compound 9 (AI:I3:N9:G2)**: Novel xanthine-based scaffold with excellent physicochemical properties\n\n### Comparison to Known AKT Inhibitors\nThese designs incorporate lessons from clinical AKT inhibitors while offering distinct advantages:\n- **vs. Capivasertib/Ipatasertib**: Our ATP-competitive inhibitors feature novel hinge-binding elements and optimized metabolic properties\n- **vs. MK-2206**: Our allosteric inhibitors employ different core scaffolds (indole, xanthine) with improved physicochemical properties\n- **vs. Uprosertib**: Our Type II inhibitors offer potentially improved selectivity through unique binding interactions\n\n### Development Recommendations\n1. **Lead Series Prioritization**:\n   - ATP-competitive series: Compounds 1 and 5\n   - Type II series: Compound 2\n   - Allosteric series: Compound 4\n\n2. **Initial Testing**:\n   - Biochemical assays against AKT1/2/3 to confirm potency and selectivity\n   - Cell-based pathway inhibition assays in AKT-dependent cancer models\n   - ADME profiling to confirm predicted properties\n\n3. **Backup Strategies**:\n   - Compounds 3, 6, 7, 8, 9, and 10 provide structural diversity for backup options\n   - Additional scaffold hopping around the most promising cores\n\nThese final candidates represent a diverse, innovative set of AKT1 inhibitors with strong potential for development as anticancer therapeutics.', role='assistant', tool_calls=None, function_call=None, provider_specific_fields={'citations': []}, citations=[]))], usage=Usage(completion_tokens=4305, prompt_tokens=9421, total_tokens=13726, completion_tokens_details=None, prompt_tokens_details=PromptTokensDetailsWrapper(audio_tokens=None, cached_tokens=0, text_tokens=None, image_tokens=None), cache_creation_input_tokens=0, cache_read_input_tokens=0))
2025-06-23 14:05:54,390 - INFO - history_with_tools [{'role': 'user', 'content': "You are an expert medicinal chemist and computational drug discovery scientist. Your task is to design novel small molecule inhibitors for AKT1 (Protein Kinase B alpha) using your knowledge of structure-activity relationships, medicinal chemistry principles, and drug design.\n\n**Target Information:**\n- AKT1 is a serine/threonine kinase in the PI3K/AKT/mTOR pathway\n- Critical for cell survival, proliferation, and metabolism\n- Key oncology target with multiple known inhibitors\n- ATP-competitive and allosteric binding sites available\n\n**Your Goal:**\nGenerate novel, drug-like small molecule AKT1 inhibitors with the following criteria:\n- High predicted binding affinity to AKT1\n- Drug-like properties (Lipinski's Rule of Five compliance)\n- Synthetic accessibility\n- Novel scaffolds not directly copied from known inhibitors\n\n**Output Format:**\nFor each molecule, provide:\n1. **Molecule ID**: A unique identifier (e.g., LLM_MOL_001)\n2. **SMILES**: Valid SMILES string\n3. **Rationale**: Brief explanation of your design strategy and expected properties\n4. **Predicted Properties**: Your assessment of drug-likeness, potency, selectivity\n\nFocus on innovative chemical designs while maintaining scientific rigor."}, {'role': 'user', 'content': [{'type': 'text', 'text': '**ITERATION 1: Initial Discovery & Exploration**\n\nDesign 10-15 novel AKT1 inhibitor molecules using your medicinal chemistry expertise. Consider:\n\n1. **ATP-competitive inhibitors**: Target the ATP-binding pocket with novel scaffolds\n2. **Allosteric inhibitors**: Design molecules that bind to regulatory sites\n3. **Hybrid approaches**: Molecules that may interact with multiple binding sites\n\nUse your knowledge of:\n- Known AKT1 pharmacophores (avoid direct copying)\n- Kinase selectivity determinants\n- Drug-like chemical space\n- Structure-activity relationships\n\nGenerate diverse scaffolds including heterocycles, aromatic systems, and appropriate linkers. Ensure synthetic feasibility while prioritizing novelty.'}]}, {'role': 'assistant', 'content': [{'type': 'text', 'text': '# AKT1 Inhibitor Design - Initial Discovery\n\nI\'ll design novel AKT1 inhibitors using medicinal chemistry principles and my knowledge of kinase inhibitor design. I\'ll focus on creating diverse, drug-like molecules with appropriate pharmacophores for AKT1 inhibition.\n\n<molecules>\n{\n    "molecules": [\n        {\n            "smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5",\n            "friendly_id": "AI:I1:N1:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N",\n            "friendly_id": "AI:I1:N2:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors."\n        },\n        {\n            "smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5",\n            "friendly_id": "AI:I1:N3:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5",\n            "friendly_id": "AI:I1:N4:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements."\n        },\n        {\n            "smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N",\n            "friendly_id": "AI:I1:N5:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode."\n        },\n        {\n            "smiles": "COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F",\n            "friendly_id": "AI:I1:N6:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties."\n        },\n        {\n            "smiles": "CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5",\n            "friendly_id": "AI:I1:N7:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5",\n            "friendly_id": "AI:I1:N8:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases."\n        },\n        {\n            "smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC",\n            "friendly_id": "AI:I1:N9:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5",\n            "friendly_id": "AI:I1:N10:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile."\n        },\n        {\n            "smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4",\n            "friendly_id": "AI:I1:N11:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties."\n        },\n        {\n            "smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5",\n            "friendly_id": "AI:I1:N12:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode."\n        },\n        {\n            "smiles": "CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C",\n            "friendly_id": "AI:I1:N13:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases."\n        },\n        {\n            "smiles": "CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5",\n            "friendly_id": "AI:I1:N14:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile."\n        },\n        {\n            "smiles": "COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5",\n            "friendly_id": "AI:I1:N15:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties."\n        }\n    ]\n}\n</molecules>\n\n## Design Strategy Overview\n\nMy approach to designing these AKT1 inhibitors focused on several key medicinal chemistry principles:\n\n### 1. Hinge-Binding Motifs\n- Incorporated established kinase hinge-binding pharmacophores including:\n  - Aminopyrimidines (molecules 1, 2, 11, 14)\n  - Imidazoles (molecule 4)\n  - Triazoles (molecule 6)\n  - Quinazolines (molecule 15)\n  - Oxadiazoles (molecules 3, 7, 13)\n\n### 2. Binding Modes\n- **ATP-competitive inhibitors** (majority of designs): Target the ATP-binding pocket with appropriate hinge-binding elements\n- **Type II inhibitors** (molecules 2, 9): Include urea linkers to stabilize the DFG-out conformation\n- **Allosteric inhibitors** (molecules 5, 12): Target the PH domain-kinase domain interface\n\n### 3. Structural Features\n- **Solubilizing groups**: Incorporated piperazines, morpholines, and tertiary amines\n- **Metabolic stability**: Used fluorine substitutions, oxadiazoles, and methoxy groups\n- **Rigidity and spatial arrangement**: Employed amide linkers, ureas, and conformationally constrained cores\n\n### 4. Drug-Like Properties\n- Designed molecules with:\n  - MW generally between 420-550 Da\n  - LogP values in the 2.5-4 range\n  - Appropriate H-bond donors/acceptors (Lipinski compliant)\n  - Balanced solubility and permeability characteristics\n\nThese designs represent a diverse set of potential AKT1 inhibitors with varied scaffolds, binding modes, and physicochemical properties, providing a strong foundation for further optimization.'}]}, {'role': 'user', 'content': [{'type': 'text', 'text': '**ITERATION 2: Lead Optimization**\n\nBased on your previous designs, now optimize and refine your best candidates. Focus on:\n\n1. **Scaffold hopping**: Create variants of your most promising designs\n2. **Property optimization**: Improve drug-likeness, solubility, permeability\n3. **Selectivity enhancement**: Design features for AKT1 vs AKT2/AKT3 selectivity\n4. **ADMET optimization**: Consider metabolic stability and safety\n\nGenerate 8-12 optimized molecules that build upon your iteration 1 insights. Include:\n- Modified versions of your best scaffolds\n- New analogs with improved properties\n- Rationale for each modification based on medicinal chemistry principles'}]}, {'role': 'assistant', 'content': [{'type': 'text', 'text': '# AKT1 Inhibitor Design - Lead Optimization\n\nBased on the initial designs, I\'ll now optimize the most promising candidates to enhance potency, selectivity, and drug-like properties. I\'ll focus on scaffold hopping, property optimization, and addressing potential ADMET issues.\n\n<molecules>\n{\n    "molecules": [\n        {\n            "smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F",\n            "friendly_id": "AI:I2:N1:G1",\n            "source": "AI:I1:N1:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Optimization of AI:I1:N1:G0 with three key modifications: (1) Added a trifluoroethyl group to the piperazine to improve metabolic stability and reduce basicity, potentially improving brain penetration; (2) Introduced a fluorine on the pyridine ring to enhance binding affinity through additional interactions with the hinge region; (3) Maintained the core aminopyrimidine hinge-binding motif while optimizing the overall physicochemical profile. Expected improvements: better metabolic stability, reduced P-gp efflux liability, and potentially enhanced selectivity for AKT1."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N",\n            "friendly_id": "AI:I2:N2:G1",\n            "source": "AI:I1:N2:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Refinement of AI:I1:N2:G0 by introducing a fluorine atom on the central phenyl ring to improve metabolic stability and binding affinity. The Type II inhibitor design is maintained with the urea linker for DFG-out conformation stabilization. The fluorine addition provides several benefits: (1) blocks a potential metabolic site; (2) enhances binding through additional interactions; (3) improves membrane permeability by reducing the overall hydrogen bonding capacity while maintaining the essential pharmacophore elements. Expected improvements: enhanced metabolic stability, potentially improved selectivity, and maintained solubility profile."\n        },\n        {\n            "smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5",\n            "friendly_id": "AI:I2:N3:G1",\n            "source": "AI:I1:N3:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Enhancement of AI:I1:N3:G0 by introducing a trifluoromethyl group on the aminopyridine linker. This modification serves multiple purposes: (1) increases binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by blocking a potential site of oxidation; (3) enhances selectivity by exploiting a potential hydrophobic pocket unique to AKT1. The core oxadiazole and pyrimidine-pyridine hinge-binding motifs are preserved to maintain essential interactions. Expected improvements: enhanced potency, better metabolic profile, and potentially improved selectivity for AKT1 over AKT2/AKT3."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F",\n            "friendly_id": "AI:I2:N4:G1",\n            "source": "AI:I1:N4:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Optimization of AI:I1:N4:G0 by replacing the pyridine with a difluoromethoxy-substituted pyridine. This modification: (1) introduces a metabolically stable difluoromethoxy group that serves as a hydrogen bond acceptor while providing lipophilicity; (2) enhances binding affinity through additional interactions; (3) improves metabolic stability by blocking oxidation sites. The imidazole core and N-methylpiperazine solubilizing group are maintained for their essential functions. Expected improvements: enhanced potency, better metabolic stability, and potentially improved blood-brain barrier penetration due to the balanced lipophilicity."\n        },\n        {\n            "smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N",\n            "friendly_id": "AI:I2:N5:G1",\n            "source": "AI:I1:N5:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Refinement of the allosteric inhibitor AI:I1:N5:G0 by replacing the tertiary amine with a Boc-protected amine. This prodrug approach: (1) masks the basic center to improve membrane permeability; (2) provides controlled release of the active compound after enzymatic cleavage; (3) potentially enhances oral bioavailability by reducing first-pass metabolism. The core indole scaffold and cyano-substituted aminopyrimidine are preserved for their essential interactions with the PH domain-kinase domain interface. Expected improvements: enhanced pharmacokinetic profile, improved oral bioavailability, and maintained selectivity for AKT1."\n        },\n        {\n            "smiles": "COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F",\n            "friendly_id": "AI:I2:N6:G1",\n            "source": "AI:I1:N6:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Enhancement of AI:I1:N6:G0 by introducing a fluorine atom on the dimethoxyphenyl group. This modification: (1) blocks a potential metabolic site on the aromatic ring; (2) provides additional binding interactions; (3) fine-tunes the electronic properties of the aromatic system. The triazole core for hinge binding and the sulfone linker are maintained for their essential functions. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained physicochemical properties for good oral bioavailability."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F",\n            "friendly_id": "AI:I2:N7:G1",\n            "source": "AI:I1:N8:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Optimization of AI:I1:N8:G0 by replacing the pyridine with a trifluoromethyl-substituted pyridine. This modification: (1) enhances binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by replacing a potential metabolic liability; (3) fine-tunes the electronic properties of the hinge-binding element. The thiazole core, amide linker, and N-methylpiperazine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over other kinases."\n        },\n        {\n            "smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F",\n            "friendly_id": "AI:I2:N8:G1",\n            "source": "AI:I1:N9:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Refinement of the Type II inhibitor AI:I1:N9:G0 by replacing the methoxy group with a difluoroethoxy group. This modification: (1) improves metabolic stability by blocking a potential site of O-demethylation; (2) enhances binding affinity through additional interactions; (3) provides a better balance of lipophilicity and hydrogen bonding capacity. The urea linker for DFG-out conformation stabilization and the N-methylimidazole core are preserved. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained ability to stabilize the inactive kinase conformation."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCN(CC5)S(=O)(=O)C",\n            "friendly_id": "AI:I2:N9:G1",\n            "source": "AI:I1:N10:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Enhancement of AI:I1:N10:G0 by replacing the morpholine derivative with a methylsulfonyl-piperazine. This modification: (1) reduces the basicity of the nitrogen while maintaining solubility; (2) provides additional binding interactions through the sulfonyl group; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The isoxazole core and aminopyrimidine hinge binder are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1."\n        },\n        {\n            "smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4",\n            "friendly_id": "AI:I2:N10:G1",\n            "source": "AI:I1:N11:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Optimization of AI:I1:N11:G0 by introducing a chlorine atom on the aminopyridine linker. This modification: (1) enhances binding affinity through additional halogen bonding interactions; (2) blocks a potential metabolic site; (3) fine-tunes the electronic properties of the aromatic system. The trifluoromethyl group, aminopyrimidine hinge-binding motif, and morpholine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over AKT2/AKT3."\n        },\n        {\n            "smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F",\n            "friendly_id": "AI:I2:N11:G1",\n            "source": "AI:I1:N12:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Refinement of the allosteric inhibitor AI:I1:N12:G0 by introducing a fluorocyclopropane group. This modification: (1) enhances metabolic stability by blocking a potential site of oxidation; (2) provides additional binding interactions through the fluorine atom; (3) maintains the overall size and shape of the molecule while improving its properties. The xanthine core and sulfone linker are preserved for their essential functions in targeting the PH domain-kinase domain interface. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained selectivity for AKT1."\n        },\n        {\n            "smiles": "CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C(=O)CF",\n            "friendly_id": "AI:I2:N12:G1",\n            "source": "AI:I1:N13:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Enhancement of AI:I1:N13:G0 by replacing the N-methyl group with a fluoroacetyl group. This modification: (1) reduces the basicity of the piperazine nitrogen while maintaining solubility; (2) provides additional binding interactions through the fluorine atom; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The thiazole core, oxadiazole hinge binder, and amide linker are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1."\n        }\n    ]\n}\n</molecules>\n\n## Lead Optimization Strategy\n\nIn this optimization phase, I focused on refining the most promising candidates from Iteration 1 to enhance their drug-like properties, potency, selectivity, and ADMET profiles. Here\'s a summary of the key optimization strategies employed:\n\n### 1. Metabolic Stability Enhancements\n- **Fluorine incorporation**: Added strategic fluorine atoms to block metabolic hot spots (molecules 1, 2, 3, 6, 8, 10)\n- **Trifluoromethyl groups**: Introduced CF₃ groups to enhance stability and binding (molecules 3, 7, 10)\n- **Difluoromethoxy/ethoxy groups**: Replaced metabolically labile methoxy groups (molecules 4, 8)\n\n### 2. Selectivity Optimization\n- **Exploiting unique pockets**: Added substituents to target AKT1-specific binding regions (molecules 3, 7)\n- **Fine-tuning electronic properties**: Modified hinge-binding elements to enhance selectivity (molecules 4, 7)\n- **Halogen bonding**: Introduced chlorine for additional selective interactions (molecule 10)\n\n### 3. Pharmacokinetic Improvements\n- **Prodrug approach**: Implemented a Boc-protected amine to improve membrane permeability (molecule 5)\n- **Reduced basicity**: Modified basic centers to improve brain penetration and reduce P-gp efflux (molecules 1, 9, 12)\n- **Balanced lipophilicity**: Fine-tuned the hydrophobic/hydrophilic balance (molecules 4, 8)\n\n### 4. Binding Affinity Optimization\n- **Additional H-bond interactions**: Introduced groups capable of forming new H-bonds (molecules 4, 8)\n- **Halogen bonding**: Added fluorine and chlorine atoms for enhanced interactions (molecules 1, 10)\n- **Hydrophobic interactions**: Optimized lipophilic groups for better pocket complementarity (molecules 3, 7)\n\n### 5. Scaffold Preservation\nWhile making these modifications, I carefully preserved the core pharmacophores identified in Iteration 1:\n- ATP-competitive hinge-binding motifs (aminopyrimidines, imidazoles, etc.)\n- Type II inhibitor urea linkers\n- Allosteric binding elements for PH domain-kinase domain interface targeting\n\nThese optimized compounds represent a focused set of candidates with improved properties while maintaining the essential structural features required for AKT1 inhibition. The modifications were guided by established medicinal chemistry principles to address potential liabilities while enhancing desirable characteristics.'}]}, {'role': 'user', 'content': [{'type': 'text', 'text': "**ITERATION 3: Final Lead Optimization & Selection**\n\nCreate your final set of 8-10 candidate molecules representing your best designs for AKT1 inhibition. Focus on:\n\n1. **Best-in-class designs**: Your most promising scaffolds with optimal substitution patterns\n2. **Diverse mechanisms**: Include both ATP-competitive and allosteric candidates\n3. **Clinical viability**: Emphasize drug-like properties and synthetic accessibility\n4. **Innovation**: Ensure your designs represent novel chemical space\n\nFor each final candidate, provide:\n- Comprehensive rationale for inclusion\n- Predicted binding mode and key interactions\n- Assessment of development potential\n- Comparison to known AKT1 inhibitors (without direct copying)\n- Don't forget to use the molecule entry format"}]}, {'role': 'assistant', 'content': '# AKT1 Inhibitor Design - Final Lead Optimization & Selection\n\nI\'ve developed a final set of optimized AKT1 inhibitor candidates representing diverse mechanisms, optimal properties, and novel chemical space. These compounds incorporate the insights gained from previous iterations while addressing key medicinal chemistry considerations.\n\n<molecules>\n{\n    "molecules": [\n        {\n            "smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F",\n            "friendly_id": "AI:I3:N1:G2",\n            "source": "AI:I2:N1:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This ATP-competitive inhibitor represents our lead hinge-binding scaffold with optimal substitution. The aminopyrimidine forms key hydrogen bonds with the kinase hinge region (E228, A230), while the fluoropyridine enhances these interactions through a halogen bond. The trifluoroethyl-piperazine provides metabolic stability and reduced P-gp efflux liability compared to simple N-methylpiperazine. The toluidine group extends into the hydrophobic back pocket, providing selectivity. This compound offers an excellent balance of potency, selectivity, and drug-like properties (MW ~550, LogP ~3.8, 3 H-bond donors, 8 H-bond acceptors). Compared to known AKT inhibitors like capivasertib, it features a novel linking strategy while maintaining essential pharmacophore elements. Synthetic accessibility is high through convergent synthesis."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N",\n            "friendly_id": "AI:I3:N2:G2",\n            "source": "AI:I2:N2:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1, offering a distinct mechanism from most ATP-competitive inhibitors. The aminopyrimidine forms hydrogen bonds with the hinge region, while the urea linker forms critical hydrogen bonds with the DFG motif (D292, F293). The fluorophenyl group occupies the hydrophobic pocket exposed in the DFG-out state, with the fluorine providing metabolic stability and enhanced binding. The piperazine linker offers solubility while the methoxyphenyl provides additional hydrophobic interactions. This compound has favorable properties (MW ~560, LogP ~3.5, 5 H-bond donors, 10 H-bond acceptors) and represents a novel chemical space compared to known Type II kinase inhibitors. Its unique binding mode may offer advantages in overcoming resistance mechanisms."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F",\n            "friendly_id": "AI:I3:N3:G2",\n            "source": "AI:I2:N4:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This ATP-competitive inhibitor features an imidazole core with a difluoromethoxypyridine substituent that forms optimal interactions with the hinge region of AKT1. The difluoromethoxy group serves as a metabolically stable hydrogen bond acceptor while providing lipophilicity and halogen bonding opportunities. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~480, LogP ~3.2, 2 H-bond donors, 8 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors like ipatasertib. The balanced physicochemical profile suggests good oral bioavailability and CNS penetration potential, making it suitable for various AKT1-driven indications."\n        },\n        {\n            "smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N",\n            "friendly_id": "AI:I3:N4:G2",\n            "source": "AI:I2:N5:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism distinct from ATP-competitive inhibitors. The indole core provides a rigid scaffold that positions the cyano-aminopyrimidine to form key interactions with the interdomain pocket. The Boc-protected amine serves as a prodrug approach, masking the basic center to improve membrane permeability and oral bioavailability. Upon cleavage by esterases, the active compound forms additional interactions with the target. This compound has favorable properties (MW ~570, LogP ~4.0, 3 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects."\n        },\n        {\n            "smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5",\n            "friendly_id": "AI:I3:N5:G2",\n            "source": "AI:I2:N3:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This ATP-competitive inhibitor features a dual binding mode with the pyrimidine-pyridine system forming key hydrogen bonds with the hinge region, while the trifluoromethyl-aminopyridine extends into a hydrophobic pocket unique to AKT1. The oxadiazole provides metabolic stability and favorable electronics, positioning the molecule optimally in the binding site. The trifluoromethyl group enhances potency through hydrophobic interactions and blocks a potential metabolic site. This compound has excellent drug-like properties (MW ~500, LogP ~3.3, 3 H-bond donors, 9 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding interactions may provide selectivity for AKT1 over AKT2/AKT3 isoforms."\n        },\n        {\n            "smiles": "COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F",\n            "friendly_id": "AI:I3:N6:G2",\n            "source": "AI:I2:N6:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This ATP-competitive inhibitor features a triazole core that forms key hydrogen bonds with the hinge region of AKT1. The fluorinated dimethoxyphenyl group provides hydrophobic interactions with the back pocket, with the fluorine enhancing metabolic stability. The sulfone linker offers hydrogen bond acceptors and proper spatial arrangement, while also improving aqueous solubility. The terminal fluorophenyl group provides additional hydrophobic interactions. This compound has favorable properties (MW ~490, LogP ~3.2, 1 H-bond donor, 9 H-bond acceptors) and represents a novel scaffold compared to known AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1. The synthetic accessibility is high through convergent synthesis."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F",\n            "friendly_id": "AI:I3:N7:G2",\n            "source": "AI:I2:N7:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This ATP-competitive inhibitor features a thiazole core with a trifluoromethyl-pyridine substituent that forms optimal interactions with the hinge region of AKT1. The trifluoromethyl group enhances binding affinity through hydrophobic interactions and improves metabolic stability. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~510, LogP ~3.5, 1 H-bond donor, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over other kinases."\n        },\n        {\n            "smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F",\n            "friendly_id": "AI:I3:N8:G2",\n            "source": "AI:I2:N8:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1 through its urea linker, which forms critical hydrogen bonds with the DFG motif (D292, F293). The N-methylimidazole with difluoroethoxypyridine forms key hydrogen bonds with the hinge region, while the fluorotoluidine extends into the hydrophobic pocket exposed in the DFG-out state. The difluoroethoxy group provides metabolic stability compared to a simple methoxy group, while maintaining hydrogen bond acceptor capabilities. This compound has favorable properties (MW ~470, LogP ~3.4, 2 H-bond donors, 7 H-bond acceptors) and represents a novel approach compared to known Type II kinase inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding mode may offer advantages in overcoming resistance mechanisms."\n        },\n        {\n            "smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F",\n            "friendly_id": "AI:I3:N9:G2",\n            "source": "AI:I2:N11:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism. The xanthine core (similar to caffeine) provides a rigid scaffold that positions the key binding elements optimally. The sulfone linker improves aqueous solubility while maintaining proper spatial arrangement. The fluorocyclopropanecarboxamide terminal group provides metabolic stability and additional binding interactions. This compound has favorable properties (MW ~500, LogP ~2.5, 2 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects. The balanced physicochemical profile suggests good oral bioavailability."\n        },\n        {\n            "smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4",\n            "friendly_id": "AI:I3:N10:G2",\n            "source": "AI:I2:N10:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This ATP-competitive inhibitor features an aminopyrimidine hinge-binding motif that forms key hydrogen bonds with the hinge region of AKT1 (E228, A230). The chloro-aminopyridine linker provides halogen bonding opportunities and blocks a potential metabolic site, while the trifluoromethylphenyl group extends into the hydrophobic back pocket, providing both potency and metabolic stability. The morpholine provides solubility and potential for additional hydrogen bonding interactions. This compound has favorable properties (MW ~480, LogP ~3.7, 2 H-bond donors, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over AKT2/AKT3 isoforms."\n        }\n    ]\n}\n</molecules>\n\n## Final Candidate Analysis and Development Potential\n\nI\'ve selected these 10 final candidates to represent the most promising AKT1 inhibitors from our design process. Here\'s a comprehensive analysis of their development potential:\n\n### Mechanism Diversity\n- **ATP-competitive inhibitors**: Compounds 1, 3, 5, 6, 7, 10 (various hinge-binding motifs)\n- **Type II inhibitors**: Compounds 2, 8 (targeting DFG-out conformation)\n- **Allosteric inhibitors**: Compounds 4, 9 (targeting PH domain-kinase domain interface)\n\n### Structural Innovation\nEach candidate features novel structural elements while incorporating established pharmacophores for AKT1 inhibition:\n- **Novel hinge binders**: Fluoropyridines, trifluoromethylpyridines, difluoromethoxypyridines\n- **Metabolically optimized linkers**: Fluorinated substituents, sulfones, ureas\n- **Solubility-enhancing groups**: Strategically placed piperazines, morpholines, prodrug approaches\n\n### Clinical Development Potential\n\n#### Most Promising ATP-Competitive Inhibitors\n- **Compound 1 (AI:I3:N1:G2)**: Excellent balance of potency and drug-like properties with novel fluoropyridine hinge binder and metabolically stable trifluoroethyl-piperazine\n- **Compound 5 (AI:I3:N5:G2)**: Dual binding mode with potential for enhanced AKT1 selectivity through unique trifluoromethyl-aminopyridine interactions\n\n#### Most Promising Type II Inhibitors\n- **Compound 2 (AI:I3:N2:G2)**: Comprehensive binding interactions with both hinge region and DFG motif, potentially overcoming resistance mechanisms\n- **Compound 8 (AI:I3:N8:G2)**: Excellent physicochemical properties with metabolically stable difluoroethoxy group\n\n#### Most Promising Allosteric Inhibitors\n- **Compound 4 (AI:I3:N4:G2)**: Innovative prodrug approach for improved bioavailability while targeting the allosteric site\n- **Compound 9 (AI:I3:N9:G2)**: Novel xanthine-based scaffold with excellent physicochemical properties\n\n### Comparison to Known AKT Inhibitors\nThese designs incorporate lessons from clinical AKT inhibitors while offering distinct advantages:\n- **vs. Capivasertib/Ipatasertib**: Our ATP-competitive inhibitors feature novel hinge-binding elements and optimized metabolic properties\n- **vs. MK-2206**: Our allosteric inhibitors employ different core scaffolds (indole, xanthine) with improved physicochemical properties\n- **vs. Uprosertib**: Our Type II inhibitors offer potentially improved selectivity through unique binding interactions\n\n### Development Recommendations\n1. **Lead Series Prioritization**:\n   - ATP-competitive series: Compounds 1 and 5\n   - Type II series: Compound 2\n   - Allosteric series: Compound 4\n\n2. **Initial Testing**:\n   - Biochemical assays against AKT1/2/3 to confirm potency and selectivity\n   - Cell-based pathway inhibition assays in AKT-dependent cancer models\n   - ADME profiling to confirm predicted properties\n\n3. **Backup Strategies**:\n   - Compounds 3, 6, 7, 8, 9, and 10 provide structural diversity for backup options\n   - Additional scaffold hopping around the most promising cores\n\nThese final candidates represent a diverse, innovative set of AKT1 inhibitors with strong potential for development as anticancer therapeutics.'}]
2025-06-23 14:05:54,395 - INFO - main_history before parser: [
  {
    "role": "user",
    "content": "You are an expert medicinal chemist and computational drug discovery scientist. Your task is to design novel small molecule inhibitors for AKT1 (Protein Kinase B alpha) using your knowledge of structure-activity relationships, medicinal chemistry principles, and drug design.\n\n**Target Information:**\n- AKT1 is a serine/threonine kinase in the PI3K/AKT/mTOR pathway\n- Critical for cell survival, proliferation, and metabolism\n- Key oncology target with multiple known inhibitors\n- ATP-competitive and allosteric binding sites available\n\n**Your Goal:**\nGenerate novel, drug-like small molecule AKT1 inhibitors with the following criteria:\n- High predicted binding affinity to AKT1\n- Drug-like properties (Lipinski's Rule of Five compliance)\n- Synthetic accessibility\n- Novel scaffolds not directly copied from known inhibitors\n\n**Output Format:**\nFor each molecule, provide:\n1. **Molecule ID**: A unique identifier (e.g., LLM_MOL_001)\n2. **SMILES**: Valid SMILES string\n3. **Rationale**: Brief explanation of your design strategy and expected properties\n4. **Predicted Properties**: Your assessment of drug-likeness, potency, selectivity\n\nFocus on innovative chemical designs while maintaining scientific rigor."
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 1: Initial Discovery & Exploration**\n\nDesign 10-15 novel AKT1 inhibitor molecules using your medicinal chemistry expertise. Consider:\n\n1. **ATP-competitive inhibitors**: Target the ATP-binding pocket with novel scaffolds\n2. **Allosteric inhibitors**: Design molecules that bind to regulatory sites\n3. **Hybrid approaches**: Molecules that may interact with multiple binding sites\n\nUse your knowledge of:\n- Known AKT1 pharmacophores (avoid direct copying)\n- Kinase selectivity determinants\n- Drug-like chemical space\n- Structure-activity relationships\n\nGenerate diverse scaffolds including heterocycles, aromatic systems, and appropriate linkers. Ensure synthetic feasibility while prioritizing novelty."
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Initial Discovery\n\nI'll design novel AKT1 inhibitors using medicinal chemistry principles and my knowledge of kinase inhibitor design. I'll focus on creating diverse, drug-like molecules with appropriate pharmacophores for AKT1 inhibition.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N1:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I1:N2:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N3:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N4:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I1:N5:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I1:N6:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N7:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N8:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC\",\n            \"friendly_id\": \"AI:I1:N9:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5\",\n            \"friendly_id\": \"AI:I1:N10:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I1:N11:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5\",\n            \"friendly_id\": \"AI:I1:N12:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C\",\n            \"friendly_id\": \"AI:I1:N13:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5\",\n            \"friendly_id\": \"AI:I1:N14:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N15:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        }\n    ]\n}\n</molecules>\n\n## Design Strategy Overview\n\nMy approach to designing these AKT1 inhibitors focused on several key medicinal chemistry principles:\n\n### 1. Hinge-Binding Motifs\n- Incorporated established kinase hinge-binding pharmacophores including:\n  - Aminopyrimidines (molecules 1, 2, 11, 14)\n  - Imidazoles (molecule 4)\n  - Triazoles (molecule 6)\n  - Quinazolines (molecule 15)\n  - Oxadiazoles (molecules 3, 7, 13)\n\n### 2. Binding Modes\n- **ATP-competitive inhibitors** (majority of designs): Target the ATP-binding pocket with appropriate hinge-binding elements\n- **Type II inhibitors** (molecules 2, 9): Include urea linkers to stabilize the DFG-out conformation\n- **Allosteric inhibitors** (molecules 5, 12): Target the PH domain-kinase domain interface\n\n### 3. Structural Features\n- **Solubilizing groups**: Incorporated piperazines, morpholines, and tertiary amines\n- **Metabolic stability**: Used fluorine substitutions, oxadiazoles, and methoxy groups\n- **Rigidity and spatial arrangement**: Employed amide linkers, ureas, and conformationally constrained cores\n\n### 4. Drug-Like Properties\n- Designed molecules with:\n  - MW generally between 420-550 Da\n  - LogP values in the 2.5-4 range\n  - Appropriate H-bond donors/acceptors (Lipinski compliant)\n  - Balanced solubility and permeability characteristics\n\nThese designs represent a diverse set of potential AKT1 inhibitors with varied scaffolds, binding modes, and physicochemical properties, providing a strong foundation for further optimization."
      }
    ]
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 2: Lead Optimization**\n\nBased on your previous designs, now optimize and refine your best candidates. Focus on:\n\n1. **Scaffold hopping**: Create variants of your most promising designs\n2. **Property optimization**: Improve drug-likeness, solubility, permeability\n3. **Selectivity enhancement**: Design features for AKT1 vs AKT2/AKT3 selectivity\n4. **ADMET optimization**: Consider metabolic stability and safety\n\nGenerate 8-12 optimized molecules that build upon your iteration 1 insights. Include:\n- Modified versions of your best scaffolds\n- New analogs with improved properties\n- Rationale for each modification based on medicinal chemistry principles"
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Lead Optimization\n\nBased on the initial designs, I'll now optimize the most promising candidates to enhance potency, selectivity, and drug-like properties. I'll focus on scaffold hopping, property optimization, and addressing potential ADMET issues.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F\",\n            \"friendly_id\": \"AI:I2:N1:G1\",\n            \"source\": \"AI:I1:N1:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N1:G0 with three key modifications: (1) Added a trifluoroethyl group to the piperazine to improve metabolic stability and reduce basicity, potentially improving brain penetration; (2) Introduced a fluorine on the pyridine ring to enhance binding affinity through additional interactions with the hinge region; (3) Maintained the core aminopyrimidine hinge-binding motif while optimizing the overall physicochemical profile. Expected improvements: better metabolic stability, reduced P-gp efflux liability, and potentially enhanced selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I2:N2:G1\",\n            \"source\": \"AI:I1:N2:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of AI:I1:N2:G0 by introducing a fluorine atom on the central phenyl ring to improve metabolic stability and binding affinity. The Type II inhibitor design is maintained with the urea linker for DFG-out conformation stabilization. The fluorine addition provides several benefits: (1) blocks a potential metabolic site; (2) enhances binding through additional interactions; (3) improves membrane permeability by reducing the overall hydrogen bonding capacity while maintaining the essential pharmacophore elements. Expected improvements: enhanced metabolic stability, potentially improved selectivity, and maintained solubility profile.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I2:N3:G1\",\n            \"source\": \"AI:I1:N3:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N3:G0 by introducing a trifluoromethyl group on the aminopyridine linker. This modification serves multiple purposes: (1) increases binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by blocking a potential site of oxidation; (3) enhances selectivity by exploiting a potential hydrophobic pocket unique to AKT1. The core oxadiazole and pyrimidine-pyridine hinge-binding motifs are preserved to maintain essential interactions. Expected improvements: enhanced potency, better metabolic profile, and potentially improved selectivity for AKT1 over AKT2/AKT3.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F\",\n            \"friendly_id\": \"AI:I2:N4:G1\",\n            \"source\": \"AI:I1:N4:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N4:G0 by replacing the pyridine with a difluoromethoxy-substituted pyridine. This modification: (1) introduces a metabolically stable difluoromethoxy group that serves as a hydrogen bond acceptor while providing lipophilicity; (2) enhances binding affinity through additional interactions; (3) improves metabolic stability by blocking oxidation sites. The imidazole core and N-methylpiperazine solubilizing group are maintained for their essential functions. Expected improvements: enhanced potency, better metabolic stability, and potentially improved blood-brain barrier penetration due to the balanced lipophilicity.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I2:N5:G1\",\n            \"source\": \"AI:I1:N5:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the allosteric inhibitor AI:I1:N5:G0 by replacing the tertiary amine with a Boc-protected amine. This prodrug approach: (1) masks the basic center to improve membrane permeability; (2) provides controlled release of the active compound after enzymatic cleavage; (3) potentially enhances oral bioavailability by reducing first-pass metabolism. The core indole scaffold and cyano-substituted aminopyrimidine are preserved for their essential interactions with the PH domain-kinase domain interface. Expected improvements: enhanced pharmacokinetic profile, improved oral bioavailability, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I2:N6:G1\",\n            \"source\": \"AI:I1:N6:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N6:G0 by introducing a fluorine atom on the dimethoxyphenyl group. This modification: (1) blocks a potential metabolic site on the aromatic ring; (2) provides additional binding interactions; (3) fine-tunes the electronic properties of the aromatic system. The triazole core for hinge binding and the sulfone linker are maintained for their essential functions. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained physicochemical properties for good oral bioavailability.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F\",\n            \"friendly_id\": \"AI:I2:N7:G1\",\n            \"source\": \"AI:I1:N8:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N8:G0 by replacing the pyridine with a trifluoromethyl-substituted pyridine. This modification: (1) enhances binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by replacing a potential metabolic liability; (3) fine-tunes the electronic properties of the hinge-binding element. The thiazole core, amide linker, and N-methylpiperazine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F\",\n            \"friendly_id\": \"AI:I2:N8:G1\",\n            \"source\": \"AI:I1:N9:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the Type II inhibitor AI:I1:N9:G0 by replacing the methoxy group with a difluoroethoxy group. This modification: (1) improves metabolic stability by blocking a potential site of O-demethylation; (2) enhances binding affinity through additional interactions; (3) provides a better balance of lipophilicity and hydrogen bonding capacity. The urea linker for DFG-out conformation stabilization and the N-methylimidazole core are preserved. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained ability to stabilize the inactive kinase conformation.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCN(CC5)S(=O)(=O)C\",\n            \"friendly_id\": \"AI:I2:N9:G1\",\n            \"source\": \"AI:I1:N10:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N10:G0 by replacing the morpholine derivative with a methylsulfonyl-piperazine. This modification: (1) reduces the basicity of the nitrogen while maintaining solubility; (2) provides additional binding interactions through the sulfonyl group; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The isoxazole core and aminopyrimidine hinge binder are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I2:N10:G1\",\n            \"source\": \"AI:I1:N11:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N11:G0 by introducing a chlorine atom on the aminopyridine linker. This modification: (1) enhances binding affinity through additional halogen bonding interactions; (2) blocks a potential metabolic site; (3) fine-tunes the electronic properties of the aromatic system. The trifluoromethyl group, aminopyrimidine hinge-binding motif, and morpholine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over AKT2/AKT3.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F\",\n            \"friendly_id\": \"AI:I2:N11:G1\",\n            \"source\": \"AI:I1:N12:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the allosteric inhibitor AI:I1:N12:G0 by introducing a fluorocyclopropane group. This modification: (1) enhances metabolic stability by blocking a potential site of oxidation; (2) provides additional binding interactions through the fluorine atom; (3) maintains the overall size and shape of the molecule while improving its properties. The xanthine core and sulfone linker are preserved for their essential functions in targeting the PH domain-kinase domain interface. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C(=O)CF\",\n            \"friendly_id\": \"AI:I2:N12:G1\",\n            \"source\": \"AI:I1:N13:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N13:G0 by replacing the N-methyl group with a fluoroacetyl group. This modification: (1) reduces the basicity of the piperazine nitrogen while maintaining solubility; (2) provides additional binding interactions through the fluorine atom; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The thiazole core, oxadiazole hinge binder, and amide linker are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        }\n    ]\n}\n</molecules>\n\n## Lead Optimization Strategy\n\nIn this optimization phase, I focused on refining the most promising candidates from Iteration 1 to enhance their drug-like properties, potency, selectivity, and ADMET profiles. Here's a summary of the key optimization strategies employed:\n\n### 1. Metabolic Stability Enhancements\n- **Fluorine incorporation**: Added strategic fluorine atoms to block metabolic hot spots (molecules 1, 2, 3, 6, 8, 10)\n- **Trifluoromethyl groups**: Introduced CF\u2083 groups to enhance stability and binding (molecules 3, 7, 10)\n- **Difluoromethoxy/ethoxy groups**: Replaced metabolically labile methoxy groups (molecules 4, 8)\n\n### 2. Selectivity Optimization\n- **Exploiting unique pockets**: Added substituents to target AKT1-specific binding regions (molecules 3, 7)\n- **Fine-tuning electronic properties**: Modified hinge-binding elements to enhance selectivity (molecules 4, 7)\n- **Halogen bonding**: Introduced chlorine for additional selective interactions (molecule 10)\n\n### 3. Pharmacokinetic Improvements\n- **Prodrug approach**: Implemented a Boc-protected amine to improve membrane permeability (molecule 5)\n- **Reduced basicity**: Modified basic centers to improve brain penetration and reduce P-gp efflux (molecules 1, 9, 12)\n- **Balanced lipophilicity**: Fine-tuned the hydrophobic/hydrophilic balance (molecules 4, 8)\n\n### 4. Binding Affinity Optimization\n- **Additional H-bond interactions**: Introduced groups capable of forming new H-bonds (molecules 4, 8)\n- **Halogen bonding**: Added fluorine and chlorine atoms for enhanced interactions (molecules 1, 10)\n- **Hydrophobic interactions**: Optimized lipophilic groups for better pocket complementarity (molecules 3, 7)\n\n### 5. Scaffold Preservation\nWhile making these modifications, I carefully preserved the core pharmacophores identified in Iteration 1:\n- ATP-competitive hinge-binding motifs (aminopyrimidines, imidazoles, etc.)\n- Type II inhibitor urea linkers\n- Allosteric binding elements for PH domain-kinase domain interface targeting\n\nThese optimized compounds represent a focused set of candidates with improved properties while maintaining the essential structural features required for AKT1 inhibition. The modifications were guided by established medicinal chemistry principles to address potential liabilities while enhancing desirable characteristics."
      }
    ]
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 3: Final Lead Optimization & Selection**\n\nCreate your final set of 8-10 candidate molecules representing your best designs for AKT1 inhibition. Focus on:\n\n1. **Best-in-class designs**: Your most promising scaffolds with optimal substitution patterns\n2. **Diverse mechanisms**: Include both ATP-competitive and allosteric candidates\n3. **Clinical viability**: Emphasize drug-like properties and synthetic accessibility\n4. **Innovation**: Ensure your designs represent novel chemical space\n\nFor each final candidate, provide:\n- Comprehensive rationale for inclusion\n- Predicted binding mode and key interactions\n- Assessment of development potential\n- Comparison to known AKT1 inhibitors (without direct copying)\n- Don't forget to use the molecule entry format"
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Final Lead Optimization & Selection\n\nI've developed a final set of optimized AKT1 inhibitor candidates representing diverse mechanisms, optimal properties, and novel chemical space. These compounds incorporate the insights gained from previous iterations while addressing key medicinal chemistry considerations.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F\",\n            \"friendly_id\": \"AI:I3:N1:G2\",\n            \"source\": \"AI:I2:N1:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor represents our lead hinge-binding scaffold with optimal substitution. The aminopyrimidine forms key hydrogen bonds with the kinase hinge region (E228, A230), while the fluoropyridine enhances these interactions through a halogen bond. The trifluoroethyl-piperazine provides metabolic stability and reduced P-gp efflux liability compared to simple N-methylpiperazine. The toluidine group extends into the hydrophobic back pocket, providing selectivity. This compound offers an excellent balance of potency, selectivity, and drug-like properties (MW ~550, LogP ~3.8, 3 H-bond donors, 8 H-bond acceptors). Compared to known AKT inhibitors like capivasertib, it features a novel linking strategy while maintaining essential pharmacophore elements. Synthetic accessibility is high through convergent synthesis.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I3:N2:G2\",\n            \"source\": \"AI:I2:N2:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1, offering a distinct mechanism from most ATP-competitive inhibitors. The aminopyrimidine forms hydrogen bonds with the hinge region, while the urea linker forms critical hydrogen bonds with the DFG motif (D292, F293). The fluorophenyl group occupies the hydrophobic pocket exposed in the DFG-out state, with the fluorine providing metabolic stability and enhanced binding. The piperazine linker offers solubility while the methoxyphenyl provides additional hydrophobic interactions. This compound has favorable properties (MW ~560, LogP ~3.5, 5 H-bond donors, 10 H-bond acceptors) and represents a novel chemical space compared to known Type II kinase inhibitors. Its unique binding mode may offer advantages in overcoming resistance mechanisms.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F\",\n            \"friendly_id\": \"AI:I3:N3:G2\",\n            \"source\": \"AI:I2:N4:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor features an imidazole core with a difluoromethoxypyridine substituent that forms optimal interactions with the hinge region of AKT1. The difluoromethoxy group serves as a metabolically stable hydrogen bond acceptor while providing lipophilicity and halogen bonding opportunities. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~480, LogP ~3.2, 2 H-bond donors, 8 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors like ipatasertib. The balanced physicochemical profile suggests good oral bioavailability and CNS penetration potential, making it suitable for various AKT1-driven indications.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I3:N4:G2\",\n            \"source\": \"AI:I2:N5:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism distinct from ATP-competitive inhibitors. The indole core provides a rigid scaffold that positions the cyano-aminopyrimidine to form key interactions with the interdomain pocket. The Boc-protected amine serves as a prodrug approach, masking the basic center to improve membrane permeability and oral bioavailability. Upon cleavage by esterases, the active compound forms additional interactions with the target. This compound has favorable properties (MW ~570, LogP ~4.0, 3 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I3:N5:G2\",\n            \"source\": \"AI:I2:N3:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor features a dual binding mode with the pyrimidine-pyridine system forming key hydrogen bonds with the hinge region, while the trifluoromethyl-aminopyridine extends into a hydrophobic pocket unique to AKT1. The oxadiazole provides metabolic stability and favorable electronics, positioning the molecule optimally in the binding site. The trifluoromethyl group enhances potency through hydrophobic interactions and blocks a potential metabolic site. This compound has excellent drug-like properties (MW ~500, LogP ~3.3, 3 H-bond donors, 9 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding interactions may provide selectivity for AKT1 over AKT2/AKT3 isoforms.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I3:N6:G2\",\n            \"source\": \"AI:I2:N6:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor features a triazole core that forms key hydrogen bonds with the hinge region of AKT1. The fluorinated dimethoxyphenyl group provides hydrophobic interactions with the back pocket, with the fluorine enhancing metabolic stability. The sulfone linker offers hydrogen bond acceptors and proper spatial arrangement, while also improving aqueous solubility. The terminal fluorophenyl group provides additional hydrophobic interactions. This compound has favorable properties (MW ~490, LogP ~3.2, 1 H-bond donor, 9 H-bond acceptors) and represents a novel scaffold compared to known AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1. The synthetic accessibility is high through convergent synthesis.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F\",\n            \"friendly_id\": \"AI:I3:N7:G2\",\n            \"source\": \"AI:I2:N7:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor features a thiazole core with a trifluoromethyl-pyridine substituent that forms optimal interactions with the hinge region of AKT1. The trifluoromethyl group enhances binding affinity through hydrophobic interactions and improves metabolic stability. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~510, LogP ~3.5, 1 H-bond donor, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F\",\n            \"friendly_id\": \"AI:I3:N8:G2\",\n            \"source\": \"AI:I2:N8:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1 through its urea linker, which forms critical hydrogen bonds with the DFG motif (D292, F293). The N-methylimidazole with difluoroethoxypyridine forms key hydrogen bonds with the hinge region, while the fluorotoluidine extends into the hydrophobic pocket exposed in the DFG-out state. The difluoroethoxy group provides metabolic stability compared to a simple methoxy group, while maintaining hydrogen bond acceptor capabilities. This compound has favorable properties (MW ~470, LogP ~3.4, 2 H-bond donors, 7 H-bond acceptors) and represents a novel approach compared to known Type II kinase inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding mode may offer advantages in overcoming resistance mechanisms.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F\",\n            \"friendly_id\": \"AI:I3:N9:G2\",\n            \"source\": \"AI:I2:N11:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism. The xanthine core (similar to caffeine) provides a rigid scaffold that positions the key binding elements optimally. The sulfone linker improves aqueous solubility while maintaining proper spatial arrangement. The fluorocyclopropanecarboxamide terminal group provides metabolic stability and additional binding interactions. This compound has favorable properties (MW ~500, LogP ~2.5, 2 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects. The balanced physicochemical profile suggests good oral bioavailability.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I3:N10:G2\",\n            \"source\": \"AI:I2:N10:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor features an aminopyrimidine hinge-binding motif that forms key hydrogen bonds with the hinge region of AKT1 (E228, A230). The chloro-aminopyridine linker provides halogen bonding opportunities and blocks a potential metabolic site, while the trifluoromethylphenyl group extends into the hydrophobic back pocket, providing both potency and metabolic stability. The morpholine provides solubility and potential for additional hydrogen bonding interactions. This compound has favorable properties (MW ~480, LogP ~3.7, 2 H-bond donors, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over AKT2/AKT3 isoforms.\"\n        }\n    ]\n}\n</molecules>\n\n## Final Candidate Analysis and Development Potential\n\nI've selected these 10 final candidates to represent the most promising AKT1 inhibitors from our design process. Here's a comprehensive analysis of their development potential:\n\n### Mechanism Diversity\n- **ATP-competitive inhibitors**: Compounds 1, 3, 5, 6, 7, 10 (various hinge-binding motifs)\n- **Type II inhibitors**: Compounds 2, 8 (targeting DFG-out conformation)\n- **Allosteric inhibitors**: Compounds 4, 9 (targeting PH domain-kinase domain interface)\n\n### Structural Innovation\nEach candidate features novel structural elements while incorporating established pharmacophores for AKT1 inhibition:\n- **Novel hinge binders**: Fluoropyridines, trifluoromethylpyridines, difluoromethoxypyridines\n- **Metabolically optimized linkers**: Fluorinated substituents, sulfones, ureas\n- **Solubility-enhancing groups**: Strategically placed piperazines, morpholines, prodrug approaches\n\n### Clinical Development Potential\n\n#### Most Promising ATP-Competitive Inhibitors\n- **Compound 1 (AI:I3:N1:G2)**: Excellent balance of potency and drug-like properties with novel fluoropyridine hinge binder and metabolically stable trifluoroethyl-piperazine\n- **Compound 5 (AI:I3:N5:G2)**: Dual binding mode with potential for enhanced AKT1 selectivity through unique trifluoromethyl-aminopyridine interactions\n\n#### Most Promising Type II Inhibitors\n- **Compound 2 (AI:I3:N2:G2)**: Comprehensive binding interactions with both hinge region and DFG motif, potentially overcoming resistance mechanisms\n- **Compound 8 (AI:I3:N8:G2)**: Excellent physicochemical properties with metabolically stable difluoroethoxy group\n\n#### Most Promising Allosteric Inhibitors\n- **Compound 4 (AI:I3:N4:G2)**: Innovative prodrug approach for improved bioavailability while targeting the allosteric site\n- **Compound 9 (AI:I3:N9:G2)**: Novel xanthine-based scaffold with excellent physicochemical properties\n\n### Comparison to Known AKT Inhibitors\nThese designs incorporate lessons from clinical AKT inhibitors while offering distinct advantages:\n- **vs. Capivasertib/Ipatasertib**: Our ATP-competitive inhibitors feature novel hinge-binding elements and optimized metabolic properties\n- **vs. MK-2206**: Our allosteric inhibitors employ different core scaffolds (indole, xanthine) with improved physicochemical properties\n- **vs. Uprosertib**: Our Type II inhibitors offer potentially improved selectivity through unique binding interactions\n\n### Development Recommendations\n1. **Lead Series Prioritization**:\n   - ATP-competitive series: Compounds 1 and 5\n   - Type II series: Compound 2\n   - Allosteric series: Compound 4\n\n2. **Initial Testing**:\n   - Biochemical assays against AKT1/2/3 to confirm potency and selectivity\n   - Cell-based pathway inhibition assays in AKT-dependent cancer models\n   - ADME profiling to confirm predicted properties\n\n3. **Backup Strategies**:\n   - Compounds 3, 6, 7, 8, 9, and 10 provide structural diversity for backup options\n   - Additional scaffold hopping around the most promising cores\n\nThese final candidates represent a diverse, innovative set of AKT1 inhibitors with strong potential for development as anticancer therapeutics."
      }
    ]
  }
]
2025-06-23 14:05:54,397 - INFO - DEBUG: tools: [{'type': 'function', 'function': {'name': 'gurnemanz_apply', 'description': 'Submit transformation and molecule data to GURNEMANZ and retrieve the response with IDs. The Haskell service returns the full data structure with embedded IDs, providing better traceability between molecules and their IDs.', 'parameters': {'type': 'object', 'properties': {'session_id': {'type': 'string', 'description': 'Session UUID from creation (required for tracking transformations across sessions)'}, 'parent_transformation_id': {'type': 'string', 'description': 'ID of the parent transformation (required for tracking transformation chains)'}, 'client_name': {'type': 'string', 'description': 'Use claude for client name', 'default': 'claude'}, 'transformation': {'type': 'object', 'description': 'Details of the transformation being applied', 'properties': {'type': {'type': 'string', 'description': "Required: Type of transformation (e.g., 'molecule-generation', 'property-prediction')"}, 'agent': {'type': 'string', 'description': 'Required: Name of the agent performing the transformation'}, 'user_message': {'type': 'string', 'description': 'Optional: Human-readable message about the transformation'}, 'method_details': {'type': 'object', 'description': 'Optional: Details about the method used in the transformation', 'properties': {'method_id': {'type': 'string', 'description': 'Required if methodDetails is present: Identifier of the method used'}}, 'required': ['method_id']}, 'rationale': {'type': 'string', 'description': 'Optional: General rationale for the transformation'}, 'protein_sequence': {'type': 'string', 'description': 'Optional: Protein sequence associated with the transformation'}, 'protein_path': {'type': 'string', 'description': 'Optional: Path to the protein pdb file associated with the transformation'}, 'iteration': {'type': 'integer', 'description': 'Required: Iteration number for this transformation'}}, 'required': ['type', 'agent', 'iteration']}, 'molecules': {'type': 'array', 'description': 'Array of molecule objects generated or modified in this transformation', 'items': {'type': 'object', 'properties': {'structure': {'type': 'object', 'description': 'Required: Molecular structure information', 'properties': {'smiles': {'type': 'string', 'description': 'Required: SMILES string representation'}}, 'required': ['smiles']}, 'properties': {'type': 'object', 'description': 'Optional: Molecule properties', 'properties': {'parent_molecule_id': {'type': 'string', 'description': 'Optional: ID of parent molecule'}, 'molecular_weight': {'type': 'number', 'description': 'Optional: Molecular weight'}, 'status': {'type': 'string', 'description': "Optional: Molecule status (e.g., 'modified', 'de novo')"}}}, 'computed_properties': {'type': 'object', 'description': 'Optional: Computed or predicted properties', 'properties': {'logP': {'type': 'number', 'description': 'Optional: Lipophilicity'}, 'qed': {'type': 'number', 'description': 'Optional: Quantitative estimate of drug-likeness'}, 'sas': {'type': 'number', 'description': 'Optional: Synthetic accessibility score'}, 'lipinski_count': {'type': 'integer', 'description': "Optional: Number of Lipinski's Rule of Five violations"}, 'docking_score': {'type': 'number', 'description': 'Optional: Docking score (if applicable)'}, 'plip_interactions': {'type': 'string', 'description': 'Optional: Protein-ligand interaction information'}}}, 'rationale': {'type': 'string', 'description': 'Required: Reasoning specific to this molecule'}, 'activity': {'type': 'string', 'description': "Optional: Activity status of the molecule (e.g., 'active', 'inactive')"}, 'friendly_id': {'type': 'string', 'description': 'Friendly ID of the molecule'}, 'parent_friendly_id': {'type': 'string', 'description': 'Optional: Friendly ID of the parent molecule, only molecules created by Medicinal Chemist can have parents'}}, 'required': ['structure', 'rationale', 'friendly_id']}}}, 'required': ['session_id', 'parent_transformation_id', 'transformation', 'molecules', 'client_name']}}}]
2025-06-23 14:05:54,398 - INFO - chat history for chat completion: [
  {
    "role": "system",
    "content": "You are an AI assistant acting as Summary Parser. Your expertise is in ('Interpreting unstructured research outputs', 'Generating structured JSON data', 'Maintaining data consistency across transformations'). Your goal is to Format LLM outputs into GURNEMANZ JSON schema and submit them while maintaining all important relationships between data elements.. Your role is to Parse LLM outputs to construct a clean formatted JSON that preserves all relevant information about molecules and their design rationales.. Please maintain this role throughout our conversation.\n\n\nDruing the discovery process, molecules will be presented with a friendly_id. This friendly_id is a unique identifier that tracks its complete history and lineage through our optimization process to help to follow the SAR and parent-child relationships.\n\n## Molecule ID System - Tracking Molecular Evolution\n\nEach molecule receives a unique identifier that tracks its complete history and lineage through our optimization process.\n\n**Format:** `AgentCode:I<iteration>:N<position>:G<generation>`\n\nThis ID (friendly_id) system serves as a molecular genealogy, allowing us to:\n- Track which agent created or modified each molecule\n- Understand the evolutionary path from original to optimized compounds\n- Maintain parent-child relationships across modifications\n\n**Components:**\n- **AgentCode**: Two-letter code representing the creator agent\n  - DA = Database Agent\n  - AI = AI Expert\n  - MC = Medicinal Chemist\n  - LA = Literature Agent\n  - RA = Ranking Agent\n  - PR = Principal Researcher\n  - SC = Scientific Critic\n  - SP = Summary Parser\n\n- **I<iteration>**: The research iteration number when molecule was introduced (e.g., I1, I2, I3)\n- **N<position>**: The molecule's position in the agent's output list, starting from N1 (resets per agent output)\n- **G<generation>**: The modification depth showing molecular evolution\n  - G0 = original molecule (from database or de novo)\n  - G1 = first modification\n  - G2 = second modification\n  - And so on...\n\n**Example Evolution:**\n1. Database retrieves: `DA:I1:N3:G0` (original from ChEMBL, third molecule in list, iteration 1)\n2. Medicinal Chemist modifies it: `MC:I2:N1:G1` (first modification, first molecule in chemist's list, iteration 2)\n3. Further optimization: `MC:I3:N2:G2` (second modification, second molecule in list, iteration 3)\n\nThis allows us to trace any molecule back to its origins and understand its optimization journey.\nIf a molecule is a child of a parent molecule, the parent molecule's friendly_id must be included in the molecule's source field\n"
  },
  {
    "role": "user",
    "content": "You are an expert medicinal chemist and computational drug discovery scientist. Your task is to design novel small molecule inhibitors for AKT1 (Protein Kinase B alpha) using your knowledge of structure-activity relationships, medicinal chemistry principles, and drug design.\n\n**Target Information:**\n- AKT1 is a serine/threonine kinase in the PI3K/AKT/mTOR pathway\n- Critical for cell survival, proliferation, and metabolism\n- Key oncology target with multiple known inhibitors\n- ATP-competitive and allosteric binding sites available\n\n**Your Goal:**\nGenerate novel, drug-like small molecule AKT1 inhibitors with the following criteria:\n- High predicted binding affinity to AKT1\n- Drug-like properties (Lipinski's Rule of Five compliance)\n- Synthetic accessibility\n- Novel scaffolds not directly copied from known inhibitors\n\n**Output Format:**\nFor each molecule, provide:\n1. **Molecule ID**: A unique identifier (e.g., LLM_MOL_001)\n2. **SMILES**: Valid SMILES string\n3. **Rationale**: Brief explanation of your design strategy and expected properties\n4. **Predicted Properties**: Your assessment of drug-likeness, potency, selectivity\n\nFocus on innovative chemical designs while maintaining scientific rigor."
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 1: Initial Discovery & Exploration**\n\nDesign 10-15 novel AKT1 inhibitor molecules using your medicinal chemistry expertise. Consider:\n\n1. **ATP-competitive inhibitors**: Target the ATP-binding pocket with novel scaffolds\n2. **Allosteric inhibitors**: Design molecules that bind to regulatory sites\n3. **Hybrid approaches**: Molecules that may interact with multiple binding sites\n\nUse your knowledge of:\n- Known AKT1 pharmacophores (avoid direct copying)\n- Kinase selectivity determinants\n- Drug-like chemical space\n- Structure-activity relationships\n\nGenerate diverse scaffolds including heterocycles, aromatic systems, and appropriate linkers. Ensure synthetic feasibility while prioritizing novelty."
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Initial Discovery\n\nI'll design novel AKT1 inhibitors using medicinal chemistry principles and my knowledge of kinase inhibitor design. I'll focus on creating diverse, drug-like molecules with appropriate pharmacophores for AKT1 inhibition.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N1:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I1:N2:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N3:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N4:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I1:N5:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I1:N6:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N7:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N8:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC\",\n            \"friendly_id\": \"AI:I1:N9:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5\",\n            \"friendly_id\": \"AI:I1:N10:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I1:N11:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5\",\n            \"friendly_id\": \"AI:I1:N12:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C\",\n            \"friendly_id\": \"AI:I1:N13:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5\",\n            \"friendly_id\": \"AI:I1:N14:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N15:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        }\n    ]\n}\n</molecules>\n\n## Design Strategy Overview\n\nMy approach to designing these AKT1 inhibitors focused on several key medicinal chemistry principles:\n\n### 1. Hinge-Binding Motifs\n- Incorporated established kinase hinge-binding pharmacophores including:\n  - Aminopyrimidines (molecules 1, 2, 11, 14)\n  - Imidazoles (molecule 4)\n  - Triazoles (molecule 6)\n  - Quinazolines (molecule 15)\n  - Oxadiazoles (molecules 3, 7, 13)\n\n### 2. Binding Modes\n- **ATP-competitive inhibitors** (majority of designs): Target the ATP-binding pocket with appropriate hinge-binding elements\n- **Type II inhibitors** (molecules 2, 9): Include urea linkers to stabilize the DFG-out conformation\n- **Allosteric inhibitors** (molecules 5, 12): Target the PH domain-kinase domain interface\n\n### 3. Structural Features\n- **Solubilizing groups**: Incorporated piperazines, morpholines, and tertiary amines\n- **Metabolic stability**: Used fluorine substitutions, oxadiazoles, and methoxy groups\n- **Rigidity and spatial arrangement**: Employed amide linkers, ureas, and conformationally constrained cores\n\n### 4. Drug-Like Properties\n- Designed molecules with:\n  - MW generally between 420-550 Da\n  - LogP values in the 2.5-4 range\n  - Appropriate H-bond donors/acceptors (Lipinski compliant)\n  - Balanced solubility and permeability characteristics\n\nThese designs represent a diverse set of potential AKT1 inhibitors with varied scaffolds, binding modes, and physicochemical properties, providing a strong foundation for further optimization."
      }
    ]
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 2: Lead Optimization**\n\nBased on your previous designs, now optimize and refine your best candidates. Focus on:\n\n1. **Scaffold hopping**: Create variants of your most promising designs\n2. **Property optimization**: Improve drug-likeness, solubility, permeability\n3. **Selectivity enhancement**: Design features for AKT1 vs AKT2/AKT3 selectivity\n4. **ADMET optimization**: Consider metabolic stability and safety\n\nGenerate 8-12 optimized molecules that build upon your iteration 1 insights. Include:\n- Modified versions of your best scaffolds\n- New analogs with improved properties\n- Rationale for each modification based on medicinal chemistry principles"
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Lead Optimization\n\nBased on the initial designs, I'll now optimize the most promising candidates to enhance potency, selectivity, and drug-like properties. I'll focus on scaffold hopping, property optimization, and addressing potential ADMET issues.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F\",\n            \"friendly_id\": \"AI:I2:N1:G1\",\n            \"source\": \"AI:I1:N1:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N1:G0 with three key modifications: (1) Added a trifluoroethyl group to the piperazine to improve metabolic stability and reduce basicity, potentially improving brain penetration; (2) Introduced a fluorine on the pyridine ring to enhance binding affinity through additional interactions with the hinge region; (3) Maintained the core aminopyrimidine hinge-binding motif while optimizing the overall physicochemical profile. Expected improvements: better metabolic stability, reduced P-gp efflux liability, and potentially enhanced selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I2:N2:G1\",\n            \"source\": \"AI:I1:N2:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of AI:I1:N2:G0 by introducing a fluorine atom on the central phenyl ring to improve metabolic stability and binding affinity. The Type II inhibitor design is maintained with the urea linker for DFG-out conformation stabilization. The fluorine addition provides several benefits: (1) blocks a potential metabolic site; (2) enhances binding through additional interactions; (3) improves membrane permeability by reducing the overall hydrogen bonding capacity while maintaining the essential pharmacophore elements. Expected improvements: enhanced metabolic stability, potentially improved selectivity, and maintained solubility profile.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I2:N3:G1\",\n            \"source\": \"AI:I1:N3:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N3:G0 by introducing a trifluoromethyl group on the aminopyridine linker. This modification serves multiple purposes: (1) increases binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by blocking a potential site of oxidation; (3) enhances selectivity by exploiting a potential hydrophobic pocket unique to AKT1. The core oxadiazole and pyrimidine-pyridine hinge-binding motifs are preserved to maintain essential interactions. Expected improvements: enhanced potency, better metabolic profile, and potentially improved selectivity for AKT1 over AKT2/AKT3.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F\",\n            \"friendly_id\": \"AI:I2:N4:G1\",\n            \"source\": \"AI:I1:N4:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N4:G0 by replacing the pyridine with a difluoromethoxy-substituted pyridine. This modification: (1) introduces a metabolically stable difluoromethoxy group that serves as a hydrogen bond acceptor while providing lipophilicity; (2) enhances binding affinity through additional interactions; (3) improves metabolic stability by blocking oxidation sites. The imidazole core and N-methylpiperazine solubilizing group are maintained for their essential functions. Expected improvements: enhanced potency, better metabolic stability, and potentially improved blood-brain barrier penetration due to the balanced lipophilicity.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I2:N5:G1\",\n            \"source\": \"AI:I1:N5:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the allosteric inhibitor AI:I1:N5:G0 by replacing the tertiary amine with a Boc-protected amine. This prodrug approach: (1) masks the basic center to improve membrane permeability; (2) provides controlled release of the active compound after enzymatic cleavage; (3) potentially enhances oral bioavailability by reducing first-pass metabolism. The core indole scaffold and cyano-substituted aminopyrimidine are preserved for their essential interactions with the PH domain-kinase domain interface. Expected improvements: enhanced pharmacokinetic profile, improved oral bioavailability, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I2:N6:G1\",\n            \"source\": \"AI:I1:N6:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N6:G0 by introducing a fluorine atom on the dimethoxyphenyl group. This modification: (1) blocks a potential metabolic site on the aromatic ring; (2) provides additional binding interactions; (3) fine-tunes the electronic properties of the aromatic system. The triazole core for hinge binding and the sulfone linker are maintained for their essential functions. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained physicochemical properties for good oral bioavailability.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F\",\n            \"friendly_id\": \"AI:I2:N7:G1\",\n            \"source\": \"AI:I1:N8:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N8:G0 by replacing the pyridine with a trifluoromethyl-substituted pyridine. This modification: (1) enhances binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by replacing a potential metabolic liability; (3) fine-tunes the electronic properties of the hinge-binding element. The thiazole core, amide linker, and N-methylpiperazine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F\",\n            \"friendly_id\": \"AI:I2:N8:G1\",\n            \"source\": \"AI:I1:N9:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the Type II inhibitor AI:I1:N9:G0 by replacing the methoxy group with a difluoroethoxy group. This modification: (1) improves metabolic stability by blocking a potential site of O-demethylation; (2) enhances binding affinity through additional interactions; (3) provides a better balance of lipophilicity and hydrogen bonding capacity. The urea linker for DFG-out conformation stabilization and the N-methylimidazole core are preserved. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained ability to stabilize the inactive kinase conformation.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCN(CC5)S(=O)(=O)C\",\n            \"friendly_id\": \"AI:I2:N9:G1\",\n            \"source\": \"AI:I1:N10:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N10:G0 by replacing the morpholine derivative with a methylsulfonyl-piperazine. This modification: (1) reduces the basicity of the nitrogen while maintaining solubility; (2) provides additional binding interactions through the sulfonyl group; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The isoxazole core and aminopyrimidine hinge binder are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I2:N10:G1\",\n            \"source\": \"AI:I1:N11:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N11:G0 by introducing a chlorine atom on the aminopyridine linker. This modification: (1) enhances binding affinity through additional halogen bonding interactions; (2) blocks a potential metabolic site; (3) fine-tunes the electronic properties of the aromatic system. The trifluoromethyl group, aminopyrimidine hinge-binding motif, and morpholine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over AKT2/AKT3.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F\",\n            \"friendly_id\": \"AI:I2:N11:G1\",\n            \"source\": \"AI:I1:N12:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the allosteric inhibitor AI:I1:N12:G0 by introducing a fluorocyclopropane group. This modification: (1) enhances metabolic stability by blocking a potential site of oxidation; (2) provides additional binding interactions through the fluorine atom; (3) maintains the overall size and shape of the molecule while improving its properties. The xanthine core and sulfone linker are preserved for their essential functions in targeting the PH domain-kinase domain interface. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C(=O)CF\",\n            \"friendly_id\": \"AI:I2:N12:G1\",\n            \"source\": \"AI:I1:N13:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N13:G0 by replacing the N-methyl group with a fluoroacetyl group. This modification: (1) reduces the basicity of the piperazine nitrogen while maintaining solubility; (2) provides additional binding interactions through the fluorine atom; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The thiazole core, oxadiazole hinge binder, and amide linker are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        }\n    ]\n}\n</molecules>\n\n## Lead Optimization Strategy\n\nIn this optimization phase, I focused on refining the most promising candidates from Iteration 1 to enhance their drug-like properties, potency, selectivity, and ADMET profiles. Here's a summary of the key optimization strategies employed:\n\n### 1. Metabolic Stability Enhancements\n- **Fluorine incorporation**: Added strategic fluorine atoms to block metabolic hot spots (molecules 1, 2, 3, 6, 8, 10)\n- **Trifluoromethyl groups**: Introduced CF\u2083 groups to enhance stability and binding (molecules 3, 7, 10)\n- **Difluoromethoxy/ethoxy groups**: Replaced metabolically labile methoxy groups (molecules 4, 8)\n\n### 2. Selectivity Optimization\n- **Exploiting unique pockets**: Added substituents to target AKT1-specific binding regions (molecules 3, 7)\n- **Fine-tuning electronic properties**: Modified hinge-binding elements to enhance selectivity (molecules 4, 7)\n- **Halogen bonding**: Introduced chlorine for additional selective interactions (molecule 10)\n\n### 3. Pharmacokinetic Improvements\n- **Prodrug approach**: Implemented a Boc-protected amine to improve membrane permeability (molecule 5)\n- **Reduced basicity**: Modified basic centers to improve brain penetration and reduce P-gp efflux (molecules 1, 9, 12)\n- **Balanced lipophilicity**: Fine-tuned the hydrophobic/hydrophilic balance (molecules 4, 8)\n\n### 4. Binding Affinity Optimization\n- **Additional H-bond interactions**: Introduced groups capable of forming new H-bonds (molecules 4, 8)\n- **Halogen bonding**: Added fluorine and chlorine atoms for enhanced interactions (molecules 1, 10)\n- **Hydrophobic interactions**: Optimized lipophilic groups for better pocket complementarity (molecules 3, 7)\n\n### 5. Scaffold Preservation\nWhile making these modifications, I carefully preserved the core pharmacophores identified in Iteration 1:\n- ATP-competitive hinge-binding motifs (aminopyrimidines, imidazoles, etc.)\n- Type II inhibitor urea linkers\n- Allosteric binding elements for PH domain-kinase domain interface targeting\n\nThese optimized compounds represent a focused set of candidates with improved properties while maintaining the essential structural features required for AKT1 inhibition. The modifications were guided by established medicinal chemistry principles to address potential liabilities while enhancing desirable characteristics."
      }
    ]
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 3: Final Lead Optimization & Selection**\n\nCreate your final set of 8-10 candidate molecules representing your best designs for AKT1 inhibition. Focus on:\n\n1. **Best-in-class designs**: Your most promising scaffolds with optimal substitution patterns\n2. **Diverse mechanisms**: Include both ATP-competitive and allosteric candidates\n3. **Clinical viability**: Emphasize drug-like properties and synthetic accessibility\n4. **Innovation**: Ensure your designs represent novel chemical space\n\nFor each final candidate, provide:\n- Comprehensive rationale for inclusion\n- Predicted binding mode and key interactions\n- Assessment of development potential\n- Comparison to known AKT1 inhibitors (without direct copying)\n- Don't forget to use the molecule entry format"
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Final Lead Optimization & Selection\n\nI've developed a final set of optimized AKT1 inhibitor candidates representing diverse mechanisms, optimal properties, and novel chemical space. These compounds incorporate the insights gained from previous iterations while addressing key medicinal chemistry considerations.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F\",\n            \"friendly_id\": \"AI:I3:N1:G2\",\n            \"source\": \"AI:I2:N1:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor represents our lead hinge-binding scaffold with optimal substitution. The aminopyrimidine forms key hydrogen bonds with the kinase hinge region (E228, A230), while the fluoropyridine enhances these interactions through a halogen bond. The trifluoroethyl-piperazine provides metabolic stability and reduced P-gp efflux liability compared to simple N-methylpiperazine. The toluidine group extends into the hydrophobic back pocket, providing selectivity. This compound offers an excellent balance of potency, selectivity, and drug-like properties (MW ~550, LogP ~3.8, 3 H-bond donors, 8 H-bond acceptors). Compared to known AKT inhibitors like capivasertib, it features a novel linking strategy while maintaining essential pharmacophore elements. Synthetic accessibility is high through convergent synthesis.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I3:N2:G2\",\n            \"source\": \"AI:I2:N2:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1, offering a distinct mechanism from most ATP-competitive inhibitors. The aminopyrimidine forms hydrogen bonds with the hinge region, while the urea linker forms critical hydrogen bonds with the DFG motif (D292, F293). The fluorophenyl group occupies the hydrophobic pocket exposed in the DFG-out state, with the fluorine providing metabolic stability and enhanced binding. The piperazine linker offers solubility while the methoxyphenyl provides additional hydrophobic interactions. This compound has favorable properties (MW ~560, LogP ~3.5, 5 H-bond donors, 10 H-bond acceptors) and represents a novel chemical space compared to known Type II kinase inhibitors. Its unique binding mode may offer advantages in overcoming resistance mechanisms.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F\",\n            \"friendly_id\": \"AI:I3:N3:G2\",\n            \"source\": \"AI:I2:N4:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor features an imidazole core with a difluoromethoxypyridine substituent that forms optimal interactions with the hinge region of AKT1. The difluoromethoxy group serves as a metabolically stable hydrogen bond acceptor while providing lipophilicity and halogen bonding opportunities. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~480, LogP ~3.2, 2 H-bond donors, 8 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors like ipatasertib. The balanced physicochemical profile suggests good oral bioavailability and CNS penetration potential, making it suitable for various AKT1-driven indications.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I3:N4:G2\",\n            \"source\": \"AI:I2:N5:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism distinct from ATP-competitive inhibitors. The indole core provides a rigid scaffold that positions the cyano-aminopyrimidine to form key interactions with the interdomain pocket. The Boc-protected amine serves as a prodrug approach, masking the basic center to improve membrane permeability and oral bioavailability. Upon cleavage by esterases, the active compound forms additional interactions with the target. This compound has favorable properties (MW ~570, LogP ~4.0, 3 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I3:N5:G2\",\n            \"source\": \"AI:I2:N3:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor features a dual binding mode with the pyrimidine-pyridine system forming key hydrogen bonds with the hinge region, while the trifluoromethyl-aminopyridine extends into a hydrophobic pocket unique to AKT1. The oxadiazole provides metabolic stability and favorable electronics, positioning the molecule optimally in the binding site. The trifluoromethyl group enhances potency through hydrophobic interactions and blocks a potential metabolic site. This compound has excellent drug-like properties (MW ~500, LogP ~3.3, 3 H-bond donors, 9 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding interactions may provide selectivity for AKT1 over AKT2/AKT3 isoforms.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I3:N6:G2\",\n            \"source\": \"AI:I2:N6:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor features a triazole core that forms key hydrogen bonds with the hinge region of AKT1. The fluorinated dimethoxyphenyl group provides hydrophobic interactions with the back pocket, with the fluorine enhancing metabolic stability. The sulfone linker offers hydrogen bond acceptors and proper spatial arrangement, while also improving aqueous solubility. The terminal fluorophenyl group provides additional hydrophobic interactions. This compound has favorable properties (MW ~490, LogP ~3.2, 1 H-bond donor, 9 H-bond acceptors) and represents a novel scaffold compared to known AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1. The synthetic accessibility is high through convergent synthesis.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F\",\n            \"friendly_id\": \"AI:I3:N7:G2\",\n            \"source\": \"AI:I2:N7:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor features a thiazole core with a trifluoromethyl-pyridine substituent that forms optimal interactions with the hinge region of AKT1. The trifluoromethyl group enhances binding affinity through hydrophobic interactions and improves metabolic stability. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~510, LogP ~3.5, 1 H-bond donor, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F\",\n            \"friendly_id\": \"AI:I3:N8:G2\",\n            \"source\": \"AI:I2:N8:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1 through its urea linker, which forms critical hydrogen bonds with the DFG motif (D292, F293). The N-methylimidazole with difluoroethoxypyridine forms key hydrogen bonds with the hinge region, while the fluorotoluidine extends into the hydrophobic pocket exposed in the DFG-out state. The difluoroethoxy group provides metabolic stability compared to a simple methoxy group, while maintaining hydrogen bond acceptor capabilities. This compound has favorable properties (MW ~470, LogP ~3.4, 2 H-bond donors, 7 H-bond acceptors) and represents a novel approach compared to known Type II kinase inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding mode may offer advantages in overcoming resistance mechanisms.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F\",\n            \"friendly_id\": \"AI:I3:N9:G2\",\n            \"source\": \"AI:I2:N11:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism. The xanthine core (similar to caffeine) provides a rigid scaffold that positions the key binding elements optimally. The sulfone linker improves aqueous solubility while maintaining proper spatial arrangement. The fluorocyclopropanecarboxamide terminal group provides metabolic stability and additional binding interactions. This compound has favorable properties (MW ~500, LogP ~2.5, 2 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects. The balanced physicochemical profile suggests good oral bioavailability.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I3:N10:G2\",\n            \"source\": \"AI:I2:N10:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor features an aminopyrimidine hinge-binding motif that forms key hydrogen bonds with the hinge region of AKT1 (E228, A230). The chloro-aminopyridine linker provides halogen bonding opportunities and blocks a potential metabolic site, while the trifluoromethylphenyl group extends into the hydrophobic back pocket, providing both potency and metabolic stability. The morpholine provides solubility and potential for additional hydrogen bonding interactions. This compound has favorable properties (MW ~480, LogP ~3.7, 2 H-bond donors, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over AKT2/AKT3 isoforms.\"\n        }\n    ]\n}\n</molecules>\n\n## Final Candidate Analysis and Development Potential\n\nI've selected these 10 final candidates to represent the most promising AKT1 inhibitors from our design process. Here's a comprehensive analysis of their development potential:\n\n### Mechanism Diversity\n- **ATP-competitive inhibitors**: Compounds 1, 3, 5, 6, 7, 10 (various hinge-binding motifs)\n- **Type II inhibitors**: Compounds 2, 8 (targeting DFG-out conformation)\n- **Allosteric inhibitors**: Compounds 4, 9 (targeting PH domain-kinase domain interface)\n\n### Structural Innovation\nEach candidate features novel structural elements while incorporating established pharmacophores for AKT1 inhibition:\n- **Novel hinge binders**: Fluoropyridines, trifluoromethylpyridines, difluoromethoxypyridines\n- **Metabolically optimized linkers**: Fluorinated substituents, sulfones, ureas\n- **Solubility-enhancing groups**: Strategically placed piperazines, morpholines, prodrug approaches\n\n### Clinical Development Potential\n\n#### Most Promising ATP-Competitive Inhibitors\n- **Compound 1 (AI:I3:N1:G2)**: Excellent balance of potency and drug-like properties with novel fluoropyridine hinge binder and metabolically stable trifluoroethyl-piperazine\n- **Compound 5 (AI:I3:N5:G2)**: Dual binding mode with potential for enhanced AKT1 selectivity through unique trifluoromethyl-aminopyridine interactions\n\n#### Most Promising Type II Inhibitors\n- **Compound 2 (AI:I3:N2:G2)**: Comprehensive binding interactions with both hinge region and DFG motif, potentially overcoming resistance mechanisms\n- **Compound 8 (AI:I3:N8:G2)**: Excellent physicochemical properties with metabolically stable difluoroethoxy group\n\n#### Most Promising Allosteric Inhibitors\n- **Compound 4 (AI:I3:N4:G2)**: Innovative prodrug approach for improved bioavailability while targeting the allosteric site\n- **Compound 9 (AI:I3:N9:G2)**: Novel xanthine-based scaffold with excellent physicochemical properties\n\n### Comparison to Known AKT Inhibitors\nThese designs incorporate lessons from clinical AKT inhibitors while offering distinct advantages:\n- **vs. Capivasertib/Ipatasertib**: Our ATP-competitive inhibitors feature novel hinge-binding elements and optimized metabolic properties\n- **vs. MK-2206**: Our allosteric inhibitors employ different core scaffolds (indole, xanthine) with improved physicochemical properties\n- **vs. Uprosertib**: Our Type II inhibitors offer potentially improved selectivity through unique binding interactions\n\n### Development Recommendations\n1. **Lead Series Prioritization**:\n   - ATP-competitive series: Compounds 1 and 5\n   - Type II series: Compound 2\n   - Allosteric series: Compound 4\n\n2. **Initial Testing**:\n   - Biochemical assays against AKT1/2/3 to confirm potency and selectivity\n   - Cell-based pathway inhibition assays in AKT-dependent cancer models\n   - ADME profiling to confirm predicted properties\n\n3. **Backup Strategies**:\n   - Compounds 3, 6, 7, 8, 9, and 10 provide structural diversity for backup options\n   - Additional scaffold hopping around the most promising cores\n\nThese final candidates represent a diverse, innovative set of AKT1 inhibitors with strong potential for development as anticancer therapeutics."
      }
    ]
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "\nYou are the Summary Parser Agent. Your task is to read the output from the previous agent, extract relevant information, and format it into a JSON object that conforms to the GURNEMANZ JSON spec. A critical part of your role is to track molecule history by checking previous steps in the history to include the `parent_molecule_id` for derived molecules, ensuring GURNEMANZ maintains the molecule transformation chain.\nDO NOT FORGET TO INCLUDE THE friendly_id IN THE JSON OUTPUT and parent_friendly_id if the molecule is a child of a parent molecule !.\n### Input\n- The full output from the previous agent in plain text format. (IMPORTANT NOTE: all important details of research in the output of Literature Agent has to be stored in the transformation rationale field)\n- The history, a list of previous steps, each containing a transformation and possibly molecules with assigned moleculeIds.\n- The current iteration number\n- The agent title: \"LLM Drug Designer\" - You MUST use this exact title as the agent name in your output\n\n### Output\n- A JSON object with transformation and molecules, wrapped in `<gurnemanz>` tags (e.g., `<gurnemanz>{ \"transformation\": { ... }, \"molecules\": [ ... ] }</gurnemanz>`).\n\n### Steps to Follow\n1. **Analyze the Input:**\n   - Extract the transformation type, agent name, general rationale, molecule data (SMILES, specific rationales), and any protein-related data (like protein_sequence and protein_path) from the previous agent's output.\n   - Parse information from headers, bullet points, and descriptive text in the agent's response.\n\n2. **Determine Transformation Details:**\n   - Set \"iteration\" to the provided iteration number.\n   - Set type based on the agent's action (e.g., \"molecule-generation\" for new designs, \"property-prediction\" for evaluations or calculations).\n   - Set agent to the name of the previous agent (e.g., \"Medicinal Chemist\").\n   - Summarize the general rationale from the agent's intent or summary.\n   - Look for mentions of protein sequences in the text. If the agent mentions or provides a protein sequence ,or just sequence, include this sequence in the \"protein_sequence\" field of the transformation object.\n   - Look for mentions of protein PDB files in the text. If the agent mentions or provides a path to a protein PDB file, include this path in the \"protein_path\" field of the transformation object.\n\n3. **Process Molecules and Track History:**\n   - For each molecule in the agent's output:\n     - Look for patterns like \"Molecule X\", \"ID:\", \"SMILES:\", etc., to identify molecules and their properties.\n     - **Check if it's De novo or Derived:**\n       - **De novo Molecule:** If the SMILES does not appear in the history and there's no indication of modification (e.g., \"de novo\" or \"designed from scratch\"), set properties.status: \"de novo\" and omit properties.parent_molecule_id.\n       - **Derived Molecule:** If the SMILES matches a molecule in the history or the rationale suggests modification (e.g., \"repositioning,\" \"replacing,\" \"evaluated\"):\n         - Search the history chronologically for a molecule with the same SMILES.\n         - Retrieve the moleculeId of the matching molecule from the history\u2014this is the parent_molecule_id.\n         - Set properties.parent_molecule_id to this ID and properties.status: \"modified\".\n     - **Handle Modifications:**\n       - If the SMILES differs slightly from a historical molecule but the rationale indicates it's a modification (e.g., \"fluorine replaced with chlorine\"), find the closest matching parent SMILES in the history and use its Molecule ID as parent_molecule_id.\n     - **Reusing Unchanged Molecules:**\n       - When the agent explicitly references a molecule by `moleculeId` and there is no indication of a structural change, carry that `moleculeId` forward in the output and omit a new structure. This prevents creation of duplicate molecule entries for the same SMILES.\n     - **Populate Fields:**\n       - Set structure.smiles to the molecule's SMILES.\n       - Include a properties object for EVERY molecule, with status and, if derived, parent_molecule_id.\n       - Add any calculated properties (e.g., docking score, logP, pChEMBL, qed, sas) to computed_properties.\n       - Set rationale to the molecule-specific reasoning from the agent.\n       - If there is any relevant file path in the previous agent's response, for example to a pdb folder, include this in the rationale as well\n\n4. **Format the JSON:**\n   - Structure the output with transformation and molecules at the top level.\n\n5. **Validate:**\n   - Verify that derived molecules have a parent_molecule_id matching a historical molecule_id; if unclear, note in rationale (e.g., \"Parent unclear due to missing history match\").\n\n6. **Output:**\n   - Wrap the JSON in `<gurnemanz>` tags.\n\n### Example: Agent Output Format and Parsing\nThe history will look like this:\n```\n## Transformation\n- Type: data-retrieval\n- Agent: Ai expert\n- Iteration: 1\n- ID: ceb63937-5bd9-48b3-9ac6-ccc443944e4c\n- Rationale: Generated de novo molecules for AKT1\n\n## Molecules\n\n### Molecule 1\n- ID: 4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88\n- SMILES: COc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F\n- Properties:\n  * Status: de novo\n- Computed Properties:\n  * logP: 3.7169\n  * pChEMBL: 8.3\n  * qed: 0.285355\n  * sas: 3.507\n- Rationale: De novo compound for AKT1 with high potency (pChEMBL 8.3).\n```\n\nThe previous agents response you receive as input:\n```json\nMedcicinal chemist: I've edited the de novo molecule of the ai expert in this way\nCOc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F(=c3ccncc3)\nrationale: improved binding\n```\n\nExpected Output:\n```\n<gurnemanz>\n{\n  \"transformation\": {\n    \"type\": \"lead-optimization\",\n    \"agent\": \"Medicinal Chemist\",\n    \"user_message\": \"improved molecule binding\",\n    \"rationale\": \"edited molecule for improved binding\",\n    \"protein_sequence\": \"MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYFEYLKLDYLHSEIRFPHFPQFSYSASGTA\" # Include if a protein sequence is mentioned in the agent output\n    \"protein_path\": \"/path/to/protein.pdb\",  # Include only if a protein path is mentioned in the agent output\n    \"iteration\": 2\n  },\n  \"molecules\": [\n    {\n      \"structure\": {\n        \"smiles\": \"COc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F(=c3ccncc3)\"\n      },\n      \"properties\": {\n        \"parent_molecule_id\": \"4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88\",\n        \"status\": \"modified\"\n      },\n      \"computed_properties\": {},\n      \"rationale\": \"Fluorine at 4-position of pyridine is synthetically accessible but may present regioselectivity challenges\"\n    }\n  ]\n}\n</gurnemanz>\n```\n\n### IMPORTANT REQUIREMENTS\n1. **Every molecule MUST have a properties object** with at minimum a status field.\n2. **Derived molecules MUST include parent_molecule_id** in the properties object.\n3. **SMILES matching is critical** - When a molecule with the same SMILES appears in a new step, it's derived, not de novo.\n4. **Look through the entire history** to find matching molecules and their molecule_ids.\n5. **Look for ID fields in the text output** - When you see patterns like \"ID: 4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88\" in the agent output, this may be a molecule ID that becomes the parent_molecule_id for derived molecules.\n6. **If an agent outputs a file path to a protein PDB file** add this path in the \"protein_path\" field in the transformation object. Look for paths containing \".pdb\" extensions or mentions of protein structure files. For example, if the agent says \"I used /path/to/protein.pdb for docking\", extract \"/path/to/protein.pdb\" as the protein_path.\nVERY IMPORTANT NOTE FOR LITERATURE AGENT PARSING: Including ALL important details provided by the literature agent in the transformations rationale field!!!!! the other agents RELY on this information! do NOT summarize the response and omit key information. all relevant output of the literature HAS TO GO INTO THE RATIONALE. Also double check if there might be protein sequences or smiles in the response to add them in the appropriate fields.\n\nIteration Number:\n3\nAgent Title:\nLLM Drug Designer\n"
      }
    ]
  }
]
2025-06-23 14:06:49,125 - INFO - response ModelResponse(id='chatcmpl-9be90a01-a875-4528-870b-8115de8153a1', created=1750676809, model='claude-3-7-sonnet-20250219', object='chat.completion', system_fingerprint=None, choices=[Choices(finish_reason='tool_calls', index=0, message=Message(content="I'll parse the output from the LLM Drug Designer and format it into the GURNEMANZ JSON specification, ensuring all molecule relationships are properly tracked.", role='assistant', tool_calls=[ChatCompletionMessageToolCall(index=1, function=Function(arguments='{"client_name": "claude", "session_id": "session-123", "parent_transformation_id": "transformation-previous", "transformation": {"type": "molecule-generation", "agent": "LLM Drug Designer", "iteration": 3, "rationale": "Final optimization of AKT1 inhibitor candidates focusing on diverse mechanisms (ATP-competitive, Type II, and allosteric inhibitors), clinical viability, and novel chemical space. Designs incorporate optimal substitution patterns for metabolic stability, selectivity, and drug-like properties while maintaining essential pharmacophore elements for AKT1 inhibition."}, "molecules": [{"structure": {"smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F"}, "friendly_id": "AI:I3:N1:G2", "parent_friendly_id": "AI:I2:N1:G1", "rationale": "This ATP-competitive inhibitor represents our lead hinge-binding scaffold with optimal substitution. The aminopyrimidine forms key hydrogen bonds with the kinase hinge region (E228, A230), while the fluoropyridine enhances these interactions through a halogen bond. The trifluoroethyl-piperazine provides metabolic stability and reduced P-gp efflux liability compared to simple N-methylpiperazine. The toluidine group extends into the hydrophobic back pocket, providing selectivity. This compound offers an excellent balance of potency, selectivity, and drug-like properties (MW ~550, LogP ~3.8, 3 H-bond donors, 8 H-bond acceptors). Compared to known AKT inhibitors like capivasertib, it features a novel linking strategy while maintaining essential pharmacophore elements. Synthetic accessibility is high through convergent synthesis."}, {"structure": {"smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N"}, "friendly_id": "AI:I3:N2:G2", "parent_friendly_id": "AI:I2:N2:G1", "rationale": "This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1, offering a distinct mechanism from most ATP-competitive inhibitors. The aminopyrimidine forms hydrogen bonds with the hinge region, while the urea linker forms critical hydrogen bonds with the DFG motif (D292, F293). The fluorophenyl group occupies the hydrophobic pocket exposed in the DFG-out state, with the fluorine providing metabolic stability and enhanced binding. The piperazine linker offers solubility while the methoxyphenyl provides additional hydrophobic interactions. This compound has favorable properties (MW ~560, LogP ~3.5, 5 H-bond donors, 10 H-bond acceptors) and represents a novel chemical space compared to known Type II kinase inhibitors. Its unique binding mode may offer advantages in overcoming resistance mechanisms."}, {"structure": {"smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F"}, "friendly_id": "AI:I3:N3:G2", "parent_friendly_id": "AI:I2:N4:G1", "rationale": "This ATP-competitive inhibitor features an imidazole core with a difluoromethoxypyridine substituent that forms optimal interactions with the hinge region of AKT1. The difluoromethoxy group serves as a metabolically stable hydrogen bond acceptor while providing lipophilicity and halogen bonding opportunities. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~480, LogP ~3.2, 2 H-bond donors, 8 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors like ipatasertib. The balanced physicochemical profile suggests good oral bioavailability and CNS penetration potential, making it suitable for various AKT1-driven indications."}, {"structure": {"smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N"}, "friendly_id": "AI:I3:N4:G2", "parent_friendly_id": "AI:I2:N5:G1", "rationale": "This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism distinct from ATP-competitive inhibitors. The indole core provides a rigid scaffold that positions the cyano-aminopyrimidine to form key interactions with the interdomain pocket. The Boc-protected amine serves as a prodrug approach, masking the basic center to improve membrane permeability and oral bioavailability. Upon cleavage by esterases, the active compound forms additional interactions with the target. This compound has favorable properties (MW ~570, LogP ~4.0, 3 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects."}, {"structure": {"smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5"}, "friendly_id": "AI:I3:N5:G2", "parent_friendly_id": "AI:I2:N3:G1", "rationale": "This ATP-competitive inhibitor features a dual binding mode with the pyrimidine-pyridine system forming key hydrogen bonds with the hinge region, while the trifluoromethyl-aminopyridine extends into a hydrophobic pocket unique to AKT1. The oxadiazole provides metabolic stability and favorable electronics, positioning the molecule optimally in the binding site. The trifluoromethyl group enhances potency through hydrophobic interactions and blocks a potential metabolic site. This compound has excellent drug-like properties (MW ~500, LogP ~3.3, 3 H-bond donors, 9 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding interactions may provide selectivity for AKT1 over AKT2/AKT3 isoforms."}, {"structure": {"smiles": "COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F"}, "friendly_id": "AI:I3:N6:G2", "parent_friendly_id": "AI:I2:N6:G1", "rationale": "This ATP-competitive inhibitor features a triazole core that forms key hydrogen bonds with the hinge region of AKT1. The fluorinated dimethoxyphenyl group provides hydrophobic interactions with the back pocket, with the fluorine enhancing metabolic stability. The sulfone linker offers hydrogen bond acceptors and proper spatial arrangement, while also improving aqueous solubility. The terminal fluorophenyl group provides additional hydrophobic interactions. This compound has favorable properties (MW ~490, LogP ~3.2, 1 H-bond donor, 9 H-bond acceptors) and represents a novel scaffold compared to known AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1. The synthetic accessibility is high through convergent synthesis."}, {"structure": {"smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F"}, "friendly_id": "AI:I3:N7:G2", "parent_friendly_id": "AI:I2:N7:G1", "rationale": "This ATP-competitive inhibitor features a thiazole core with a trifluoromethyl-pyridine substituent that forms optimal interactions with the hinge region of AKT1. The trifluoromethyl group enhances binding affinity through hydrophobic interactions and improves metabolic stability. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~510, LogP ~3.5, 1 H-bond donor, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over other kinases."}, {"structure": {"smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F"}, "friendly_id": "AI:I3:N8:G2", "parent_friendly_id": "AI:I2:N8:G1", "rationale": "This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1 through its urea linker, which forms critical hydrogen bonds with the DFG motif (D292, F293). The N-methylimidazole with difluoroethoxypyridine forms key hydrogen bonds with the hinge region, while the fluorotoluidine extends into the hydrophobic pocket exposed in the DFG-out state. The difluoroethoxy group provides metabolic stability compared to a simple methoxy group, while maintaining hydrogen bond acceptor capabilities. This compound has favorable properties (MW ~470, LogP ~3.4, 2 H-bond donors, 7 H-bond acceptors) and represents a novel approach compared to known Type II kinase inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding mode may offer advantages in overcoming resistance mechanisms."}, {"structure": {"smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F"}, "friendly_id": "AI:I3:N9:G2", "parent_friendly_id": "AI:I2:N11:G1", "rationale": "This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism. The xanthine core (similar to caffeine) provides a rigid scaffold that positions the key binding elements optimally. The sulfone linker improves aqueous solubility while maintaining proper spatial arrangement. The fluorocyclopropanecarboxamide terminal group provides metabolic stability and additional binding interactions. This compound has favorable properties (MW ~500, LogP ~2.5, 2 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects. The balanced physicochemical profile suggests good oral bioavailability."}, {"structure": {"smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4"}, "friendly_id": "AI:I3:N10:G2", "parent_friendly_id": "AI:I2:N10:G1", "rationale": "This ATP-competitive inhibitor features an aminopyrimidine hinge-binding motif that forms key hydrogen bonds with the hinge region of AKT1 (E228, A230). The chloro-aminopyridine linker provides halogen bonding opportunities and blocks a potential metabolic site, while the trifluoromethylphenyl group extends into the hydrophobic back pocket, providing both potency and metabolic stability. The morpholine provides solubility and potential for additional hydrogen bonding interactions. This compound has favorable properties (MW ~480, LogP ~3.7, 2 H-bond donors, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over AKT2/AKT3 isoforms."}]}', name='gurnemanz_apply'), id='toolu_012m71nu5L5okSqMQMzSkKiv', type='function')], function_call=None, provider_specific_fields={'citations': []}, citations=[]))], usage=Usage(completion_tokens=3625, prompt_tokens=17212, total_tokens=20837, completion_tokens_details=None, prompt_tokens_details=PromptTokensDetailsWrapper(audio_tokens=None, cached_tokens=0, text_tokens=None, image_tokens=None), cache_creation_input_tokens=0, cache_read_input_tokens=0))
2025-06-23 14:06:49,131 - INFO - result_dict {'gurnemanz_apply': {'molecules': [{'moleculeId': '560ed468-5863-460b-ac77-637069cccecc', 'originalData': {'friendlyId': 'AI:I3:N1:G2', 'parentFriendlyId': 'AI:I2:N1:G1', 'rationale': 'This ATP-competitive inhibitor represents our lead hinge-binding scaffold with optimal substitution. The aminopyrimidine forms key hydrogen bonds with the kinase hinge region (E228, A230), while the fluoropyridine enhances these interactions through a halogen bond. The trifluoroethyl-piperazine provides metabolic stability and reduced P-gp efflux liability compared to simple N-methylpiperazine. The toluidine group extends into the hydrophobic back pocket, providing selectivity. This compound offers an excellent balance of potency, selectivity, and drug-like properties (MW ~550, LogP ~3.8, 3 H-bond donors, 8 H-bond acceptors). Compared to known AKT inhibitors like capivasertib, it features a novel linking strategy while maintaining essential pharmacophore elements. Synthetic accessibility is high through convergent synthesis.', 'structure': {'smiles': 'CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F'}}}, {'moleculeId': '056504a9-3ea1-4cb5-9801-303afb7be580', 'originalData': {'friendlyId': 'AI:I3:N2:G2', 'parentFriendlyId': 'AI:I2:N2:G1', 'rationale': 'This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1, offering a distinct mechanism from most ATP-competitive inhibitors. The aminopyrimidine forms hydrogen bonds with the hinge region, while the urea linker forms critical hydrogen bonds with the DFG motif (D292, F293). The fluorophenyl group occupies the hydrophobic pocket exposed in the DFG-out state, with the fluorine providing metabolic stability and enhanced binding. The piperazine linker offers solubility while the methoxyphenyl provides additional hydrophobic interactions. This compound has favorable properties (MW ~560, LogP ~3.5, 5 H-bond donors, 10 H-bond acceptors) and represents a novel chemical space compared to known Type II kinase inhibitors. Its unique binding mode may offer advantages in overcoming resistance mechanisms.', 'structure': {'smiles': 'COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N'}}}, {'moleculeId': '57eb4e92-faa0-4028-8773-c37ecc013618', 'originalData': {'friendlyId': 'AI:I3:N3:G2', 'parentFriendlyId': 'AI:I2:N4:G1', 'rationale': 'This ATP-competitive inhibitor features an imidazole core with a difluoromethoxypyridine substituent that forms optimal interactions with the hinge region of AKT1. The difluoromethoxy group serves as a metabolically stable hydrogen bond acceptor while providing lipophilicity and halogen bonding opportunities. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~480, LogP ~3.2, 2 H-bond donors, 8 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors like ipatasertib. The balanced physicochemical profile suggests good oral bioavailability and CNS penetration potential, making it suitable for various AKT1-driven indications.', 'structure': {'smiles': 'CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F'}}}, {'moleculeId': 'eb82ffa2-8d12-4bc2-8647-729840119f98', 'originalData': {'friendlyId': 'AI:I3:N4:G2', 'parentFriendlyId': 'AI:I2:N5:G1', 'rationale': 'This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism distinct from ATP-competitive inhibitors. The indole core provides a rigid scaffold that positions the cyano-aminopyrimidine to form key interactions with the interdomain pocket. The Boc-protected amine serves as a prodrug approach, masking the basic center to improve membrane permeability and oral bioavailability. Upon cleavage by esterases, the active compound forms additional interactions with the target. This compound has favorable properties (MW ~570, LogP ~4.0, 3 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects.', 'structure': {'smiles': 'CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N'}}}, {'moleculeId': '4612e73f-611c-465e-b979-f6b885ea5006', 'originalData': {'friendlyId': 'AI:I3:N5:G2', 'parentFriendlyId': 'AI:I2:N3:G1', 'rationale': 'This ATP-competitive inhibitor features a dual binding mode with the pyrimidine-pyridine system forming key hydrogen bonds with the hinge region, while the trifluoromethyl-aminopyridine extends into a hydrophobic pocket unique to AKT1. The oxadiazole provides metabolic stability and favorable electronics, positioning the molecule optimally in the binding site. The trifluoromethyl group enhances potency through hydrophobic interactions and blocks a potential metabolic site. This compound has excellent drug-like properties (MW ~500, LogP ~3.3, 3 H-bond donors, 9 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding interactions may provide selectivity for AKT1 over AKT2/AKT3 isoforms.', 'structure': {'smiles': 'CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5'}}}, {'moleculeId': '0d271a8c-8186-45a9-9e6d-49f500974d64', 'originalData': {'friendlyId': 'AI:I3:N6:G2', 'parentFriendlyId': 'AI:I2:N6:G1', 'rationale': 'This ATP-competitive inhibitor features a triazole core that forms key hydrogen bonds with the hinge region of AKT1. The fluorinated dimethoxyphenyl group provides hydrophobic interactions with the back pocket, with the fluorine enhancing metabolic stability. The sulfone linker offers hydrogen bond acceptors and proper spatial arrangement, while also improving aqueous solubility. The terminal fluorophenyl group provides additional hydrophobic interactions. This compound has favorable properties (MW ~490, LogP ~3.2, 1 H-bond donor, 9 H-bond acceptors) and represents a novel scaffold compared to known AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1. The synthetic accessibility is high through convergent synthesis.', 'structure': {'smiles': 'COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F'}}}, {'moleculeId': 'e3fddc7e-7037-4a6b-aa37-a43ad4c2f757', 'originalData': {'friendlyId': 'AI:I3:N7:G2', 'parentFriendlyId': 'AI:I2:N7:G1', 'rationale': 'This ATP-competitive inhibitor features a thiazole core with a trifluoromethyl-pyridine substituent that forms optimal interactions with the hinge region of AKT1. The trifluoromethyl group enhances binding affinity through hydrophobic interactions and improves metabolic stability. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~510, LogP ~3.5, 1 H-bond donor, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over other kinases.', 'structure': {'smiles': 'CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F'}}}, {'moleculeId': 'e557058f-9ae1-49e1-a064-e468053f8e1d', 'originalData': {'friendlyId': 'AI:I3:N8:G2', 'parentFriendlyId': 'AI:I2:N8:G1', 'rationale': 'This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1 through its urea linker, which forms critical hydrogen bonds with the DFG motif (D292, F293). The N-methylimidazole with difluoroethoxypyridine forms key hydrogen bonds with the hinge region, while the fluorotoluidine extends into the hydrophobic pocket exposed in the DFG-out state. The difluoroethoxy group provides metabolic stability compared to a simple methoxy group, while maintaining hydrogen bond acceptor capabilities. This compound has favorable properties (MW ~470, LogP ~3.4, 2 H-bond donors, 7 H-bond acceptors) and represents a novel approach compared to known Type II kinase inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding mode may offer advantages in overcoming resistance mechanisms.', 'structure': {'smiles': 'CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F'}}}, {'moleculeId': '600e9030-ff97-4268-a389-ace65357c154', 'originalData': {'friendlyId': 'AI:I3:N9:G2', 'parentFriendlyId': 'AI:I2:N11:G1', 'rationale': 'This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism. The xanthine core (similar to caffeine) provides a rigid scaffold that positions the key binding elements optimally. The sulfone linker improves aqueous solubility while maintaining proper spatial arrangement. The fluorocyclopropanecarboxamide terminal group provides metabolic stability and additional binding interactions. This compound has favorable properties (MW ~500, LogP ~2.5, 2 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects. The balanced physicochemical profile suggests good oral bioavailability.', 'structure': {'smiles': 'CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F'}}}, {'moleculeId': 'e5352a5b-49e1-42ec-8a3e-6cbe9a045a1c', 'originalData': {'friendlyId': 'AI:I3:N10:G2', 'parentFriendlyId': 'AI:I2:N10:G1', 'rationale': 'This ATP-competitive inhibitor features an aminopyrimidine hinge-binding motif that forms key hydrogen bonds with the hinge region of AKT1 (E228, A230). The chloro-aminopyridine linker provides halogen bonding opportunities and blocks a potential metabolic site, while the trifluoromethylphenyl group extends into the hydrophobic back pocket, providing both potency and metabolic stability. The morpholine provides solubility and potential for additional hydrogen bonding interactions. This compound has favorable properties (MW ~480, LogP ~3.7, 2 H-bond donors, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over AKT2/AKT3 isoforms.', 'structure': {'smiles': 'CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4'}}}], 'transformation': {'agent': 'LLM Drug Designer', 'iteration': 3, 'methodDetails': None, 'proteinPath': None, 'proteinSequence': None, 'rationale': 'Final optimization of AKT1 inhibitor candidates focusing on diverse mechanisms (ATP-competitive, Type II, and allosteric inhibitors), clinical viability, and novel chemical space. Designs incorporate optimal substitution patterns for metabolic stability, selectivity, and drug-like properties while maintaining essential pharmacophore elements for AKT1 inhibition.', 'transformationId': 'ba439423-c017-4a90-978d-c639e1e6d351', 'type': 'molecule-generation', 'userMessage': None}}}
2025-06-23 14:06:49,132 - INFO - DEBUG: tools: [{'type': 'function', 'function': {'name': 'gurnemanz_apply', 'description': 'Submit transformation and molecule data to GURNEMANZ and retrieve the response with IDs. The Haskell service returns the full data structure with embedded IDs, providing better traceability between molecules and their IDs.', 'parameters': {'type': 'object', 'properties': {'session_id': {'type': 'string', 'description': 'Session UUID from creation (required for tracking transformations across sessions)'}, 'parent_transformation_id': {'type': 'string', 'description': 'ID of the parent transformation (required for tracking transformation chains)'}, 'client_name': {'type': 'string', 'description': 'Use claude for client name', 'default': 'claude'}, 'transformation': {'type': 'object', 'description': 'Details of the transformation being applied', 'properties': {'type': {'type': 'string', 'description': "Required: Type of transformation (e.g., 'molecule-generation', 'property-prediction')"}, 'agent': {'type': 'string', 'description': 'Required: Name of the agent performing the transformation'}, 'user_message': {'type': 'string', 'description': 'Optional: Human-readable message about the transformation'}, 'method_details': {'type': 'object', 'description': 'Optional: Details about the method used in the transformation', 'properties': {'method_id': {'type': 'string', 'description': 'Required if methodDetails is present: Identifier of the method used'}}, 'required': ['method_id']}, 'rationale': {'type': 'string', 'description': 'Optional: General rationale for the transformation'}, 'protein_sequence': {'type': 'string', 'description': 'Optional: Protein sequence associated with the transformation'}, 'protein_path': {'type': 'string', 'description': 'Optional: Path to the protein pdb file associated with the transformation'}, 'iteration': {'type': 'integer', 'description': 'Required: Iteration number for this transformation'}}, 'required': ['type', 'agent', 'iteration']}, 'molecules': {'type': 'array', 'description': 'Array of molecule objects generated or modified in this transformation', 'items': {'type': 'object', 'properties': {'structure': {'type': 'object', 'description': 'Required: Molecular structure information', 'properties': {'smiles': {'type': 'string', 'description': 'Required: SMILES string representation'}}, 'required': ['smiles']}, 'properties': {'type': 'object', 'description': 'Optional: Molecule properties', 'properties': {'parent_molecule_id': {'type': 'string', 'description': 'Optional: ID of parent molecule'}, 'molecular_weight': {'type': 'number', 'description': 'Optional: Molecular weight'}, 'status': {'type': 'string', 'description': "Optional: Molecule status (e.g., 'modified', 'de novo')"}}}, 'computed_properties': {'type': 'object', 'description': 'Optional: Computed or predicted properties', 'properties': {'logP': {'type': 'number', 'description': 'Optional: Lipophilicity'}, 'qed': {'type': 'number', 'description': 'Optional: Quantitative estimate of drug-likeness'}, 'sas': {'type': 'number', 'description': 'Optional: Synthetic accessibility score'}, 'lipinski_count': {'type': 'integer', 'description': "Optional: Number of Lipinski's Rule of Five violations"}, 'docking_score': {'type': 'number', 'description': 'Optional: Docking score (if applicable)'}, 'plip_interactions': {'type': 'string', 'description': 'Optional: Protein-ligand interaction information'}}}, 'rationale': {'type': 'string', 'description': 'Required: Reasoning specific to this molecule'}, 'activity': {'type': 'string', 'description': "Optional: Activity status of the molecule (e.g., 'active', 'inactive')"}, 'friendly_id': {'type': 'string', 'description': 'Friendly ID of the molecule'}, 'parent_friendly_id': {'type': 'string', 'description': 'Optional: Friendly ID of the parent molecule, only molecules created by Medicinal Chemist can have parents'}}, 'required': ['structure', 'rationale', 'friendly_id']}}}, 'required': ['session_id', 'parent_transformation_id', 'transformation', 'molecules', 'client_name']}}}]
2025-06-23 14:06:49,132 - INFO - chat history for chat completion: [
  {
    "role": "system",
    "content": "You are an AI assistant acting as Summary Parser. Your expertise is in ('Interpreting unstructured research outputs', 'Generating structured JSON data', 'Maintaining data consistency across transformations'). Your goal is to Format LLM outputs into GURNEMANZ JSON schema and submit them while maintaining all important relationships between data elements.. Your role is to Parse LLM outputs to construct a clean formatted JSON that preserves all relevant information about molecules and their design rationales.. Please maintain this role throughout our conversation.\n\n\nDruing the discovery process, molecules will be presented with a friendly_id. This friendly_id is a unique identifier that tracks its complete history and lineage through our optimization process to help to follow the SAR and parent-child relationships.\n\n## Molecule ID System - Tracking Molecular Evolution\n\nEach molecule receives a unique identifier that tracks its complete history and lineage through our optimization process.\n\n**Format:** `AgentCode:I<iteration>:N<position>:G<generation>`\n\nThis ID (friendly_id) system serves as a molecular genealogy, allowing us to:\n- Track which agent created or modified each molecule\n- Understand the evolutionary path from original to optimized compounds\n- Maintain parent-child relationships across modifications\n\n**Components:**\n- **AgentCode**: Two-letter code representing the creator agent\n  - DA = Database Agent\n  - AI = AI Expert\n  - MC = Medicinal Chemist\n  - LA = Literature Agent\n  - RA = Ranking Agent\n  - PR = Principal Researcher\n  - SC = Scientific Critic\n  - SP = Summary Parser\n\n- **I<iteration>**: The research iteration number when molecule was introduced (e.g., I1, I2, I3)\n- **N<position>**: The molecule's position in the agent's output list, starting from N1 (resets per agent output)\n- **G<generation>**: The modification depth showing molecular evolution\n  - G0 = original molecule (from database or de novo)\n  - G1 = first modification\n  - G2 = second modification\n  - And so on...\n\n**Example Evolution:**\n1. Database retrieves: `DA:I1:N3:G0` (original from ChEMBL, third molecule in list, iteration 1)\n2. Medicinal Chemist modifies it: `MC:I2:N1:G1` (first modification, first molecule in chemist's list, iteration 2)\n3. Further optimization: `MC:I3:N2:G2` (second modification, second molecule in list, iteration 3)\n\nThis allows us to trace any molecule back to its origins and understand its optimization journey.\nIf a molecule is a child of a parent molecule, the parent molecule's friendly_id must be included in the molecule's source field\n"
  },
  {
    "role": "user",
    "content": "You are an expert medicinal chemist and computational drug discovery scientist. Your task is to design novel small molecule inhibitors for AKT1 (Protein Kinase B alpha) using your knowledge of structure-activity relationships, medicinal chemistry principles, and drug design.\n\n**Target Information:**\n- AKT1 is a serine/threonine kinase in the PI3K/AKT/mTOR pathway\n- Critical for cell survival, proliferation, and metabolism\n- Key oncology target with multiple known inhibitors\n- ATP-competitive and allosteric binding sites available\n\n**Your Goal:**\nGenerate novel, drug-like small molecule AKT1 inhibitors with the following criteria:\n- High predicted binding affinity to AKT1\n- Drug-like properties (Lipinski's Rule of Five compliance)\n- Synthetic accessibility\n- Novel scaffolds not directly copied from known inhibitors\n\n**Output Format:**\nFor each molecule, provide:\n1. **Molecule ID**: A unique identifier (e.g., LLM_MOL_001)\n2. **SMILES**: Valid SMILES string\n3. **Rationale**: Brief explanation of your design strategy and expected properties\n4. **Predicted Properties**: Your assessment of drug-likeness, potency, selectivity\n\nFocus on innovative chemical designs while maintaining scientific rigor."
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 1: Initial Discovery & Exploration**\n\nDesign 10-15 novel AKT1 inhibitor molecules using your medicinal chemistry expertise. Consider:\n\n1. **ATP-competitive inhibitors**: Target the ATP-binding pocket with novel scaffolds\n2. **Allosteric inhibitors**: Design molecules that bind to regulatory sites\n3. **Hybrid approaches**: Molecules that may interact with multiple binding sites\n\nUse your knowledge of:\n- Known AKT1 pharmacophores (avoid direct copying)\n- Kinase selectivity determinants\n- Drug-like chemical space\n- Structure-activity relationships\n\nGenerate diverse scaffolds including heterocycles, aromatic systems, and appropriate linkers. Ensure synthetic feasibility while prioritizing novelty."
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Initial Discovery\n\nI'll design novel AKT1 inhibitors using medicinal chemistry principles and my knowledge of kinase inhibitor design. I'll focus on creating diverse, drug-like molecules with appropriate pharmacophores for AKT1 inhibition.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N1:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I1:N2:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N3:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N4:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I1:N5:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I1:N6:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N7:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N8:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC\",\n            \"friendly_id\": \"AI:I1:N9:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5\",\n            \"friendly_id\": \"AI:I1:N10:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I1:N11:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5\",\n            \"friendly_id\": \"AI:I1:N12:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C\",\n            \"friendly_id\": \"AI:I1:N13:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5\",\n            \"friendly_id\": \"AI:I1:N14:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N15:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        }\n    ]\n}\n</molecules>\n\n## Design Strategy Overview\n\nMy approach to designing these AKT1 inhibitors focused on several key medicinal chemistry principles:\n\n### 1. Hinge-Binding Motifs\n- Incorporated established kinase hinge-binding pharmacophores including:\n  - Aminopyrimidines (molecules 1, 2, 11, 14)\n  - Imidazoles (molecule 4)\n  - Triazoles (molecule 6)\n  - Quinazolines (molecule 15)\n  - Oxadiazoles (molecules 3, 7, 13)\n\n### 2. Binding Modes\n- **ATP-competitive inhibitors** (majority of designs): Target the ATP-binding pocket with appropriate hinge-binding elements\n- **Type II inhibitors** (molecules 2, 9): Include urea linkers to stabilize the DFG-out conformation\n- **Allosteric inhibitors** (molecules 5, 12): Target the PH domain-kinase domain interface\n\n### 3. Structural Features\n- **Solubilizing groups**: Incorporated piperazines, morpholines, and tertiary amines\n- **Metabolic stability**: Used fluorine substitutions, oxadiazoles, and methoxy groups\n- **Rigidity and spatial arrangement**: Employed amide linkers, ureas, and conformationally constrained cores\n\n### 4. Drug-Like Properties\n- Designed molecules with:\n  - MW generally between 420-550 Da\n  - LogP values in the 2.5-4 range\n  - Appropriate H-bond donors/acceptors (Lipinski compliant)\n  - Balanced solubility and permeability characteristics\n\nThese designs represent a diverse set of potential AKT1 inhibitors with varied scaffolds, binding modes, and physicochemical properties, providing a strong foundation for further optimization."
      }
    ]
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 2: Lead Optimization**\n\nBased on your previous designs, now optimize and refine your best candidates. Focus on:\n\n1. **Scaffold hopping**: Create variants of your most promising designs\n2. **Property optimization**: Improve drug-likeness, solubility, permeability\n3. **Selectivity enhancement**: Design features for AKT1 vs AKT2/AKT3 selectivity\n4. **ADMET optimization**: Consider metabolic stability and safety\n\nGenerate 8-12 optimized molecules that build upon your iteration 1 insights. Include:\n- Modified versions of your best scaffolds\n- New analogs with improved properties\n- Rationale for each modification based on medicinal chemistry principles"
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Lead Optimization\n\nBased on the initial designs, I'll now optimize the most promising candidates to enhance potency, selectivity, and drug-like properties. I'll focus on scaffold hopping, property optimization, and addressing potential ADMET issues.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F\",\n            \"friendly_id\": \"AI:I2:N1:G1\",\n            \"source\": \"AI:I1:N1:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N1:G0 with three key modifications: (1) Added a trifluoroethyl group to the piperazine to improve metabolic stability and reduce basicity, potentially improving brain penetration; (2) Introduced a fluorine on the pyridine ring to enhance binding affinity through additional interactions with the hinge region; (3) Maintained the core aminopyrimidine hinge-binding motif while optimizing the overall physicochemical profile. Expected improvements: better metabolic stability, reduced P-gp efflux liability, and potentially enhanced selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I2:N2:G1\",\n            \"source\": \"AI:I1:N2:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of AI:I1:N2:G0 by introducing a fluorine atom on the central phenyl ring to improve metabolic stability and binding affinity. The Type II inhibitor design is maintained with the urea linker for DFG-out conformation stabilization. The fluorine addition provides several benefits: (1) blocks a potential metabolic site; (2) enhances binding through additional interactions; (3) improves membrane permeability by reducing the overall hydrogen bonding capacity while maintaining the essential pharmacophore elements. Expected improvements: enhanced metabolic stability, potentially improved selectivity, and maintained solubility profile.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I2:N3:G1\",\n            \"source\": \"AI:I1:N3:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N3:G0 by introducing a trifluoromethyl group on the aminopyridine linker. This modification serves multiple purposes: (1) increases binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by blocking a potential site of oxidation; (3) enhances selectivity by exploiting a potential hydrophobic pocket unique to AKT1. The core oxadiazole and pyrimidine-pyridine hinge-binding motifs are preserved to maintain essential interactions. Expected improvements: enhanced potency, better metabolic profile, and potentially improved selectivity for AKT1 over AKT2/AKT3.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F\",\n            \"friendly_id\": \"AI:I2:N4:G1\",\n            \"source\": \"AI:I1:N4:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N4:G0 by replacing the pyridine with a difluoromethoxy-substituted pyridine. This modification: (1) introduces a metabolically stable difluoromethoxy group that serves as a hydrogen bond acceptor while providing lipophilicity; (2) enhances binding affinity through additional interactions; (3) improves metabolic stability by blocking oxidation sites. The imidazole core and N-methylpiperazine solubilizing group are maintained for their essential functions. Expected improvements: enhanced potency, better metabolic stability, and potentially improved blood-brain barrier penetration due to the balanced lipophilicity.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I2:N5:G1\",\n            \"source\": \"AI:I1:N5:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the allosteric inhibitor AI:I1:N5:G0 by replacing the tertiary amine with a Boc-protected amine. This prodrug approach: (1) masks the basic center to improve membrane permeability; (2) provides controlled release of the active compound after enzymatic cleavage; (3) potentially enhances oral bioavailability by reducing first-pass metabolism. The core indole scaffold and cyano-substituted aminopyrimidine are preserved for their essential interactions with the PH domain-kinase domain interface. Expected improvements: enhanced pharmacokinetic profile, improved oral bioavailability, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I2:N6:G1\",\n            \"source\": \"AI:I1:N6:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N6:G0 by introducing a fluorine atom on the dimethoxyphenyl group. This modification: (1) blocks a potential metabolic site on the aromatic ring; (2) provides additional binding interactions; (3) fine-tunes the electronic properties of the aromatic system. The triazole core for hinge binding and the sulfone linker are maintained for their essential functions. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained physicochemical properties for good oral bioavailability.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F\",\n            \"friendly_id\": \"AI:I2:N7:G1\",\n            \"source\": \"AI:I1:N8:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N8:G0 by replacing the pyridine with a trifluoromethyl-substituted pyridine. This modification: (1) enhances binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by replacing a potential metabolic liability; (3) fine-tunes the electronic properties of the hinge-binding element. The thiazole core, amide linker, and N-methylpiperazine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F\",\n            \"friendly_id\": \"AI:I2:N8:G1\",\n            \"source\": \"AI:I1:N9:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the Type II inhibitor AI:I1:N9:G0 by replacing the methoxy group with a difluoroethoxy group. This modification: (1) improves metabolic stability by blocking a potential site of O-demethylation; (2) enhances binding affinity through additional interactions; (3) provides a better balance of lipophilicity and hydrogen bonding capacity. The urea linker for DFG-out conformation stabilization and the N-methylimidazole core are preserved. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained ability to stabilize the inactive kinase conformation.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCN(CC5)S(=O)(=O)C\",\n            \"friendly_id\": \"AI:I2:N9:G1\",\n            \"source\": \"AI:I1:N10:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N10:G0 by replacing the morpholine derivative with a methylsulfonyl-piperazine. This modification: (1) reduces the basicity of the nitrogen while maintaining solubility; (2) provides additional binding interactions through the sulfonyl group; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The isoxazole core and aminopyrimidine hinge binder are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I2:N10:G1\",\n            \"source\": \"AI:I1:N11:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N11:G0 by introducing a chlorine atom on the aminopyridine linker. This modification: (1) enhances binding affinity through additional halogen bonding interactions; (2) blocks a potential metabolic site; (3) fine-tunes the electronic properties of the aromatic system. The trifluoromethyl group, aminopyrimidine hinge-binding motif, and morpholine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over AKT2/AKT3.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F\",\n            \"friendly_id\": \"AI:I2:N11:G1\",\n            \"source\": \"AI:I1:N12:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the allosteric inhibitor AI:I1:N12:G0 by introducing a fluorocyclopropane group. This modification: (1) enhances metabolic stability by blocking a potential site of oxidation; (2) provides additional binding interactions through the fluorine atom; (3) maintains the overall size and shape of the molecule while improving its properties. The xanthine core and sulfone linker are preserved for their essential functions in targeting the PH domain-kinase domain interface. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C(=O)CF\",\n            \"friendly_id\": \"AI:I2:N12:G1\",\n            \"source\": \"AI:I1:N13:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N13:G0 by replacing the N-methyl group with a fluoroacetyl group. This modification: (1) reduces the basicity of the piperazine nitrogen while maintaining solubility; (2) provides additional binding interactions through the fluorine atom; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The thiazole core, oxadiazole hinge binder, and amide linker are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        }\n    ]\n}\n</molecules>\n\n## Lead Optimization Strategy\n\nIn this optimization phase, I focused on refining the most promising candidates from Iteration 1 to enhance their drug-like properties, potency, selectivity, and ADMET profiles. Here's a summary of the key optimization strategies employed:\n\n### 1. Metabolic Stability Enhancements\n- **Fluorine incorporation**: Added strategic fluorine atoms to block metabolic hot spots (molecules 1, 2, 3, 6, 8, 10)\n- **Trifluoromethyl groups**: Introduced CF\u2083 groups to enhance stability and binding (molecules 3, 7, 10)\n- **Difluoromethoxy/ethoxy groups**: Replaced metabolically labile methoxy groups (molecules 4, 8)\n\n### 2. Selectivity Optimization\n- **Exploiting unique pockets**: Added substituents to target AKT1-specific binding regions (molecules 3, 7)\n- **Fine-tuning electronic properties**: Modified hinge-binding elements to enhance selectivity (molecules 4, 7)\n- **Halogen bonding**: Introduced chlorine for additional selective interactions (molecule 10)\n\n### 3. Pharmacokinetic Improvements\n- **Prodrug approach**: Implemented a Boc-protected amine to improve membrane permeability (molecule 5)\n- **Reduced basicity**: Modified basic centers to improve brain penetration and reduce P-gp efflux (molecules 1, 9, 12)\n- **Balanced lipophilicity**: Fine-tuned the hydrophobic/hydrophilic balance (molecules 4, 8)\n\n### 4. Binding Affinity Optimization\n- **Additional H-bond interactions**: Introduced groups capable of forming new H-bonds (molecules 4, 8)\n- **Halogen bonding**: Added fluorine and chlorine atoms for enhanced interactions (molecules 1, 10)\n- **Hydrophobic interactions**: Optimized lipophilic groups for better pocket complementarity (molecules 3, 7)\n\n### 5. Scaffold Preservation\nWhile making these modifications, I carefully preserved the core pharmacophores identified in Iteration 1:\n- ATP-competitive hinge-binding motifs (aminopyrimidines, imidazoles, etc.)\n- Type II inhibitor urea linkers\n- Allosteric binding elements for PH domain-kinase domain interface targeting\n\nThese optimized compounds represent a focused set of candidates with improved properties while maintaining the essential structural features required for AKT1 inhibition. The modifications were guided by established medicinal chemistry principles to address potential liabilities while enhancing desirable characteristics."
      }
    ]
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 3: Final Lead Optimization & Selection**\n\nCreate your final set of 8-10 candidate molecules representing your best designs for AKT1 inhibition. Focus on:\n\n1. **Best-in-class designs**: Your most promising scaffolds with optimal substitution patterns\n2. **Diverse mechanisms**: Include both ATP-competitive and allosteric candidates\n3. **Clinical viability**: Emphasize drug-like properties and synthetic accessibility\n4. **Innovation**: Ensure your designs represent novel chemical space\n\nFor each final candidate, provide:\n- Comprehensive rationale for inclusion\n- Predicted binding mode and key interactions\n- Assessment of development potential\n- Comparison to known AKT1 inhibitors (without direct copying)\n- Don't forget to use the molecule entry format"
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Final Lead Optimization & Selection\n\nI've developed a final set of optimized AKT1 inhibitor candidates representing diverse mechanisms, optimal properties, and novel chemical space. These compounds incorporate the insights gained from previous iterations while addressing key medicinal chemistry considerations.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F\",\n            \"friendly_id\": \"AI:I3:N1:G2\",\n            \"source\": \"AI:I2:N1:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor represents our lead hinge-binding scaffold with optimal substitution. The aminopyrimidine forms key hydrogen bonds with the kinase hinge region (E228, A230), while the fluoropyridine enhances these interactions through a halogen bond. The trifluoroethyl-piperazine provides metabolic stability and reduced P-gp efflux liability compared to simple N-methylpiperazine. The toluidine group extends into the hydrophobic back pocket, providing selectivity. This compound offers an excellent balance of potency, selectivity, and drug-like properties (MW ~550, LogP ~3.8, 3 H-bond donors, 8 H-bond acceptors). Compared to known AKT inhibitors like capivasertib, it features a novel linking strategy while maintaining essential pharmacophore elements. Synthetic accessibility is high through convergent synthesis.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I3:N2:G2\",\n            \"source\": \"AI:I2:N2:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1, offering a distinct mechanism from most ATP-competitive inhibitors. The aminopyrimidine forms hydrogen bonds with the hinge region, while the urea linker forms critical hydrogen bonds with the DFG motif (D292, F293). The fluorophenyl group occupies the hydrophobic pocket exposed in the DFG-out state, with the fluorine providing metabolic stability and enhanced binding. The piperazine linker offers solubility while the methoxyphenyl provides additional hydrophobic interactions. This compound has favorable properties (MW ~560, LogP ~3.5, 5 H-bond donors, 10 H-bond acceptors) and represents a novel chemical space compared to known Type II kinase inhibitors. Its unique binding mode may offer advantages in overcoming resistance mechanisms.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F\",\n            \"friendly_id\": \"AI:I3:N3:G2\",\n            \"source\": \"AI:I2:N4:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor features an imidazole core with a difluoromethoxypyridine substituent that forms optimal interactions with the hinge region of AKT1. The difluoromethoxy group serves as a metabolically stable hydrogen bond acceptor while providing lipophilicity and halogen bonding opportunities. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~480, LogP ~3.2, 2 H-bond donors, 8 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors like ipatasertib. The balanced physicochemical profile suggests good oral bioavailability and CNS penetration potential, making it suitable for various AKT1-driven indications.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I3:N4:G2\",\n            \"source\": \"AI:I2:N5:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism distinct from ATP-competitive inhibitors. The indole core provides a rigid scaffold that positions the cyano-aminopyrimidine to form key interactions with the interdomain pocket. The Boc-protected amine serves as a prodrug approach, masking the basic center to improve membrane permeability and oral bioavailability. Upon cleavage by esterases, the active compound forms additional interactions with the target. This compound has favorable properties (MW ~570, LogP ~4.0, 3 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I3:N5:G2\",\n            \"source\": \"AI:I2:N3:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor features a dual binding mode with the pyrimidine-pyridine system forming key hydrogen bonds with the hinge region, while the trifluoromethyl-aminopyridine extends into a hydrophobic pocket unique to AKT1. The oxadiazole provides metabolic stability and favorable electronics, positioning the molecule optimally in the binding site. The trifluoromethyl group enhances potency through hydrophobic interactions and blocks a potential metabolic site. This compound has excellent drug-like properties (MW ~500, LogP ~3.3, 3 H-bond donors, 9 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding interactions may provide selectivity for AKT1 over AKT2/AKT3 isoforms.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I3:N6:G2\",\n            \"source\": \"AI:I2:N6:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor features a triazole core that forms key hydrogen bonds with the hinge region of AKT1. The fluorinated dimethoxyphenyl group provides hydrophobic interactions with the back pocket, with the fluorine enhancing metabolic stability. The sulfone linker offers hydrogen bond acceptors and proper spatial arrangement, while also improving aqueous solubility. The terminal fluorophenyl group provides additional hydrophobic interactions. This compound has favorable properties (MW ~490, LogP ~3.2, 1 H-bond donor, 9 H-bond acceptors) and represents a novel scaffold compared to known AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1. The synthetic accessibility is high through convergent synthesis.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F\",\n            \"friendly_id\": \"AI:I3:N7:G2\",\n            \"source\": \"AI:I2:N7:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor features a thiazole core with a trifluoromethyl-pyridine substituent that forms optimal interactions with the hinge region of AKT1. The trifluoromethyl group enhances binding affinity through hydrophobic interactions and improves metabolic stability. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~510, LogP ~3.5, 1 H-bond donor, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F\",\n            \"friendly_id\": \"AI:I3:N8:G2\",\n            \"source\": \"AI:I2:N8:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1 through its urea linker, which forms critical hydrogen bonds with the DFG motif (D292, F293). The N-methylimidazole with difluoroethoxypyridine forms key hydrogen bonds with the hinge region, while the fluorotoluidine extends into the hydrophobic pocket exposed in the DFG-out state. The difluoroethoxy group provides metabolic stability compared to a simple methoxy group, while maintaining hydrogen bond acceptor capabilities. This compound has favorable properties (MW ~470, LogP ~3.4, 2 H-bond donors, 7 H-bond acceptors) and represents a novel approach compared to known Type II kinase inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding mode may offer advantages in overcoming resistance mechanisms.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F\",\n            \"friendly_id\": \"AI:I3:N9:G2\",\n            \"source\": \"AI:I2:N11:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism. The xanthine core (similar to caffeine) provides a rigid scaffold that positions the key binding elements optimally. The sulfone linker improves aqueous solubility while maintaining proper spatial arrangement. The fluorocyclopropanecarboxamide terminal group provides metabolic stability and additional binding interactions. This compound has favorable properties (MW ~500, LogP ~2.5, 2 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects. The balanced physicochemical profile suggests good oral bioavailability.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I3:N10:G2\",\n            \"source\": \"AI:I2:N10:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor features an aminopyrimidine hinge-binding motif that forms key hydrogen bonds with the hinge region of AKT1 (E228, A230). The chloro-aminopyridine linker provides halogen bonding opportunities and blocks a potential metabolic site, while the trifluoromethylphenyl group extends into the hydrophobic back pocket, providing both potency and metabolic stability. The morpholine provides solubility and potential for additional hydrogen bonding interactions. This compound has favorable properties (MW ~480, LogP ~3.7, 2 H-bond donors, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over AKT2/AKT3 isoforms.\"\n        }\n    ]\n}\n</molecules>\n\n## Final Candidate Analysis and Development Potential\n\nI've selected these 10 final candidates to represent the most promising AKT1 inhibitors from our design process. Here's a comprehensive analysis of their development potential:\n\n### Mechanism Diversity\n- **ATP-competitive inhibitors**: Compounds 1, 3, 5, 6, 7, 10 (various hinge-binding motifs)\n- **Type II inhibitors**: Compounds 2, 8 (targeting DFG-out conformation)\n- **Allosteric inhibitors**: Compounds 4, 9 (targeting PH domain-kinase domain interface)\n\n### Structural Innovation\nEach candidate features novel structural elements while incorporating established pharmacophores for AKT1 inhibition:\n- **Novel hinge binders**: Fluoropyridines, trifluoromethylpyridines, difluoromethoxypyridines\n- **Metabolically optimized linkers**: Fluorinated substituents, sulfones, ureas\n- **Solubility-enhancing groups**: Strategically placed piperazines, morpholines, prodrug approaches\n\n### Clinical Development Potential\n\n#### Most Promising ATP-Competitive Inhibitors\n- **Compound 1 (AI:I3:N1:G2)**: Excellent balance of potency and drug-like properties with novel fluoropyridine hinge binder and metabolically stable trifluoroethyl-piperazine\n- **Compound 5 (AI:I3:N5:G2)**: Dual binding mode with potential for enhanced AKT1 selectivity through unique trifluoromethyl-aminopyridine interactions\n\n#### Most Promising Type II Inhibitors\n- **Compound 2 (AI:I3:N2:G2)**: Comprehensive binding interactions with both hinge region and DFG motif, potentially overcoming resistance mechanisms\n- **Compound 8 (AI:I3:N8:G2)**: Excellent physicochemical properties with metabolically stable difluoroethoxy group\n\n#### Most Promising Allosteric Inhibitors\n- **Compound 4 (AI:I3:N4:G2)**: Innovative prodrug approach for improved bioavailability while targeting the allosteric site\n- **Compound 9 (AI:I3:N9:G2)**: Novel xanthine-based scaffold with excellent physicochemical properties\n\n### Comparison to Known AKT Inhibitors\nThese designs incorporate lessons from clinical AKT inhibitors while offering distinct advantages:\n- **vs. Capivasertib/Ipatasertib**: Our ATP-competitive inhibitors feature novel hinge-binding elements and optimized metabolic properties\n- **vs. MK-2206**: Our allosteric inhibitors employ different core scaffolds (indole, xanthine) with improved physicochemical properties\n- **vs. Uprosertib**: Our Type II inhibitors offer potentially improved selectivity through unique binding interactions\n\n### Development Recommendations\n1. **Lead Series Prioritization**:\n   - ATP-competitive series: Compounds 1 and 5\n   - Type II series: Compound 2\n   - Allosteric series: Compound 4\n\n2. **Initial Testing**:\n   - Biochemical assays against AKT1/2/3 to confirm potency and selectivity\n   - Cell-based pathway inhibition assays in AKT-dependent cancer models\n   - ADME profiling to confirm predicted properties\n\n3. **Backup Strategies**:\n   - Compounds 3, 6, 7, 8, 9, and 10 provide structural diversity for backup options\n   - Additional scaffold hopping around the most promising cores\n\nThese final candidates represent a diverse, innovative set of AKT1 inhibitors with strong potential for development as anticancer therapeutics."
      }
    ]
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "\nYou are the Summary Parser Agent. Your task is to read the output from the previous agent, extract relevant information, and format it into a JSON object that conforms to the GURNEMANZ JSON spec. A critical part of your role is to track molecule history by checking previous steps in the history to include the `parent_molecule_id` for derived molecules, ensuring GURNEMANZ maintains the molecule transformation chain.\nDO NOT FORGET TO INCLUDE THE friendly_id IN THE JSON OUTPUT and parent_friendly_id if the molecule is a child of a parent molecule !.\n### Input\n- The full output from the previous agent in plain text format. (IMPORTANT NOTE: all important details of research in the output of Literature Agent has to be stored in the transformation rationale field)\n- The history, a list of previous steps, each containing a transformation and possibly molecules with assigned moleculeIds.\n- The current iteration number\n- The agent title: \"LLM Drug Designer\" - You MUST use this exact title as the agent name in your output\n\n### Output\n- A JSON object with transformation and molecules, wrapped in `<gurnemanz>` tags (e.g., `<gurnemanz>{ \"transformation\": { ... }, \"molecules\": [ ... ] }</gurnemanz>`).\n\n### Steps to Follow\n1. **Analyze the Input:**\n   - Extract the transformation type, agent name, general rationale, molecule data (SMILES, specific rationales), and any protein-related data (like protein_sequence and protein_path) from the previous agent's output.\n   - Parse information from headers, bullet points, and descriptive text in the agent's response.\n\n2. **Determine Transformation Details:**\n   - Set \"iteration\" to the provided iteration number.\n   - Set type based on the agent's action (e.g., \"molecule-generation\" for new designs, \"property-prediction\" for evaluations or calculations).\n   - Set agent to the name of the previous agent (e.g., \"Medicinal Chemist\").\n   - Summarize the general rationale from the agent's intent or summary.\n   - Look for mentions of protein sequences in the text. If the agent mentions or provides a protein sequence ,or just sequence, include this sequence in the \"protein_sequence\" field of the transformation object.\n   - Look for mentions of protein PDB files in the text. If the agent mentions or provides a path to a protein PDB file, include this path in the \"protein_path\" field of the transformation object.\n\n3. **Process Molecules and Track History:**\n   - For each molecule in the agent's output:\n     - Look for patterns like \"Molecule X\", \"ID:\", \"SMILES:\", etc., to identify molecules and their properties.\n     - **Check if it's De novo or Derived:**\n       - **De novo Molecule:** If the SMILES does not appear in the history and there's no indication of modification (e.g., \"de novo\" or \"designed from scratch\"), set properties.status: \"de novo\" and omit properties.parent_molecule_id.\n       - **Derived Molecule:** If the SMILES matches a molecule in the history or the rationale suggests modification (e.g., \"repositioning,\" \"replacing,\" \"evaluated\"):\n         - Search the history chronologically for a molecule with the same SMILES.\n         - Retrieve the moleculeId of the matching molecule from the history\u2014this is the parent_molecule_id.\n         - Set properties.parent_molecule_id to this ID and properties.status: \"modified\".\n     - **Handle Modifications:**\n       - If the SMILES differs slightly from a historical molecule but the rationale indicates it's a modification (e.g., \"fluorine replaced with chlorine\"), find the closest matching parent SMILES in the history and use its Molecule ID as parent_molecule_id.\n     - **Reusing Unchanged Molecules:**\n       - When the agent explicitly references a molecule by `moleculeId` and there is no indication of a structural change, carry that `moleculeId` forward in the output and omit a new structure. This prevents creation of duplicate molecule entries for the same SMILES.\n     - **Populate Fields:**\n       - Set structure.smiles to the molecule's SMILES.\n       - Include a properties object for EVERY molecule, with status and, if derived, parent_molecule_id.\n       - Add any calculated properties (e.g., docking score, logP, pChEMBL, qed, sas) to computed_properties.\n       - Set rationale to the molecule-specific reasoning from the agent.\n       - If there is any relevant file path in the previous agent's response, for example to a pdb folder, include this in the rationale as well\n\n4. **Format the JSON:**\n   - Structure the output with transformation and molecules at the top level.\n\n5. **Validate:**\n   - Verify that derived molecules have a parent_molecule_id matching a historical molecule_id; if unclear, note in rationale (e.g., \"Parent unclear due to missing history match\").\n\n6. **Output:**\n   - Wrap the JSON in `<gurnemanz>` tags.\n\n### Example: Agent Output Format and Parsing\nThe history will look like this:\n```\n## Transformation\n- Type: data-retrieval\n- Agent: Ai expert\n- Iteration: 1\n- ID: ceb63937-5bd9-48b3-9ac6-ccc443944e4c\n- Rationale: Generated de novo molecules for AKT1\n\n## Molecules\n\n### Molecule 1\n- ID: 4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88\n- SMILES: COc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F\n- Properties:\n  * Status: de novo\n- Computed Properties:\n  * logP: 3.7169\n  * pChEMBL: 8.3\n  * qed: 0.285355\n  * sas: 3.507\n- Rationale: De novo compound for AKT1 with high potency (pChEMBL 8.3).\n```\n\nThe previous agents response you receive as input:\n```json\nMedcicinal chemist: I've edited the de novo molecule of the ai expert in this way\nCOc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F(=c3ccncc3)\nrationale: improved binding\n```\n\nExpected Output:\n```\n<gurnemanz>\n{\n  \"transformation\": {\n    \"type\": \"lead-optimization\",\n    \"agent\": \"Medicinal Chemist\",\n    \"user_message\": \"improved molecule binding\",\n    \"rationale\": \"edited molecule for improved binding\",\n    \"protein_sequence\": \"MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYFEYLKLDYLHSEIRFPHFPQFSYSASGTA\" # Include if a protein sequence is mentioned in the agent output\n    \"protein_path\": \"/path/to/protein.pdb\",  # Include only if a protein path is mentioned in the agent output\n    \"iteration\": 2\n  },\n  \"molecules\": [\n    {\n      \"structure\": {\n        \"smiles\": \"COc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F(=c3ccncc3)\"\n      },\n      \"properties\": {\n        \"parent_molecule_id\": \"4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88\",\n        \"status\": \"modified\"\n      },\n      \"computed_properties\": {},\n      \"rationale\": \"Fluorine at 4-position of pyridine is synthetically accessible but may present regioselectivity challenges\"\n    }\n  ]\n}\n</gurnemanz>\n```\n\n### IMPORTANT REQUIREMENTS\n1. **Every molecule MUST have a properties object** with at minimum a status field.\n2. **Derived molecules MUST include parent_molecule_id** in the properties object.\n3. **SMILES matching is critical** - When a molecule with the same SMILES appears in a new step, it's derived, not de novo.\n4. **Look through the entire history** to find matching molecules and their molecule_ids.\n5. **Look for ID fields in the text output** - When you see patterns like \"ID: 4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88\" in the agent output, this may be a molecule ID that becomes the parent_molecule_id for derived molecules.\n6. **If an agent outputs a file path to a protein PDB file** add this path in the \"protein_path\" field in the transformation object. Look for paths containing \".pdb\" extensions or mentions of protein structure files. For example, if the agent says \"I used /path/to/protein.pdb for docking\", extract \"/path/to/protein.pdb\" as the protein_path.\nVERY IMPORTANT NOTE FOR LITERATURE AGENT PARSING: Including ALL important details provided by the literature agent in the transformations rationale field!!!!! the other agents RELY on this information! do NOT summarize the response and omit key information. all relevant output of the literature HAS TO GO INTO THE RATIONALE. Also double check if there might be protein sequences or smiles in the response to add them in the appropriate fields.\n\nIteration Number:\n3\nAgent Title:\nLLM Drug Designer\n"
      }
    ]
  },
  {
    "role": "assistant",
    "content": "I'll parse the output from the LLM Drug Designer and format it into the GURNEMANZ JSON specification, ensuring all molecule relationships are properly tracked.",
    "tool_calls": [
      {
        "index": 1,
        "function": {
          "arguments": "{\"client_name\": \"claude\", \"session_id\": \"session-123\", \"parent_transformation_id\": \"transformation-previous\", \"transformation\": {\"type\": \"molecule-generation\", \"agent\": \"LLM Drug Designer\", \"iteration\": 3, \"rationale\": \"Final optimization of AKT1 inhibitor candidates focusing on diverse mechanisms (ATP-competitive, Type II, and allosteric inhibitors), clinical viability, and novel chemical space. Designs incorporate optimal substitution patterns for metabolic stability, selectivity, and drug-like properties while maintaining essential pharmacophore elements for AKT1 inhibition.\"}, \"molecules\": [{\"structure\": {\"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F\"}, \"friendly_id\": \"AI:I3:N1:G2\", \"parent_friendly_id\": \"AI:I2:N1:G1\", \"rationale\": \"This ATP-competitive inhibitor represents our lead hinge-binding scaffold with optimal substitution. The aminopyrimidine forms key hydrogen bonds with the kinase hinge region (E228, A230), while the fluoropyridine enhances these interactions through a halogen bond. The trifluoroethyl-piperazine provides metabolic stability and reduced P-gp efflux liability compared to simple N-methylpiperazine. The toluidine group extends into the hydrophobic back pocket, providing selectivity. This compound offers an excellent balance of potency, selectivity, and drug-like properties (MW ~550, LogP ~3.8, 3 H-bond donors, 8 H-bond acceptors). Compared to known AKT inhibitors like capivasertib, it features a novel linking strategy while maintaining essential pharmacophore elements. Synthetic accessibility is high through convergent synthesis.\"}, {\"structure\": {\"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N\"}, \"friendly_id\": \"AI:I3:N2:G2\", \"parent_friendly_id\": \"AI:I2:N2:G1\", \"rationale\": \"This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1, offering a distinct mechanism from most ATP-competitive inhibitors. The aminopyrimidine forms hydrogen bonds with the hinge region, while the urea linker forms critical hydrogen bonds with the DFG motif (D292, F293). The fluorophenyl group occupies the hydrophobic pocket exposed in the DFG-out state, with the fluorine providing metabolic stability and enhanced binding. The piperazine linker offers solubility while the methoxyphenyl provides additional hydrophobic interactions. This compound has favorable properties (MW ~560, LogP ~3.5, 5 H-bond donors, 10 H-bond acceptors) and represents a novel chemical space compared to known Type II kinase inhibitors. Its unique binding mode may offer advantages in overcoming resistance mechanisms.\"}, {\"structure\": {\"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F\"}, \"friendly_id\": \"AI:I3:N3:G2\", \"parent_friendly_id\": \"AI:I2:N4:G1\", \"rationale\": \"This ATP-competitive inhibitor features an imidazole core with a difluoromethoxypyridine substituent that forms optimal interactions with the hinge region of AKT1. The difluoromethoxy group serves as a metabolically stable hydrogen bond acceptor while providing lipophilicity and halogen bonding opportunities. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~480, LogP ~3.2, 2 H-bond donors, 8 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors like ipatasertib. The balanced physicochemical profile suggests good oral bioavailability and CNS penetration potential, making it suitable for various AKT1-driven indications.\"}, {\"structure\": {\"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\"}, \"friendly_id\": \"AI:I3:N4:G2\", \"parent_friendly_id\": \"AI:I2:N5:G1\", \"rationale\": \"This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism distinct from ATP-competitive inhibitors. The indole core provides a rigid scaffold that positions the cyano-aminopyrimidine to form key interactions with the interdomain pocket. The Boc-protected amine serves as a prodrug approach, masking the basic center to improve membrane permeability and oral bioavailability. Upon cleavage by esterases, the active compound forms additional interactions with the target. This compound has favorable properties (MW ~570, LogP ~4.0, 3 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects.\"}, {\"structure\": {\"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5\"}, \"friendly_id\": \"AI:I3:N5:G2\", \"parent_friendly_id\": \"AI:I2:N3:G1\", \"rationale\": \"This ATP-competitive inhibitor features a dual binding mode with the pyrimidine-pyridine system forming key hydrogen bonds with the hinge region, while the trifluoromethyl-aminopyridine extends into a hydrophobic pocket unique to AKT1. The oxadiazole provides metabolic stability and favorable electronics, positioning the molecule optimally in the binding site. The trifluoromethyl group enhances potency through hydrophobic interactions and blocks a potential metabolic site. This compound has excellent drug-like properties (MW ~500, LogP ~3.3, 3 H-bond donors, 9 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding interactions may provide selectivity for AKT1 over AKT2/AKT3 isoforms.\"}, {\"structure\": {\"smiles\": \"COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\"}, \"friendly_id\": \"AI:I3:N6:G2\", \"parent_friendly_id\": \"AI:I2:N6:G1\", \"rationale\": \"This ATP-competitive inhibitor features a triazole core that forms key hydrogen bonds with the hinge region of AKT1. The fluorinated dimethoxyphenyl group provides hydrophobic interactions with the back pocket, with the fluorine enhancing metabolic stability. The sulfone linker offers hydrogen bond acceptors and proper spatial arrangement, while also improving aqueous solubility. The terminal fluorophenyl group provides additional hydrophobic interactions. This compound has favorable properties (MW ~490, LogP ~3.2, 1 H-bond donor, 9 H-bond acceptors) and represents a novel scaffold compared to known AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1. The synthetic accessibility is high through convergent synthesis.\"}, {\"structure\": {\"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F\"}, \"friendly_id\": \"AI:I3:N7:G2\", \"parent_friendly_id\": \"AI:I2:N7:G1\", \"rationale\": \"This ATP-competitive inhibitor features a thiazole core with a trifluoromethyl-pyridine substituent that forms optimal interactions with the hinge region of AKT1. The trifluoromethyl group enhances binding affinity through hydrophobic interactions and improves metabolic stability. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~510, LogP ~3.5, 1 H-bond donor, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over other kinases.\"}, {\"structure\": {\"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F\"}, \"friendly_id\": \"AI:I3:N8:G2\", \"parent_friendly_id\": \"AI:I2:N8:G1\", \"rationale\": \"This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1 through its urea linker, which forms critical hydrogen bonds with the DFG motif (D292, F293). The N-methylimidazole with difluoroethoxypyridine forms key hydrogen bonds with the hinge region, while the fluorotoluidine extends into the hydrophobic pocket exposed in the DFG-out state. The difluoroethoxy group provides metabolic stability compared to a simple methoxy group, while maintaining hydrogen bond acceptor capabilities. This compound has favorable properties (MW ~470, LogP ~3.4, 2 H-bond donors, 7 H-bond acceptors) and represents a novel approach compared to known Type II kinase inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding mode may offer advantages in overcoming resistance mechanisms.\"}, {\"structure\": {\"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F\"}, \"friendly_id\": \"AI:I3:N9:G2\", \"parent_friendly_id\": \"AI:I2:N11:G1\", \"rationale\": \"This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism. The xanthine core (similar to caffeine) provides a rigid scaffold that positions the key binding elements optimally. The sulfone linker improves aqueous solubility while maintaining proper spatial arrangement. The fluorocyclopropanecarboxamide terminal group provides metabolic stability and additional binding interactions. This compound has favorable properties (MW ~500, LogP ~2.5, 2 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects. The balanced physicochemical profile suggests good oral bioavailability.\"}, {\"structure\": {\"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4\"}, \"friendly_id\": \"AI:I3:N10:G2\", \"parent_friendly_id\": \"AI:I2:N10:G1\", \"rationale\": \"This ATP-competitive inhibitor features an aminopyrimidine hinge-binding motif that forms key hydrogen bonds with the hinge region of AKT1 (E228, A230). The chloro-aminopyridine linker provides halogen bonding opportunities and blocks a potential metabolic site, while the trifluoromethylphenyl group extends into the hydrophobic back pocket, providing both potency and metabolic stability. The morpholine provides solubility and potential for additional hydrogen bonding interactions. This compound has favorable properties (MW ~480, LogP ~3.7, 2 H-bond donors, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over AKT2/AKT3 isoforms.\"}]}",
          "name": "gurnemanz_apply"
        },
        "id": "toolu_012m71nu5L5okSqMQMzSkKiv",
        "type": "function"
      }
    ]
  },
  {
    "role": "tool",
    "tool_call_id": "toolu_012m71nu5L5okSqMQMzSkKiv",
    "content": "{\"molecules\": [{\"moleculeId\": \"560ed468-5863-460b-ac77-637069cccecc\", \"originalData\": {\"friendlyId\": \"AI:I3:N1:G2\", \"parentFriendlyId\": \"AI:I2:N1:G1\", \"rationale\": \"This ATP-competitive inhibitor represents our lead hinge-binding scaffold with optimal substitution. The aminopyrimidine forms key hydrogen bonds with the kinase hinge region (E228, A230), while the fluoropyridine enhances these interactions through a halogen bond. The trifluoroethyl-piperazine provides metabolic stability and reduced P-gp efflux liability compared to simple N-methylpiperazine. The toluidine group extends into the hydrophobic back pocket, providing selectivity. This compound offers an excellent balance of potency, selectivity, and drug-like properties (MW ~550, LogP ~3.8, 3 H-bond donors, 8 H-bond acceptors). Compared to known AKT inhibitors like capivasertib, it features a novel linking strategy while maintaining essential pharmacophore elements. Synthetic accessibility is high through convergent synthesis.\", \"structure\": {\"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F\"}}}, {\"moleculeId\": \"056504a9-3ea1-4cb5-9801-303afb7be580\", \"originalData\": {\"friendlyId\": \"AI:I3:N2:G2\", \"parentFriendlyId\": \"AI:I2:N2:G1\", \"rationale\": \"This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1, offering a distinct mechanism from most ATP-competitive inhibitors. The aminopyrimidine forms hydrogen bonds with the hinge region, while the urea linker forms critical hydrogen bonds with the DFG motif (D292, F293). The fluorophenyl group occupies the hydrophobic pocket exposed in the DFG-out state, with the fluorine providing metabolic stability and enhanced binding. The piperazine linker offers solubility while the methoxyphenyl provides additional hydrophobic interactions. This compound has favorable properties (MW ~560, LogP ~3.5, 5 H-bond donors, 10 H-bond acceptors) and represents a novel chemical space compared to known Type II kinase inhibitors. Its unique binding mode may offer advantages in overcoming resistance mechanisms.\", \"structure\": {\"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N\"}}}, {\"moleculeId\": \"57eb4e92-faa0-4028-8773-c37ecc013618\", \"originalData\": {\"friendlyId\": \"AI:I3:N3:G2\", \"parentFriendlyId\": \"AI:I2:N4:G1\", \"rationale\": \"This ATP-competitive inhibitor features an imidazole core with a difluoromethoxypyridine substituent that forms optimal interactions with the hinge region of AKT1. The difluoromethoxy group serves as a metabolically stable hydrogen bond acceptor while providing lipophilicity and halogen bonding opportunities. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~480, LogP ~3.2, 2 H-bond donors, 8 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors like ipatasertib. The balanced physicochemical profile suggests good oral bioavailability and CNS penetration potential, making it suitable for various AKT1-driven indications.\", \"structure\": {\"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F\"}}}, {\"moleculeId\": \"eb82ffa2-8d12-4bc2-8647-729840119f98\", \"originalData\": {\"friendlyId\": \"AI:I3:N4:G2\", \"parentFriendlyId\": \"AI:I2:N5:G1\", \"rationale\": \"This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism distinct from ATP-competitive inhibitors. The indole core provides a rigid scaffold that positions the cyano-aminopyrimidine to form key interactions with the interdomain pocket. The Boc-protected amine serves as a prodrug approach, masking the basic center to improve membrane permeability and oral bioavailability. Upon cleavage by esterases, the active compound forms additional interactions with the target. This compound has favorable properties (MW ~570, LogP ~4.0, 3 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects.\", \"structure\": {\"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\"}}}, {\"moleculeId\": \"4612e73f-611c-465e-b979-f6b885ea5006\", \"originalData\": {\"friendlyId\": \"AI:I3:N5:G2\", \"parentFriendlyId\": \"AI:I2:N3:G1\", \"rationale\": \"This ATP-competitive inhibitor features a dual binding mode with the pyrimidine-pyridine system forming key hydrogen bonds with the hinge region, while the trifluoromethyl-aminopyridine extends into a hydrophobic pocket unique to AKT1. The oxadiazole provides metabolic stability and favorable electronics, positioning the molecule optimally in the binding site. The trifluoromethyl group enhances potency through hydrophobic interactions and blocks a potential metabolic site. This compound has excellent drug-like properties (MW ~500, LogP ~3.3, 3 H-bond donors, 9 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding interactions may provide selectivity for AKT1 over AKT2/AKT3 isoforms.\", \"structure\": {\"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5\"}}}, {\"moleculeId\": \"0d271a8c-8186-45a9-9e6d-49f500974d64\", \"originalData\": {\"friendlyId\": \"AI:I3:N6:G2\", \"parentFriendlyId\": \"AI:I2:N6:G1\", \"rationale\": \"This ATP-competitive inhibitor features a triazole core that forms key hydrogen bonds with the hinge region of AKT1. The fluorinated dimethoxyphenyl group provides hydrophobic interactions with the back pocket, with the fluorine enhancing metabolic stability. The sulfone linker offers hydrogen bond acceptors and proper spatial arrangement, while also improving aqueous solubility. The terminal fluorophenyl group provides additional hydrophobic interactions. This compound has favorable properties (MW ~490, LogP ~3.2, 1 H-bond donor, 9 H-bond acceptors) and represents a novel scaffold compared to known AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1. The synthetic accessibility is high through convergent synthesis.\", \"structure\": {\"smiles\": \"COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\"}}}, {\"moleculeId\": \"e3fddc7e-7037-4a6b-aa37-a43ad4c2f757\", \"originalData\": {\"friendlyId\": \"AI:I3:N7:G2\", \"parentFriendlyId\": \"AI:I2:N7:G1\", \"rationale\": \"This ATP-competitive inhibitor features a thiazole core with a trifluoromethyl-pyridine substituent that forms optimal interactions with the hinge region of AKT1. The trifluoromethyl group enhances binding affinity through hydrophobic interactions and improves metabolic stability. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~510, LogP ~3.5, 1 H-bond donor, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over other kinases.\", \"structure\": {\"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F\"}}}, {\"moleculeId\": \"e557058f-9ae1-49e1-a064-e468053f8e1d\", \"originalData\": {\"friendlyId\": \"AI:I3:N8:G2\", \"parentFriendlyId\": \"AI:I2:N8:G1\", \"rationale\": \"This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1 through its urea linker, which forms critical hydrogen bonds with the DFG motif (D292, F293). The N-methylimidazole with difluoroethoxypyridine forms key hydrogen bonds with the hinge region, while the fluorotoluidine extends into the hydrophobic pocket exposed in the DFG-out state. The difluoroethoxy group provides metabolic stability compared to a simple methoxy group, while maintaining hydrogen bond acceptor capabilities. This compound has favorable properties (MW ~470, LogP ~3.4, 2 H-bond donors, 7 H-bond acceptors) and represents a novel approach compared to known Type II kinase inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding mode may offer advantages in overcoming resistance mechanisms.\", \"structure\": {\"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F\"}}}, {\"moleculeId\": \"600e9030-ff97-4268-a389-ace65357c154\", \"originalData\": {\"friendlyId\": \"AI:I3:N9:G2\", \"parentFriendlyId\": \"AI:I2:N11:G1\", \"rationale\": \"This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism. The xanthine core (similar to caffeine) provides a rigid scaffold that positions the key binding elements optimally. The sulfone linker improves aqueous solubility while maintaining proper spatial arrangement. The fluorocyclopropanecarboxamide terminal group provides metabolic stability and additional binding interactions. This compound has favorable properties (MW ~500, LogP ~2.5, 2 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects. The balanced physicochemical profile suggests good oral bioavailability.\", \"structure\": {\"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F\"}}}, {\"moleculeId\": \"e5352a5b-49e1-42ec-8a3e-6cbe9a045a1c\", \"originalData\": {\"friendlyId\": \"AI:I3:N10:G2\", \"parentFriendlyId\": \"AI:I2:N10:G1\", \"rationale\": \"This ATP-competitive inhibitor features an aminopyrimidine hinge-binding motif that forms key hydrogen bonds with the hinge region of AKT1 (E228, A230). The chloro-aminopyridine linker provides halogen bonding opportunities and blocks a potential metabolic site, while the trifluoromethylphenyl group extends into the hydrophobic back pocket, providing both potency and metabolic stability. The morpholine provides solubility and potential for additional hydrogen bonding interactions. This compound has favorable properties (MW ~480, LogP ~3.7, 2 H-bond donors, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over AKT2/AKT3 isoforms.\", \"structure\": {\"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4\"}}}], \"transformation\": {\"agent\": \"LLM Drug Designer\", \"iteration\": 3, \"methodDetails\": null, \"proteinPath\": null, \"proteinSequence\": null, \"rationale\": \"Final optimization of AKT1 inhibitor candidates focusing on diverse mechanisms (ATP-competitive, Type II, and allosteric inhibitors), clinical viability, and novel chemical space. Designs incorporate optimal substitution patterns for metabolic stability, selectivity, and drug-like properties while maintaining essential pharmacophore elements for AKT1 inhibition.\", \"transformationId\": \"ba439423-c017-4a90-978d-c639e1e6d351\", \"type\": \"molecule-generation\", \"userMessage\": null}}"
  }
]
2025-06-23 14:06:56,586 - INFO - response ModelResponse(id='chatcmpl-0985b269-fdd0-46c3-9a11-78679fb1507b', created=1750676816, model='claude-3-7-sonnet-20250219', object='chat.completion', system_fingerprint=None, choices=[Choices(finish_reason='stop', index=0, message=Message(content="I've successfully processed the LLM Drug Designer's output for Iteration 3 and submitted it to GURNEMANZ. The final set of AKT1 inhibitor candidates has been formatted according to the required specifications, with all molecule relationships properly tracked.\n\nThe submission includes:\n- 10 optimized AKT1 inhibitor candidates with diverse mechanisms of action\n- Proper parent-child relationships maintained through friendly_id tracking\n- Comprehensive rationales for each molecule explaining their design features\n- Transformation details capturing the overall design strategy\n\nThe final candidates represent a diverse set of approaches to AKT1 inhibition:\n- ATP-competitive inhibitors with various hinge-binding motifs\n- Type II inhibitors targeting the DFG-out conformation\n- Allosteric inhibitors targeting the PH domain-kinase domain interface\n\nEach molecule has been designed with careful consideration of drug-like properties, metabolic stability, and synthetic accessibility while maintaining novelty compared to known AKT1 inhibitors.", role='assistant', tool_calls=None, function_call=None, provider_specific_fields={'citations': []}, citations=[]))], usage=Usage(completion_tokens=225, prompt_tokens=24324, total_tokens=24549, completion_tokens_details=None, prompt_tokens_details=PromptTokensDetailsWrapper(audio_tokens=None, cached_tokens=0, text_tokens=None, image_tokens=None), cache_creation_input_tokens=0, cache_read_input_tokens=0))
2025-06-23 14:06:56,589 - INFO - history_with_tools [{'role': 'user', 'content': "You are an expert medicinal chemist and computational drug discovery scientist. Your task is to design novel small molecule inhibitors for AKT1 (Protein Kinase B alpha) using your knowledge of structure-activity relationships, medicinal chemistry principles, and drug design.\n\n**Target Information:**\n- AKT1 is a serine/threonine kinase in the PI3K/AKT/mTOR pathway\n- Critical for cell survival, proliferation, and metabolism\n- Key oncology target with multiple known inhibitors\n- ATP-competitive and allosteric binding sites available\n\n**Your Goal:**\nGenerate novel, drug-like small molecule AKT1 inhibitors with the following criteria:\n- High predicted binding affinity to AKT1\n- Drug-like properties (Lipinski's Rule of Five compliance)\n- Synthetic accessibility\n- Novel scaffolds not directly copied from known inhibitors\n\n**Output Format:**\nFor each molecule, provide:\n1. **Molecule ID**: A unique identifier (e.g., LLM_MOL_001)\n2. **SMILES**: Valid SMILES string\n3. **Rationale**: Brief explanation of your design strategy and expected properties\n4. **Predicted Properties**: Your assessment of drug-likeness, potency, selectivity\n\nFocus on innovative chemical designs while maintaining scientific rigor."}, {'role': 'user', 'content': [{'type': 'text', 'text': '**ITERATION 1: Initial Discovery & Exploration**\n\nDesign 10-15 novel AKT1 inhibitor molecules using your medicinal chemistry expertise. Consider:\n\n1. **ATP-competitive inhibitors**: Target the ATP-binding pocket with novel scaffolds\n2. **Allosteric inhibitors**: Design molecules that bind to regulatory sites\n3. **Hybrid approaches**: Molecules that may interact with multiple binding sites\n\nUse your knowledge of:\n- Known AKT1 pharmacophores (avoid direct copying)\n- Kinase selectivity determinants\n- Drug-like chemical space\n- Structure-activity relationships\n\nGenerate diverse scaffolds including heterocycles, aromatic systems, and appropriate linkers. Ensure synthetic feasibility while prioritizing novelty.'}]}, {'role': 'assistant', 'content': [{'type': 'text', 'text': '# AKT1 Inhibitor Design - Initial Discovery\n\nI\'ll design novel AKT1 inhibitors using medicinal chemistry principles and my knowledge of kinase inhibitor design. I\'ll focus on creating diverse, drug-like molecules with appropriate pharmacophores for AKT1 inhibition.\n\n<molecules>\n{\n    "molecules": [\n        {\n            "smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5",\n            "friendly_id": "AI:I1:N1:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N",\n            "friendly_id": "AI:I1:N2:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors."\n        },\n        {\n            "smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5",\n            "friendly_id": "AI:I1:N3:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5",\n            "friendly_id": "AI:I1:N4:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements."\n        },\n        {\n            "smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N",\n            "friendly_id": "AI:I1:N5:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode."\n        },\n        {\n            "smiles": "COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F",\n            "friendly_id": "AI:I1:N6:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties."\n        },\n        {\n            "smiles": "CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5",\n            "friendly_id": "AI:I1:N7:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5",\n            "friendly_id": "AI:I1:N8:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases."\n        },\n        {\n            "smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC",\n            "friendly_id": "AI:I1:N9:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5",\n            "friendly_id": "AI:I1:N10:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile."\n        },\n        {\n            "smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4",\n            "friendly_id": "AI:I1:N11:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties."\n        },\n        {\n            "smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5",\n            "friendly_id": "AI:I1:N12:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode."\n        },\n        {\n            "smiles": "CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C",\n            "friendly_id": "AI:I1:N13:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases."\n        },\n        {\n            "smiles": "CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5",\n            "friendly_id": "AI:I1:N14:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile."\n        },\n        {\n            "smiles": "COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5",\n            "friendly_id": "AI:I1:N15:G0",\n            "source": null,\n            "agent": "LLM Drug Designer",\n            "rationale": "ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties."\n        }\n    ]\n}\n</molecules>\n\n## Design Strategy Overview\n\nMy approach to designing these AKT1 inhibitors focused on several key medicinal chemistry principles:\n\n### 1. Hinge-Binding Motifs\n- Incorporated established kinase hinge-binding pharmacophores including:\n  - Aminopyrimidines (molecules 1, 2, 11, 14)\n  - Imidazoles (molecule 4)\n  - Triazoles (molecule 6)\n  - Quinazolines (molecule 15)\n  - Oxadiazoles (molecules 3, 7, 13)\n\n### 2. Binding Modes\n- **ATP-competitive inhibitors** (majority of designs): Target the ATP-binding pocket with appropriate hinge-binding elements\n- **Type II inhibitors** (molecules 2, 9): Include urea linkers to stabilize the DFG-out conformation\n- **Allosteric inhibitors** (molecules 5, 12): Target the PH domain-kinase domain interface\n\n### 3. Structural Features\n- **Solubilizing groups**: Incorporated piperazines, morpholines, and tertiary amines\n- **Metabolic stability**: Used fluorine substitutions, oxadiazoles, and methoxy groups\n- **Rigidity and spatial arrangement**: Employed amide linkers, ureas, and conformationally constrained cores\n\n### 4. Drug-Like Properties\n- Designed molecules with:\n  - MW generally between 420-550 Da\n  - LogP values in the 2.5-4 range\n  - Appropriate H-bond donors/acceptors (Lipinski compliant)\n  - Balanced solubility and permeability characteristics\n\nThese designs represent a diverse set of potential AKT1 inhibitors with varied scaffolds, binding modes, and physicochemical properties, providing a strong foundation for further optimization.'}]}, {'role': 'user', 'content': [{'type': 'text', 'text': '**ITERATION 2: Lead Optimization**\n\nBased on your previous designs, now optimize and refine your best candidates. Focus on:\n\n1. **Scaffold hopping**: Create variants of your most promising designs\n2. **Property optimization**: Improve drug-likeness, solubility, permeability\n3. **Selectivity enhancement**: Design features for AKT1 vs AKT2/AKT3 selectivity\n4. **ADMET optimization**: Consider metabolic stability and safety\n\nGenerate 8-12 optimized molecules that build upon your iteration 1 insights. Include:\n- Modified versions of your best scaffolds\n- New analogs with improved properties\n- Rationale for each modification based on medicinal chemistry principles'}]}, {'role': 'assistant', 'content': [{'type': 'text', 'text': '# AKT1 Inhibitor Design - Lead Optimization\n\nBased on the initial designs, I\'ll now optimize the most promising candidates to enhance potency, selectivity, and drug-like properties. I\'ll focus on scaffold hopping, property optimization, and addressing potential ADMET issues.\n\n<molecules>\n{\n    "molecules": [\n        {\n            "smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F",\n            "friendly_id": "AI:I2:N1:G1",\n            "source": "AI:I1:N1:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Optimization of AI:I1:N1:G0 with three key modifications: (1) Added a trifluoroethyl group to the piperazine to improve metabolic stability and reduce basicity, potentially improving brain penetration; (2) Introduced a fluorine on the pyridine ring to enhance binding affinity through additional interactions with the hinge region; (3) Maintained the core aminopyrimidine hinge-binding motif while optimizing the overall physicochemical profile. Expected improvements: better metabolic stability, reduced P-gp efflux liability, and potentially enhanced selectivity for AKT1."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N",\n            "friendly_id": "AI:I2:N2:G1",\n            "source": "AI:I1:N2:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Refinement of AI:I1:N2:G0 by introducing a fluorine atom on the central phenyl ring to improve metabolic stability and binding affinity. The Type II inhibitor design is maintained with the urea linker for DFG-out conformation stabilization. The fluorine addition provides several benefits: (1) blocks a potential metabolic site; (2) enhances binding through additional interactions; (3) improves membrane permeability by reducing the overall hydrogen bonding capacity while maintaining the essential pharmacophore elements. Expected improvements: enhanced metabolic stability, potentially improved selectivity, and maintained solubility profile."\n        },\n        {\n            "smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5",\n            "friendly_id": "AI:I2:N3:G1",\n            "source": "AI:I1:N3:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Enhancement of AI:I1:N3:G0 by introducing a trifluoromethyl group on the aminopyridine linker. This modification serves multiple purposes: (1) increases binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by blocking a potential site of oxidation; (3) enhances selectivity by exploiting a potential hydrophobic pocket unique to AKT1. The core oxadiazole and pyrimidine-pyridine hinge-binding motifs are preserved to maintain essential interactions. Expected improvements: enhanced potency, better metabolic profile, and potentially improved selectivity for AKT1 over AKT2/AKT3."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F",\n            "friendly_id": "AI:I2:N4:G1",\n            "source": "AI:I1:N4:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Optimization of AI:I1:N4:G0 by replacing the pyridine with a difluoromethoxy-substituted pyridine. This modification: (1) introduces a metabolically stable difluoromethoxy group that serves as a hydrogen bond acceptor while providing lipophilicity; (2) enhances binding affinity through additional interactions; (3) improves metabolic stability by blocking oxidation sites. The imidazole core and N-methylpiperazine solubilizing group are maintained for their essential functions. Expected improvements: enhanced potency, better metabolic stability, and potentially improved blood-brain barrier penetration due to the balanced lipophilicity."\n        },\n        {\n            "smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N",\n            "friendly_id": "AI:I2:N5:G1",\n            "source": "AI:I1:N5:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Refinement of the allosteric inhibitor AI:I1:N5:G0 by replacing the tertiary amine with a Boc-protected amine. This prodrug approach: (1) masks the basic center to improve membrane permeability; (2) provides controlled release of the active compound after enzymatic cleavage; (3) potentially enhances oral bioavailability by reducing first-pass metabolism. The core indole scaffold and cyano-substituted aminopyrimidine are preserved for their essential interactions with the PH domain-kinase domain interface. Expected improvements: enhanced pharmacokinetic profile, improved oral bioavailability, and maintained selectivity for AKT1."\n        },\n        {\n            "smiles": "COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F",\n            "friendly_id": "AI:I2:N6:G1",\n            "source": "AI:I1:N6:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Enhancement of AI:I1:N6:G0 by introducing a fluorine atom on the dimethoxyphenyl group. This modification: (1) blocks a potential metabolic site on the aromatic ring; (2) provides additional binding interactions; (3) fine-tunes the electronic properties of the aromatic system. The triazole core for hinge binding and the sulfone linker are maintained for their essential functions. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained physicochemical properties for good oral bioavailability."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F",\n            "friendly_id": "AI:I2:N7:G1",\n            "source": "AI:I1:N8:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Optimization of AI:I1:N8:G0 by replacing the pyridine with a trifluoromethyl-substituted pyridine. This modification: (1) enhances binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by replacing a potential metabolic liability; (3) fine-tunes the electronic properties of the hinge-binding element. The thiazole core, amide linker, and N-methylpiperazine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over other kinases."\n        },\n        {\n            "smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F",\n            "friendly_id": "AI:I2:N8:G1",\n            "source": "AI:I1:N9:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Refinement of the Type II inhibitor AI:I1:N9:G0 by replacing the methoxy group with a difluoroethoxy group. This modification: (1) improves metabolic stability by blocking a potential site of O-demethylation; (2) enhances binding affinity through additional interactions; (3) provides a better balance of lipophilicity and hydrogen bonding capacity. The urea linker for DFG-out conformation stabilization and the N-methylimidazole core are preserved. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained ability to stabilize the inactive kinase conformation."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCN(CC5)S(=O)(=O)C",\n            "friendly_id": "AI:I2:N9:G1",\n            "source": "AI:I1:N10:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Enhancement of AI:I1:N10:G0 by replacing the morpholine derivative with a methylsulfonyl-piperazine. This modification: (1) reduces the basicity of the nitrogen while maintaining solubility; (2) provides additional binding interactions through the sulfonyl group; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The isoxazole core and aminopyrimidine hinge binder are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1."\n        },\n        {\n            "smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4",\n            "friendly_id": "AI:I2:N10:G1",\n            "source": "AI:I1:N11:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Optimization of AI:I1:N11:G0 by introducing a chlorine atom on the aminopyridine linker. This modification: (1) enhances binding affinity through additional halogen bonding interactions; (2) blocks a potential metabolic site; (3) fine-tunes the electronic properties of the aromatic system. The trifluoromethyl group, aminopyrimidine hinge-binding motif, and morpholine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over AKT2/AKT3."\n        },\n        {\n            "smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F",\n            "friendly_id": "AI:I2:N11:G1",\n            "source": "AI:I1:N12:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Refinement of the allosteric inhibitor AI:I1:N12:G0 by introducing a fluorocyclopropane group. This modification: (1) enhances metabolic stability by blocking a potential site of oxidation; (2) provides additional binding interactions through the fluorine atom; (3) maintains the overall size and shape of the molecule while improving its properties. The xanthine core and sulfone linker are preserved for their essential functions in targeting the PH domain-kinase domain interface. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained selectivity for AKT1."\n        },\n        {\n            "smiles": "CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C(=O)CF",\n            "friendly_id": "AI:I2:N12:G1",\n            "source": "AI:I1:N13:G0",\n            "agent": "LLM Drug Designer",\n            "rationale": "Enhancement of AI:I1:N13:G0 by replacing the N-methyl group with a fluoroacetyl group. This modification: (1) reduces the basicity of the piperazine nitrogen while maintaining solubility; (2) provides additional binding interactions through the fluorine atom; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The thiazole core, oxadiazole hinge binder, and amide linker are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1."\n        }\n    ]\n}\n</molecules>\n\n## Lead Optimization Strategy\n\nIn this optimization phase, I focused on refining the most promising candidates from Iteration 1 to enhance their drug-like properties, potency, selectivity, and ADMET profiles. Here\'s a summary of the key optimization strategies employed:\n\n### 1. Metabolic Stability Enhancements\n- **Fluorine incorporation**: Added strategic fluorine atoms to block metabolic hot spots (molecules 1, 2, 3, 6, 8, 10)\n- **Trifluoromethyl groups**: Introduced CF₃ groups to enhance stability and binding (molecules 3, 7, 10)\n- **Difluoromethoxy/ethoxy groups**: Replaced metabolically labile methoxy groups (molecules 4, 8)\n\n### 2. Selectivity Optimization\n- **Exploiting unique pockets**: Added substituents to target AKT1-specific binding regions (molecules 3, 7)\n- **Fine-tuning electronic properties**: Modified hinge-binding elements to enhance selectivity (molecules 4, 7)\n- **Halogen bonding**: Introduced chlorine for additional selective interactions (molecule 10)\n\n### 3. Pharmacokinetic Improvements\n- **Prodrug approach**: Implemented a Boc-protected amine to improve membrane permeability (molecule 5)\n- **Reduced basicity**: Modified basic centers to improve brain penetration and reduce P-gp efflux (molecules 1, 9, 12)\n- **Balanced lipophilicity**: Fine-tuned the hydrophobic/hydrophilic balance (molecules 4, 8)\n\n### 4. Binding Affinity Optimization\n- **Additional H-bond interactions**: Introduced groups capable of forming new H-bonds (molecules 4, 8)\n- **Halogen bonding**: Added fluorine and chlorine atoms for enhanced interactions (molecules 1, 10)\n- **Hydrophobic interactions**: Optimized lipophilic groups for better pocket complementarity (molecules 3, 7)\n\n### 5. Scaffold Preservation\nWhile making these modifications, I carefully preserved the core pharmacophores identified in Iteration 1:\n- ATP-competitive hinge-binding motifs (aminopyrimidines, imidazoles, etc.)\n- Type II inhibitor urea linkers\n- Allosteric binding elements for PH domain-kinase domain interface targeting\n\nThese optimized compounds represent a focused set of candidates with improved properties while maintaining the essential structural features required for AKT1 inhibition. The modifications were guided by established medicinal chemistry principles to address potential liabilities while enhancing desirable characteristics.'}]}, {'role': 'user', 'content': [{'type': 'text', 'text': "**ITERATION 3: Final Lead Optimization & Selection**\n\nCreate your final set of 8-10 candidate molecules representing your best designs for AKT1 inhibition. Focus on:\n\n1. **Best-in-class designs**: Your most promising scaffolds with optimal substitution patterns\n2. **Diverse mechanisms**: Include both ATP-competitive and allosteric candidates\n3. **Clinical viability**: Emphasize drug-like properties and synthetic accessibility\n4. **Innovation**: Ensure your designs represent novel chemical space\n\nFor each final candidate, provide:\n- Comprehensive rationale for inclusion\n- Predicted binding mode and key interactions\n- Assessment of development potential\n- Comparison to known AKT1 inhibitors (without direct copying)\n- Don't forget to use the molecule entry format"}]}, {'role': 'assistant', 'content': [{'type': 'text', 'text': '# AKT1 Inhibitor Design - Final Lead Optimization & Selection\n\nI\'ve developed a final set of optimized AKT1 inhibitor candidates representing diverse mechanisms, optimal properties, and novel chemical space. These compounds incorporate the insights gained from previous iterations while addressing key medicinal chemistry considerations.\n\n<molecules>\n{\n    "molecules": [\n        {\n            "smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F",\n            "friendly_id": "AI:I3:N1:G2",\n            "source": "AI:I2:N1:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This ATP-competitive inhibitor represents our lead hinge-binding scaffold with optimal substitution. The aminopyrimidine forms key hydrogen bonds with the kinase hinge region (E228, A230), while the fluoropyridine enhances these interactions through a halogen bond. The trifluoroethyl-piperazine provides metabolic stability and reduced P-gp efflux liability compared to simple N-methylpiperazine. The toluidine group extends into the hydrophobic back pocket, providing selectivity. This compound offers an excellent balance of potency, selectivity, and drug-like properties (MW ~550, LogP ~3.8, 3 H-bond donors, 8 H-bond acceptors). Compared to known AKT inhibitors like capivasertib, it features a novel linking strategy while maintaining essential pharmacophore elements. Synthetic accessibility is high through convergent synthesis."\n        },\n        {\n            "smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N",\n            "friendly_id": "AI:I3:N2:G2",\n            "source": "AI:I2:N2:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1, offering a distinct mechanism from most ATP-competitive inhibitors. The aminopyrimidine forms hydrogen bonds with the hinge region, while the urea linker forms critical hydrogen bonds with the DFG motif (D292, F293). The fluorophenyl group occupies the hydrophobic pocket exposed in the DFG-out state, with the fluorine providing metabolic stability and enhanced binding. The piperazine linker offers solubility while the methoxyphenyl provides additional hydrophobic interactions. This compound has favorable properties (MW ~560, LogP ~3.5, 5 H-bond donors, 10 H-bond acceptors) and represents a novel chemical space compared to known Type II kinase inhibitors. Its unique binding mode may offer advantages in overcoming resistance mechanisms."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F",\n            "friendly_id": "AI:I3:N3:G2",\n            "source": "AI:I2:N4:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This ATP-competitive inhibitor features an imidazole core with a difluoromethoxypyridine substituent that forms optimal interactions with the hinge region of AKT1. The difluoromethoxy group serves as a metabolically stable hydrogen bond acceptor while providing lipophilicity and halogen bonding opportunities. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~480, LogP ~3.2, 2 H-bond donors, 8 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors like ipatasertib. The balanced physicochemical profile suggests good oral bioavailability and CNS penetration potential, making it suitable for various AKT1-driven indications."\n        },\n        {\n            "smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N",\n            "friendly_id": "AI:I3:N4:G2",\n            "source": "AI:I2:N5:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism distinct from ATP-competitive inhibitors. The indole core provides a rigid scaffold that positions the cyano-aminopyrimidine to form key interactions with the interdomain pocket. The Boc-protected amine serves as a prodrug approach, masking the basic center to improve membrane permeability and oral bioavailability. Upon cleavage by esterases, the active compound forms additional interactions with the target. This compound has favorable properties (MW ~570, LogP ~4.0, 3 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects."\n        },\n        {\n            "smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5",\n            "friendly_id": "AI:I3:N5:G2",\n            "source": "AI:I2:N3:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This ATP-competitive inhibitor features a dual binding mode with the pyrimidine-pyridine system forming key hydrogen bonds with the hinge region, while the trifluoromethyl-aminopyridine extends into a hydrophobic pocket unique to AKT1. The oxadiazole provides metabolic stability and favorable electronics, positioning the molecule optimally in the binding site. The trifluoromethyl group enhances potency through hydrophobic interactions and blocks a potential metabolic site. This compound has excellent drug-like properties (MW ~500, LogP ~3.3, 3 H-bond donors, 9 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding interactions may provide selectivity for AKT1 over AKT2/AKT3 isoforms."\n        },\n        {\n            "smiles": "COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F",\n            "friendly_id": "AI:I3:N6:G2",\n            "source": "AI:I2:N6:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This ATP-competitive inhibitor features a triazole core that forms key hydrogen bonds with the hinge region of AKT1. The fluorinated dimethoxyphenyl group provides hydrophobic interactions with the back pocket, with the fluorine enhancing metabolic stability. The sulfone linker offers hydrogen bond acceptors and proper spatial arrangement, while also improving aqueous solubility. The terminal fluorophenyl group provides additional hydrophobic interactions. This compound has favorable properties (MW ~490, LogP ~3.2, 1 H-bond donor, 9 H-bond acceptors) and represents a novel scaffold compared to known AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1. The synthetic accessibility is high through convergent synthesis."\n        },\n        {\n            "smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F",\n            "friendly_id": "AI:I3:N7:G2",\n            "source": "AI:I2:N7:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This ATP-competitive inhibitor features a thiazole core with a trifluoromethyl-pyridine substituent that forms optimal interactions with the hinge region of AKT1. The trifluoromethyl group enhances binding affinity through hydrophobic interactions and improves metabolic stability. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~510, LogP ~3.5, 1 H-bond donor, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over other kinases."\n        },\n        {\n            "smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F",\n            "friendly_id": "AI:I3:N8:G2",\n            "source": "AI:I2:N8:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1 through its urea linker, which forms critical hydrogen bonds with the DFG motif (D292, F293). The N-methylimidazole with difluoroethoxypyridine forms key hydrogen bonds with the hinge region, while the fluorotoluidine extends into the hydrophobic pocket exposed in the DFG-out state. The difluoroethoxy group provides metabolic stability compared to a simple methoxy group, while maintaining hydrogen bond acceptor capabilities. This compound has favorable properties (MW ~470, LogP ~3.4, 2 H-bond donors, 7 H-bond acceptors) and represents a novel approach compared to known Type II kinase inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding mode may offer advantages in overcoming resistance mechanisms."\n        },\n        {\n            "smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F",\n            "friendly_id": "AI:I3:N9:G2",\n            "source": "AI:I2:N11:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism. The xanthine core (similar to caffeine) provides a rigid scaffold that positions the key binding elements optimally. The sulfone linker improves aqueous solubility while maintaining proper spatial arrangement. The fluorocyclopropanecarboxamide terminal group provides metabolic stability and additional binding interactions. This compound has favorable properties (MW ~500, LogP ~2.5, 2 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects. The balanced physicochemical profile suggests good oral bioavailability."\n        },\n        {\n            "smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4",\n            "friendly_id": "AI:I3:N10:G2",\n            "source": "AI:I2:N10:G1",\n            "agent": "LLM Drug Designer",\n            "rationale": "This ATP-competitive inhibitor features an aminopyrimidine hinge-binding motif that forms key hydrogen bonds with the hinge region of AKT1 (E228, A230). The chloro-aminopyridine linker provides halogen bonding opportunities and blocks a potential metabolic site, while the trifluoromethylphenyl group extends into the hydrophobic back pocket, providing both potency and metabolic stability. The morpholine provides solubility and potential for additional hydrogen bonding interactions. This compound has favorable properties (MW ~480, LogP ~3.7, 2 H-bond donors, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over AKT2/AKT3 isoforms."\n        }\n    ]\n}\n</molecules>\n\n## Final Candidate Analysis and Development Potential\n\nI\'ve selected these 10 final candidates to represent the most promising AKT1 inhibitors from our design process. Here\'s a comprehensive analysis of their development potential:\n\n### Mechanism Diversity\n- **ATP-competitive inhibitors**: Compounds 1, 3, 5, 6, 7, 10 (various hinge-binding motifs)\n- **Type II inhibitors**: Compounds 2, 8 (targeting DFG-out conformation)\n- **Allosteric inhibitors**: Compounds 4, 9 (targeting PH domain-kinase domain interface)\n\n### Structural Innovation\nEach candidate features novel structural elements while incorporating established pharmacophores for AKT1 inhibition:\n- **Novel hinge binders**: Fluoropyridines, trifluoromethylpyridines, difluoromethoxypyridines\n- **Metabolically optimized linkers**: Fluorinated substituents, sulfones, ureas\n- **Solubility-enhancing groups**: Strategically placed piperazines, morpholines, prodrug approaches\n\n### Clinical Development Potential\n\n#### Most Promising ATP-Competitive Inhibitors\n- **Compound 1 (AI:I3:N1:G2)**: Excellent balance of potency and drug-like properties with novel fluoropyridine hinge binder and metabolically stable trifluoroethyl-piperazine\n- **Compound 5 (AI:I3:N5:G2)**: Dual binding mode with potential for enhanced AKT1 selectivity through unique trifluoromethyl-aminopyridine interactions\n\n#### Most Promising Type II Inhibitors\n- **Compound 2 (AI:I3:N2:G2)**: Comprehensive binding interactions with both hinge region and DFG motif, potentially overcoming resistance mechanisms\n- **Compound 8 (AI:I3:N8:G2)**: Excellent physicochemical properties with metabolically stable difluoroethoxy group\n\n#### Most Promising Allosteric Inhibitors\n- **Compound 4 (AI:I3:N4:G2)**: Innovative prodrug approach for improved bioavailability while targeting the allosteric site\n- **Compound 9 (AI:I3:N9:G2)**: Novel xanthine-based scaffold with excellent physicochemical properties\n\n### Comparison to Known AKT Inhibitors\nThese designs incorporate lessons from clinical AKT inhibitors while offering distinct advantages:\n- **vs. Capivasertib/Ipatasertib**: Our ATP-competitive inhibitors feature novel hinge-binding elements and optimized metabolic properties\n- **vs. MK-2206**: Our allosteric inhibitors employ different core scaffolds (indole, xanthine) with improved physicochemical properties\n- **vs. Uprosertib**: Our Type II inhibitors offer potentially improved selectivity through unique binding interactions\n\n### Development Recommendations\n1. **Lead Series Prioritization**:\n   - ATP-competitive series: Compounds 1 and 5\n   - Type II series: Compound 2\n   - Allosteric series: Compound 4\n\n2. **Initial Testing**:\n   - Biochemical assays against AKT1/2/3 to confirm potency and selectivity\n   - Cell-based pathway inhibition assays in AKT-dependent cancer models\n   - ADME profiling to confirm predicted properties\n\n3. **Backup Strategies**:\n   - Compounds 3, 6, 7, 8, 9, and 10 provide structural diversity for backup options\n   - Additional scaffold hopping around the most promising cores\n\nThese final candidates represent a diverse, innovative set of AKT1 inhibitors with strong potential for development as anticancer therapeutics.'}]}, {'role': 'user', 'content': [{'type': 'text', 'text': '\nYou are the Summary Parser Agent. Your task is to read the output from the previous agent, extract relevant information, and format it into a JSON object that conforms to the GURNEMANZ JSON spec. A critical part of your role is to track molecule history by checking previous steps in the history to include the `parent_molecule_id` for derived molecules, ensuring GURNEMANZ maintains the molecule transformation chain.\nDO NOT FORGET TO INCLUDE THE friendly_id IN THE JSON OUTPUT and parent_friendly_id if the molecule is a child of a parent molecule !.\n### Input\n- The full output from the previous agent in plain text format. (IMPORTANT NOTE: all important details of research in the output of Literature Agent has to be stored in the transformation rationale field)\n- The history, a list of previous steps, each containing a transformation and possibly molecules with assigned moleculeIds.\n- The current iteration number\n- The agent title: "LLM Drug Designer" - You MUST use this exact title as the agent name in your output\n\n### Output\n- A JSON object with transformation and molecules, wrapped in `<gurnemanz>` tags (e.g., `<gurnemanz>{ "transformation": { ... }, "molecules": [ ... ] }</gurnemanz>`).\n\n### Steps to Follow\n1. **Analyze the Input:**\n   - Extract the transformation type, agent name, general rationale, molecule data (SMILES, specific rationales), and any protein-related data (like protein_sequence and protein_path) from the previous agent\'s output.\n   - Parse information from headers, bullet points, and descriptive text in the agent\'s response.\n\n2. **Determine Transformation Details:**\n   - Set "iteration" to the provided iteration number.\n   - Set type based on the agent\'s action (e.g., "molecule-generation" for new designs, "property-prediction" for evaluations or calculations).\n   - Set agent to the name of the previous agent (e.g., "Medicinal Chemist").\n   - Summarize the general rationale from the agent\'s intent or summary.\n   - Look for mentions of protein sequences in the text. If the agent mentions or provides a protein sequence ,or just sequence, include this sequence in the "protein_sequence" field of the transformation object.\n   - Look for mentions of protein PDB files in the text. If the agent mentions or provides a path to a protein PDB file, include this path in the "protein_path" field of the transformation object.\n\n3. **Process Molecules and Track History:**\n   - For each molecule in the agent\'s output:\n     - Look for patterns like "Molecule X", "ID:", "SMILES:", etc., to identify molecules and their properties.\n     - **Check if it\'s De novo or Derived:**\n       - **De novo Molecule:** If the SMILES does not appear in the history and there\'s no indication of modification (e.g., "de novo" or "designed from scratch"), set properties.status: "de novo" and omit properties.parent_molecule_id.\n       - **Derived Molecule:** If the SMILES matches a molecule in the history or the rationale suggests modification (e.g., "repositioning," "replacing," "evaluated"):\n         - Search the history chronologically for a molecule with the same SMILES.\n         - Retrieve the moleculeId of the matching molecule from the history—this is the parent_molecule_id.\n         - Set properties.parent_molecule_id to this ID and properties.status: "modified".\n     - **Handle Modifications:**\n       - If the SMILES differs slightly from a historical molecule but the rationale indicates it\'s a modification (e.g., "fluorine replaced with chlorine"), find the closest matching parent SMILES in the history and use its Molecule ID as parent_molecule_id.\n     - **Reusing Unchanged Molecules:**\n       - When the agent explicitly references a molecule by `moleculeId` and there is no indication of a structural change, carry that `moleculeId` forward in the output and omit a new structure. This prevents creation of duplicate molecule entries for the same SMILES.\n     - **Populate Fields:**\n       - Set structure.smiles to the molecule\'s SMILES.\n       - Include a properties object for EVERY molecule, with status and, if derived, parent_molecule_id.\n       - Add any calculated properties (e.g., docking score, logP, pChEMBL, qed, sas) to computed_properties.\n       - Set rationale to the molecule-specific reasoning from the agent.\n       - If there is any relevant file path in the previous agent\'s response, for example to a pdb folder, include this in the rationale as well\n\n4. **Format the JSON:**\n   - Structure the output with transformation and molecules at the top level.\n\n5. **Validate:**\n   - Verify that derived molecules have a parent_molecule_id matching a historical molecule_id; if unclear, note in rationale (e.g., "Parent unclear due to missing history match").\n\n6. **Output:**\n   - Wrap the JSON in `<gurnemanz>` tags.\n\n### Example: Agent Output Format and Parsing\nThe history will look like this:\n```\n## Transformation\n- Type: data-retrieval\n- Agent: Ai expert\n- Iteration: 1\n- ID: ceb63937-5bd9-48b3-9ac6-ccc443944e4c\n- Rationale: Generated de novo molecules for AKT1\n\n## Molecules\n\n### Molecule 1\n- ID: 4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88\n- SMILES: COc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F\n- Properties:\n  * Status: de novo\n- Computed Properties:\n  * logP: 3.7169\n  * pChEMBL: 8.3\n  * qed: 0.285355\n  * sas: 3.507\n- Rationale: De novo compound for AKT1 with high potency (pChEMBL 8.3).\n```\n\nThe previous agents response you receive as input:\n```json\nMedcicinal chemist: I\'ve edited the de novo molecule of the ai expert in this way\nCOc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F(=c3ccncc3)\nrationale: improved binding\n```\n\nExpected Output:\n```\n<gurnemanz>\n{\n  "transformation": {\n    "type": "lead-optimization",\n    "agent": "Medicinal Chemist",\n    "user_message": "improved molecule binding",\n    "rationale": "edited molecule for improved binding",\n    "protein_sequence": "MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYFEYLKLDYLHSEIRFPHFPQFSYSASGTA" # Include if a protein sequence is mentioned in the agent output\n    "protein_path": "/path/to/protein.pdb",  # Include only if a protein path is mentioned in the agent output\n    "iteration": 2\n  },\n  "molecules": [\n    {\n      "structure": {\n        "smiles": "COc1ccc(O)c(C(=O)c2ccc(C(=O)O[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F(=c3ccncc3)"\n      },\n      "properties": {\n        "parent_molecule_id": "4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88",\n        "status": "modified"\n      },\n      "computed_properties": {},\n      "rationale": "Fluorine at 4-position of pyridine is synthetically accessible but may present regioselectivity challenges"\n    }\n  ]\n}\n</gurnemanz>\n```\n\n### IMPORTANT REQUIREMENTS\n1. **Every molecule MUST have a properties object** with at minimum a status field.\n2. **Derived molecules MUST include parent_molecule_id** in the properties object.\n3. **SMILES matching is critical** - When a molecule with the same SMILES appears in a new step, it\'s derived, not de novo.\n4. **Look through the entire history** to find matching molecules and their molecule_ids.\n5. **Look for ID fields in the text output** - When you see patterns like "ID: 4f6f07e1-25ba-4f1e-a58f-02a09a2c6e88" in the agent output, this may be a molecule ID that becomes the parent_molecule_id for derived molecules.\n6. **If an agent outputs a file path to a protein PDB file** add this path in the "protein_path" field in the transformation object. Look for paths containing ".pdb" extensions or mentions of protein structure files. For example, if the agent says "I used /path/to/protein.pdb for docking", extract "/path/to/protein.pdb" as the protein_path.\nVERY IMPORTANT NOTE FOR LITERATURE AGENT PARSING: Including ALL important details provided by the literature agent in the transformations rationale field!!!!! the other agents RELY on this information! do NOT summarize the response and omit key information. all relevant output of the literature HAS TO GO INTO THE RATIONALE. Also double check if there might be protein sequences or smiles in the response to add them in the appropriate fields.\n\nIteration Number:\n3\nAgent Title:\nLLM Drug Designer\n'}]}, {'role': 'assistant', 'content': "I'll parse the output from the LLM Drug Designer and format it into the GURNEMANZ JSON specification, ensuring all molecule relationships are properly tracked.", 'tool_calls': [{'index': 1, 'function': {'arguments': '{"client_name": "claude", "session_id": "session-123", "parent_transformation_id": "transformation-previous", "transformation": {"type": "molecule-generation", "agent": "LLM Drug Designer", "iteration": 3, "rationale": "Final optimization of AKT1 inhibitor candidates focusing on diverse mechanisms (ATP-competitive, Type II, and allosteric inhibitors), clinical viability, and novel chemical space. Designs incorporate optimal substitution patterns for metabolic stability, selectivity, and drug-like properties while maintaining essential pharmacophore elements for AKT1 inhibition."}, "molecules": [{"structure": {"smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F"}, "friendly_id": "AI:I3:N1:G2", "parent_friendly_id": "AI:I2:N1:G1", "rationale": "This ATP-competitive inhibitor represents our lead hinge-binding scaffold with optimal substitution. The aminopyrimidine forms key hydrogen bonds with the kinase hinge region (E228, A230), while the fluoropyridine enhances these interactions through a halogen bond. The trifluoroethyl-piperazine provides metabolic stability and reduced P-gp efflux liability compared to simple N-methylpiperazine. The toluidine group extends into the hydrophobic back pocket, providing selectivity. This compound offers an excellent balance of potency, selectivity, and drug-like properties (MW ~550, LogP ~3.8, 3 H-bond donors, 8 H-bond acceptors). Compared to known AKT inhibitors like capivasertib, it features a novel linking strategy while maintaining essential pharmacophore elements. Synthetic accessibility is high through convergent synthesis."}, {"structure": {"smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N"}, "friendly_id": "AI:I3:N2:G2", "parent_friendly_id": "AI:I2:N2:G1", "rationale": "This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1, offering a distinct mechanism from most ATP-competitive inhibitors. The aminopyrimidine forms hydrogen bonds with the hinge region, while the urea linker forms critical hydrogen bonds with the DFG motif (D292, F293). The fluorophenyl group occupies the hydrophobic pocket exposed in the DFG-out state, with the fluorine providing metabolic stability and enhanced binding. The piperazine linker offers solubility while the methoxyphenyl provides additional hydrophobic interactions. This compound has favorable properties (MW ~560, LogP ~3.5, 5 H-bond donors, 10 H-bond acceptors) and represents a novel chemical space compared to known Type II kinase inhibitors. Its unique binding mode may offer advantages in overcoming resistance mechanisms."}, {"structure": {"smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F"}, "friendly_id": "AI:I3:N3:G2", "parent_friendly_id": "AI:I2:N4:G1", "rationale": "This ATP-competitive inhibitor features an imidazole core with a difluoromethoxypyridine substituent that forms optimal interactions with the hinge region of AKT1. The difluoromethoxy group serves as a metabolically stable hydrogen bond acceptor while providing lipophilicity and halogen bonding opportunities. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~480, LogP ~3.2, 2 H-bond donors, 8 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors like ipatasertib. The balanced physicochemical profile suggests good oral bioavailability and CNS penetration potential, making it suitable for various AKT1-driven indications."}, {"structure": {"smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N"}, "friendly_id": "AI:I3:N4:G2", "parent_friendly_id": "AI:I2:N5:G1", "rationale": "This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism distinct from ATP-competitive inhibitors. The indole core provides a rigid scaffold that positions the cyano-aminopyrimidine to form key interactions with the interdomain pocket. The Boc-protected amine serves as a prodrug approach, masking the basic center to improve membrane permeability and oral bioavailability. Upon cleavage by esterases, the active compound forms additional interactions with the target. This compound has favorable properties (MW ~570, LogP ~4.0, 3 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects."}, {"structure": {"smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5"}, "friendly_id": "AI:I3:N5:G2", "parent_friendly_id": "AI:I2:N3:G1", "rationale": "This ATP-competitive inhibitor features a dual binding mode with the pyrimidine-pyridine system forming key hydrogen bonds with the hinge region, while the trifluoromethyl-aminopyridine extends into a hydrophobic pocket unique to AKT1. The oxadiazole provides metabolic stability and favorable electronics, positioning the molecule optimally in the binding site. The trifluoromethyl group enhances potency through hydrophobic interactions and blocks a potential metabolic site. This compound has excellent drug-like properties (MW ~500, LogP ~3.3, 3 H-bond donors, 9 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding interactions may provide selectivity for AKT1 over AKT2/AKT3 isoforms."}, {"structure": {"smiles": "COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F"}, "friendly_id": "AI:I3:N6:G2", "parent_friendly_id": "AI:I2:N6:G1", "rationale": "This ATP-competitive inhibitor features a triazole core that forms key hydrogen bonds with the hinge region of AKT1. The fluorinated dimethoxyphenyl group provides hydrophobic interactions with the back pocket, with the fluorine enhancing metabolic stability. The sulfone linker offers hydrogen bond acceptors and proper spatial arrangement, while also improving aqueous solubility. The terminal fluorophenyl group provides additional hydrophobic interactions. This compound has favorable properties (MW ~490, LogP ~3.2, 1 H-bond donor, 9 H-bond acceptors) and represents a novel scaffold compared to known AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1. The synthetic accessibility is high through convergent synthesis."}, {"structure": {"smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F"}, "friendly_id": "AI:I3:N7:G2", "parent_friendly_id": "AI:I2:N7:G1", "rationale": "This ATP-competitive inhibitor features a thiazole core with a trifluoromethyl-pyridine substituent that forms optimal interactions with the hinge region of AKT1. The trifluoromethyl group enhances binding affinity through hydrophobic interactions and improves metabolic stability. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~510, LogP ~3.5, 1 H-bond donor, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over other kinases."}, {"structure": {"smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F"}, "friendly_id": "AI:I3:N8:G2", "parent_friendly_id": "AI:I2:N8:G1", "rationale": "This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1 through its urea linker, which forms critical hydrogen bonds with the DFG motif (D292, F293). The N-methylimidazole with difluoroethoxypyridine forms key hydrogen bonds with the hinge region, while the fluorotoluidine extends into the hydrophobic pocket exposed in the DFG-out state. The difluoroethoxy group provides metabolic stability compared to a simple methoxy group, while maintaining hydrogen bond acceptor capabilities. This compound has favorable properties (MW ~470, LogP ~3.4, 2 H-bond donors, 7 H-bond acceptors) and represents a novel approach compared to known Type II kinase inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding mode may offer advantages in overcoming resistance mechanisms."}, {"structure": {"smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F"}, "friendly_id": "AI:I3:N9:G2", "parent_friendly_id": "AI:I2:N11:G1", "rationale": "This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism. The xanthine core (similar to caffeine) provides a rigid scaffold that positions the key binding elements optimally. The sulfone linker improves aqueous solubility while maintaining proper spatial arrangement. The fluorocyclopropanecarboxamide terminal group provides metabolic stability and additional binding interactions. This compound has favorable properties (MW ~500, LogP ~2.5, 2 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects. The balanced physicochemical profile suggests good oral bioavailability."}, {"structure": {"smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4"}, "friendly_id": "AI:I3:N10:G2", "parent_friendly_id": "AI:I2:N10:G1", "rationale": "This ATP-competitive inhibitor features an aminopyrimidine hinge-binding motif that forms key hydrogen bonds with the hinge region of AKT1 (E228, A230). The chloro-aminopyridine linker provides halogen bonding opportunities and blocks a potential metabolic site, while the trifluoromethylphenyl group extends into the hydrophobic back pocket, providing both potency and metabolic stability. The morpholine provides solubility and potential for additional hydrogen bonding interactions. This compound has favorable properties (MW ~480, LogP ~3.7, 2 H-bond donors, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over AKT2/AKT3 isoforms."}]}', 'name': 'gurnemanz_apply'}, 'id': 'toolu_012m71nu5L5okSqMQMzSkKiv', 'type': 'function'}]}, {'role': 'tool', 'tool_call_id': 'toolu_012m71nu5L5okSqMQMzSkKiv', 'content': '{"molecules": [{"moleculeId": "560ed468-5863-460b-ac77-637069cccecc", "originalData": {"friendlyId": "AI:I3:N1:G2", "parentFriendlyId": "AI:I2:N1:G1", "rationale": "This ATP-competitive inhibitor represents our lead hinge-binding scaffold with optimal substitution. The aminopyrimidine forms key hydrogen bonds with the kinase hinge region (E228, A230), while the fluoropyridine enhances these interactions through a halogen bond. The trifluoroethyl-piperazine provides metabolic stability and reduced P-gp efflux liability compared to simple N-methylpiperazine. The toluidine group extends into the hydrophobic back pocket, providing selectivity. This compound offers an excellent balance of potency, selectivity, and drug-like properties (MW ~550, LogP ~3.8, 3 H-bond donors, 8 H-bond acceptors). Compared to known AKT inhibitors like capivasertib, it features a novel linking strategy while maintaining essential pharmacophore elements. Synthetic accessibility is high through convergent synthesis.", "structure": {"smiles": "CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F"}}}, {"moleculeId": "056504a9-3ea1-4cb5-9801-303afb7be580", "originalData": {"friendlyId": "AI:I3:N2:G2", "parentFriendlyId": "AI:I2:N2:G1", "rationale": "This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1, offering a distinct mechanism from most ATP-competitive inhibitors. The aminopyrimidine forms hydrogen bonds with the hinge region, while the urea linker forms critical hydrogen bonds with the DFG motif (D292, F293). The fluorophenyl group occupies the hydrophobic pocket exposed in the DFG-out state, with the fluorine providing metabolic stability and enhanced binding. The piperazine linker offers solubility while the methoxyphenyl provides additional hydrophobic interactions. This compound has favorable properties (MW ~560, LogP ~3.5, 5 H-bond donors, 10 H-bond acceptors) and represents a novel chemical space compared to known Type II kinase inhibitors. Its unique binding mode may offer advantages in overcoming resistance mechanisms.", "structure": {"smiles": "COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N"}}}, {"moleculeId": "57eb4e92-faa0-4028-8773-c37ecc013618", "originalData": {"friendlyId": "AI:I3:N3:G2", "parentFriendlyId": "AI:I2:N4:G1", "rationale": "This ATP-competitive inhibitor features an imidazole core with a difluoromethoxypyridine substituent that forms optimal interactions with the hinge region of AKT1. The difluoromethoxy group serves as a metabolically stable hydrogen bond acceptor while providing lipophilicity and halogen bonding opportunities. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~480, LogP ~3.2, 2 H-bond donors, 8 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors like ipatasertib. The balanced physicochemical profile suggests good oral bioavailability and CNS penetration potential, making it suitable for various AKT1-driven indications.", "structure": {"smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F"}}}, {"moleculeId": "eb82ffa2-8d12-4bc2-8647-729840119f98", "originalData": {"friendlyId": "AI:I3:N4:G2", "parentFriendlyId": "AI:I2:N5:G1", "rationale": "This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism distinct from ATP-competitive inhibitors. The indole core provides a rigid scaffold that positions the cyano-aminopyrimidine to form key interactions with the interdomain pocket. The Boc-protected amine serves as a prodrug approach, masking the basic center to improve membrane permeability and oral bioavailability. Upon cleavage by esterases, the active compound forms additional interactions with the target. This compound has favorable properties (MW ~570, LogP ~4.0, 3 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects.", "structure": {"smiles": "CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N"}}}, {"moleculeId": "4612e73f-611c-465e-b979-f6b885ea5006", "originalData": {"friendlyId": "AI:I3:N5:G2", "parentFriendlyId": "AI:I2:N3:G1", "rationale": "This ATP-competitive inhibitor features a dual binding mode with the pyrimidine-pyridine system forming key hydrogen bonds with the hinge region, while the trifluoromethyl-aminopyridine extends into a hydrophobic pocket unique to AKT1. The oxadiazole provides metabolic stability and favorable electronics, positioning the molecule optimally in the binding site. The trifluoromethyl group enhances potency through hydrophobic interactions and blocks a potential metabolic site. This compound has excellent drug-like properties (MW ~500, LogP ~3.3, 3 H-bond donors, 9 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding interactions may provide selectivity for AKT1 over AKT2/AKT3 isoforms.", "structure": {"smiles": "CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5"}}}, {"moleculeId": "0d271a8c-8186-45a9-9e6d-49f500974d64", "originalData": {"friendlyId": "AI:I3:N6:G2", "parentFriendlyId": "AI:I2:N6:G1", "rationale": "This ATP-competitive inhibitor features a triazole core that forms key hydrogen bonds with the hinge region of AKT1. The fluorinated dimethoxyphenyl group provides hydrophobic interactions with the back pocket, with the fluorine enhancing metabolic stability. The sulfone linker offers hydrogen bond acceptors and proper spatial arrangement, while also improving aqueous solubility. The terminal fluorophenyl group provides additional hydrophobic interactions. This compound has favorable properties (MW ~490, LogP ~3.2, 1 H-bond donor, 9 H-bond acceptors) and represents a novel scaffold compared to known AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1. The synthetic accessibility is high through convergent synthesis.", "structure": {"smiles": "COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F"}}}, {"moleculeId": "e3fddc7e-7037-4a6b-aa37-a43ad4c2f757", "originalData": {"friendlyId": "AI:I3:N7:G2", "parentFriendlyId": "AI:I2:N7:G1", "rationale": "This ATP-competitive inhibitor features a thiazole core with a trifluoromethyl-pyridine substituent that forms optimal interactions with the hinge region of AKT1. The trifluoromethyl group enhances binding affinity through hydrophobic interactions and improves metabolic stability. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~510, LogP ~3.5, 1 H-bond donor, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over other kinases.", "structure": {"smiles": "CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F"}}}, {"moleculeId": "e557058f-9ae1-49e1-a064-e468053f8e1d", "originalData": {"friendlyId": "AI:I3:N8:G2", "parentFriendlyId": "AI:I2:N8:G1", "rationale": "This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1 through its urea linker, which forms critical hydrogen bonds with the DFG motif (D292, F293). The N-methylimidazole with difluoroethoxypyridine forms key hydrogen bonds with the hinge region, while the fluorotoluidine extends into the hydrophobic pocket exposed in the DFG-out state. The difluoroethoxy group provides metabolic stability compared to a simple methoxy group, while maintaining hydrogen bond acceptor capabilities. This compound has favorable properties (MW ~470, LogP ~3.4, 2 H-bond donors, 7 H-bond acceptors) and represents a novel approach compared to known Type II kinase inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding mode may offer advantages in overcoming resistance mechanisms.", "structure": {"smiles": "CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F"}}}, {"moleculeId": "600e9030-ff97-4268-a389-ace65357c154", "originalData": {"friendlyId": "AI:I3:N9:G2", "parentFriendlyId": "AI:I2:N11:G1", "rationale": "This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism. The xanthine core (similar to caffeine) provides a rigid scaffold that positions the key binding elements optimally. The sulfone linker improves aqueous solubility while maintaining proper spatial arrangement. The fluorocyclopropanecarboxamide terminal group provides metabolic stability and additional binding interactions. This compound has favorable properties (MW ~500, LogP ~2.5, 2 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects. The balanced physicochemical profile suggests good oral bioavailability.", "structure": {"smiles": "CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F"}}}, {"moleculeId": "e5352a5b-49e1-42ec-8a3e-6cbe9a045a1c", "originalData": {"friendlyId": "AI:I3:N10:G2", "parentFriendlyId": "AI:I2:N10:G1", "rationale": "This ATP-competitive inhibitor features an aminopyrimidine hinge-binding motif that forms key hydrogen bonds with the hinge region of AKT1 (E228, A230). The chloro-aminopyridine linker provides halogen bonding opportunities and blocks a potential metabolic site, while the trifluoromethylphenyl group extends into the hydrophobic back pocket, providing both potency and metabolic stability. The morpholine provides solubility and potential for additional hydrogen bonding interactions. This compound has favorable properties (MW ~480, LogP ~3.7, 2 H-bond donors, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over AKT2/AKT3 isoforms.", "structure": {"smiles": "CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4"}}}], "transformation": {"agent": "LLM Drug Designer", "iteration": 3, "methodDetails": null, "proteinPath": null, "proteinSequence": null, "rationale": "Final optimization of AKT1 inhibitor candidates focusing on diverse mechanisms (ATP-competitive, Type II, and allosteric inhibitors), clinical viability, and novel chemical space. Designs incorporate optimal substitution patterns for metabolic stability, selectivity, and drug-like properties while maintaining essential pharmacophore elements for AKT1 inhibition.", "transformationId": "ba439423-c017-4a90-978d-c639e1e6d351", "type": "molecule-generation", "userMessage": null}}'}, {'role': 'assistant', 'content': "I've successfully processed the LLM Drug Designer's output for Iteration 3 and submitted it to GURNEMANZ. The final set of AKT1 inhibitor candidates has been formatted according to the required specifications, with all molecule relationships properly tracked.\n\nThe submission includes:\n- 10 optimized AKT1 inhibitor candidates with diverse mechanisms of action\n- Proper parent-child relationships maintained through friendly_id tracking\n- Comprehensive rationales for each molecule explaining their design features\n- Transformation details capturing the overall design strategy\n\nThe final candidates represent a diverse set of approaches to AKT1 inhibition:\n- ATP-competitive inhibitors with various hinge-binding motifs\n- Type II inhibitors targeting the DFG-out conformation\n- Allosteric inhibitors targeting the PH domain-kinase domain interface\n\nEach molecule has been designed with careful consideration of drug-like properties, metabolic stability, and synthetic accessibility while maintaining novelty compared to known AKT1 inhibitors."}]
2025-06-23 14:06:56,591 - INFO - main_history after parser: [
  {
    "role": "user",
    "content": "You are an expert medicinal chemist and computational drug discovery scientist. Your task is to design novel small molecule inhibitors for AKT1 (Protein Kinase B alpha) using your knowledge of structure-activity relationships, medicinal chemistry principles, and drug design.\n\n**Target Information:**\n- AKT1 is a serine/threonine kinase in the PI3K/AKT/mTOR pathway\n- Critical for cell survival, proliferation, and metabolism\n- Key oncology target with multiple known inhibitors\n- ATP-competitive and allosteric binding sites available\n\n**Your Goal:**\nGenerate novel, drug-like small molecule AKT1 inhibitors with the following criteria:\n- High predicted binding affinity to AKT1\n- Drug-like properties (Lipinski's Rule of Five compliance)\n- Synthetic accessibility\n- Novel scaffolds not directly copied from known inhibitors\n\n**Output Format:**\nFor each molecule, provide:\n1. **Molecule ID**: A unique identifier (e.g., LLM_MOL_001)\n2. **SMILES**: Valid SMILES string\n3. **Rationale**: Brief explanation of your design strategy and expected properties\n4. **Predicted Properties**: Your assessment of drug-likeness, potency, selectivity\n\nFocus on innovative chemical designs while maintaining scientific rigor."
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 1: Initial Discovery & Exploration**\n\nDesign 10-15 novel AKT1 inhibitor molecules using your medicinal chemistry expertise. Consider:\n\n1. **ATP-competitive inhibitors**: Target the ATP-binding pocket with novel scaffolds\n2. **Allosteric inhibitors**: Design molecules that bind to regulatory sites\n3. **Hybrid approaches**: Molecules that may interact with multiple binding sites\n\nUse your knowledge of:\n- Known AKT1 pharmacophores (avoid direct copying)\n- Kinase selectivity determinants\n- Drug-like chemical space\n- Structure-activity relationships\n\nGenerate diverse scaffolds including heterocycles, aromatic systems, and appropriate linkers. Ensure synthetic feasibility while prioritizing novelty."
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Initial Discovery\n\nI'll design novel AKT1 inhibitors using medicinal chemistry principles and my knowledge of kinase inhibitor design. I'll focus on creating diverse, drug-like molecules with appropriate pharmacophores for AKT1 inhibition.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N1:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a 4-aminopyrimidine hinge-binding motif. Contains a piperazine solubilizing group and a pyridine moiety for additional H-bonding. The toluidine group provides hydrophobic interactions with the kinase back pocket. Expected properties: MW ~500, LogP ~3.5-4, good solubility due to basic centers, and potential for high AKT1 affinity through multiple binding interactions.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I1:N2:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor designed to stabilize the inactive DFG-out conformation. Features an aminopyrimidine hinge binder, a urea linker to form H-bonds with the DFG motif, and a terminal methoxyphenyl group for hydrophobic pocket binding. The piperazine provides solubility and potential for H-bond interactions. Expected properties: MW ~550, LogP ~3-4, 3-4 H-bond donors, 8-10 H-bond acceptors.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC=N3)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N3:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a pyrimidine-pyridine system as the hinge-binding motif. The oxadiazole provides metabolic stability and favorable electronics. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3, good kinase selectivity due to the specific arrangement of H-bond donors/acceptors, and favorable ADMET profile with limited metabolism sites.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N4:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring an imidazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~440, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases due to the specific arrangement of binding elements.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I1:N5:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a conformationally constrained indole core with a cyano-substituted aminopyrimidine for specific interactions. The tertiary amine provides solubility and potential for salt formation. Expected properties: MW ~480, LogP ~3.5-4, good membrane permeability, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC=C1OC)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I1:N6:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a triazole core for hinge binding. The dimethoxyphenyl group provides hydrophobic interactions with the back pocket, while the sulfone linker offers H-bond acceptors and proper spatial arrangement. Expected properties: MW ~470, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with balanced physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC(=N1)NC2=CC=CC=C2)C(=O)NC3=CC(=CC=C3)C4=NN=C(O4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I1:N7:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole-pyridine hinge binder. The anilino group provides additional hydrophobic interactions, while the amide linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~450, LogP ~3.5-4, good metabolic stability, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N8:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor featuring a thiazole core with a pyridine substituent for hinge binding. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~460, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OC\",\n            \"friendly_id\": \"AI:I1:N9:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Type II kinase inhibitor with a urea linker to stabilize the DFG-out conformation. Features an N-methylimidazole core with a methoxypyridine for hinge binding. The fluorotoluidine provides hydrophobic interactions with the back pocket. Expected properties: MW ~420, LogP ~3-3.5, good metabolic stability due to the fluorine substitution, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCOCC5\",\n            \"friendly_id\": \"AI:I1:N10:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an isoxazole core and an aminopyrimidine hinge binder. The methoxyphenyl group provides hydrophobic interactions with the back pocket, while the morpholine derivative offers solubility and potential for H-bond interactions. Expected properties: MW ~460, LogP ~2.5-3, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC=N2)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I1:N11:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The trifluoromethyl group enhances potency and metabolic stability, while the morpholine provides solubility. The aminopyridine linker offers H-bonding capabilities and proper spatial arrangement. Expected properties: MW ~445, LogP ~3-3.5, good metabolic stability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5CC5\",\n            \"friendly_id\": \"AI:I1:N12:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Allosteric AKT1 inhibitor targeting the PH domain-kinase domain interface. Features a xanthine core (similar to caffeine) with a sulfone linker and a cyclopropanecarboxamide terminal group. Expected properties: MW ~480, LogP ~2-2.5, good solubility due to the sulfone group, and potential for high selectivity for AKT1 over other kinases due to the allosteric binding mode.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C\",\n            \"friendly_id\": \"AI:I1:N13:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a thiazole core and an oxadiazole hinge binder. The N-methylpiperazine provides solubility and potential for salt formation. The amide linker offers rigidity and H-bonding capabilities. Expected properties: MW ~450, LogP ~2.5-3, good oral bioavailability, and potential for high AKT1 affinity with selectivity over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1)NC2=NC=CC(=N2)NC(=O)C3=CC=C(C=C3)N4CCN(CC4)C(=O)C5=CC=CO5\",\n            \"friendly_id\": \"AI:I1:N14:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with an aminopyrimidine hinge-binding motif. The toluidine group provides hydrophobic interactions with the kinase back pocket. The piperazine-furoyl group offers solubility and additional binding interactions. Expected properties: MW ~485, LogP ~3-3.5, good solubility, and potential for high AKT1 affinity with favorable ADMET profile.\"\n        },\n        {\n            \"smiles\": \"COC1=CC2=C(C=C1)N=C(N2)NC(=O)C3=CC=C(C=C3)C4=NN=C(O4)C5=CC=NC=C5\",\n            \"friendly_id\": \"AI:I1:N15:G0\",\n            \"source\": null,\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"ATP-competitive inhibitor with a quinazoline core for hinge binding. The oxadiazole-pyridine system provides additional H-bonding capabilities and proper spatial arrangement. The methoxy group enhances metabolic stability. Expected properties: MW ~425, LogP ~3-3.5, good oral bioavailability, and potential for high AKT1 affinity with favorable physicochemical properties.\"\n        }\n    ]\n}\n</molecules>\n\n## Design Strategy Overview\n\nMy approach to designing these AKT1 inhibitors focused on several key medicinal chemistry principles:\n\n### 1. Hinge-Binding Motifs\n- Incorporated established kinase hinge-binding pharmacophores including:\n  - Aminopyrimidines (molecules 1, 2, 11, 14)\n  - Imidazoles (molecule 4)\n  - Triazoles (molecule 6)\n  - Quinazolines (molecule 15)\n  - Oxadiazoles (molecules 3, 7, 13)\n\n### 2. Binding Modes\n- **ATP-competitive inhibitors** (majority of designs): Target the ATP-binding pocket with appropriate hinge-binding elements\n- **Type II inhibitors** (molecules 2, 9): Include urea linkers to stabilize the DFG-out conformation\n- **Allosteric inhibitors** (molecules 5, 12): Target the PH domain-kinase domain interface\n\n### 3. Structural Features\n- **Solubilizing groups**: Incorporated piperazines, morpholines, and tertiary amines\n- **Metabolic stability**: Used fluorine substitutions, oxadiazoles, and methoxy groups\n- **Rigidity and spatial arrangement**: Employed amide linkers, ureas, and conformationally constrained cores\n\n### 4. Drug-Like Properties\n- Designed molecules with:\n  - MW generally between 420-550 Da\n  - LogP values in the 2.5-4 range\n  - Appropriate H-bond donors/acceptors (Lipinski compliant)\n  - Balanced solubility and permeability characteristics\n\nThese designs represent a diverse set of potential AKT1 inhibitors with varied scaffolds, binding modes, and physicochemical properties, providing a strong foundation for further optimization."
      }
    ]
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 2: Lead Optimization**\n\nBased on your previous designs, now optimize and refine your best candidates. Focus on:\n\n1. **Scaffold hopping**: Create variants of your most promising designs\n2. **Property optimization**: Improve drug-likeness, solubility, permeability\n3. **Selectivity enhancement**: Design features for AKT1 vs AKT2/AKT3 selectivity\n4. **ADMET optimization**: Consider metabolic stability and safety\n\nGenerate 8-12 optimized molecules that build upon your iteration 1 insights. Include:\n- Modified versions of your best scaffolds\n- New analogs with improved properties\n- Rationale for each modification based on medicinal chemistry principles"
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Lead Optimization\n\nBased on the initial designs, I'll now optimize the most promising candidates to enhance potency, selectivity, and drug-like properties. I'll focus on scaffold hopping, property optimization, and addressing potential ADMET issues.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F\",\n            \"friendly_id\": \"AI:I2:N1:G1\",\n            \"source\": \"AI:I1:N1:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N1:G0 with three key modifications: (1) Added a trifluoroethyl group to the piperazine to improve metabolic stability and reduce basicity, potentially improving brain penetration; (2) Introduced a fluorine on the pyridine ring to enhance binding affinity through additional interactions with the hinge region; (3) Maintained the core aminopyrimidine hinge-binding motif while optimizing the overall physicochemical profile. Expected improvements: better metabolic stability, reduced P-gp efflux liability, and potentially enhanced selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I2:N2:G1\",\n            \"source\": \"AI:I1:N2:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of AI:I1:N2:G0 by introducing a fluorine atom on the central phenyl ring to improve metabolic stability and binding affinity. The Type II inhibitor design is maintained with the urea linker for DFG-out conformation stabilization. The fluorine addition provides several benefits: (1) blocks a potential metabolic site; (2) enhances binding through additional interactions; (3) improves membrane permeability by reducing the overall hydrogen bonding capacity while maintaining the essential pharmacophore elements. Expected improvements: enhanced metabolic stability, potentially improved selectivity, and maintained solubility profile.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I2:N3:G1\",\n            \"source\": \"AI:I1:N3:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N3:G0 by introducing a trifluoromethyl group on the aminopyridine linker. This modification serves multiple purposes: (1) increases binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by blocking a potential site of oxidation; (3) enhances selectivity by exploiting a potential hydrophobic pocket unique to AKT1. The core oxadiazole and pyrimidine-pyridine hinge-binding motifs are preserved to maintain essential interactions. Expected improvements: enhanced potency, better metabolic profile, and potentially improved selectivity for AKT1 over AKT2/AKT3.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F\",\n            \"friendly_id\": \"AI:I2:N4:G1\",\n            \"source\": \"AI:I1:N4:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N4:G0 by replacing the pyridine with a difluoromethoxy-substituted pyridine. This modification: (1) introduces a metabolically stable difluoromethoxy group that serves as a hydrogen bond acceptor while providing lipophilicity; (2) enhances binding affinity through additional interactions; (3) improves metabolic stability by blocking oxidation sites. The imidazole core and N-methylpiperazine solubilizing group are maintained for their essential functions. Expected improvements: enhanced potency, better metabolic stability, and potentially improved blood-brain barrier penetration due to the balanced lipophilicity.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I2:N5:G1\",\n            \"source\": \"AI:I1:N5:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the allosteric inhibitor AI:I1:N5:G0 by replacing the tertiary amine with a Boc-protected amine. This prodrug approach: (1) masks the basic center to improve membrane permeability; (2) provides controlled release of the active compound after enzymatic cleavage; (3) potentially enhances oral bioavailability by reducing first-pass metabolism. The core indole scaffold and cyano-substituted aminopyrimidine are preserved for their essential interactions with the PH domain-kinase domain interface. Expected improvements: enhanced pharmacokinetic profile, improved oral bioavailability, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I2:N6:G1\",\n            \"source\": \"AI:I1:N6:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N6:G0 by introducing a fluorine atom on the dimethoxyphenyl group. This modification: (1) blocks a potential metabolic site on the aromatic ring; (2) provides additional binding interactions; (3) fine-tunes the electronic properties of the aromatic system. The triazole core for hinge binding and the sulfone linker are maintained for their essential functions. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained physicochemical properties for good oral bioavailability.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F\",\n            \"friendly_id\": \"AI:I2:N7:G1\",\n            \"source\": \"AI:I1:N8:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N8:G0 by replacing the pyridine with a trifluoromethyl-substituted pyridine. This modification: (1) enhances binding affinity through additional hydrophobic interactions; (2) improves metabolic stability by replacing a potential metabolic liability; (3) fine-tunes the electronic properties of the hinge-binding element. The thiazole core, amide linker, and N-methylpiperazine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F\",\n            \"friendly_id\": \"AI:I2:N8:G1\",\n            \"source\": \"AI:I1:N9:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the Type II inhibitor AI:I1:N9:G0 by replacing the methoxy group with a difluoroethoxy group. This modification: (1) improves metabolic stability by blocking a potential site of O-demethylation; (2) enhances binding affinity through additional interactions; (3) provides a better balance of lipophilicity and hydrogen bonding capacity. The urea linker for DFG-out conformation stabilization and the N-methylimidazole core are preserved. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained ability to stabilize the inactive kinase conformation.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C2=CC(=NO2)C(=O)NC3=CC=C(C=C3)C4=CN=C(N=C4)NC5CCN(CC5)S(=O)(=O)C\",\n            \"friendly_id\": \"AI:I2:N9:G1\",\n            \"source\": \"AI:I1:N10:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N10:G0 by replacing the morpholine derivative with a methylsulfonyl-piperazine. This modification: (1) reduces the basicity of the nitrogen while maintaining solubility; (2) provides additional binding interactions through the sulfonyl group; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The isoxazole core and aminopyrimidine hinge binder are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I2:N10:G1\",\n            \"source\": \"AI:I1:N11:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Optimization of AI:I1:N11:G0 by introducing a chlorine atom on the aminopyridine linker. This modification: (1) enhances binding affinity through additional halogen bonding interactions; (2) blocks a potential metabolic site; (3) fine-tunes the electronic properties of the aromatic system. The trifluoromethyl group, aminopyrimidine hinge-binding motif, and morpholine solubilizing group are maintained. Expected improvements: enhanced potency, better metabolic stability, and potentially improved selectivity for AKT1 over AKT2/AKT3.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F\",\n            \"friendly_id\": \"AI:I2:N11:G1\",\n            \"source\": \"AI:I1:N12:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Refinement of the allosteric inhibitor AI:I1:N12:G0 by introducing a fluorocyclopropane group. This modification: (1) enhances metabolic stability by blocking a potential site of oxidation; (2) provides additional binding interactions through the fluorine atom; (3) maintains the overall size and shape of the molecule while improving its properties. The xanthine core and sulfone linker are preserved for their essential functions in targeting the PH domain-kinase domain interface. Expected improvements: enhanced metabolic stability, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        },\n        {\n            \"smiles\": \"CC1=C(SC=N1)C(=O)NC2=CC=C(C=C2)C3=NN=C(O3)C4=CC=C(C=C4)N5CCN(CC5)C(=O)CF\",\n            \"friendly_id\": \"AI:I2:N12:G1\",\n            \"source\": \"AI:I1:N13:G0\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"Enhancement of AI:I1:N13:G0 by replacing the N-methyl group with a fluoroacetyl group. This modification: (1) reduces the basicity of the piperazine nitrogen while maintaining solubility; (2) provides additional binding interactions through the fluorine atom; (3) potentially improves metabolic stability and reduces P-gp efflux liability. The thiazole core, oxadiazole hinge binder, and amide linker are preserved for their essential functions. Expected improvements: enhanced pharmacokinetic profile, potentially improved binding affinity, and maintained selectivity for AKT1.\"\n        }\n    ]\n}\n</molecules>\n\n## Lead Optimization Strategy\n\nIn this optimization phase, I focused on refining the most promising candidates from Iteration 1 to enhance their drug-like properties, potency, selectivity, and ADMET profiles. Here's a summary of the key optimization strategies employed:\n\n### 1. Metabolic Stability Enhancements\n- **Fluorine incorporation**: Added strategic fluorine atoms to block metabolic hot spots (molecules 1, 2, 3, 6, 8, 10)\n- **Trifluoromethyl groups**: Introduced CF\u2083 groups to enhance stability and binding (molecules 3, 7, 10)\n- **Difluoromethoxy/ethoxy groups**: Replaced metabolically labile methoxy groups (molecules 4, 8)\n\n### 2. Selectivity Optimization\n- **Exploiting unique pockets**: Added substituents to target AKT1-specific binding regions (molecules 3, 7)\n- **Fine-tuning electronic properties**: Modified hinge-binding elements to enhance selectivity (molecules 4, 7)\n- **Halogen bonding**: Introduced chlorine for additional selective interactions (molecule 10)\n\n### 3. Pharmacokinetic Improvements\n- **Prodrug approach**: Implemented a Boc-protected amine to improve membrane permeability (molecule 5)\n- **Reduced basicity**: Modified basic centers to improve brain penetration and reduce P-gp efflux (molecules 1, 9, 12)\n- **Balanced lipophilicity**: Fine-tuned the hydrophobic/hydrophilic balance (molecules 4, 8)\n\n### 4. Binding Affinity Optimization\n- **Additional H-bond interactions**: Introduced groups capable of forming new H-bonds (molecules 4, 8)\n- **Halogen bonding**: Added fluorine and chlorine atoms for enhanced interactions (molecules 1, 10)\n- **Hydrophobic interactions**: Optimized lipophilic groups for better pocket complementarity (molecules 3, 7)\n\n### 5. Scaffold Preservation\nWhile making these modifications, I carefully preserved the core pharmacophores identified in Iteration 1:\n- ATP-competitive hinge-binding motifs (aminopyrimidines, imidazoles, etc.)\n- Type II inhibitor urea linkers\n- Allosteric binding elements for PH domain-kinase domain interface targeting\n\nThese optimized compounds represent a focused set of candidates with improved properties while maintaining the essential structural features required for AKT1 inhibition. The modifications were guided by established medicinal chemistry principles to address potential liabilities while enhancing desirable characteristics."
      }
    ]
  },
  {
    "role": "user",
    "content": [
      {
        "type": "text",
        "text": "**ITERATION 3: Final Lead Optimization & Selection**\n\nCreate your final set of 8-10 candidate molecules representing your best designs for AKT1 inhibition. Focus on:\n\n1. **Best-in-class designs**: Your most promising scaffolds with optimal substitution patterns\n2. **Diverse mechanisms**: Include both ATP-competitive and allosteric candidates\n3. **Clinical viability**: Emphasize drug-like properties and synthetic accessibility\n4. **Innovation**: Ensure your designs represent novel chemical space\n\nFor each final candidate, provide:\n- Comprehensive rationale for inclusion\n- Predicted binding mode and key interactions\n- Assessment of development potential\n- Comparison to known AKT1 inhibitors (without direct copying)\n- Don't forget to use the molecule entry format"
      }
    ]
  },
  {
    "role": "assistant",
    "content": [
      {
        "type": "text",
        "text": "# AKT1 Inhibitor Design - Final Lead Optimization & Selection\n\nI've developed a final set of optimized AKT1 inhibitor candidates representing diverse mechanisms, optimal properties, and novel chemical space. These compounds incorporate the insights gained from previous iterations while addressing key medicinal chemistry considerations.\n\n<molecules>\n{\n    \"molecules\": [\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(F)(F)F)NC4=NC=CC(=N4)C5=CN=C(C=C5)F\",\n            \"friendly_id\": \"AI:I3:N1:G2\",\n            \"source\": \"AI:I2:N1:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor represents our lead hinge-binding scaffold with optimal substitution. The aminopyrimidine forms key hydrogen bonds with the kinase hinge region (E228, A230), while the fluoropyridine enhances these interactions through a halogen bond. The trifluoroethyl-piperazine provides metabolic stability and reduced P-gp efflux liability compared to simple N-methylpiperazine. The toluidine group extends into the hydrophobic back pocket, providing selectivity. This compound offers an excellent balance of potency, selectivity, and drug-like properties (MW ~550, LogP ~3.8, 3 H-bond donors, 8 H-bond acceptors). Compared to known AKT inhibitors like capivasertib, it features a novel linking strategy while maintaining essential pharmacophore elements. Synthetic accessibility is high through convergent synthesis.\"\n        },\n        {\n            \"smiles\": \"COC1=CC=C(C=C1)C(=O)N2CCN(CC2)CC3=CC=C(C=C3)NC(=O)NC4=CC=C(F)C(=C4)NC5=NC=NC=C5N\",\n            \"friendly_id\": \"AI:I3:N2:G2\",\n            \"source\": \"AI:I2:N2:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1, offering a distinct mechanism from most ATP-competitive inhibitors. The aminopyrimidine forms hydrogen bonds with the hinge region, while the urea linker forms critical hydrogen bonds with the DFG motif (D292, F293). The fluorophenyl group occupies the hydrophobic pocket exposed in the DFG-out state, with the fluorine providing metabolic stability and enhanced binding. The piperazine linker offers solubility while the methoxyphenyl provides additional hydrophobic interactions. This compound has favorable properties (MW ~560, LogP ~3.5, 5 H-bond donors, 10 H-bond acceptors) and represents a novel chemical space compared to known Type II kinase inhibitors. Its unique binding mode may offer advantages in overcoming resistance mechanisms.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=C(N=CN4)C5=CC(=CN=C5)OC(F)F\",\n            \"friendly_id\": \"AI:I3:N3:G2\",\n            \"source\": \"AI:I2:N4:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor features an imidazole core with a difluoromethoxypyridine substituent that forms optimal interactions with the hinge region of AKT1. The difluoromethoxy group serves as a metabolically stable hydrogen bond acceptor while providing lipophilicity and halogen bonding opportunities. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~480, LogP ~3.2, 2 H-bond donors, 8 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors like ipatasertib. The balanced physicochemical profile suggests good oral bioavailability and CNS penetration potential, making it suitable for various AKT1-driven indications.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C(=O)N(C2=CC=CC=C12)C3CCN(CC3)C(=O)OC(C)(C)C)NC(=O)C4=CC=C(C=C4)NC5=NC=CC(=N5)C#N\",\n            \"friendly_id\": \"AI:I3:N4:G2\",\n            \"source\": \"AI:I2:N5:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism distinct from ATP-competitive inhibitors. The indole core provides a rigid scaffold that positions the cyano-aminopyrimidine to form key interactions with the interdomain pocket. The Boc-protected amine serves as a prodrug approach, masking the basic center to improve membrane permeability and oral bioavailability. Upon cleavage by esterases, the active compound forms additional interactions with the target. This compound has favorable properties (MW ~570, LogP ~4.0, 3 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects.\"\n        },\n        {\n            \"smiles\": \"CC1=NN=C(O1)C2=CC(=CC=C2)NC(=O)C3=C(C=CC(=N3)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CC=C5\",\n            \"friendly_id\": \"AI:I3:N5:G2\",\n            \"source\": \"AI:I2:N3:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor features a dual binding mode with the pyrimidine-pyridine system forming key hydrogen bonds with the hinge region, while the trifluoromethyl-aminopyridine extends into a hydrophobic pocket unique to AKT1. The oxadiazole provides metabolic stability and favorable electronics, positioning the molecule optimally in the binding site. The trifluoromethyl group enhances potency through hydrophobic interactions and blocks a potential metabolic site. This compound has excellent drug-like properties (MW ~500, LogP ~3.3, 3 H-bond donors, 9 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding interactions may provide selectivity for AKT1 over AKT2/AKT3 isoforms.\"\n        },\n        {\n            \"smiles\": \"COC1=CC(=CC(=C1OC)F)C2=NN=C(N2)NC(=O)C3=CC=C(C=C3)CS(=O)(=O)C4=CC=C(C=C4)F\",\n            \"friendly_id\": \"AI:I3:N6:G2\",\n            \"source\": \"AI:I2:N6:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor features a triazole core that forms key hydrogen bonds with the hinge region of AKT1. The fluorinated dimethoxyphenyl group provides hydrophobic interactions with the back pocket, with the fluorine enhancing metabolic stability. The sulfone linker offers hydrogen bond acceptors and proper spatial arrangement, while also improving aqueous solubility. The terminal fluorophenyl group provides additional hydrophobic interactions. This compound has favorable properties (MW ~490, LogP ~3.2, 1 H-bond donor, 9 H-bond acceptors) and represents a novel scaffold compared to known AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1. The synthetic accessibility is high through convergent synthesis.\"\n        },\n        {\n            \"smiles\": \"CN1CCN(CC1)C2=CC=C(C=C2)C(=O)NC3=CC=C(C=C3)C4=NN=C(S4)C5=CC(=CN=C5)C(F)(F)F\",\n            \"friendly_id\": \"AI:I3:N7:G2\",\n            \"source\": \"AI:I2:N7:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor features a thiazole core with a trifluoromethyl-pyridine substituent that forms optimal interactions with the hinge region of AKT1. The trifluoromethyl group enhances binding affinity through hydrophobic interactions and improves metabolic stability. The N-methylpiperazine provides solubility and potential for salt formation, while the amide linker offers rigidity and hydrogen bonding capabilities. This compound has excellent drug-like properties (MW ~510, LogP ~3.5, 1 H-bond donor, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over other kinases.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C=C2)C3=C(N=CN3C)C4=CC(=CN=C4)OCC(F)F\",\n            \"friendly_id\": \"AI:I3:N8:G2\",\n            \"source\": \"AI:I2:N8:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This Type II inhibitor stabilizes the inactive DFG-out conformation of AKT1 through its urea linker, which forms critical hydrogen bonds with the DFG motif (D292, F293). The N-methylimidazole with difluoroethoxypyridine forms key hydrogen bonds with the hinge region, while the fluorotoluidine extends into the hydrophobic pocket exposed in the DFG-out state. The difluoroethoxy group provides metabolic stability compared to a simple methoxy group, while maintaining hydrogen bond acceptor capabilities. This compound has favorable properties (MW ~470, LogP ~3.4, 2 H-bond donors, 7 H-bond acceptors) and represents a novel approach compared to known Type II kinase inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique binding mode may offer advantages in overcoming resistance mechanisms.\"\n        },\n        {\n            \"smiles\": \"CN1C(=O)C2=C(N=CN2C)C(=N1)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC(=O)C5(CC5)F\",\n            \"friendly_id\": \"AI:I3:N9:G2\",\n            \"source\": \"AI:I2:N11:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This allosteric AKT1 inhibitor targets the PH domain-kinase domain interface, offering a highly selective mechanism. The xanthine core (similar to caffeine) provides a rigid scaffold that positions the key binding elements optimally. The sulfone linker improves aqueous solubility while maintaining proper spatial arrangement. The fluorocyclopropanecarboxamide terminal group provides metabolic stability and additional binding interactions. This compound has favorable properties (MW ~500, LogP ~2.5, 2 H-bond donors, 9 H-bond acceptors) and represents a novel approach compared to allosteric inhibitors like MK-2206. The allosteric mechanism provides exquisite selectivity for AKT1 over other kinases, potentially reducing off-target effects. The balanced physicochemical profile suggests good oral bioavailability.\"\n        },\n        {\n            \"smiles\": \"CC1=C(C=C(C=C1)C(F)(F)F)NC(=O)C2=C(C=CC(=N2)Cl)NC3=NC=CC(=N3)N4CCOCC4\",\n            \"friendly_id\": \"AI:I3:N10:G2\",\n            \"source\": \"AI:I2:N10:G1\",\n            \"agent\": \"LLM Drug Designer\",\n            \"rationale\": \"This ATP-competitive inhibitor features an aminopyrimidine hinge-binding motif that forms key hydrogen bonds with the hinge region of AKT1 (E228, A230). The chloro-aminopyridine linker provides halogen bonding opportunities and blocks a potential metabolic site, while the trifluoromethylphenyl group extends into the hydrophobic back pocket, providing both potency and metabolic stability. The morpholine provides solubility and potential for additional hydrogen bonding interactions. This compound has favorable properties (MW ~480, LogP ~3.7, 2 H-bond donors, 7 H-bond acceptors) and represents a novel scaffold compared to clinical AKT inhibitors. The balanced physicochemical profile suggests good oral bioavailability, while the unique combination of binding elements may provide selectivity for AKT1 over AKT2/AKT3 isoforms.\"\n        }\n    ]\n}\n</molecules>\n\n## Final Candidate Analysis and Development Potential\n\nI've selected these 10 final candidates to represent the most promising AKT1 inhibitors from our design process. Here's a comprehensive analysis of their development potential:\n\n### Mechanism Diversity\n- **ATP-competitive inhibitors**: Compounds 1, 3, 5, 6, 7, 10 (various hinge-binding motifs)\n- **Type II inhibitors**: Compounds 2, 8 (targeting DFG-out conformation)\n- **Allosteric inhibitors**: Compounds 4, 9 (targeting PH domain-kinase domain interface)\n\n### Structural Innovation\nEach candidate features novel structural elements while incorporating established pharmacophores for AKT1 inhibition:\n- **Novel hinge binders**: Fluoropyridines, trifluoromethylpyridines, difluoromethoxypyridines\n- **Metabolically optimized linkers**: Fluorinated substituents, sulfones, ureas\n- **Solubility-enhancing groups**: Strategically placed piperazines, morpholines, prodrug approaches\n\n### Clinical Development Potential\n\n#### Most Promising ATP-Competitive Inhibitors\n- **Compound 1 (AI:I3:N1:G2)**: Excellent balance of potency and drug-like properties with novel fluoropyridine hinge binder and metabolically stable trifluoroethyl-piperazine\n- **Compound 5 (AI:I3:N5:G2)**: Dual binding mode with potential for enhanced AKT1 selectivity through unique trifluoromethyl-aminopyridine interactions\n\n#### Most Promising Type II Inhibitors\n- **Compound 2 (AI:I3:N2:G2)**: Comprehensive binding interactions with both hinge region and DFG motif, potentially overcoming resistance mechanisms\n- **Compound 8 (AI:I3:N8:G2)**: Excellent physicochemical properties with metabolically stable difluoroethoxy group\n\n#### Most Promising Allosteric Inhibitors\n- **Compound 4 (AI:I3:N4:G2)**: Innovative prodrug approach for improved bioavailability while targeting the allosteric site\n- **Compound 9 (AI:I3:N9:G2)**: Novel xanthine-based scaffold with excellent physicochemical properties\n\n### Comparison to Known AKT Inhibitors\nThese designs incorporate lessons from clinical AKT inhibitors while offering distinct advantages:\n- **vs. Capivasertib/Ipatasertib**: Our ATP-competitive inhibitors feature novel hinge-binding elements and optimized metabolic properties\n- **vs. MK-2206**: Our allosteric inhibitors employ different core scaffolds (indole, xanthine) with improved physicochemical properties\n- **vs. Uprosertib**: Our Type II inhibitors offer potentially improved selectivity through unique binding interactions\n\n### Development Recommendations\n1. **Lead Series Prioritization**:\n   - ATP-competitive series: Compounds 1 and 5\n   - Type II series: Compound 2\n   - Allosteric series: Compound 4\n\n2. **Initial Testing**:\n   - Biochemical assays against AKT1/2/3 to confirm potency and selectivity\n   - Cell-based pathway inhibition assays in AKT-dependent cancer models\n   - ADME profiling to confirm predicted properties\n\n3. **Backup Strategies**:\n   - Compounds 3, 6, 7, 8, 9, and 10 provide structural diversity for backup options\n   - Additional scaffold hopping around the most promising cores\n\nThese final candidates represent a diverse, innovative set of AKT1 inhibitors with strong potential for development as anticancer therapeutics."
      }
    ]
  }
]
2025-06-23 14:06:56,594 - INFO - Completed Iteration 3
2025-06-23 14:06:56,594 - INFO - LLM pipeline completed successfully
2025-06-23 14:06:56,595 - INFO - 
# LLM Pipeline Final Summary

## Project Overview
- **Target**: AKT1 inhibitor discovery
- **Approach**: Direct LLM-based molecule generation (no tools)
- **Iterations**: 3
- **Total molecules generated**: 37

## Key Insights
This pipeline demonstrates the capability of large language models to:
1. Generate novel chemical structures based on medicinal chemistry knowledge
2. Provide scientific rationales for design decisions
3. Iterate and optimize molecular designs across multiple rounds

## Generated Molecules
Total unique molecules extracted: 37

This represents a pure LLM-based approach for comparison in ablation studies against tool-augmented pipelines.

